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Abstract 
This thesis describes the synthesis, structural preferences and biological properties of 
oxetane-containing peptidomimetics in which one of the amide C=O bonds of a peptide 
backbone is replaced by an oxetane ring. Chapter 1 gives a brief introduction on 
peptidomimetics, oxetanes in medicinal chemistry and oxetane-containing 
peptidomimetics. 
Chapter 2 describes the development of a simple two-step sequence to spirocyclic 
analogues of 2,5-diketopiperazines. Conjugate addition of α-amino methyl esters to 
nitroalkenes, generated from oxetan-3-one or N-Boc-azetidin-3-one, followed by 
reduction of the nitro group with Raney Ni under an atmosphere of hydrogen provides, 
after spontaneous cyclisation of the primary amine, the spirocycles in good overall yields. 
These novel spirocycles can be functionalised by selective N-alkylations as well as by 
carbonyl reduction to the corresponding piperazines.   
Chapter 3 describes the development of a practical route to oxetane-modified peptides 
(OMPs) using solid-phase peptide synthesis (SPPS) techniques. Our approach involves 
the application of oxetane-containing dipeptide building blocks which are easily prepared 
in three steps in solution.  The building blocks are then integrated into peptide chains 
using conventional Fmoc/tBu SPPS. This approach was used to prepare a range of OMPs 
in high purity including oxetane analogues of Met- and Leu-enkephalin and the 
nonapeptide bradykinin.  
Chapter 4 explores the impact of oxetane-modification on the structure and stability of α-
helices. Initially, an asymmetric route to a dipeptide building block in which the oxetane-
residue is based on alanine is described. Following this, the SPPS methodology described 
in Chapter 3 was used to prepare oxetane-modified analogues of an alanine-based α-
helical peptide in which a single alanine residue is replaced with an oxetane-modified 
residue. The structural preferences of the oxetane-modified analogues were then studied 
using circular-dichroism (CD) spectroscopy. These studies revealed that introduction of 
an oxetane-modification results in a helix-destabilising effect.  
Chapter 5 gives a summary of the key findings and possible future work.  
Chapter 6 provides detailed experimental procedures for the work carried out in Chapters 
2-4.  
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Chapter 1: Introduction 
1.1 Project Aims 
This thesis builds upon previous research within our group and describes the synthesis, 
structural preferences and biological properties of novel oxetane-containing 
peptidomimetics, in which one of the amide C=O bonds of a peptide backbone is replaced 
by an oxetane ring (Figure 1.1).1 Initially, the project will focus on the development of 
practical methods for the synthesis of oxetane-modified peptides (OMPs). Following this, 
the emergent chemical methods will be used to investigate the impact of oxetane-
modification on the properties and structure of biologically interesting peptides. Through 
these investigations, we hope to gain the tools and knowledge to selectively modify 
peptides and learn how the changes induced by oxetane-modification influence the 
properties and secondary structure of peptides.  
 
Figure 1.1 Oxetane-modified peptides (OMPs).1  
 
1.2 Peptidomimetics 
Peptides and their larger counterparts, proteins, are oligomers of amino acids covalently 
linked together by amide bonds (peptide bonds).2 Although they are constructed from 
relatively simple building blocks, the resulting oligomeric structures form complex 
architectures that play vital roles in almost all biological processes, for example 
functioning as hormones, enzyme inhibitors or substrates, growth promoters or inhibitors 
and neurotransmitters.3,4 Consequently, the therapeutic application of peptides and 
proteins is of great interest in biomedical research.5–7 Despite this, the use of peptides as 
therapeutics is limited by their vulnerability to proteases, poor bioavailability and 
undesired effects due to interaction of flexible peptides with several receptors.8,9 To tackle 
these problems, molecules called peptidomimetics have been designed to mimic the 
structure and/or action of a natural peptide and potentially improve the physicochemical 
and biochemical properties. 
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oxetane-modified
peptide (OMP)
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1.2.1 Peptidomimetics via Modification of the Peptide Backbone 
There are a number of excellent reviews on the synthesis and medicinal chemistry of 
peptidomimetics.4,8–12 This section does not aim to replicate these reports but to highlight 
some relevant examples.  
A common method for preparing peptidomimetics is via modification of the amino acid 
backbone of native peptides.4 Such modifications can create novel structures with 
increased bioavailability, enzymatic stability and increased activity and/or selectivity for 
a target receptor. Examples of backbone modifications include: isosteric replacement or 
alkylation of the amino functionality, substitution or replacement of the α-carbon, 
backbone extension and modification of the carbonyl group (Figure 1.2).  
 
Figure 1.2 Peptidomimetics with modification of the peptide backbone.4 
Azapeptides are peptide analogues in which the α-carbon of one or more of the amino 
acid residues is replaced with a nitrogen atom and can be easily prepared via acylation of 
hydrazines.4,13,14 They exhibit a preference to adopt β-turn conformations and are more 
resistant to enzymatic hydrolysis. Azapeptides are attractive targets in drug discovery and 
have been used as inhibitors of hepatitis C virus NS3 serine protease and human 
immunodeficiency virus (HIV) protease.15,16 Atazanavir 1 (ReyatazTM), a highly active 
HIV protease inhibitor, is an example of an FDA-approved azapeptide drug (Figure 
1.3).17   
N
H
N
R H
N
R
H
N
O
R
O
O
N
R H
N
R
H
N
O
R
O
OMe
N
H
H
N
R
H
N
O
R
O
O
R Me
N
H
R H
N
R
H
N
O
R
O
S
O
R H
N
R
H
N
O
R
O
O
N
H
R H
N
R
H
N
O
R
O
O
conventional
peptide
azapeptide
N-methylationCα-substitution
depsipeptide thiopeptideN
H
H
N
O O
N
H O
R R
R
β3-peptide
 15 
 
Figure 1.3 Atazanavir 1 an azapeptide inhibitor of HIV protease.17 
Depsipeptides are peptidomimetics in which one or more amino groups in the peptide 
chain is replaced by an oxygen atom.4 Replacement of the N-H group results in reduced 
H-bonding ability and a lower barrier of rotation for cis-trans isomerisation than native 
peptides, which has a significant effect on the secondary structure of depsipeptides.18 
Numerous depsipeptides, particularly cyclic structures, have been isolated from various 
microorganisms and exhibit a wide spectrum of biological activity including 
antimicrobial, antitumour and immunosuppressive activity.19 Consequently, naturally 
occurring depsipeptides have emerged as promising lead structures for the development 
of novel synthetically derived drugs.20 Romidepsin 2 (IstodaxTM) is an FDA-approved 
cyclic depsipeptide anticancer drug used for the treatment of cutaneous T-cell lymphoma. 
(Figure 1.4).21  
 
Figure 1.4 Romidepsin 2, a depsipeptide anticancer drug.21 
Thiopeptides, perhaps one of the simplest modifications, are peptide analogues in which 
the oxygen atom of one or more of the amide bonds is replaced with a sulphur atom.22 
Despite their similarity, replacement of an amide bond with a thioamide has a significant 
impact on the structural and biological properties of a peptide. This is a result of the 
significantly longer C=S bond and change in H-bonding properties. These aspects have 
been utilised in the design and study of synthetic foldamers, such as β-sheets and α-
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helices.23,24 In addition, thiopeptides have displayed enhanced in vivo activity due to their 
increased resistance to enzymatic hydrolysis.25 This has been demonstrated by 
Strømgaard and co-workers, who identified thiopeptide 3 as a potent and plasma-stable 
inhibitor of the postsynaptic density-95 (PSD-95) and N-methyl-D-aspartate (NMDA) 
receptor interaction, which is a potential target in the treatment of Alzheimer’s disease 
(Figure 1.5).26  
 
Figure 1.5 Thiopeptide 3, a potent and plasma-stable inhibitor of the PSD-95/NMDA receptor 
interaction.26 
 
1.3 Oxetanes in Medicinal Chemistry 
There are a number of excellent reviews on the synthesis, reactivity and medicinal 
chemistry of oxetanes.27–31 This section does not aim to replicate these reports but to 
highlight the relevance of oxetanes in medicinal chemistry.  
 
1.3.1 Oxetane 
Oxetane 4 is a four-membered heterocyclic ring containing an oxygen atom that adopts 
an essentially planar conformation with a small puckering angle of ~9° at 140 K and ~11° 
at 90 K (Figure 1.6).27,32 The oxetane ring is an excellent H-bond acceptor and is used as 
a stable motif in medicinal chemistry to influence the physicochemical properties of 
potential drug candidates.27,29 In addition, the oxetane ring is a valuable synthetic 
intermediate due to its ability to undergo ring-opening reactions under acidic 
conditions.27,28 These characteristics have led to the development of numerous synthetic 
approaches to novel oxetane derivatives.27,29  
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Figure 1.6 Structure and ring puckering of oxetane 4.32 
 
1.3.2 Oxetanes in Natural Products 
There are relatively few natural products that contain the oxetane ring.27 The structures 
of those that do range from simple β-peptides to highly functionalised fused ring systems 
(Figure 1.7). Perhaps, the most well-known example is paclitaxel, sold under the brand 
name Taxol 5, which was first isolated in 1971 by McPhail and co-workers and is used 
as a chemotherapy drug.33 Other examples include the β-amino acid oxetin 6,34 which 
displays antibacterial and herbicidal activity, the nucleoside analogue oxetanocin A 7,35 
which is a potent antitumour, antiviral and antibacterial agent, and the marine diterpene 
dictyoxetane 8,36 whose biological properties are currently not well understood.  
 
Figure 1.7 Oxetane-containing natural products. 
 
1.3.3 Oxetanes as Replacement Groups in Medicinal Chemistry 
Studies by Carreira, Roger-Evans, Müller and co-workers have demonstrated the benefits 
of the oxetane motif as an isosteric replacement for gem-dimethyl, carbonyl and 
morpholine groups in medicinal chemistry.29,30,37,38  
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1.3.3.1 Oxetane as a Replacement for gem-Dimethyl Groups 
gem-Dimethyl groups have commonly been used in medicinal chemistry to block 
metabolic attack of methylene groups. However, replacement of the hydrogen atoms with 
methyl groups results in a significant increase in lipophilicity, which can have an adverse 
effect on the physicochemical and pharmacological properties.37 In addition, the gem-
dimethyl group itself can become a target of metabolic attack. Carreira and co-workers 
have proposed that the oxetane ring can be used as a polar equivalent of the gem-dimethyl 
group, as the oxetane ring is similar in molecular volume to the gem-dimethyl group and 
can provide a reduction in lipophilicity and metabolic vulnerability (Figure 1.8).29,37    
 
Figure 1.8 Comparison of gem-dimethyl and oxetane modules.37 
The impact of replacing a gem-dimethyl unit with an oxetane ring was demonstrated by 
replacing the tert-butyl group in parent compound 9 with a methyl-substituted oxetane 10 
(Table 1.1).37 Comparison of the physicochemical and biochemical properties revealed 
that oxetane-modified 10 was significantly more polar and soluble than the parent 
compound 9. In addition, oxetane-modified 10 had improved metabolic stability as 
indicated by reduced intrinsic clearance rates (CLint) measured in human (h) and mouse 
(m) liver microsomes. Replacement of the tert-butyl group with a methyl-substituted 
oxetane also resulted in reduction of hERG (human ether-a-go-go-related gene) 
inhibition, as a result of the decrease in lipophilicity.  
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R1 R2
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logD (logP) 1.8 (4.3) 0.8 (3.3) 
Solubility (µg mL−1) <1 4,400 
hCLint (min−1 mg −1 µL) 16 0 
mCLint (min−1 mg −1 µL) 417 43 
hERG IC50 (µM) 7.5 35 
Table 1.1 Physicochemical and biochemical properties of parent compound 9 and oxetane-modified 
compound 10.37  
 
1.3.3.2 Oxetane as a Replacement for Carbonyl Groups 
Carreira and co-workers have examined the benefits of oxetanes as replacements for 
carbonyl groups in medicinal chemistry.29,30 Oxetane can be a valuable replacement for a 
carbonyl group due to their similar dipoles, H-bonding properties and spatial arrangement 
of lone pair electrons (Figure 1.9). In addition, carbonyl functional groups in drug-like 
structures are susceptible to enzymatic modification and to epimerisation at neighbouring 
stereogenic centres, whereas oxetane derivatives are stable to both of these concerns. One 
main difference between an oxetane and carbonyl group is the longer length and larger 
volume, which could potentially be beneficial or detrimental at a receptor pocket.  
 
Figure 1.9 Comparison between carbonyl and oxetane.29  
The impact of oxetane as a replacement for a carbonyl group was studied by comparison 
of the physicochemical and biochemical properties of carbonyl-containing heterocycle 
compounds (11 and 13) with their oxetane-containing spirocyclic derivatives (12 and 14, 
Table 1.2).38 In both the piperidine and pyrrolidine series, replacement of the carbonyl 
group with an oxetane ring resulted in a decrease in solubility. No significant change in 
NMe2
Parent compound, 9
NMe2
O
Oxetane-modified compound, 10
O
R2R1
O
R2R1
1.2 Å 2.1 Å
 20 
lipophilicity was observed for the piperidine series, whilst a small increase was observed 
for oxetane-modified pyrrolidine 14. However, both oxetane-modified analogues 12 and 
14 had improved metabolic profiles as indicated by reduced intrinsic clearance rates 
(CLint) measured in human (h) and mouse (m) liver microsomes. 
     
logD (logP) 1.2 (1.6) 1.0 (2.0) −0.1 (−0.1) 0.7 (1.5) 
Solubility (µg mL−1) 4,000 1,400 4,100 730 
hCLint (min−1 mg −1 µL) 120 6 100 2 
mCLint (min−1 mg −1 µL) 88 22 580 27 
Table 1.2 Physicochemical and biochemical properties of 11-14.38 
In an additional study, Carreira and co-workers investigated the impact of carbonyl to 
oxetane substitution in the drugs thalidomide 15 and lenalidomide 16 (Figure 1.10).39 The 
two enantiomers of thalidomide are known to rapidly interconvert in vivo, and each 
enantiomer causes a distinct effect, with (R)-15 acting as a sedative and (S)-15 as a 
teratogen. Substitution of the imide C=O with an oxetane ring produced analogues 17 and 
18 which displayed similar physiochemical and in vitro properties to the parent drugs, but 
were significantly more stable in human plasma. Importantly, oxetane-modification of 
thalidomide prevents in vivo racemisation. This work did not include any studies into the 
biological activities of oxetane-modified analogues 17 and 18.  
 
Figure 1.10 Oxetane analogues of thalidomide and lenalidomide.39 
In addition to these reports, a recent study by Ballatore and co-workers has demonstrated 
that oxetan-3-ol may be considered as an alternative bioisostere to the carboxylic acid 
functional group (Figure 1.11).40 The authors’ investigation revealed that replacement of 
R =
O
O RN O
11
RN
12
O RN
O
13
RN
14 O
N
O
O
NH
O
OR
N
O
O
NH
O
R
oxetane-
modification
Thalidomide, 15 (R = H)
Lenalidomide, 16 (R = NH2)
Oxetano-thalidomide, 17 (R = H)
Oxetano-lenalidomide, 18 (R = NH2)
O
* *
racemisable
centre
non-racemisable
centre
 21 
the carboxylic acid group in model compound 19 with oxetan-3-ol causes a significant 
decrease in acidic character and an increase in permeability. These properties are 
desirable in context of central nervous system (CNS) drug design, when isosteric 
replacement of the carboxylic acid is often required to improve the brain penetration of a 
candidate compound. 
 
Figure 1.11 Oxetan-3-ol as a bioisostere of the carboxylic acid functional group.40 a Effective 
permeability. 
 
1.3.3.3 Spirocyclic Oxetanes as a Replacement for Morpholine 
Morpholine units are often introduced into drug scaffolds to improve aqueous solubility.  
However, morpholine is known to be vulnerable to oxidative metabolism. Carreira and 
co-workers have proposed that spirocyclic oxetanes can be considered as structural 
analogues of morpholine, as they are able to increase solubility while remaining stable 
towards oxidative metabolism (Figure 1.12).38  
 
 
Figure 1.12 Spirocyclic oxetane as a replacement for morpholine.38 
Following this publication, Carreira and co-workers reported the synthesis of 1,6-
heteroatom-substituted spiro[3.3]heptanes 22 as alternatives to 1,3-heteroatom-
substituted cyclohexanes 21 (Figure 1.13).41 The instability of 21 has prevented their 
application in drug discovery. In contrast, spiro[3.3]heptanes 22  have no associated 
instability and are able to position the heteroatoms in a similar orientation to 21, hence 
making them attractive replacements. 
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Figure 1.13 1,6-Heteroatom-substituted spiro[3.3]heptanes 22 as alternatives to 1,3-heteroatom-
substituted cyclohexanes 21.41 
 
1.4 Oxetane-Containing Peptidomimetics 
1.4.1 Homo-Oligomers of Oxetin 
Aitken and co-workers have prepared homo-oligomers of oxetin 6 (Figure 1.7) and 
studied their conformational preferences in solution and solid state.42 Analysis of the 
secondary structure using 1H-NMR, CD and X-ray diffraction techniques indicate that C- 
and N-terminal protected oxetin-hexamer 23 adopts an uncommon left-handed 10-helix 
β-peptide manifold, wherein a network of 10-membered ring H-bonds is formed between 
the NH group at position i to the C=O at position i + 1. The 10-helix is further stabilised 
by a cooperative 5-membered ring H-bonding network between the NH at position i with 
the O(oxetane) at position i – 1 (Figure 1.14). Helical patterns of β-peptides have been 
shown to possess promising biological activity, hence the 10-helix architecture of oxetin 
homo-oligomers may have applications in medicinal chemistry. Similar studies have been 
reported by Fleet and co-workers, who have demonstrated that hexamers of C4-
substituted oxetins also preferentially adopt 10-helix β-peptide architectures.43,44  
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Figure 1.14 Cooperative 5- (blue arrows) and 10-membered (red arrows) ring interactions in the 10-
helix folding of oxetin hexamer 23 and X-ray structure of 23.42 Figure of X-ray structure taken from 
Chem. Commun. 2018, 54, 1968-1971.42 
 
1.4.2 Oxetane-Modified Peptides 
In 2014, Shipman and co-workers reported the preparation of a new class of 
peptidomimetic in which one of the amide C=O bonds of a peptide backbone is replaced 
by an oxetane ring (Figure 1.1).1 Several features of oxetane-modified peptides were 
expected to make them of interest as peptidomimetics. Firstly, substitution of an amide 
bond with the 3-aminooxetane unit was expected to produce peptidomimetics with greatly 
reduced vulnerability to proteases. Secondly, the 3-aminooxetane is able to participate in 
H-bonding, as both a donor and acceptor, therefore OMPs were expected to support 
conventional secondary structures. Finally, changes in the conformational preferences of 
OMPs, arising from removal of the double bond character of the peptide bond, might 
open up new areas of peptide structural space.  
Initially, the authors’ investigation focused on the preparation of oxetane-containing 
tripeptide analogues, in which the central C=O amide bond was substituted for an oxetane 
ring.1 The general synthetic approach is given in Scheme 1.1. The first step involved 
conjugate addition of a chiral α-amino ester 25 to oxetane-substituted nitroalkene 24. 
Following this, reduction of the nitro group in 26, and coupling of the resulting amine 27 
with an N-protected amino acid gave the protected peptidomimetic with the oxetane 
residue centrally located. Deprotection of the N- and C- terminal protecting groups 
provided the desired oxetane-modified tripeptide 28.  
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Scheme 1.1 Synthetic strategy to oxetane-based peptidomimetics developed by Shipman and co-
workers.1 
Two oxetane-substituted nitroalkenes 30 (R1 = H) and 31 (R2 = Bn) were used in this 
study to produce peptidomimetics of glycine (GOx) and phenylalanine (FOx), respectively 
(Scheme 1.2).1 The nitroalkenes were prepared via nitro-aldol reaction of commercially 
available oxetan-3-one 29 with the appropriate nitroalkane and elimination of the 
resulting alcohol with methanesulfonyl chloride. In the case of nitroalkene 30 (R = H), it 
proved more convenient to generate 30 in situ and react it directly without work-up. 
Following this, conjugate addition of an amino ester to nitroalkene 30 or 31 generally 
gave the addition products 32 in good overall yields. A wide selection of polar and 
hydrophobic amino esters, as well as dipeptide based nucleophiles, were demonstrated in 
the addition step. Interestingly, addition of L-valine methyl ester to trisubstituted 
nitroalkene 31 (R = Bn) gave the addition product 36 as a mixture of diastereoisomers, 
with the inherent chirality of L-valine exerting little influence on the resulting 
stereochemistry. The diastereoisomers were inseparable by column chromatography. 
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Scheme 1.2 Conjugate addition of a variety of amino esters and dipeptides to oxetane-substituted 
nitroalkenes.1,45 
Next, reduction of the nitro group and coupling of the resulting amine with a N-terminal 
protected amino acid was demonstrated.1 The most reliable conditions for reduction 
proved to be indium in aq. HCl-THF followed by immediate coupling of the resulting 
amine with EDC and the appropriate N-Cbz protected amino acid (Scheme 1.3). Finally, 
concomitant removal of the Cbz and benzyl ester groups by hydrogenolysis gave the 
oxetane-modified tripeptides 41-46 in high purity and good overall yields.  
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Schemes 1.3 Synthesis of oxetane-containing tripeptide motifs.1 
In addition to mid-chain oxetane-containing tripeptides, the authors also prepared N- and 
C-terminal oxetane-modified tripeptides (47 and 49) using variations of the chemistry 
described above (Scheme 1.4).45  
(a) 
 
(b) 
 
Scheme 1.4 Synthesis and structure of (a) N-terminal 47 and (b) C-terminal 49 oxetane 
peptidomimetics.45 
Following the synthesis of oxetane-modified tripeptides, the authors investigated the 
structural preferences of these novel peptidomimetics.1 In the solid state, oxetane-
modified tripeptide 41 was shown to be zwitterionic with the terminal amine protonated, 
not the secondary amine of the 3-aminooxetane unit, and displayed antiparallel sheet-like 
arrangements (Figure 1.15). Both the secondary amine and the oxygen of the 3-
aminooxetane unit were involved in the hydrogen bonding network, with the oxygen of 
the oxetane hydrogen bonding outside the plane of the sheet. Further analysis of the X-
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ray crystal structure revealed that the nitrogen atom adjacent to the oxetane is pyramidal 
and the averaged C-N-COx-C torsional angle (ω) was 60.2°. This is compared to a 
conventional sp2-hybridised peptide bond where the nitrogen atom is trigonal and ω = 
~180° (Figure 1.15). 
  
 
 
Figure 1.15 Antiparallel sheet-like arrangement of 41 in the solid state.1 Figure of X-ray structure taken 
from Chem. Commun. 2014, 50, 8797-8800.1 
Molecular dynamic (MD) simulations indicate that oxetane-modified tripeptide 41 has 
greater conformational flexibility compared to the native tripeptide 50.1 Snapshots of the 
two most populated clusters for 50 and 41 are shown in Figure 1.16. The native tripeptide 
50 adopts extended conformations in which the C- and N-termini are separated by >7 Å. 
In contrast, oxetane-modified tripeptide 41 adopts folded conformations in which the C- 
and N- termini distance is 3-4 Å. The preference for 41 to adopt folded conformations 
likely arises from the change in hybridisation (sp2 to sp3) and dihedral angle at the 3-
aminooxetane unit. These observations suggest that oxetane-modification could give rise 
to turn-like conformations in longer chain peptidomimetics.  
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Figure 1.16 Snapshots of the two most populated clusters of 50 and 41 derived from MD simulations, 
along with the percentages of total structures accounted for by each cluster.1 Figure of MD derived 
snapshots taken from Chem. Commun. 2014, 50, 8797-8800.1 
Shortly after the publication of this work, Carreira and co-workers independently reported 
on the chemical synthesis of oxetane-modified peptides.46 The authors developed a 
similar approach to oxetane-containing dipeptides 52 via conjugate addition of α-amino 
n-propyl esters to nitroalkene 24 followed by nitro reduction with Raney Ni and in situ 
protection of the resulting amine (Scheme 1.5). Similar to observations reported by 
Shipman and co-workers, addition of chiral amino esters to trisubstituted nitroalkenes 24 
(R1 ≠ H) gave the addition products as a mixture of diastereoisomers which were 
inseparable by column chromatography. Subsequent deprotection of the N- or C-terminal 
protecting group, followed by standard amide coupling conditions gave longer chain 
peptidomimetics. This work did not include any structural insights into the folding of 
oxetane-modified peptides. 
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Scheme 1.5 Synthetic route to oxetane-containing dipeptides developed by Carreira and co-workers.46 
The synthetic approach to oxetane-modified peptides, developed independently by 
Shipman1 and Carreira,46 is highly efficient for the preparation of oxetane-containing 
peptides in which the oxetane residue is based on glycine (GOx). However, this route is 
currently not suitable for the preparation of oxetane-containing peptides in which the 
oxetane residue is based on residues other than glycine as a mixture of inseparable 
diastereoisomers is obtained. 
In 2017, during the course of the authors’ research described in this thesis, Carreira and 
co-workers published an asymmetric route to oxetane-containing dipeptide building 
blocks 53.47 Their expeditious route involved substitution of activated (i.e. X = OTf) 
enantiopure hydroxyesters 55 with enantiopure 3-aminooxetanes 54 (Scheme 1.6). The 
enantiopure amines 54 were prepared via addition of an organometallic reagent to chiral 
imine 56, which in turn, was accessed from commercially available Tris hydrochloride 
58. Enantiopure hydroxyesters 55 were derived from D-amino acids. 
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Scheme 1.6 Carreira and co-workers’ synthetic approach to oxetane-containing dipeptide building 
blocks.47  
Chiral imine 63 was prepared in 7 steps from Tris·HCl 58 (Scheme 1.7).47 Tris·HCl 58 
was first converted to hydroxy-oxetane 61 using a route that involved protection of the 
amine and formation of the oxetane ring. Following this, Swern oxidation and 
condensation of the resulting aldehyde with Ellman’s auxiliary 62 gave the desired chiral 
imine 63.   
 
Scheme 1.7 Carreira and co-workers’ synthesis of chiral imine 63.47 
Chiral imine 63 served as a crucial intermediate for the synthesis of enantiopure 3-
aminooxetane building blocks 54. For example, the synthetic route to an oxetane-
modified alanine (AOx) building block 66 is detailed below (Scheme 1.8).47 Addition of 
methyllithium to chiral imine 63 gave the addition product 64 as a single diastereoisomer 
(dr >95:5). Following this, cleavage of Ellman’s auxiliary and Boc-protection of the 
resulting amine gave intermediate 65. Finally, tosyl and benzyl deprotection gave the 
desired AOx residue 66 as a single enantiomer. Using variations of this route, Carreira and 
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co-workers were able to prepare several enantiopure 3-aminooxetane building blocks 54, 
including analogues of phenylalanine (FOx), tyrosine (YOx), valine (VOx) and proline 
(POx).  
 
Scheme 1.8 Carreira and co-workers’ synthesis of enantiopure 3-aminooxetane 66.47 
Effenberger and co-workers have demonstrated that displacement of triflates with an 
amine proceeds exclusively in an SN2 fashion to produce a single enantiomer.48 On this 
basis, Carreira and co-workers prepared a number of triflates 69 from the corresponding 
hydroxyesters 68, which in turn, were prepared from D-amino acids 57 (Scheme 1.9).47  
 
Scheme 1.9 Synthesis of triflates from D-amino acids.47 
With access to a variety of enantiopure 3-aminooxetanes 54 and activated hydroxyesters 
55, a collection of oxetane-containing dipeptide building blocks 53 were prepared 
(Scheme, 1.10).47 Alkylation of enantiopure 3-aminooxetanes 54 with triflates 55 
proceeded exclusively in an SN2 fashion to provide the building blocks 53 as single 
diastereoisomers. In the case of dipeptides incorporating a glycine residue, commercially 
available bromo acetates were used.  
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Scheme 1.10 Carreira and co-workers’ synthesis of oxetane-containing dipeptide building blocks.47 
Although the approach developed by Carreira provided access to dipeptide building 
blocks containing a variety of oxetane-modified residues, the route to prepare enantiopure 
3-aminooxetanes 54 was not particularly practical. The route involved a significant 
number of steps, requiring the use of a number of protecting groups and chromatographic 
purifications. Therefore, shorter routes to enantiopure 3-aminooxetanes 54 would be of 
advantage.  
The authors demonstrated the application of these building blocks by preparing analogues 
of Leu-enkephalin 75, an opioid peptide that modulates the reception of pain,3 wherein 
each amide bond was sequentially replaced by the 3-aminooxetane unit (Figure 1.17).47 
Investigations on the impact of oxetane-modification on the biological activity of Leu-
enkephalin revealed that the oxetane-modified analogues showed largely improved 
hydrolytic stability in human serum and two of the analogues retained affinity towards 
the δ-opioid receptor comparable to the native system. These results provide proof of 
concept that oxetane-modification of an amide bond can be used to increase the stability 
of a peptide towards proteases while retaining bioactivity. A more detailed discussion on 
the stability and biological activity of oxetane-modified Leu-enkephalin analogues is 
included in Chapter 3. 
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Figure 1.17 Example of an oxetane-modified analogue 76 of Leu-enkephalin 75 with improved 
hydrolytic stability in human serum.47 
 
1.4.3 Oxetane-Modification of Proteins 
Recently, Bernardes and co-workers have reported a method for the chemoselective 
introduction of oxetane moieties into proteins through alkylation of cysteine residues 
under mild conditions.49 Initially, the authors demonstrated the site-selective 
incorporation of the 3-S-oxetane motif into proteins via SN2 reaction of 3-bromooxetane 
79 with single-Cys mutants of the C2A domain of Synaptotagmin-I Cys95 (C2Am, 77) 
and Annexin-V (AnxV, 78) to afford Cys-to-oxetane alkylation products 80 and 81 in 
>95% conversion (Scheme 1.11). Stability studies revealed that the 3-S-oxetane motif 
was stable upon incubation with human plasma, reduced glutathione (GSH), and other S- 
and N-nucleophiles. Importantly, C2Am-3-S-Ox 80 retained its inherent binding activity 
against phosphatidylserine (PS), an internal membrane lipid externalised during 
apoptosis.  
 
Scheme 1.11 Site-selective modification of proteins with oxetanes.49 a Pi = phosphate. 
Next, the authors reported an extension of this chemistry to include other oxetanes. 
Reaction of C2Am 77 with 3,3-bis(bromomethyl)oxetane 82 afforded C2Am-S-Ox-
CH2Br 83 in >95% conversion (Scheme 1.12).49 The resulting modified protein 83 
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contained an electrophilic handle (S-Ox-CH2Br) amenable to a second round of chemical 
modification after incubation with an appropriate nucleophile (e.g. post-translational 
modifications, cytotoxics and spectroscopic tags). Subsequently, incubation of 83 with 2-
mercaptoethanol, βGalSNa, thiophenol and benzylamine gave substitution products 84a-
d in >95% conversion. Interestingly, the oxetane linker (S-CH2-Ox-CH2-S/N) proved to 
be a more rigid scaffold compared to a common aliphatic linker (S-CH2-CH2-CH2-S/N) 
containing the same number of carbons. Hence, this rigid and soluble oxetane linker may 
find application in the development of vaccine conjugates.  
 
     
Scheme 1.12 Selective incorporation of an S-to-S/N oxetane linker on proteins.49 a Pi = phosphate. 
Following this study, Bernardes and co-workers reported an efficient method for the site-
selective installation of an oxetane-containing constraint for disulphide containing 
peptides and proteins under mild and biocompatible aqueous conditions  (Figure 1.13).50 
Somatostatin 85 and octreotide 87, which can be used for imaging and treating 
neuroendocrine tumours, were reacted simultaneously with tris(2-carboxyethyl)-
phosphine (TCEP) and 82 in 10% DMF in water to give, after HPLC purification, the 
grafted cyclic peptides 86 and 88 in 76% and 81% yield, respectively. Investigations into 
the binding properties of these derivatives to the somatostatin receptor 2 (SSTR2) 
revealed that octreotide 87 and oxetane-grafted surrogate 88 had similar affinity against 
this receptor, while oxetane-grafted 86 showed a 4-fold enhancement in binding affinity 
compared to somatostatin 85. MD simulations suggested that oxetane-grafted 
somatostatin 86 was more rigid and displayed a more defined conformation in solution 
than 85, which is ideal for a more efficient binding to the receptor. Both oxetane-grafted 
peptides 86 and 88 were stable in human plasma and in the presence of GSH. 
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Scheme 1.13 Installation of an oxetane-containing constraint for disulphide-containing cyclic peptides.50 
Next, the authors demonstrated the utility of this chemistry to prepare oxetane-grafted 
antibodies (Scheme 1.14).50 The exposed disulphide bond of a Fab fragment of Herceptin 
(Fab-Her, 89), an antibody currently used to treat Her2+ breast cancer patients, was 
reacted with 82 under aqueous buffered conditions in the presence of TCEP to give 
oxetane-grafted Fab-Her 90 in >95% conversion. Unlike the native antibody 89, oxetane-
grafted 90 was stable under reducing conditions and in human plasma, which is a key 
aspect in antibody therapeutics design as thiol-exchange reactions in plasma lowers 
efficacy and adds side-toxicity. Importantly, oxetane-grafted 90 showed a small increase 
in binding affinity (KD) to the Her2 receptor compared with the native antibody 89. Taken 
together, these results demonstrate that installation of an oxetane-graft in disulphides 
present in peptides and proteins enables stabilisation of folded structures and results in 
disulphide-grafted products with improved bioactivity that are stable under biological 
conditions. 
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Scheme 1.14 Representation of a disulphide constraint in native antibody sequences using an oxetane 
graft.50 a Pi = phosphate. 
 
1.5 Conclusions 
This chapter has discussed the relevance of peptidomimetics and oxetanes in medicinal 
chemistry. Recently, these exciting areas of research have led to the development of a 
novel class of peptidomimetic in which one of the amide C=O bonds of a peptide 
backbone is replaced by an oxetane ring. Independent publications by Shipman1 and 
Carreira46,47 have begun to explore the properties and structure of these novel 
peptidomimetics, and have demonstrated that oxetane-modification within a peptide 
sequence can promote turn-like conformations and improve stability towards proteases. 
In order to establish the full potential of oxetane-modified peptides, it is important to 
further develop methods for their synthesis and to investigate the impact of oxetane-
modification on the properties and structure of biologically interesting peptides.  
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Chapter 2: Synthesis of Oxetane- and Azetidine-Containing 
Spirocycles Related to the 2,5-Diketopiperazine Framework 
2.1 Previous Work and Project Aims  
Previous research in our group explored conditions for the reduction of the nitro group in 
nitro amino esters to the corresponding amine for the synthesis of oxetane-containing 
peptides. During this investigation, reduction of the nitro group in 91 using samarium (II) 
iodide failed to give the desired primary amine 92 but instead gave oxetane-containing 
spirocycle 93, as a result of reduction followed by spontaneous cyclisation. This novel 
spirocyclic scaffold is similar in structure to the 2,5-diketopiperazine framework (2,5-
DKP 94, Scheme 2.1).45 
 
Scheme 2.1 Synthesis of 93 via reduction of the nitro group of 91. 
As part of an ongoing interest in the preparation of spirocyclic heterocycles, oxetane-
containing frameworks and 2,5-DKP templates in drug discovery projects,31,51–53 we 
thought it would be worthwhile to examine the feasibility of optimising this process and 
preparing a series of novel spirocyclic scaffolds related to the 2,5-DKP framework. 
Additionally, this investigation would allow us to further examine the scope of the 
conjugate addition chemistry developed in earlier publications by us1,45 and by Carreira.46 
Furthermore, this project would serve as a good starting point for the author to familiarise 
himself with the chemistry previously developed.      
 
2.2 Introduction 
There are a number of excellent reviews written on 2,5-DKPs53,54 and spirocyclic 
heterocycles.31,51,52 This short introduction does not aim to replicate these reports but to 
highlight the relevance of 2,5-DKPs and spirocyclic heterocycles in drug discovery.    
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2.2.1 2,5-Diketopiperazines  
2,5-Diketopiperazines (2,5-DKPs, Scheme 2.1) are the smallest possible cyclic peptides 
derived from the condensation of two α-amino acids and are found in numerous natural 
products and biologically active compounds. These small, conformationally constrained, 
chiral scaffolds contain multiple H-bond donors and acceptors, are stable to proteolysis 
and have the potential for derivatisation at up to four positions. These properties make 
them attractive motifs in drug discovery.53 
The structures of bioactive natural products containing the 2,5-DKP framework range 
from simple cyclic dipeptides to highly functionalised fused ring systems. Examples 
include, the naturally occurring peptide antibiotic brevianamide F 9555 and bicyclomycin 
96,56 as well as the indolic alkaloid spirotryprostatin A 97,57 a promising antimitotic arrest 
agent (Figure 2.1). Due to their therapeutic potential, the total syntheses of natural 
products containing the 2,5-DKP framework is a major pursuit of organic chemists. 
 
Figure 2.1 Bioactive natural products containing the 2,5-DKP framework. 
Chirally enriched 2,5-DKPs are easily prepared from readily available α-amino acids 
using robust chemistry and have been used as core templates from which to construct 
libraries of compounds in medicinal chemistry projects. Structure-activity relationship 
(SAR) has been investigated for many of these compounds, and has led to the 
development of several clinical drugs. Examples include the marketed drug Tadalafil 
9858,59 and Retosiban 99,60,61 as well as Plinabulin 100, which is currently in phase 3 
clinical trials for non-small cell lung cancer (Figure 2.2).62,63  
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Figure 2.2 Therapeutic agents containing the 2,5-DKP framework. 
In addition to this, peptidomimetics containing 2,5-DKPs have been used to construct 
conformational mimics of linear peptides. For example, 2,5-DKP 101, containing a 
carboxylic acid and amino functionality in a cis-relationship, has been used to prepare 
peptide sequences that result in the formation of β-hairpin mimic 101 containing 10- and 
18-membered H-bonded rings (Scheme 2.2).64  
 
Scheme 2.2 Bifunctional 2,5-DKP 101 acting as a β-hairpin inducer.64  
 
2.2.2 Spirocycles in Drug Discovery 
Spiro compounds (spirocycles) are molecules containing two rings linked together by the 
same atom, referred to as the spiroatom. Recent progress towards the synthesis of 
spirocyclic systems has seen a significant increase in the incorporation of spirocycles into 
pharmaceutically active molecules. Properties of spirocycles that make them of benefit in 
medicinal chemistry projects include their inherent rigidity, ability to place functional 
groups precisely in three-dimensional space, and structural novelty for 
patentability.31,51,52  
Recent examples of spirocyclic compounds in drug development projects include 
Zoliflodacin (ETX0914) 103,65 a novel oral antibiotic currently in clinical trials for the 
treatment of gonorrhoea, and AMG-8718 104, a BACE1 (β-site APP cleaving enzyme) 
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inhibitor which is a potential target for the development of an Alzheimer’s disease 
therapy.66 Irbesartan 105, which is widely used to treat high blood pressure, is an example 
of a marketed drug containing a spirocyclic moiety (Figure 2.3).51,67   
 
Figure 2.3 Therapeutic agents containing spirocyclic scaffolds. 
More recently, as part of an ongoing interest in four-membered rings and the need to 
access novel structures, there has been a significant increase in the number of oxetane- 
and azetidine-containing spirocycles in drug discovery programmes (Figure 2.4).31,52 
Examples include spiro-oxetane 106 as a potential anti-hepatitis C virus (HCV) agent,68 
spiro-oxetane 107 a potent inhibitor of respiratory syncytial virus (RSV) RNA 
polymerase,69 and spiro-oxetane-azetidine 108 a clinical candidate for weight loss.70  
 
Figure 2.4 Spirocyclic compounds incorporating oxetane and azetidine rings. a TP = triphosphate  
It is worth noting that it is often difficult to determine whether a spirocycle has been 
introduced to improve the pharmaceutical properties of a compound or to create novel 
scaffolds that do not impede on existing intellectual property space.52 
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2.3 Results and Discussion 
2.3.1 Optimisation of Reduction and Cyclisation Conditions 
The first task was to make suitable substrates to optimise the reduction-cyclisation 
sequence presented in Scheme 2.1. Methyl ester (S)-109, benzyl ester 110 and tert-butyl 
ester 111, all possessing the same valine backbone substitution, were selected as test 
substrates and were prepared following a previously described literature procedure 
(Scheme 2.3).1 Conjugate addition of the appropriate valine ester (2.0 equiv) to 3-
(nitromethylene)oxetane 30 (1.0 equiv), which was prepared in situ from oxetane-3-one 
29 (1.0 equiv) and nitromethane (1.4 equiv), gave the desired oxetane-modified DKP 
precursors.   
 
 
Scheme 2.3 Synthesis of test substrates. a Method: MeNO2 (1.4 equiv), oxetan-3-one (1.0 equiv), 
NEt3 (0.2 equiv); NEt3 (2.0 equiv), MsCl (1.0 equiv); amino ester hydrochloride (2.0 equiv), NEt3 
(2.0 equiv). 
With these test-substrates in hand, a variety of conditions for the controlled reduction of 
the nitro group in methyl ester (S)-109 were explored (Table 3.1, entries 1-6). In each 
case, the DKP analogue 112 was isolated as a result of spontaneous cyclisation of the 
reduced primary amine. Reduction using zinc71,72 and indium73 under acidic conditions 
gave 112 in poor yields. Catalytic hydrogenation using Pd/C gave 112 in a slightly 
improved yield of 50%, whereas Pt/C gave a lower yield of 21%. The use of Raney Ni 
under an atmosphere of hydrogen proved to be most effective. Under these conditions, 
which were adapted from chemistry previously reported by Carreira and co-workers (see 
Scheme 1.5),46 112 was isolated in 81% yield after chromatography. Following this result, 
the impact of the C-terminal ester group on the cyclisation was investigated (Table 3.1, 
entries 7-8). When benzyl ester 110 was subjected to the optimised conditions, 112 was 
isolated in a significantly lower yield. The tert-butyl group of 111 prevented cyclisation 
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after reduction of the nitro group and only the corresponding primary amine was observed 
in the crude product. 
 
Entry Substrate R Conditionsa Yield (%)b 
1 (S)-109 Me Zn, AcOH, THF71 22 
2 (S)-109 Me Zn, aq. NH4Cl, EtOH72, c 26 
3 (S)-109 Me In, HCl, THF/H2O (1:3)73 25 
4 (S)-109 Me 10% Pd/C, H2, MeOH 50 
5 (S)-109 Me 10% Pt/C, H2, MeOH 23 
6 (S)-109 Me Raney Ni, H2, MeOH 81 
7 110 Bn Raney Ni, H2, MeOH 17 
8 111 tBu Raney Ni, H2, MeOH 0d 
Table 2.1 Optimisation of cyclisation conditions to 112. a Conducted at room temperature unless 
otherwise stated. b Isolated yield after chromatography. c Reduction at 30 °C, then heated at reflux 
for 24 h. d Major product was the primary amine from reduction of nitro group without concomitant 
cyclisation.  
 
2.3.2 Synthesis of Oxetane-Modified Diketopiperazine Precursors 
With conditions for the reduction-cyclisation optimised, we next wanted to explore the 
substrate scope of this chemistry. We began by preparing a set of oxetane-modified DKP 
precursors. Using the previously described conditions, conjugate addition of 
commercially available α-amino methyl esters (2.0 equiv) to nitroalkene 30 (1.0 equiv) 
gave access to a variety of oxetane-modified DKP precursors (Scheme 2.4). Whilst this 
methodology is based on earlier publications by us1 and by Carreira,46 it should be noted 
that all the examples contained within Scheme 2.4, with the exception of 109 and 115, 
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are novel. The new examples include those involving non-polar (Gly 113, Ala 114), 
aromatic (Phe 116), acidic (Asp 117) and basic (Lys 118) residues. In addition to this, 
secondary amines (Pro 119) and non-proteinogenic (phenyl glycine 120) examples have 
been demonstrated in the conjugate addition step for the first time.  
 
 
Scheme 2.4 Synthesis of oxetane-modified DKP precursors. a Method: MeNO2 (1.4 equiv), oxetan-3-
one (1.0 equiv), NEt3 (0.2 equiv); NEt3 (2.0 equiv), MsCl (1.0 equiv); amino methyl ester 
hydrochloride (2.0 equiv), NEt3 (2.0 equiv). b Isolated as an inseparable mixture with the nitro-aldol 
intermediate. c Isolated as an inseparable mixture with nitroalkene 30.  
Although addition of L-tryptophan methyl ester to nitroalkene 30 was successful, the 
product 121 co-eluted with the nitro-aldol intermediate and attempts to purify the material 
by chromatography were unsuccessful (Scheme 2.4). When sarcosine methyl ester was 
used, some conversion to product 122 was observed. However, attempts to purify the 
material by chromatography resulted in retro-aza-Michael reaction and gave the product 
as an inseparable mixture with nitroalkene 30. Achiral quaternary α-aminoisobutyric acid 
(Aib) methyl ester only gave traces of product 123 when used in the conjugate addition. 
As the Aib residue is sterically hindered, it is possible that the rate of addition to 
nitroalkene 30 is significantly reduced and instead rearrangement to isoxazole 124 is 
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favoured, although only traces of 124 were observed in the 1H-NMR spectrum of the 
crude reaction mixture. This rearrangement is known to be promoted by secondary and 
tertiary amines, and has been used to prepare a series of substituted isoxazoles from 
oxetane-substituted nitroalkenes (Scheme 2.5).74 
 
Scheme 2.5 Proposed mechanism for the rearrangement of oxetane-substituted nitroalkenes to 
isoxazoles.74  
Next, we examined the preparation of oxetane-modified DKP precursors with variation 
at the α-carbon of the nitroalkane. This had previously been studied by Dr Nicola Powell 
in the group by conjugate addition of amino esters to trisubstituted nitroalkenes.1 On this 
basis, we first prepared trisubstituted nitroalkenes 31 and 128 following modified 
procedures previously reported by Carreira74 and Ellman,75 respectively. (Scheme 2.6). 
Henry reaction using either 2-phenylnitroethane 126 or nitroethane with oxetan-3-one, 
followed by elimination with methanesulfonyl chloride, gave nitroalkenes 31 and 128 in 
good isolated yields. As nitroalkane 126 was not commercially available, it was first 
prepared by reduction of trans-β-nitrostyrene following a literature method.76  
(a) 
 
(b) 
 
Scheme 2.6. Synthesis of trisubstituted nitroalkenes 31 and 128. 
Having obtained nitroalkenes 31 and 128, the conjugate addition of α-amino methyl esters 
was studied (Scheme 2.7). Initially, conjugate addition of glycine methyl ester was 
investigated to avoid the complication of diastereoisomers. Glycine methyl ester was first 
prepared from the corresponding hydrochloride salt following a literature procedure and 
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used immediately in the addition step due to its tendency to polymerise.77 Using this route, 
methyl esters 91 and 131 were prepared in excellent yields from nitroalkenes 31 and 128 
respectively. We next investigated the conjugate addition of L-valine methyl ester to 
trisubstituted nitroalkenes. L-Valine methyl ester was first prepared from the 
corresponding hydrochloride salt and then added to 128 to give methyl ester 132 in 
excellent yield. The inherent chirality of L-valine had no influence on the resulting 
stereochemistry, providing 132 as a 50:50 mixture of diastereoisomers that could not be 
separated by column chromatography. A more detailed discussion on the conjugate 
addition of chiral amine nucleophiles to trisubstituted nitroalkenes is included in Chapter 
4.  
 
 
Scheme 2.7. Synthesis of oxetane-modified precursors. a Prepared from the corresponding 
hydrochloride salt and used immediately.77 b Method: Nitroalkene (1.0 equiv), amino methyl ester 
(2.0 equiv). c Formed and isolated as a 50:50 mixture of diastereoisomers determined by 1H-NMR 
analysis (see Section 6.7). 
 
2.3.3 Synthesis of Oxetane-Containing Spirocycles 
With a variety of oxetane-modified DKP precursors in hand the scope of the optimised 
reduction-cyclisation conditions was explored. Using Raney Ni under an atmosphere of 
hydrogen, a variety of 2,5-DKP analogues bearing different side chains and substitution 
patterns were produced in good yields (Scheme 2.8). All of the substrates used were 
tolerant of the reaction conditions. Both enantiomers of 112 were made, and we were able 
to confirm by 1H-NMR analysis in the presence of Pirkle’s reagent that no detectable 
racemisation occurs during the reduction-cyclisation sequence (Section 6.4). 
Disubstituted derivatives such as 142 can be produced in high yield as a mixture of 
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diastereoisomers. Unfortunately, attempts to separate the diastereoisomers using column 
chromatography were unsuccessful and 142 was isolated as a 50:50 mixture.  
 
 
Scheme 2.8 Synthesis of oxetane containing spirocycles. a >95% ee as determined by 700 MHz 1H-
NMR analysis in the presence of Pirkle’s reagent (see Section 6.4). b Obtained as a 50:50 mixture of 
diastereoisomers determined by 1H-NMR analysis (see Section 6.7). 
 
2.3.4 Synthesis of Azetidine-Containing Spirocycles  
Having successfully developed conditions for the reduction-cyclisation chemistry and 
synthesised a library of novel oxetane-containing DKP analogues, we were interested to 
know if the scope of the chemistry could be expanded to prepare novel spirocycles 
containing other four-membered rings such as azetidines or cyclobutanes.  
We began by investigating whether azetidine-modified DKP precursors could be 
synthesised. We proposed that azetidine-containing nitroalkene 144 could be prepared 
using commercially available N-Boc-azetidin-3-one 143 and nitromethane using the same 
conditions as for the oxetane chemistry. Starting from 143, Henry reaction with 
nitromethane followed by elimination with methanesulfonyl chloride generated 
HN
NH
O
O
O2N
H
N
O
CO2Me
R2
Raney Ni, H2,
MeOH, rt, 16 h
R2R
1
R1
HN
NH
O
O
(S)-112, 81%a
(R)-112, 78%
HN
NH
O
O
133, 87%
HN
NH
O
O
134, 80%
Me
HN
NH
O
O
138, 61%
NHBoc
HN
NH
O
O
136, 80%
Ph
HN
NH
O
O
135, 71%
OH
HN
N
O
O
139, 68%
H
HN
NH
O
O
140, 85%
Ph
HN
NH
O
O
137, 69%
CO2tBu
HN
NH
O
O
141, 81%
Me
HN
NH
O
O
93, 74%
HN
NH
O
O
142, 74%
(dr 50:50)b
Me
Ph
*
 47 
nitroalkene 144 in situ. In this case, nitromethane was used as a solvent in the nitro-aldol 
step as N-Boc-azetidin-3-one 143 is a solid. Following this, conjugate addition of glycine 
and L-valine methyl ester gave the desired azetidine-modified DKP precursors 145 and 
146 (Scheme 2.9). To our knowledge, these are the first examples of the conjugate 
addition of amine nucleophiles to azetidine-substituted nitroalkenes.  
 
Scheme 2.9 Synthesis of azetidine-modified DKP precursors. a Method: MeNO2 (1.0 M), N-Boc-
azetidin-3-one (1.0 equiv), NEt3 (0.2 equiv); NEt3 (2.0 equiv), MsCl (1.0 equiv); amino methyl ester 
hydrochloride (2.0 equiv), NEt3 (2.0 equiv). 
With azetidine-modified DKP precursors in hand, the reduction-cyclisation to azetidine-
containing DKP analogues was attempted. When 145 and 146 were treated with Raney 
Ni under an atmosphere of hydrogen the corresponding DKP analogues 147 and 149 were 
produced in good yields (Scheme 2.10).  
 
Scheme 2.10 Synthesis of azetidine-containing spirocycles. 
Following the successful synthesis of azetidine-containing DKP analogues, we turned our 
attention to whether the synthesis of cyclobutane-containing analogues was possible. 
Again, we proposed that cyclobutane-containing nitroalkene 150 could be prepared from 
cyclobutanone 149. Addition of an α-amino methyl ester would then provide the desired 
cyclobutane-modified DKP precursor. Unfortunately, attempts to access the cyclobutane 
precursor 141 using our standard reaction conditions were unsuccessful (Scheme 2.11).  
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Scheme 2.11 Attempted synthesis of cyclobutane-modified DKP precursor 151. a Method: MeNO2 
(1.4 equiv), cyclobutane (1.0 equiv), NEt3 (0.2 equiv); NEt3 (2.0 equiv), MsCl (1.0 equiv); H-Gly-OMe
･HCl (2.0 equiv), NEt3 (2.0 equiv). 
The reaction was analysed in more detail to determine why the synthesis had been 
unsuccessful. 1H-NMR analysis of the initial nitro-aldol reaction between cyclobutanone 
149 and nitromethane showed that no reaction had taken place (Scheme 2.12).  
 
Scheme 2.12 Attempted nitro-aldol reaction between cyclobutanone 149 and nitromethane.  
A literature search for nitro-aldol reactions involving cyclobutanone 149 gave limited 
results but suggested that a stronger base than triethylamine may be required for this 
reaction to proceed. For example, Stoermer and co-workers have previously prepared 152 
in 45% yield from cyclobutanone 149 and nitromethane using sodium ethoxide as the 
base.78 In addition to this, Jørgensen and co-workers have prepared trisubstituted-
nitroalkene 155 from cyclobutanone 149 and nitroethane using Verkade’s base 153 
(conjugate acid, pKa [MeCN] = 33.63)79 and magnesium sulfate in the nitro-aldol step 
(Scheme 2.13).80 At this stage, further attempts to prepare cyclobutane-containing DKP 
precursors were abandoned as any synthetic route appeared difficult and low yielding. 
 
Scheme 2.13 Jørgensen’s synthesis of nitroalkene 155 using Verkade’s base 153.80 
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2.3.5 X-Ray Crystal Structures of Oxetane-Containing Spirocycles 
Crystals of (S)-112 and 93 were grown and their structures confirmed by X-ray 
crystallography (Figure 2.5).† In the solid-state, both oxetane-containing spirocycles 
adopt an envelope-type structure with the spiroatom projecting out of the ring and the 
neighbouring nitrogen sp3-hybridised. Unfortunately, crystal structures of the parent 2,5-
DKP systems were not available for direct comparisons between the conformations. 
However, it is known that 2,5-DKPs typically adopt planar or puckered boat 
conformations in the solid-state (Figure 2.5).53  
 
 
 
Figure 2.5 X-ray crystal structures of oxetane-containing spirocycles (S)-112 and 93 with thermal 
ellipsoids drawn at 50% probability level and typical confirmations of 2,5-DKPs.53 
 
 
 
 
                                                
† Crystals of 93 were grown by Dr Nicola Powell. 
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2.3.6 Further Modifications of Oxetane-Containing Spirocycles  
With a simple and efficient route to oxetane- and azetidine-containing spirocycles 
developed, we next explored the synthetic value of these novel spirocyclic scaffolds by 
investigating what additional modifications could be made to them.  
Our initial investigations focused on whether selective alkylation of the amine and amide 
nitrogens was possible. The differences in the nucleophilicity and basicity of these 
nitrogens should allow us to selectively alkylate one centre over the other. Selective 
amine benzylation was achieved when oxetane-analogue 134 was treated with benzyl 
bromide in the presence of sodium iodide in acetonitrile at reflux, providing benzyl amine 
156 in good yield (Scheme 2.14). Following this, selective amide benzylation of 134 was 
realised. Deprotonation of the amide with sodium hydride in DMF followed by addition 
of benzyl bromide gave benzyl amide 157 in good yield (Scheme 2.14).  
 
Scheme 2.14 Selective benzylation of the amine and amide nitrogens in spirocycle 134. 
Next, we turned our attention to the reduction of the amide carbonyl to furnish the 
corresponding piperazine framework as substituted piperazines are valuable structural 
motifs in biologically active compounds.81 Recently, Bode and co-workers have 
developed routes to spirocyclic-piperazines using stannyl amine protocol (SnAP) 
reagents (Scheme 2.15).82 However, SnAP reagents are expensive and potentially toxic, 
therefore additional routes to these structures would be of benefit. 
 
Scheme 2.15 Bode and co-workers’ synthesis of spirocycle 160 from oxetan-3-one 29 and SnAP reagent 
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knowledge in hand, we attempted the reduction of oxetane-containing DKP analogues 
(S)-112 and 134 to the corresponding piperazine 161 and 162, respectively (Scheme 
2.16). Unfortunately, when lithium aluminium hydride was used for the reduction 
significant opening of the oxetane ring was observed in addition to reduction of the amide 
carbonyl. This observation was confirmed by 1H-NMR and ESI-MS (163, m/z = 173 
[M+H]+; 164, m/z = 145 [M+H]+) analysis of the crude reaction mixtures. Attempts using 
alternative reducing agents, such as borane tetrahydrofuran complex, also resulted in 
opening of the oxetane ring.  
 
Scheme 2.16 Reduction of oxetane-containing DKP analogues with LiAlH4 or BH3･THF. 
As direct reduction of the amide carbonyl to the corresponding piperazine appeared 
problematic we explored alternative routes. We decided to investigate a two-step 
sequence that involved converting the amide to the corresponding thioamide which could 
then be reduced under milder conditions to give the desired piperazine. This route 
therefore might prevent opening of the oxetane ring and would also provide novel 
sprirocyclic-thioamides that could also be of interest to medicinal chemistry. 
Using Lawesson’s reagent, we were first able to convert the amide of 156 to the 
corresponding thioamide 165 which was isolated in good yield. Following this, reductive 
desulfurisation of thioamide 165 using Raney Ni gave piperazine 166 in good yield with 
the oxetane ring still intact (Scheme 2.17).  
 
Scheme 2.17 Synthesis of piperazine 166 via synthesis and reduction of thioamide 165. 
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2.4 Conclusions 
In conclusion, this chapter describes the development of a simple and efficient synthesis 
of novel oxetane- and azetidine-containing spirocycles related to the 2,5-diketopiperazine 
framework. Conjugate addition of α-amino methyl esters to nitroalkenes prepared from 
oxetan-3-one or N-Boc-azetidin-3-one provides the spirocyclic precursors. Subsequent 
reduction of the nitro group with Raney Ni under an atmosphere of hydrogen gives, after 
spontaneous cyclisation, the spirocycles in good overall yield (Scheme 2.18). 
 
Scheme 2.18 Synthesis of oxetane- and azetidine-containing spirocycles. 
Further manipulations of compound 134 have demonstrated the utility of these novel 
scaffolds. Selective alkylation of the amide and amine nitrogens has been shown along 
with reduction of the amide carbonyl to the corresponding piperazine (Scheme 2.19). 
Thus, these building blocks may have potential for library generation in medicinal 
chemistry.  
 
Scheme 2.19 Illustrative manipulations of oxetane spirocycles. 
Currently, the known limitations to this work include: (i) acyclic secondary and 
quaternary amino esters are not compatible with the conjugate addition chemistry; (ii) 
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bias providing the addition product as a mixture of diastereoisomers; (iii) the approach is 
not readily extendable to the synthesis of cyclobutane-containing spirocycles as there is 
no reaction between nitromethane and cyclobutanone using our standard reaction 
conditions.  
The work discussed in this chapter was published in Synlett in 2016.83 
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Chapter 3: Solid-Phase Synthesis of Oxetane-Modified 
Peptides 
3.1 Project Aims 
To date, oxetane-modified peptides (OMPs) have been prepared using solution-based 
methods.1,46,47 However, in order to study the impact of oxetane-modification on the 
properties and structures of larger peptides of biological interest, more practical and 
general methods for the synthesis of OMPs were required. Solid-phase peptide synthesis 
(SPPS) seemed an ideal route to OMPs as SPPS is largely automated and the products 
can be readily purified.84 
Thus, we set ourselves the goal of developing general methodology to introduce oxetane-
modification into larger peptides using SPPS techniques. This work was done in 
collaboration with Dr Andrew Jamieson of the University of Leicester, and since 2016, 
the University of Glasgow.  
 
3.2 Introduction 
3.2.1 Solid-Phase Peptide Synthesis 
The preparation of peptides using solid support techniques was first reported by 
Merrifield in 1963.85  This work revolutionised peptide synthesis and earned Merrifield 
the Nobel Prize for Chemistry in 1986.86 Since then, SPPS has become the standard 
technique for the preparation of peptides.  
The main principle of SPPS involves the stepwise coupling of the C-terminal carboxylic 
acid of an amino acid with the N-terminal amine of a growing peptide chain covalently 
bound to an insoluble polymer support, also referred to as the resin. After each coupling 
or deprotection step, the unreacted reagents and by-products can be easily removed by 
filtration leaving behind the resin bound peptide chain. Once the desired peptide sequence 
has been prepared, the peptide is cleaved from the resin and purified typically by reverse-
phase HPLC (Scheme 3.1).2 A major advantage of SPPS is that peptides of various length 
and complexity can be rapidly prepared, without the need to perform time-consuming 
isolation and purification procedures of the intermediates, as would be necessary for 
solution-phase synthesis.87 
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Scheme 3.1 Generalised depiction of solid-phase peptide synthesis.  
Resins used in SPPS consist of polymeric beads functionalised with reactive linker 
groups, such as an amine or alcohol, which can be used to covalently attach the C-
terminus of the peptide (Figure 3.1). The linker group also dictates the functionality of 
the C-terminus of the peptide once it is cleaved from the resin. Conditions required for 
cleavage of the peptide from the resin depend on the nature of the resin used.87   
 
Figure 3.1 Examples of resins used for SPPS. 
High yields are required in each coupling step to produce the peptide sequence in good 
overall yield and to minimise the formation of difficult to separate peptides with one or 
more deleted residues. Typically, this is achieved by using a large excess of the incoming 
N-terminal protected amino acid along with highly efficient coupling reagents that have 
been optimised to minimise racemisation and other side reactions.87 There are many 
different examples of coupling reagents that are widely used in SPPS. Uronium-based 
coupling reagents, such as HATU, HBTU and HCTU, are particularly suited for SPPS, 
as they are exceptionally stable in solutions of DMF (Figure 3.2).88 
 n chain 
elongation
cycles
PgHN CO2H
R
+ X
resin
loading
PgHN
R
O
X deprotection H2N
R
O
X
N
H
R
O
XPgHN CO2H
R
coupling
O
PgHN
R
N
H
R
O
X
OH
N
RO
PgHN
R
n
N
H
R
O
X
OH
N
RO
H2N
R
n
1. resin clevage
2. purification Pg = protection groupR = amino acid side chains
X = OH or NH2
n = 0, 1, 2, 3, etc.
= resin
Cl
Cl
chlorotrityl resin
O
HO
Wang resin
H
N
O
O
OMe
OMe
NH2
Rink amide resin
= polymer support
 56 
 
Figure 3.2 Uronium-based peptide coupling reagents used in SPPS. 
As with solution-phase synthesis, SPPS requires protection of amino acid side-chains that 
contain potentially reactive functional groups to avoid unwanted reactions during the 
synthesis. The protecting groups used must be stable to the conditions required for the 
removal of the N-terminal protecting group. A common protecting group strategy used in 
SPPS is the Fmoc/tBu approach. The N-terminal Fmoc protecting group is removed using 
mild conditions, typically 20-50% piperidine in DMF, which does not disturb the acid 
labile linker or side-chain protecting groups. A major advantage with the Fmoc strategy 
is that the fulvene-piperidine group 167 generated during the deprotection is highly UV 
active, allowing the progress of the reaction to be monitored by UV spectroscopy 
(Scheme 3.2). On completion of the peptide sequence, the Boc/tBu side-chain protecting 
groups are removed concomitantly with cleavage of the peptide from the resin using high 
concentrations of TFA in the presence of cation scavengers.89 
 
Scheme 3.2 Mechanism of Fmoc deprotection with piperidine. 
Recently, microwave-assisted peptide synthesis has become a popular tool for the 
synthesis of both routine and difficult peptide sequences. Microwave energy allows the 
majority of amino acid couplings to be completed within 5 min and for Fmoc deprotection 
steps to be complete within 3 min. This significantly reduces the overall synthesis time 
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of the peptides produced. In addition, microwave-assisted peptide synthesis generally 
gives higher crude yields and purities of the peptides produced.90 
 
3.2.2 Solid-Phase Synthesis of Peptidomimetics 
There are numerous examples of solid-phase peptide synthesis (SPPS) strategies that have 
been used to prepare analogues of biologically or structurally interesting peptides that 
contain a peptidomimetic modification.91–95 Some relevant examples are summarised 
below.    
Lubell and co-workers reported a general protocol for the synthesis of azapeptides on the 
solid-phase by introducing the aza-modified residue as an aza-containing dipeptide.13 
Aza-containing dipeptides 171 were first prepared in solution by reaction of N-Boc-N’-
alkyl hydrazines 169 with isocyanates 168 derived from α-amino acids (Scheme 3.3-A). 
These building blocks were then incorporated on the solid-phase using a Boc/Bn 
protection strategy on an oxime resin (Scheme 3.3-B). This approach was used to prepare 
aza-modified analogues, up to 11 residues in length, of the C-terminal peptide fragment 
of the human calcitonin gene-related peptide (hCGRP).13 
 
Scheme 3.3 Solid-phase synthesis of azapeptides. (a) Synthesis of aza-dipeptides. (b) Application of 
aza-dipeptides in solid-phase peptide synthesis.13 
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Cai and co-workers, reported an efficient synthesis of oligomers of 𝛾-substituted-N-
acylated-N-aminoethyl amino acids (𝛾-AApeptides) using SPPS techniques.96 The 
method makes use of common  N-alloc 𝛾-AApeptide building blocks 172 that are 
prepared in solution using the chemistry described in Route 1 or Route 2 (Scheme 3.4-a). 
These building blocks are then integrated onto the solid-phase. The key step of this work 
involves the removal of the alloc-protecting group on the solid phase, using Pd(PPh3)4 
and borane dimethylamine complex, to reveal the secondary amine. Following this, a 
variety of carboxylic acids and acyl chlorides were used to acylate the backbone nitrogen 
of the 𝛾-AApeptides (Scheme 3.4-b). This methodology was used to prepare a diverse 
library of 𝛾-AApeptide sequences and their application as peptidomimetics is currently 
being explored.96 
 
Scheme 3.4 Synthesis of 𝛾-AApeptides. (a) Synthesis of N-alloc 𝛾-AApeptide building blocks. (b) Solid-
phase synthesis of 𝛾-AApeptide sequences.96  
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3.3 Results and Discussion 
3.3.1 SPPS Route to Oxetane-Modified Peptides 
Our approach to introduce oxetane-modification into larger peptides by use of SPPS was 
to prepare oxetane-containing Fmoc-protected dipeptides such as 173 in solution and then 
integrate them into a growing peptide chain using conventional Fmoc/tBu SPPS 
techniques (Scheme 3.5). Initially, we focused our attention on the preparation of Fmoc-
protected dipeptide building blocks in which the oxetane residue is based on glycine. 
Efforts towards Fmoc-protected dipeptide building blocks in which the oxetane residue 
is based on other amino acid residues is discussed in Chapter 4. 
 
Scheme 3.5 Proposed SPPS route to oxetane-modified peptides. 
 
3.3.2 Initial Synthesis of an Oxetane-Containing Dipeptide Building Block 
Our initial route to oxetane-containing dipeptide building block 175 is detailed below 
(Scheme 3.6). Previously described nitroalkane 34 was prepared by conjugate addition of 
L-phenylalanine benzyl ester (2.0 equiv) to nitroalkene 30 (1.0 equiv).1 Reduction of the 
nitro group with Raney Ni in the presence of Fmoc N-hydroxysuccinimide ester 
(FmocOSu, 1.2 equiv) provided the N- and C-terminal protected dipeptide 174. This 
approach builds upon chemistry previously reported by Carreira and co-workers (see 
Scheme 1.5).46 Following this, deprotection of the C-terminal ester was examined. 
Hydrogenation of the benzyl ester appeared to proceed to full conversion. However, poor 
solubility of the product 175 in methanol made separation from the palladium catalyst 
difficult. In order to isolate the product, the reaction mixture was diluted with EtOAc and 
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heated to 60 °C. The mixture was then filtered through a plug of Celite® and the eluent 
concentrated under reduced pressure to give the desired building block 175 in 50% 
isolated yield.  
 
Scheme 3.6 Initial synthesis of Fmoc-GOx-Phe-OH 175. 
 
3.3.3 Initial Solid-Phase Synthesis of an Oxetane-Modified Peptide 
With an oxetane-containing dipeptide building block in hand, we examined its application 
in solid-phase peptide synthesis (SPPS). This portion of work was carried out in the 
laboratories of Dr Andrew Jamieson at the University of Leicester, where the author spent 
two weeks developing the skills to conduct SPPS. 
Using building block 175, we set out to prepare a simple oxetane-containing tetrapeptide 
176 on a CEM microwave peptide synthesiser on a 0.1 mmol scale using Rink amide 
resin (Scheme 3.7). Rink amide resin was first preloaded with Fmoc-alanine using 
standard coupling conditions [HCTU, DIPEA, DMF], followed by Fmoc removal [20% 
piperidine/DMF]. Oxetane-containing building block 175 was then coupled in a similar 
fashion using HCTU activation. Standard conditions for Fmoc removal [20% 
piperidine/DMF] and coupling [Fmoc-Ala-OH, HCTU, DIPEA, DMF] gave the resin-
bound tetrapeptide. Finally, N-terminal acetylation [Ac2O, DIPEA, DMF] and resin 
cleavage [TFA/TIS/H2O, 95:2.5:2.5, v/v/v] gave crude tetrapeptide 176. After reverse-
phase HPLC purification, oxetane-modified tetrapeptide 176 was isolated in high purity 
as confirmed by HPLC, HRMS and 1H-NMR. For full details, see Section 6.6. 
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Scheme 3.7 Solid-phase synthesis of 176. a By reverse-phase HPLC (at 214 nm). b GOx = oxetane-
modified glycine. 
LC-MS analysis of the crude material also showed the presence of a small amount of 
impurity with a molecular mass of 18 Da more than the tetrapeptide. This observation 
suggests that opening of the oxetane ring with water to give diol 177 is happening during 
the synthesis, possibly when the peptide is cleaved from the resin using high 
concentrations of TFA in the presence of water (Scheme 3.8). Unfortunately, we were not 
able to isolate this material to confirm whether opening of the oxetane ring had occurred.   
 
Scheme 3.8 Possible ring-opening of 176 to give diol 177. 
 
3.3.4 Synthesis of Oxetane-Containing Dipeptide Building Blocks 
Encouraged by these preliminary results, we set out to optimise the synthesis of oxetane-
containing dipeptide building blocks and further explore their use in SPPS.  
As previously discussed, hydrogenolysis of benzyl ester 174 appeared to proceed to full 
conversion but poor solubility of the corresponding carboxylic acid 175 made isolation 
difficult. Following this observation, we investigated alternative solvents in the 
hydrogenolysis reaction. A small solvent screen gave no improvement in the isolated 
yield of acid 175 (Table 3.1, entries 1-4). When EtOAc or THF was used the reaction 
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appeared to proceed quantitatively by TLC and ESI-MS analysis, however, problems with 
solubility made isolation of 175 difficult. When DMF was used as reaction solvent, the 
product 175 was soluble. However, an EtOAc/brine work-up was required to remove the 
DMF which resulted in a poor isolated yield of 175.  
 
Entry Solvent Yield (%) Comments 
1 MeOH 50a Product insoluble in reaction solvent 
2 EtOAc - Product insoluble in reaction solvent 
3 THF - Product insoluble in reaction solvent 
4 DMF 42b  
Table 3.1 Solvent screen for the hydrogenation of 174. a Isolated yield after hot filtration with EtOAc 
through Celite®. b Isolated yield after DMF removed with an EtOAc and brine work-up.  
As poor solubility of carboxylic acid 175 was making isolation difficult, we were 
interested to see if building blocks containing alternative amino acid residues could be 
prepared using this route. We began by preparing dipeptide building blocks containing a 
glycine and valine residue. Using the same route as before, benzyl protected building 
blocks 179 and 180 were readily prepared from the corresponding α-amino benzyl esters 
(Scheme 3.9).  
 
Scheme 3.9 Synthesis of benzyl ester building blocks 179 and 180. 
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With the building blocks in hand, removal of the benzyl group was explored (Scheme 
3.10). When 179 and 180 were subjected to catalytic hydrogenation conditions complete 
consumption of the starting material was observed. However, no desired product was 
isolated after work-up. 1H-NMR analysis of the crude material showed the presence of 9-
methyl-9H-fluorene 183 and the corresponding unprotected oxetane-containing dipeptide 
184 and 185. This observation indicated that the Fmoc group of the building blocks was 
susceptible to cleavage under the hydrogenolysis conditions. Similar observations for the 
cleavage of Fmoc groups under hydrogenation conditions have previously been reported 
in the literature.97 We propose that the success observed for 175 was a result of its poor 
solubility. During hydrogenolysis, the product 175 rapidly precipitates preventing further 
Fmoc cleavage. At this point, routes involving benzyl esters for the synthesis of oxetane-
containing dipeptide building blocks were abandoned.  
 
Scheme 3.10 N-Fmoc cleavage during hydrogenolysis of benzyl esters 179 and 180. 
We next explored other C-terminal protecting groups for the synthesis of oxetane-
containing building blocks. We began with methyl esters which are typically removed by 
hydrolysis with LiOH or NaOH.98 Starting from previously prepared nitro alkane 116, N-
Fmoc protected methyl ester 186 was synthesised in excellent yield (Scheme 3.11). 
 
Scheme 3.11 Synthesis of oxetane-containing dipeptide building block 186. 
With methyl ester 186 in hand, conditions for the hydrolysis to carboxylic acid 187 were 
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cleavage and no desired product was isolated after work-up. Other conditions that 
reported to leave Fmoc groups intact, such as Me3SnOH99 and NaOH/CaCl2,100 also 
caused Fmoc cleavage which results in poor yields. LiI, which has been used as a mild 
reagent for the cleavage of methyl esters,101 resulted in the formation of unknown 
products and poor mass recovery. As hydrolysis conditions resulted in Fmoc cleavage, 
routes involving methyl esters for the synthesis of oxetane-containing dipeptide building 
blocks were abandoned. 
 
Entry Conditions Yield (%) Comments 
1 LiOH-THF/H2O 0 Fmoc cleavage observed 
2 Me3SnOH, DCE, 80 °C 40a Fmoc cleavage observed 
3 1 M NaOH, 0.8 M CaCl2, iPrOH 20a Fmoc cleavage observed 
4 LiI, EtOAc, reflux 0 Poor mass recovery, unknown products 
Table 3.2 Attempted hydrolysis of methyl ester 186. a Isolated yield after acid-base extraction.  
Following the investigation of C-terminal benzyl and methyl esters, we next explored the 
use of acid labile protecting groups. As our strategy involved using amino acid residues 
containing tBu or Boc protected side chains, which are typically removed using high 
concentrations of TFA,98 we focused our attention on the use of ester protecting groups 
that can be removed under mildly acidic conditions. This led us to investigate 2,4-
dimethoxybenzyl (2,4-DMB)102 and 2-phenyl-2-propyl (cumyl) esters103,104 which are 
typically hydrolysed using 1-4% TFA in CH2Cl2. 
The first step in the preparation of dipeptide building blocks containing C-terminal acid 
labile protecting groups required the synthesis of the 2,4-DMB and cumyl esters. Using 
Steglich esterification conditions, Fmoc-L-phenylalanine was protected as 2,4-DMB ester 
189 using 2,4-dimethoxybenzyl alcohol 188 (Scheme 3.12-a). Following a modified 
procedure,103 cumyl ester 192 was prepared by reaction of Fmoc-Phe-OH with imidate 
191, which was derived from the condensation of 2-phenyl-2-propanol 190 with 
trichloroacetonitrile (Scheme 3.12-b).  
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Scheme 3.12 Synthesis of acid-labile ester protecting groups 189 and 192. a Contaminated with 2-
phenyl-2-propanol 190 (~19:1 by 1H-NMR).  
Next, conjugate addition of 2 equivalents of the amino esters to nitroalkene 30 was 
explored. The Fmoc groups of 189 and 192 were first removed using diethylamine. Upon 
completion, the diethylamine was removed under reduced pressure to give the crude 
amine which was used in the conjugate addition step without further purification. This 
gave the addition products 193 and 194 in good isolated yields. Following this, nitro 
reduction and Fmoc protection furnished the desired oxetane-containing dipeptide 
building blocks 195 and 196 (Scheme 3.13).  
 
Scheme 3.13 Synthesis of oxetane-containing dipeptide building blocks 195 and 196. a Method: MeNO2 
(1.4 equiv), oxetan-3-one (1.0 equiv), NEt3 (0.2 equiv); NEt3 (2.0 equiv), MsCl (1.0 equiv); N-Fmoc 
amino ester (2.0 equiv), 50% Et2NH in CH2Cl2 (0.5 M). 
With acid-labile protected building blocks 195 and 196 in hand, deprotection to 
carboxylic acid 175 was investigated (Table 3.3, entries 1-3). Removal of the 2,4-
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dimethoxybenzyl group in 195 using 1% TFA in CH2Cl2 with anisole as a scavenger gave 
175 along with significant amounts of an insoluble by-product that could not be identified. 
Poor results were also observed when 1% HCl in CH2Cl2 was used. Much better outcomes 
were achieved with the cumyl ester 196. When 196 was treated with 2% TFA in CH2Cl2 
quantitative conversion to 175 was observed after 1.5 h, which was isolated in 61% yield 
after precipitation with Et2O. 
 
Entry Substrate Conditions Yield (%) Comments 
1 195 1% TFA in CH2Cl2, anisole n.d.a Unknown products 
2 195 1% HCl in CH2Cl2 0 Unknown products 
3 196 2% TFA in CH2Cl2 61b  
Table 3.3 Deprotection of acid-labile esters 195 and 196. a Product isolated with significant amounts of 
an insoluble impurity. b Isolated yield after precipitation with Et2O. 
With cumyl ester identified as an optimal C-terminal protecting group in the synthesis of 
oxetane-containing dipeptide building blocks, we next focused our efforts on preparing a 
series of building blocks containing other amino acid residues. 
Following a modified procedure of Potier,103 the C-terminus of commercially available 
Fmoc-amino acids, containing a range of protected side chain types, were protected to 
give the corresponding cumyl esters (Scheme 3.14). Residues containing potentially 
reactive side chains 198-200 were purchased with their functional groups either tBu or 
Boc protected to prevent reaction of the functional groups with imidate 191 and ready for 
SPPS. Cumyl esters 192, 198 and 199 were isolated with traces of 2-phenyl-2-propanol 
190, which was later removed during purification of the conjugate addition products using 
column chromatography (Scheme 3.16). 
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Scheme 3.14 Synthesis of N-Fmoc amino cumyl esters. a Method: 190 (2.2 equiv), NaH (60% 
dispersion in mineral oil, 0.5 equiv); Cl3CCN (2.0 equiv); N-Fmoc amino acid (1.0 equiv). b 
Contaminated with 2-phenyl-2-propanol 190 (~19:1 by 1H-NMR). c Contaminated with 2-phenyl-2-
propanol 190 (~9:1 by 1H-NMR). d Isolated as an inseparable mixture with trichloroacetamide and 2-
phenyl-2-propanol 190. 
Although cumyl protection of Fmoc-L-proline was successful, the desired product 201 
co-eluted with significant amounts of trichloroacetamide and 2-phenyl-2-propanol 190, 
and attempts to purify the material by chromatography were unsuccessful. It proved more 
convenient to remove the Fmoc group of the crude material and purify the product using 
column chromatography to give secondary amine 203 in good overall yield (Scheme 
3.15).  
 
Scheme 3.15 Synthesis of H-Pro-OCumyl 203. 
Following this, the N-Fmoc amino cumyl esters were investigated in the conjugate 
addition step (Scheme 3.16). At this stage, the cumyl esters were considered more 
synthetically valuable than nitroalkene 30. Consequently, the cumyl esters were used as 
the limiting reagent in the addition step along with 2 equivalents of nitroalkene 30, which 
was generated in situ from oxetan-3-one 29 (2.0 equiv) and nitromethane (2.8 equiv). 
Using these conditions, removal of the Fmoc group and addition of the resulting crude 
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amine to nitroalkene 30 gave the addition products in moderate to good yields. Secondary 
amine 203 was used directly in the conjugate addition, to give proline 208 in good yield. 
 
 
Scheme 3.16 Synthesis of nitro amino cumyl esters. a Method: MeNO2 (2.8 equiv), oxetan-3-one (2.0 
equiv), NEt3 (0.4 equiv); NEt3 (4.0 equiv), MsCl (2.0 equiv); N-Fmoc amino cumyl ester (1.0 equiv), 
50% Et2NH in CH2Cl2 (0.5 M). b Made directly from isolated H-Pro-OCumyl 203.  
The penultimate step in the synthesis required reduction of the nitro group and in situ 
Fmoc protection of the resulting amine. Reduction with Raney Ni under an atmosphere 
of hydrogen in the presence of FmocOSu generally gave the N-Fmoc protected cumyl 
esters in good yields (Scheme 3.17). Using this route, seven representative dipeptide 
building blocks with a variety of protected side chains were produced. 
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Scheme 3.17 Synthesis of oxetane-containing dipeptide building blocks. a Method: Nitroalkane (1.0 
equiv), FmocOSu (2.0 equiv), NaHCO3 (4.0 equiv), Raney Ni (slurry in H2O, 1 mL/mmol), H2 (balloon). 
b 52% yield on a larger 2.3 g scale. 
With a variety of N- and C-terminal protected dipeptide building blocks in hand, cleavage 
of the cumyl ester to the carboxylic acid was investigated. The dipeptide building blocks 
were treated with 2% TFA in CH2Cl2 to give the corresponding carboxylic acid (Scheme 
3.18). UPLC-MS analysis of the crude reaction mixtures demonstrated full conversion to 
the carboxylic acids along with a common by-product, assumed to be α-methylstyrene. 
However, not all attempts to purify the crude products were successful. As previously 
discussed, phenylalanine analogue 175 was isolated in 61% yield after precipitation with 
diethyl ether. Valine 182 and tBu-serine 216 analogues were isolated in excellent yields, 
as improved solubility meant that they could be purified using column chromatography. 
Unfortunately, attempts to purify the aspartic acid 217 and lysine 218 analogues using 
column chromatography resulted in decomposition.  
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Scheme 3.18 Cumyl ester deprotection scope. a Isolated yield after precipitation with Et2O. b Isolated 
yield after column chromatography. c Product decomposed during column chromatography. 
Following these observations, it was decided that it was more convenient to store the 
building blocks as the cumyl esters and, after C-terminal deprotection with 2% TFA in 
CH2Cl2, use the crude acids directly on SPPS without purification. Furthermore, the 
majority of the cumyl ester building blocks were easy to handle crystalline solids.  
 
3.3.5 Solution-Phase Chemistry of Oxetane-Containing Building Blocks 
Before examining the use of the dipeptide building-blocks in SPPS, we decided to further 
study their chemistry in solution. We began by investigating couplings of these oxetane-
containing building blocks at the C-terminus. Cleavage of the cumyl ester from 210, using 
2% TFA in CH2Cl2, followed by coupling of the crude acid with L-phenylalanine tert-
butyl ester with HCTU gave (S,S)-219 in excellent yield (Scheme 3.19). Following this, 
the configurational integrity of the C-terminal amino acid residue of the dipeptide 
building block during the coupling was determined by preparing the corresponding 
diastereoisomer (S,R)-219. Using D-phenylalanine tert-butyl ester, the procedure was 
repeated to give (S,R)-219. The diastereotopic purity of (S,S)-219 and (S,R)-219 was 
determined by comparison of the diastereotopic CH3-Val signals in the 1H-NMR spectra 
of the crude reaction mixtures. Spectral analysis confirmed that (S,S)-219 and (S,R)-219 
was of dr >95:5 indicating that no detectable epimerisation arose during these couplings. 
(see Section 6.5).  
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Scheme 3.19 C-Terminal couplings of oxetane-containing dipeptides proceed with no detectable 
epimerisation. a Determined by 1H-NMR analysis of the crude reaction mixture (see Section 6.5). b 
Coupling conditions: H-Phe-OtBu･HCl (2.0 equiv), HCTU (1.0 equiv), DIPEA (4.0 equiv).  
Next, we examined whether the cumyl ester group could selectively be removed in the 
presence of other acid labile protecting groups. Building block 213, containing an acid-
sensitive Boc protected lysine residue, was treated with 2% TFA in CH2Cl2, then coupled 
with L-phenylalanine tert-butyl ester to give tripeptide 220 in excellent yield (Scheme 
3.20). No products resulting from Boc-deprotection and reaction of the resulting amine 
were observed by 1H-NMR or ESI-MS, indicating that the cumyl ester can be selectively 
cleaved with 2% TFA in CH2Cl2 in the presence of other acid labile protecting groups.  
 
Scheme 3.20 Selective cumyl ester deprotection of oxetane-containing dipeptide building block 213. a 
Coupling conditions: H-L-Phe-OtBu･HCl (2.0 equiv), HCTU (1.0 equiv), DIPEA (4.0 equiv).  
We then focused our attention on N-terminal couplings of oxetane-containing building 
blocks. As solid-phase peptide synthesis typically uses N-protected amino acids and 
coupling reagents in large excess to drive reactions to completion,87 there was some 
concern that unwanted acylation of the unprotected 3-aminooxetane unit may take place. 
We investigated N-terminal solution-phase couplings with the building blocks mimicking 
conditions typically used for solid-phase synthesis. The Fmoc group of 196 was removed 
using diethylamine and the resulting crude amine coupled with 4 equivalents of both Boc-
glycine and HCTU (Scheme 3.21). Using these conditions, tripeptide 221 was isolated in 
good yield, and no products resulting from acylation of the 3-aminooxetane unit were 
observed by 1H-NMR or ESI-MS.  
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Scheme 3.21 N-Terminal coupling of oxetane-containing dipeptide building block 196. a Coupling 
conditions: Boc-Gly-OH (4.0 equiv), HCTU (4.0 equiv), DIPEA (8.0 equiv).  
In addition to this, further studies have demonstrated that Boc protection of the nitrogen 
of the 3-aminooxetane unit is not only difficult but also results in opening of the oxetane 
ring. For example, attempts to protect the 3-aminooxetane unit when the N- and C-
terminals were both protected were unsuccessful (Scheme 3.22). It was possible to protect 
this nitrogen when the carboxylic acid was unprotected with the reaction presumably 
proceeding via a mixed anhydride intermediate. However, the resulting Boc protected 3-
aminooxetane unit underwent spontaneous ring expansion to give the corresponding 
oxazolidinone 224, as indicated by ESI-MS analysis (m/z = 469 [M+H]+). Similar ring 
expansions of Boc protected 3-aminooxetanes under acidic conditions have previously 
been reported in the literature.105  
 
Scheme 3.22 Boc protection of the 3-aminooxetane unit undergoes ring expansion to oxazolidinone 224. 
a Experiment carried out by Lauren Chapman.  
Taken together, these findings encouraged us to explore the use of our building blocks on 
the solid-phase without protection of the 3-aminooxetane unit. 
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3.3.6 Solid-Phase Synthesis of Oxetane-Modified Peptides 
With oxetane-containing building blocks in hand and their chemistry established in the 
solution-phase, we set out to examine their use in SPPS. 
During the course of this project our collaborator Dr Andrew Jamieson, and his research 
group, moved from the University of Leicester to the University of Glasgow. This meant 
that it was no longer convenient for the author to examine the use of the building blocks 
in SPPS under the supervision of Dr Andrew Jamieson. Instead, it was decided that the 
building blocks would be delivered to the University of Glasgow and our collaborators 
would explore their use on SPPS. Therefore, the work reported in this section was carried 
out by Dr Andrew Jamieson, Dr Astrid Knuhtsen and Dr Alex Hoose at the University of 
Glasgow. 
Experiments for the preparation of oxetane-modified peptides were conducted on a 
Biotage Initiator + Alsta microwave assisted peptide synthesiser on a 0.1 mmol scale 
using preloaded chlorotrityl resin. Fmoc deprotection was carried out using 20% 
piperidine in DMF + 0.1 M Oxyma Pure at 75 °C.106 Couplings were performed with four 
equivalents of Fmoc-protected amino acids using HCTU activation with DIPEA in DMF 
at 75 °C. Peptide cleavage and concomitant side chain deprotection was performed using 
a cleavage cocktail of TFA/CH2Cl2/TIS (70:20:10, v/v/v). For full details, see Section 
6.6. 
To begin with, six oxetane-modified tetrapeptides 225-230 were prepared using each of 
the building blocks (Table 3.4, entries 1-6).‡ Two equivalents of the oxetane-containing 
building blocks were first deprotected using 2% TFA in CH2Cl2 to give the crude acid 
which was dissolved in DMF and coupled with resin bound alanine using HCTU 
activation. Following this, standard conditions for Fmoc deprotection, coupling of Fmoc-
Trp(Boc)-OH and resin cleavage/deprotection gave the crude tetrapeptides. Purification 
by reverse phase HPLC gave the oxetane-modified tetrapeptides 225-230 in high purity 
and acceptable yields. Lower purities were initially observed for tetrapeptides 227 and 
228 but could be improved to ≥90% after a second purification. No ring opening of the 
oxetane was observed under the harsh acidic conditions required for resin cleavage and 
concomitant side chain deprotection. However, traces of ring opening were observed 
during reverse phase HPLC purification which was performed using solvent systems 
                                                
‡ Building block 215, containing an alanine residue, was later used to prepare an oxetane-modified peptide 
described in Chapter 4. 
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consisting of H2O in MeCN + 0.1% TFA. This problem was overcome by immediately 
combining and freeze-drying fractions containing the desired peptide to avoid prolonged 
exposure to the acidic aqueous solvent.  
 
Entry 
Building 
Blocka 
Peptide sequence Purity (%)d 
Mass, mg 
(yield, %) 
Peptide Content 
(%)e 
1 196 W-GOx-F-A, 225 89 10.7 (21) 75 
2 210 W-GOx-V-A, 226 93 8.4 (18) 55 
3 211 W-GOx-S-A, 227 81 (90)f 12.0 (27) 73 
4 212 W-GOx-D-A, 228 81 (91)f 13.7 (29) 75 
5 213 W-GOx-K-A, 229 93 5.0 (10) 48 
6 214 W-GOx-P-A, 230 94 14.6 (32) 62 
7 196 Y-G-GOx-F-M, 231 91 17.0 (28) 81 
8 196 Y-G-GOx-F-L, 232 91 16.4 (28) 79 
9 196 R-P-P-GOx-F-S-P-F-R, 233 94 25.3 (46) 63 
Table 3.4 Solid-phase synthesis of oxetane-modified peptides. a Treated with 2% TFA in CH2Cl2 for 
2 h to reveal the free carboxylic acid from 196 and 210-214 prior to coupling with the resin-bound 
peptide. b 30 s, then 3 min with fresh reagents. c All couplings preformed at 75 °C for 10 min except 
arginine (60 min at rt, then 5 min at 75 °C, repeated with fresh reagents). d By reverse-phase HPLC 
(at 214 nm). e Determined by UV spectroscopy (at 280 nm) except 233 (at 214 nm). f Improved to 
≥90% by second purification.  
= chlorotrityl resin
(AA)m and (AA)n = peptide sequence of m and n amino acids respectively
GOx = oxetane-modified glycine
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Encouraged by these results, we next examined the use of our building blocks to prepare 
oxetane-modified analogues of biologically important peptides. We began with analogues 
of the endogenous opioid peptides Met- and Leu-enkephalin, in which the central glycine 
was replaced. Using the same conditions as before, pentapeptides 231 and 232 were 
prepared from phenylalanine-containing building block 196 in good yield and high purity 
(Table 3.4, entries 7 and 8).  
Finally, this methodology was further extended to include nonapeptide 233 as an 
analogue of the blood vessel dilator bradykinin, which was produced in good yield and 
excellent purity (Table 3.4, entry 9). No loss in peptide yield and purity was observed 
during the synthesis of the oxetane-modified bradykinin analogue 233 indicating that the 
3-aminooxetane unit tolerates repetitive rounds of coupling and Fmoc deprotection. The 
benefits of our SPPS methodology for the synthesis of oxetane-modified peptides is 
demonstrated by comparison of our synthesis of  Leu-enkephalin analogue 232 with the 
previously reported solution-phase synthesis reported by Carreira and co-workers, that 
required multiple steps and chromatographic purifications (Scheme 3.23).47 
 
Scheme 3.23 Carreira’s solution-phase synthesis of oxetane-modified Leu-enkephalin 232 using dipeptide 
building block 74.47 a Isolated as the TFA salt after reverse-phase HPLC. 
 
3.3.6 Further Synthesis of Oxetane-Containing Dipeptide Building Blocks 
Following the successful development of a methodology for the synthesis of oxetane-
modified peptides using SPPS techniques, the scope of the oxetane-containing dipeptide 
building blocks has been further explored by other members of the group (Scheme 3.24). 
Five additional building blocks have been prepared in generally good overall yield using 
BocHN
O
H
N CO2Bn
Ph
BocHN
O
H
N
Ph
O
N
H
CO2Bn
1. Pd/C, H2
    MeOH, rt
2. H-Leu-OBn•HCl
    HATU, DIPEA
    DMF, 0 °C to rt
234, 80%
1. TFA, CH2Cl2, 0 °C
2. Cbz-Tyr(OBn)-Gly-OH
    HATU, DMF, DIPEA 
    0 °C to rt
N
H
O
H
N
Ph
O
N
H
CO2H
232•TFA,a 24%
OH
N
O
H2N
HO
3. Pd/C, H2, MeOH, rt
74
 76 
the chemistry described in this chapter. A modified route towards methionine-analogue 
236 was used, as reduction of the nitro group in the precursor using Raney Ni under an 
atmosphere of hydrogen resulted in cleavage of the S−C bond. Consequently, this 
analogue was prepared via reduction of the nitro group using Zn-AcOH followed by 
protection of the crude primary amine with FmocOSu to give 236 in 37% yield. The 
application of these building blocks in solution and on the solid-phase is currently being 
further explored by our group. 
 
 
Scheme 3.24 Further examples of oxetane-containing dipeptide building blocks prepared by the 
Shipman group. a Prepared by George Saunders. b Prepared by Leo Tam. c Prepared by Dr Stefan Roesner. 
d Prepared by Dr Ina Wilkening. e Reaction conditions: i) Zn, AcOH; ii) FmocOSu, NaHCO3. 
 
3.3.7 Binding Affinity Studies of Oxetane-Modified Analogues of Met- and Leu-
Enkephalin 
With a practical route to oxetane-modified analogues of biologically interesting peptides 
developed, the impact of oxetane-modification on the biological properties of Met- and 
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of Michigan, the binding affinities of oxetane-modified Met- 231 and Leu-enkephalin 
232 to the δ- and µ-opioid receptors was examined. 
Opioid receptor binding affinities of oxetane-modified Met- 231 and Leu-enkephalin 232 
analogues were determined by displacement of the radioligand [3H]-diprenorphine 241 
from the δ- and µ-opioid receptors. The binding affinities (Ki) of the parent Met- 240 and 
Leu-enkephalin 75 peptides were found to be 1.5 nM and 4.1 nM for the δ-opioid receptor 
and 4.0 nM and 25 nM for the µ-opioid receptor (Table 3.5 entries 1 and 2). These values 
were comparable to those previously reported.107 Oxetane-modified Met-enkephalin 231 
showed weak affinity towards the δ- and µ-opioid receptors with binding affinities of 6.4 
µM and 18.9 µM (Table 3.5, entry 3). Oxetane-modified Leu-enkephalin 232 also showed 
weak affinity towards δ- and µ-opioid receptors with binding affinities of 5.0 µM and 
12.9 µM (Table 3.5, entry 4).  
  
Entry Peptide Sequencea A R 
δ-Affinity Ki 
(nM)b,c 
µ-Affinity Ki 
(nM)b,c 
1 
Y-G-G-F-M, 240 
Met-enkephalin  
CH2CH2SMe 1.5 4.0 
2 
Y-G-G-F-L, 75  
Leu-enkephalin  
CH2iPr 4.1 25 
3 Y-G-GOx-F-M, 231 
 
CH2CH2SMe 6,400 18,900 
4 Y-G-GOx-F-L, 232 
 
CH2iPr 5,000 12,900 
Table 3.5 Binding affinities of Met- 240 and Leu-enkephalin 75 and their oxetane analogues 231 and 
232 to δ- and µ-opioid receptors. a GOx = oxetane-modified glycine. b Displacement of [3H]-
diprenorphine 241 from opioid receptors. c Affinity values are given as a mean (n = 3). 
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Our investigations indicate that oxetane-modification of the central glycine residue in 
Met- and Leu-enkephalin has a detrimental impact on the binding affinities towards the 
δ- and µ-opioid receptors. Although the bioactive conformation of the enkephalins has 
not yet been confirmed, it has been proposed that they adopt a β-turn in their bioactive 
conformations, stabilised via a H-bond between the tyrosine C=O (i) and the 
phenylalanine NH (i + 3).108,109 It is possible that substitution of the amide group with the 
3-aminooxetane unit reduces the strength of this intramolecular H-bond,110 potentially 
destabilising the β-turn conformation relative to competing 𝛾-turn or linear conformations 
(Scheme 3.25). This consequently disrupts binding with the opioid receptors. However, 
further structural investigations would be required to confirm this.  
 
Scheme 3.25 Potential β-turn and 𝛾-turn conformations of oxetane-modified enkephalin analogues. 
During our investigation into the impact oxetane-modification had on the biological 
properties of Met- and Leu-enkephalin, Carreira and co-workers published a complete 
study on the binding affinities of oxetane-modified analogues of Leu-enkephalin towards 
the δ-receptor.47 This study used oxetane-modified dipeptide building blocks to prepare 
four analogues of Leu-enkephalin, wherein each amide bond was sequentially replaced 
by the 3-aminooxetane unit (Table 3.6). 
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Entry Peptide sequencea A B C D 
δ-affinity 
Ki (nM)b,c 
Serum 
half-lifed 
1 
Y-G-G-F-L, 75 
(Leu-enkephalin)     
9.2 ≈10 min 
2 YOx-G-G-F-L, 242 
    
>1000 ≈3.2 h 
3 Y-GOx-G-F-L, 76 
    
>1000 ≈18 h	
4 Y-G-GOx-F-L, 232 
    
157 ≈15 min 
5 Y-G-G-FOx-L, 243 
    
43 ≈26 min 
Table 3.6 Stability and binding affinities of oxetane-modified analogues of Leu-enkephalin 75 prepared 
by Carreira and co-workers.47 a YOx = oxetane-modified tyrosine, GOx = oxetane-modified glycine, FOx 
= oxetane-modified phenylalanine. b Displacement of [3H]-DPDPE 244 from δ-opioid receptor. c 
Affinity values are given as a mean (n = 3). d Half-life in human serum. 
Binding affinities of oxetane-modified Leu-enkephalin analogues were determined by 
displacement of the radio ligand [3H]-DPDPE 244 from the δ-opioid receptor (Table 3.6). 
In this assay, the binding affinity for natural Leu-enkephalin 75 was 9.2 nM, which is 
comparable to the value reported by us and in the literature.107 Analogue 232, in which 
the central glycine residue has been modified, showed significant nanomolar affinity 
towards the δ-opioid receptor with a binding affinity of 157 nM. This is in contrast to 
results from our assay, that found 232 had a binding affinity of 5,000 nM. Analogue 243 
showed affinity comparable to the parent Leu-enkephalin 75 with a binding affinity of 43 
nM. Analogues 242 and 76 did not show any affinity towards the δ-opioid receptor up to 
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a concentration of 1 µM. The reason for the large difference in the binding affinity values 
for analogue 232, obtained independently by us and Carreira, is unclear. One possible 
explanation is that the material prepared by us decomposed en route to the University of 
Michigan for testing. 
In addition to examining the binding affinities to the δ-opioid receptor, Carreira and co-
workers also investigated the degradation of oxetane-modified Leu-enkephalin analogues 
in human serum (Table 3.6 and Figure 3.3). Leu-enkephalin 75 is known to readily 
degrade in human serum with a half-life of 10-12 min.111 The mechanism of hydrolysis 
has been extensively studied and has identified that the Tyr-Gly bond is the most 
susceptible to proteolytic cleavage.112,113 Analogue 232, in which the central glycine has 
been replaced, shows a slightly increased half-life of ~15 min compared to the native 
system. Phenylalanine-modified analogue 243 is even more stable to hydrolysis (half-life 
~26 min). Analogue 242, in which the Tyr-Gly connection has been modified, shows a 
significant increase in proteolytic stability with a half-life of ~3.2 h. Finally, analogue 76 
has the highest half-life in human serum with a half-life of ~18 h. It is likely that in this 
substrate, the oxetane-modification inhibits the hydrolysis of both the Tyr-Gly and the 
Gly-Gly bond by interfering with the substrate recognition process of proteases.     
 
Figure 3.3 Stability of Leu-enkephalin (75, ■) and its analogues (242, ●), (76, ▲), (232, ▼) and (243, 
◆) in human serum. Figure taken from Org. Lett. 2017, 19, 2510-2513.47	
Carreira and co-workers’ investigation has demonstrated that oxetane-modification of the 
central glycine 232 and phenylalanine residue 243 can produce analogues of Leu-
enkephalin that display affinity towards the δ-opioid receptor comparable to natural Leu-
enkephalin 75. Furthermore, all oxetane-modified analogues showed greater hydrolytic 
stability in human serum compared to the parent system 75. These results provide proof 
of concept that oxetane-modification of an amide bond can be used to increase the 
stability of a peptide towards proteases while retaining bioactivity.47 No further efforts to 
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study this system were undertaken in light of the thorough published investigation by 
Carreira and co-workers. 
 
3.4 Enzymatically-Stable Oxetane-Based Dipeptide Hydrogels 
In addition to the work described in this chapter, a further collaborative project with 
Professor Dave Adams and Dr Andrew Jamieson at the University of Glasgow has 
demonstrated that oxetane-modified dipeptides can be used to form hydrogels. This 
section aims to provide a brief summary of this work. 
Low molecular weight hydrogels arise from the self-assembly of small molecules 
(gelators) in water to form three-dimensional supramolecular structures that trap large 
amounts of water.114 These supramolecular structures are currently being investigated for 
a number of applications such as imaging, tissue engineering, drug delivery and wound 
healing.114–116 For some of these applications it is desirable that the self-assembled 
network is not easily degraded by enzymes. Since Fmoc-dipeptides are a well-known, 
effective class of gelator,114,117–119 we proposed that oxetane-based Fmoc-dipeptides 
could be used to prepare gels with increased resistance to enzymatic cleavage (Figure 
3.4). 
 
Figure 3.4 Concept of oxetane modification of Fmoc dipeptide gelators. 
A pH-triggered approach was used to investigate the ability of oxetane-based dipeptides 
as gelators. The dipeptides were first suspended in water and a molar equivalent of 
sodium carbonate added. Following this, the pH of the solution was decreased via the 
addition of glucono-δ-lactone (GdL).120 GdL slowly hydrolyses in water to give gluconic 
acid, which controllably lowers the pH (Scheme 3.28). As the pH decreases the molecules 
begin to self-assemble into fibrous structures that then entangle to form supra-molecular 
networks that trap water.  
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Scheme 3.28 Hydrolysis of GdL to gluconic acid.120 
Using this approach, oxetane-containing dipeptide 175 was found to be an effective 
gelator, forming a self-supporting material at a concentration of 3 mg mL−1 after standing 
overnight (Figure 3.5). Remarkably, the impact of oxetane-modification is immediately 
apparent as the corresponding parent analogue, Fmoc-Gly-Phe-OH 245, is known to not 
be able to form gels.121,122  
          
Figure 3.5 (a) Photograph of a solution of 175 at a concentration of 3 mg mL−1 at high pH. (b) 
Photograph of the sample shown in (a) after the pH has been lowered via the hydrolysis of GdL. The 
white bands in (b) are labels on the sample tubes. Photographs taken from Chem. Commun. 2018, 54, 
1793-1796.123  
Next, the stability of oxetane-modified dipeptide 175 to proteolysis, relative to Fmoc-
Gly-Phe-OH 245, was examined. Carboxypeptidase A, an exopeptidase that hydrolyses 
peptide bonds of C-terminal residues with aromatic side chains, was added to solutions 
of 175 and Fmoc-Gly-Phe-OH 245 in Tris buffer at pH 7.9 and the products probed by 
HPLC. Under these conditions, Fmoc-Gly-Phe-OH 245 rapidly degraded, with 98% 
conversion to Fmoc-Gly-OH after 1 minute and complete conversion after 5 mins (Figure 
3.6-a). In comparison, 175 showed significant stability with no enzymatic conversion 
after 24 hours (Figure 3.6-b).  
 
 
 
O
O
HO
HO
OH
HO
+ H2O CO2H
OH
OH
OH
OH
HO
Glucono-δ-lactone (GdL) Gluconic acid
FmocHN
O
H
N CO2H
Ph
175
(a) (b)
 83 
(a) 
 
(b) 
 
 
Figure 3.6 (a) Degradation of Fmoc-Gly-Phe-OH 245 over 5 min to Fmoc-Gly-OH. (b) 175 was sampled 
at t = 0, 1 min, 5 min, 4 h and 24 h. No degradation was observed over this timescale. Negative control 
containing no enzyme was conducted in parallel.  
Taken together, these results demonstrate that gels can be formed from oxetane-based 
dipeptides that are significantly more stable to proteolysis compared to native dipeptides 
(Figure 3.7). Consequently, this class of material may have applications in vivo. 
 
Scheme 3.7 Enzymatically-stable oxetane-based dipeptide hydrogels.123 
The work described in this section was published in Chemical Communications in 
2018.123 
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3.5 Conclusions 
In conclusion, this chapter has described the development of a practical route to oxetane-
modified peptides (OMPs) using conventional Fmoc/tBu solid-phase peptide synthesis 
(SPPS) techniques. Our strategy involves using cumyl protected dipeptide building 
blocks that are readily prepared in three steps in solution-phase (Scheme 3.26). The cumyl 
ester is then selectively cleaved with 2% TFA in CH2Cl2 to reveal the terminal carboxylic 
acid immediately prior to coupling. Since the work described in this chapter has been 
carried out, additional examples of oxetane-containing dipeptide building blocks have 
been prepared and used by other members of the group.  
 
Scheme 3.26 Solution-phase synthesis of oxetane-containing dipeptide building blocks. 
Solution and solid-phase experiments demonstrated that amide couplings using these 
building blocks can proceed in high yield, without racemisation, and without the need to 
protect the secondary amine of the 3-aminooxetane unit. Hence, oxetane-modified 
peptides can be produced in high purities and acceptable yields using conventional SPPS 
methods for coupling, deprotection, resin cleavage and purification (Scheme 3.27). This 
methodology has been used to prepare oxetane-modified analogues of enkephalin and 
bradykinin. 
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Scheme 3.27 Solid-phase synthesis of oxetane-modified peptides. 
Preliminary studies towards the impact of oxetane-modification on the biological 
properties of native peptides by investigating the binding affinities of oxetane-modified 
enkephalin analogues towards the δ- and µ-opioid receptors were conducted. However, a 
more complete study by Carreira and co-workers was reported during our own 
investigations which demonstrated that oxetane-modified analogues of Leu-enkephalin 
have improved hydrolytic stability in human serum, and that two of four analogues retain 
appreciable affinity towards the δ-opioid receptor.47 
This methodology is currently being used to produce a variety of OMPs in order to further 
explore the impact of oxetane-modification on the secondary structure and biological 
properties of these peptides. 
Much of the work described in this chapter was published in Organic Letters in 2017.124 
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Chapter 4: Incorporation of Oxetanes into α-Helices 
4.1 Project Aims 
Following the development of a practical route to oxetane-modified peptides (OMPs) 
using solid-phase peptide synthesis (SPPS) techniques, we were interested to explore the 
impact of oxetane-modification on common types of secondary structures (e.g. turns, α-
helices and β-sheets). Here, we begin by investigating the impact on α-helices. 
The α-helix is one of the most common types of secondary structure in proteins and 
polypeptide chains.125 Therefore, it would be of great interest to explore the impact of 
oxetane-modification on the structure and stability of known α-helices. Alanine-based 
model peptides have been well-studied and are known to form α-helices.24,126–128 Hence, 
these alanine-rich sequences are ideal systems to investigate the impact of oxetane-
modification on the structure and stability of α-helices (Figure 4.1).  
 
Figure 4.1 Proposed structure of an oxetane-modified alanine-based model peptide required for this 
study. 
To study the impact of oxetane-modification on the structure and stability of α-helices, 
this project is focused in three parts: 
1. The asymmetric synthesis of an oxetane-modified alanine (AOx) containing 
dipeptide building block, suitable for solid-phase peptide synthesis (SPPS). 
2. The preparation of oxetane-modified analogues of alanine-based model peptides 
using the SPPS methodology described in Chapter 3. 
3. Study the secondary structure of these oxetane-modified peptides using circular 
dichroism (CD) and NMR spectroscopy.  
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4.2 Introduction 
4.2.1 The α-Helix 
The α-helix was first characterised by Pauling in 1951 and is one of the most common 
secondary structure conformations in natural proteins, with ~40% of all residues adopting 
helical conformations.125,129 A typical α-helix, also known as a 3.613-helix, consists of 
amino acids arranged in a helical structure where the C=O group at the i position is 
hydrogen-bonded to the NH group at the i + 4 position (Figure 4.2). Each residue is 
related to the next one by a translation of 1.5 Å along the helix axis and a 100° rotation, 
which gives 3.6 residues per turn of the helix. The pitch of the helix, the vertical distance 
between consecutive turns of the helix, is 5.4 Å and is equal to the product of the 
translation (1.5 Å) and the number of residues per turn (3.6). Although the screw-sense 
of an α-helix can be right- or left-handed, an α-helix composed of L-amino acids typically 
adopts a right-handed conformation as the corresponding left-handed conformation is 
destabilised due to steric crowding of the side chains and the carbonyl groups. Virtually 
all α-helices found in proteins are right-handed.3,130 
  
Figure 4.2 Hydrogen bonding scheme and a ball-and-stick depiction of an α-helix. Ball-and-stick image 
from Biochemistry 6th Edition, W. H. Freeman and Company, New York, 2006.3 
 
4.2.2 Alanine-Based Helical Peptides 
Baldwin and co-workers have demonstrated that short alanine-based peptides form highly 
stable α-helices in water.24,126–128 For example, under optimal helix-forming conditions 
alanine-based peptide 247, containing three lysines and thirteen alanines, can display up 
to 80% helix content (Figure 4.3).126 These model systems have been used in amino acid 
substitution experiments to measure the helix forming propensities of various amino 
acids.127,128 
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Figure 4.3 Structure of alanine-based peptide 247 displaying 80% helix content.126 a Mean helix content 
measured in 1.0 M NaCl, pH 7.0 at 1 °C. 
Alanine-based model peptides have also been used to investigate the influence of 
peptidomimetic modifications on α-helix structure and stability. For example, Kiefhaber 
and co-workers determined the impact of single thioamide bonds on α-helix structure and 
stability by preparing thioamide-analogues of alanine-based peptides 248 and 250 in 
which a single amide to thioamide substitution was introduced at a central 249 and N-
terminal position 251 (Table 4.1). Circular dichroism (CD) studies revealed that 
introducing a thioamide group at these two positions results in a highly helix-destabilising 
effect, with the decrease in helical content more prominent in the central region compared 
with the N-terminal substitution. Comparison of the helical content values with other 
reference peptides confirmed that the effect of an amide to thioamide substitution is of 
similar magnitude as an alanine to glycine substitution. Despite this, 1H-NMR 
characterisation of N-terminal analogue 251 demonstrated that the thioamide group was 
engaged in an i  → i + 4  hydrogen bond, indicating that thioamides can be tolerated in 
α-helical structures.24  
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Entry Peptide Sequencea 𝑓H (%)b 
1 Ac-KAAAA-KAAAA-KAAAA-KGY-NH2, 248 68 
2 Ac-KAAAA-KAAYAA-KAAAA-KGY-NH2, 249 24 
3 Ac-DFAAA-KAAAA-KAAAA-K-NH2, 250 69 
4 Ac-DFYAAA-KAAAA-KAAAA-K-NH2, 251 48 
Table 4.1 Effect of thioamide bonds on helix content.24 a Y denotes the substitution of the 
amide bond [CO−NH] by a thioamide bond [CS−NH]. b Mean helix content measured in 10 
mM potassium phosphate, pH 7.0 at 0 °C, with the addition of 1.0 M NaCl. 
 
4.3 Results and Discussion 
4.3.1 Design of Alanine-Based Model Peptides 
Alanine-rich peptide 248 was chosen as a model system to investigate the impact of 
oxetane-modification on α-helix structure and stability and has been shown to have a 
helical content of ~68% at 0 °C (Figure 4.4).24 The peptide 248 contains lysine residues 
at every fifth position to increase solubility and the N- and C-termini have been capped 
to prevent unfavourable electrostatic interactions with the helix dipole. 248 also contains 
a C-terminal Tyr residue that is separated from the Ala-Lys sequence by a Gly residue. 
Addition of a Tyr residue enables accurate determination of the peptide concentration by 
Tyr absorbance (ε275 = 1450 M−1) and does not significantly affect the far-UV CD 
spectrum when separated by a Gly residue.24,128  
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Figure 4.4 Structure of alanine-based model peptide 248.24 a Mean helix content measured in 10 mM 
phosphate buffer, pH 7.0 at 0 °C with the addition of 1.0 M NaCl.  
Helical content is expected to reach a maximum at the centre of peptide making this 
section particularly sensitive to modifications. In comparison, the terminal regions exhibit 
significantly less helical content, hence modifications to these regions are expected to 
have less effect on helix content.24,127 To investigate the impact of oxetane-modification 
on α-helix structure and stability, we proposed to prepare oxetane-modified analogues of 
248 in which a single central and N-terminal alanine residue is replaced by an oxetane-
modified alanine (AOx) residue (Table 4.2, entries 1 and 2). In addition, we also proposed 
to prepare analogues containing an oxetane-modified glycine (GOx) residue as deletion of 
the methyl side-chain might make it easier to accommodate the oxetane-modified residue 
into the α-helix (Table 4.2, entries 3 and 4). Following this, analysis of secondary 
structure content of the oxetane-modified analogues using circular dichroism (CD) and 
NMR spectroscopy was expected to enable us to assess the impact of oxetane-
modification on α-helix structure and stability. 
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Entry Peptidea Peptide Sequencea R 
1 Central AOx, 246 Ac-KAAAA-KAAOxAA-KAAAA-KGY-NH2 Me 
2 N-Terminal AOx, 252 Ac-KAAOxAA-KAAAA-KAAAA-KGY-NH2 Me 
3 Central GOx, 253 Ac-KAAAA-KAGOxAA-KAAAA-KGY-NH2 H 
4 N-Terminal GOx, 254 Ac-KAGOxAA-KAAAA-KAAAA-KGY-NH2 H 
Table 4.2 Sequences of oxetane-modified peptides required for this study. a AOx = oxetane-modified 
alanine, GOx = oxetane-modified glycine. 
 
4.3.2 Towards the Stereocontrolled Synthesis of Oxetane-Containing Dipeptide 
Building Blocks 
The oxetane-modified peptides required for this study could be prepared using the 
methodology described in Chapter 3. However, this required the preparation of an Fmoc-
protected dipeptide building block in which the oxetane residue is based on alanine. 
Therefore, our initial efforts focused on routes towards AOx-containing dipeptide building 
block 255 (Scheme 4.1). The synthesis of the required GOx-containing dipeptide building 
block 215 has previously been reported in Chapter 3.   
 
Scheme 4.1 Structure of the oxetane-containing building block required for this study. a AOx = oxetane-
modified alanine. 
 
4.3.2.1 Addition of Chiral Amines to Trisubstituted Nitroalkenes 
To begin with, we focused our efforts on the synthesis of AOx-containing dipeptide 
building block 255 using the route described in Chapter 3. Although previous work by us 
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and Carreira suggested that this route would produce the building block as a mixture of 
diastereoisomers,45,46 we envisaged that it might be possible to separate these 
diastereoisomers after the conjugate addition step or after the nitro reduction-Fmoc 
protection step. Starting from alanine cumyl ester 202, the Fmoc group was first removed 
using diethylamine and the resulting crude amine 256 added to nitroalkene 128 to give 
the addition product as a 50:50 mixture of diastereoisomers (Scheme 4.2). Attempts to 
separate the diastereoisomers using column chromatography were unsuccessful and 257 
was isolated in excellent yield as a 55:45 mixture of diastereoisomers. Following this, 
nitro reduction with Raney Ni under an atmosphere of hydrogen and in situ Fmoc 
protection gave the crude Fmoc-protected dipeptide building block 255. Attempts to 
separate the diastereoisomers at this stage were also unsuccessful and AOx-containing 
building block 255 was isolated as a 58:42 mixture of diastereoisomers as determined by 
chiral HPLC analysis (see Section 6.8).  
 
Scheme 4.2 Synthesis of AOx containing dipeptide building block 255 via conjugate addition of 256 to 
trisubstituted nitroalkene 128. a Determined by 1H-NMR analysis of the crude reaction mixture (see 
Section 6.7). b Determined by 1H-NMR analysis. c Determined by chiral HPLC analysis (see Section 
6.8). 
Following this result, we investigated the addition of other chiral α-amino esters to 
nitroalkene 128 to determine if any diastereoselectivity could be obtained and whether 
the resulting diastereoisomers could be separated. A series of α-amino esters, containing 
various side chains and ester protecting groups, were added to trisubstituted nitroalkene 
128 (Table 4.3). Alanine methyl ester gave no diastereoselectivity and the resulting 
addition product 263 was formed as a 50:50 mixture of diastereoisomers, which were not 
separable using column chromatography (Table 4.3, entry 2). More sterically hindered 
valine cumyl ester gave a small amount of selectivity to provide the addition product 264 
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as a 55:45 mixture of diastereoisomers which were not separable using column 
chromatography (Table 4.3 entry 3). Valine, serine and phenylglycine methyl esters gave 
no diastereoselectivity and the corresponding addition products (132, 265-266) were 
produced as 50:50 mixtures of diastereoisomers; none of which were separable using 
column chromatography (Table 4.3, entries 4-6). The addition of proline methyl ester to 
nitroalkene 128 gave a significant increase in diastereoselectivity to provide tertiary 
amine 267 as a 70:30 mixture of diastereoisomers (Table 4.3, entry 7). However, similar 
to the previous examples, the diastereoisomers were not separable using column 
chromatography.   
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Entrya Amino ester Solvent Product Conversion (%)b drb 
1c 
 
CH2Cl2 
 
>95 50:50 
2d 
 
THF 
 
>95 50:50 
3c 
 
CH2Cl2 
 
>95 55:45 
4d 
 
THF 
 
>95 50:50 
5d 
 
THF 
 
>95 50:50 
6d 
 
CH2Cl2 
 
>95 50:50 
7d 
 
THF 
 
>95 70:30 
Table 4.3 Conjugate addition of chiral amino esters to trisubstituted nitroalkene 128. a Method: 128 (1.0 
equiv), amino ester (1.2-2.0 equiv), solvent (0.1 M). b Determined by 1H-NMR analysis of the crude 
reaction mixture (see Section 6.7). c Prepared by deprotection of the corresponding Fmoc-protected 
amino ester and used without purification. d Prepared from the corresponding hydrochloride salt.    
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Our screening results for the addition of various α-amino esters to nitroalkene 128 
indicate that chiral primary amino esters exert little stereochemical bias on the reaction 
providing the addition products as a mixture of diastereoisomers. Furthermore, none of 
the resulting diastereoisomers could be readily separated using column chromatography. 
A possible explanation for the lack of diastereoselectivity in the conjugate addition-
protonation reaction is the conformational freedom of the primary amino esters and the 
remoteness of R1 and R2 from the site of protonation. Assuming the addition of an amino 
ester 268 to nitroalkene 128 proceeds in a stepwise manner, the first step corresponds to 
the formation of the Cβ−N bond in a reaction leading to a 6-membered nitronate transition 
state 269 (Scheme 4.3). In this transition state, there is a low energy barrier for rotation 
around the X(R1)Cα−N bond resulting in a conformational equilibrium between 269a and 
269b. Consequently, in the following protonation step, there is little preference between 
protonation of the Si face 270a or Re face 270b of the nitronate intermediate, resulting in 
formation of the addition product 271 as a mixture of diastereoisomers.  
 
Scheme 4.3 Proposed reaction pathway for the conjugate addition of primary amino esters 268 to 
nitroalkene 128. 
In comparison, modest diastereoselectivity was obtained using proline methyl ester in the 
conjugate addition. A possible explanation for the selectivity, is that proline is 
significantly more conformationally restricted compared to primary α-amino acid 
residues.131 This could cause the conjugate addition reaction to proceed via a lower energy 
transition state 272 which leads to preferential protonation of one face of the nitronate 
intermediate in 272 over the other (Scheme 4.4). As this project did not require the 
preparation of building blocks containing a proline residue, the conjugate addition of 
proline to trisubstituted nitroalkenes was not investigated any further. It may be of interest 
to revisit this reaction in the future.  
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Scheme 4.4 Proposed transition state for the conjugate addition of 262 to nitroalkene 128. 
Following the screening of chiral α-amino esters, additional chiral nitrogen nucleophiles 
were investigated in the conjugate addition reaction (Table 4.4). Both enantiomers of α-
methylbenzylamine 273, which has previously been used in stereoselective aza-Michael 
additions,132 were used and gave the addition products 277 as a 60:40 mixture of 
diastereoisomers. Encouragingly, the major diastereoisomers could be isolated (dr >95:5) 
using column chromatography (Table 4.4, entries 1 and 2). No improvement in 
diastereoselectivity was observed using amine 274, containing a sterically bulky tert-
butyl group. The addition product 278 was produced as 60:40 mixture of diastereoisomers 
which were not separable using column chromatography (Table 4.4, entry 3). Formation 
of isoxazole 281 was observed when chiral acyclic secondary amine 275 was used in the 
conjugate addition with no formation of the addition product 279 (Table 4.4, entry 4). 
This observation is in agreement with reports by Carreira and co-workers.74 Following 
the observation with proline, oxazolidinone 276 was used in the conjugate addition. 
Deprotonation of 276 using potassium tert-butoxide followed by addition to nitroalkene 
128 gave the addition product 280 as a 70:30 mixture of diastereoisomers (Table 4.4, 
entry 5). However, the resulting diastereoisomers were not separable using column 
chromatography. 
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Entrya Nucleophile Product Conversion (%)b drb 
1 
 
 
>95 (56)d 60:40 
2 
 
 
>95 (50)d 60:40 
3 
  
>95 60:40 
4 
 
 
0b − 
5e 
  
>95 70:30 
Table 4.4 Conjugate addition of chiral nitrogen nucleophiles to trisubstituted nitroalkene 128. a Method: 
128 (1.0 equiv), nucleophile (1.2 equiv), CH2Cl2 (0.1 M). b Determined by 1H-NMR analysis of the crude 
reaction mixture (see Section 6.7). c Major product was rearrangement product 281. d Isolated yield of the 
major diastereoisomer (dr >95:5, see Section 6.7). e Reaction conditions:  128 (1.0 equiv), 276 (1.0 equiv), 
KOtBu, (1.0 equiv), 18-crown-6, (1.0 equiv), THF, 0 °C to rt, 16 h. 
Following these observations, we were encouraged by the result for the addition of α-
methylbenzylamine 273 to nitroalkene 128 (Table 4.4, entries 1 and 2). We proposed that 
the major diastereoisomer 277 isolated from the reaction could be used to access the 
required AOx-containing building block 255 via modification of the synthetic approach 
developed by Carreira and co-workers in a much more expedient fashion (Scheme 4.5).47 
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Enantiopure 3-aminooxetane 282 could be prepared from 277 via reduction of the nitro 
group, cleavage of the α-methylbenzyl group and Fmoc protection of the less sterically 
hindered amine. Alkylation of enantiopure amine 282 with triflate 283 could then provide 
AOx-containing building block 255 (Scheme 4.5). Both enantiomers of 255 would be 
accessible using this route, which in turn could be used to prepare both enantiomers of an 
AOx residue.    
 
Scheme 4.5 Synthetic approach to AOx-containing dipeptide building block 255.  
 
4.3.2.2 Optimisation Studies for the Addition of (S)-273 to Nitroalkene 128 
Before investigating routes towards enantiopure 3-aminooxetane 282, we attempted to 
maximise the diastereoselectivity in the addition reaction of (S)-273 to nitroalkene 128. 
We began by investigating the influence of reaction solvent on the diastereoselectivity 
(Table 4.5). The majority of solvents investigated gave no improvement. Toluene and n-
hexane gave a small improvement producing the addition product 277 as 65:35 mixture 
of diastereoisomers (Table 4.5, entries 4-5). No change in diastereoselectivity was 
observed using the protic solvents ethanol or nitromethane (Table 4.5, entries 9-10). 
Hexafluoroisopropanol (HFP) resulted in a decrease in the conversion and 
diastereoselectivity, and produced the addition product 277 as 55:45 mixture of 
diastereoisomers (Table 4.5, entry 11). The decrease in conversion is likely a result of 
acidic hexafluoroisopropanol (pKa = 9.3)133 promoting the retro-aza-Michael reaction. 
Performing the reaction using (S)-(+)-α-methylbenzylamine 273 as the solvent gave no 
improvement in the diastereoselectivity (Table 4.5, entry 12). 
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Entry Solvent Conversion (%)a dra Entry Solvent Conversion (%)b drb 
1 CH2Cl2 >95 60:40 7 dioxane >95 60:40 
2 DCE >95 60:40 8 EtOAc >95 60:40 
3 MeCN >95 60:40 9 EtOH >95 60:40 
4 toluene >95 65:35 10 NO2Me >95 60:40 
5 n-hexane >95 65:35 11 HFPc 80 55:45 
6 THF >95 60:40 12d - >95 60:40 
Table 4.5 Solvent screen for the conjugate addition-protonation reaction of (S)-273 with 128. a Method: 
128 (1.0 equiv), (S)-273 (1.2 equiv), solvent (0.1 M). b Determined by 1H-NMR analysis of the crude 
reaction mixture (see Section 6.7). c HFP = hexafluoroisopropanol. d Reaction conditions: 128 (1.0 
equiv), (S)-273 (1.0 M), rt, 16 h.   
Following the solvent screen, we examined the effect of temperature (t) on the 
diastereoselectivity. The addition of (S)-273 to nitroalkene 128 was performed in toluene, 
n-hexane and dichloromethane at either −20 or −78 °C (Table 4.6). In all cases, 
performing the reaction at lower temperature gave no improvement to the 
diastereoselectivity. 
 
 
 
 
 
 
 
MeO2N
O
+
H2N Ph
Me
solvent, rt, 16 h
O2N
Me
O
H
N Ph
Me
128 (S)-273 277
 100 
 
Entrya Solvent t Conversion (%)b drb 
1 PhMe −20 °C to rt >95 65:35 
2 n-hexane −20 °C to rt >95 65:35 
3 CH2Cl2 −78 °C to rt >95 60:40 
4 PhMe −78 °C to rt >95 65:35 
5 n-hexane −78 °C to rt >95 65:35 
Table 4.6 Temperature screen for the conjugate addition of (S)-273 to 128. a Method: 128 (1.0 equiv), 
(S)-273 (1.2 equiv), solvent (0.1 M). b Determined by 1H-NMR analysis of the crude reaction mixture 
(see Section 6.7). 
Following the results of the solvent and temperature screen, we explored the application 
of additives in the conjugate addition reaction (Table 4.7). The addition of a suitable 
reagent has been shown to enhance the reactivity and selectivity in certain reactions.134 
To begin with, the reaction was carried out in the presence of 10 mol% acetic acid, phenol 
and triethylamine hydrochloride as an additional proton source. The introduction of these 
additives had no impact on the diastereoselectivity and addition product 277 was isolated 
as a 60:40 mixture of diastereoisomers (Table 4.7, entries 2-4). Next, the addition of basic 
additives was investigated. Addition of 10 mol% triethylamine had no impact on the 
diastereoselective and promoted rearrangement of nitroalkene 128 to isoxazole 281 
(Table 4.7, entry 5). Addition of 10 mol% (−)-sparteine 285, which has been used as a 
chiral base,135 had no impact on the diastereoselectivity (Table 4.7, entry 6). Addition of 
120 mol% acetic acid gave no improvement in the diastereoselectivity and resulted in a 
decrease in conversion (Table 4.7, entry 7). No change in diastereoselectivity was 
observed with the addition of 120 mol% triethylamine hydrochloride (Table 4.7, entry 8). 
Finally, addition of 120 mol% triethylamine gave no improvement in the 
diastereoselectivity and resulted in significant amounts of isoxazole 281 formation (Table 
4.7, entry 9).  
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Entrya Additive Conversion (%)b drb 
1 − >95 60:40 
2 AcOH >95 60:40 
3 phenol >95 60:40 
4 NEt3･HCl >95 60:40 
5 NEt3 85 (+15% 281) 60:40 
6 (−)-sparteine, 285 >95 60:40 
7c AcOH (120 mol%) 80 60:40 
8c NEt3･HCl (120 mol%) >95 60:40 
9c NEt3 (120 mol%) 65 (+35% 281) 60:40 
Table 4.7 Additive screen for the addition reaction of (S)-273 to 128. a Method: 128 (1.0 equiv), (S)-273 
(1.2 equiv), additive (10 mol%), CH2Cl2 (0.1 M). b Determined by 1H-NMR analysis of the crude 
reaction mixture (see Section 6.7). c Method: 128 (1.0 equiv), (S)-273 (1.2 equiv), additive (120 mol%), 
CH2Cl2 (0.1 M). 
Recently, Ellman and co-workers have developed a catalytic enantioselective addition of 
thioacids to azetidine- and oxetane-containing trisubstituted nitroalkenes using 
bifunctional thiourea catalysts 286 and 287 (Scheme 4.6).75 Conjugate addition into the 
nitroalkenes and subsequent enantioselective protonation led to 1,2-nitrothioacetates in 
high yields and enantioselectivities. This methodology has been extended to include the 
enantioselective addition of pyrazol-5-ones.136 Encouraged by these reports, we 
investigated the application of bifunctional thiourea catalysts in the conjugate addition 
reaction. 
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Scheme 4.6 Catalytic enantioselective addition of thioacids to trisubstituted nitroalkenes developed 
by Ellman and co-workers.75 
The application of bifunctional thiourea catalyst 287 was investigated in the addition 
reaction. (S)-273 was added to a mixture of 128 and 10 mol% 287 in dichloromethane at 
−78 °C. After 24 h, 1H-NMR analysis indicated that addition of catalyst 287 gave no 
improvement in the diastereoselectivity and addition product 277 was formed as 60:40 
mixture of diastereoisomers (Table 4.8, entry 1). Following this, the (R)-273 enantiomer 
was used in the addition reaction to determine if unfavourable interactions between the 
chiral catalyst 287 and the (S)-enantiomer 273 had prevented control in the protonation 
step. Under identical conditions, addition of (R)-273 gave the addition product as a 60:40 
mixture of diastereoisomers, indicating that the lack of control in the protonation step was 
not a result of unfavourable interactions between chiral catalyst 287 and the (S)- or (R)-
enantiomer 273 (Table 4.8, entry 2). Although far from exhaustive, attempts to use 
bifunctional thiourea 287 to influence the diastereoselectivity in the addition of 273 to 
nitroalkene 128 were unsuccessful. Further investigations into the application of chiral 
bifunctional thiourea catalysts in the conjugate addition reaction were not carried out.  
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Entrya Amine Product Conversion (%)b drb 
1 
 
 
>95 60:40 
2 
 
 
>95 60:40 
Table 4.8 Application of bifunctional thiourea catalyst 287 in the addition reaction. a Method: 128 
(1.0 equiv), 273 (1.0 equiv), 287 (10 mol%), CH2Cl2 (0.1 M). b Determined by 1H-NMR analysis 
of the crude reaction mixture (see Section 6.7). 
Attempts to maximise the diastereoselectivity in the addition of (S)-273 to nitroalkene 
128 were unsuccessful. Varying the reaction solvent and temperature gave no significant 
improvement to the diastereoselectivity and, under the majority of conditions, the 
addition product 277 was formed as a 60:40 mixture of diastereoisomers. Introduction of 
basic and acidic additives to the reaction gave no observable improvement to the 
diastereoselectivity and, in some cases, promoted rearrangement to isoxazole 281 or 
retro-aza-Michael reaction. Attempts to influence the diastereoselectivity using 
bifunctional thiourea catalyst 287 also proved unsuccessful. At this point, no further 
attempts to improve the diastereoselectivity were investigated.  
 
4.3.2.3 Addition of (S)-273 to Trisubstituted Nitroalkenes 
We next explored the addition of (S)-273 to a variety of other oxetane-substituted 
nitroalkenes to determine the influence of the α-substituent of the nitroalkene on the 
diastereoselectivity in the conjugate reaction and to see if the resulting diastereoisomers 
were separable. This investigation would also provide insight into whether additional 
oxetane-modified residues could be prepared via this route.  
MeO2N
O
H2N
+ O2N
Me
O
H
N
Ph
Me Ph
Me
CF3
F3C NH
N
H
S
NMe2287 (10 mol%)
CH2Cl2, −78 °C to rt, 24 h
128 273 277
PhH2N
Me
(S)-273
Ph
Me
H
NO2N
O
Me
277a
PhH2N
Me
(R)-273
Ph
Me
H
NO2N
O
Me
277b
 104 
We began by preparing trisubstituted nitroalkene 289, containing an ethyl substituent,  
which was prepared following a modified procedure previously reported by Ellman and 
co-workers (Scheme 4.7).75 Henry reaction of nitropropane with oxetan-3-one, followed 
by elimination with methanesulfonyl chloride, gave 289 in moderate yield.  
 
Scheme 4.7 Synthesis of trisubstituted nitroalkene 289.75  
Trisubstituted nitroalkene 293, containing an isopropyl substitution, had previously been 
accessed from 2-methyl-1-nitropropane 291.75 However, no commercial supplies of 191 
were available. On this basis, nitroalkene 293 was prepared using a modified route 
(Scheme 4.8). Nucleophilic substitution of 1-iodo-2-methylpropane 291 with silver nitrite 
gave crude nitroalkane 291. Nitro-aldol reaction of 291 with oxetane-3-one at 60 °C gave 
alcohol 292, which was isolated in low yield. Elimination with methanesulfonyl chloride 
yielded trisubstituted nitroalkene 293 in 36% yield.  
 
Scheme 4.8 Synthesis of trisubstituted nitroalkene 293. 
Attempts to isolate phenyl-substituted nitroalkene 295 were unsuccessful (Scheme 4.9). 
Reaction of (nitromethyl)benzene 294 with oxetan-3-one, followed by elimination with 
methanesulfonyl chloride gave 295 along with significant amounts of isoxazole 296. 
Purification using column chromatography resulted in further rearrangement of phenyl-
substituted nitroalkene 295 to isoxazole 296.  
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Scheme 4.9 Attempted synthesis of trisubstituted nitroalkene 295. 
With a collection of trisubstituted nitroalkenes in hand, the relationship between the α-
substituent and diastereoselectivity in the addition reaction was explored (Table 4.9). The 
addition of (S)-273 to trisubstituted nitroalkenes was performed in dichloromethane at 
room temperature and in n-hexane at −20 °C. As previously discussed, addition of (S)-
273 to methyl-substituted nitroalkene 128 gave a 60:40 mixture of diastereoisomers in 
dichloromethane and a 65:35 mixture in n-hexane at −20 °C (Table 4.9, entries 1 and 2). 
Addition of (S)-273 to ethyl-substituted nitroalkene 289 resulted in a small increase in the 
diastereoselectivity producing the addition product 297 as a 65:35 mixture of 
diastereoisomers in dichloromethane and a 70:30 mixture in n-hexane at −20 °C (Table 
4.9, entries 3 and 4). Attempts to separate the diastereoisomers of 297 using column 
chromatography were unsuccessful. Similarly, addition of (S)-273 to benzyl-substituted 
nitroalkene 31 gave a 65:35 and 70:30 mixture of diastereoisomers in dichloromethane 
and n-hexane respectively (Table 4.9, entries 5 and 6). Attempts to separate the 
diastereoisomers of 298 using column chromatography were unsuccessful. Isopropyl-
substituted nitroalkene 293 gave the highest observed diastereoselectivity. Addition of 
(S)-273 to nitroalkene 293 gave the addition product 299 as an 80:20 mixture of 
diastereoisomers in dichloromethane and an 85:15 mixture in n-hexane (Table 4.9, entries 
7 and 8). Encouragingly, the major diastereoisomer 299 could be isolated in 71% yield 
using column chromatography (Table 4.9, entry 8).  
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Entrya Nitroalkene 
A-value 
(substituent)b 
Conditions Product 
Conversion 
(%)c 
drc 
1 
 
1.74         
(Me)137 
(a) 
 
>95 60:40 
2 (b) >95 65:35 
3 
 
1.79137       
(CH2CH3)137 
(a) 
 
>95 65:35 
4 (b) >95 70:30 
5 
 
1.81    
(CH2Ph)138 
(a) 
 
>95 65:35 
6 (b) >95 70:30 
7 
 
2.21           
(iPr)137   
(a) 
 
>95 80:20 
8 (b) >95 (71)d 85:15 
Table 4.9 Conjugate addition of (S)-273 to trisubstituted nitroalkenes. a Method: Nitroalkene (1.0 equiv), 
(S)-273 (1.2 equiv), solvent (0.1 M). b Derived from equilibrium measurements of monsubstituted 
cyclohexanes.  c Determined by 1H-NMR analysis of the crude reaction mixture (see Section 6.7). d 
Isolated yield of the major diastereoisomer (dr >95:5). 
The relationship between the nitroalkene α-substituent and the diastereoselectivity was 
studied by plotting the A-value of the α-substituents against the diastereomeric excess 
(de) of the addition products (Table 4.9 and Figure 4.5). A-values are numerical 
measurements of steric bulk and are derived from equilibrium measurements of 
monosubstituted cyclohexanes.139  
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Figure 4.5 A value vs. de for the addition of (S)-273 to trisubstituted nitroalkenes in n-hexane, −20 °C 
to rt. a Derived from equilibrium measurements of monsubstituted cyclohexanes.  b Determined by 1H-
NMR analysis of the crude reaction mixture. 
Analysis of the plot indicates that there is a strong relationship between the steric bulk of 
the nitroalkene α-substituent and the diastereoselectivity, although additional data points 
are required to confirm this trend. As steric bulk increases the diastereoselectivity of the 
addition reaction increases. It would be of interest to prepare tert-butyl-substituted 
nitroalkene 300 (A-value [tBu] = >4)137 to determine if the addition product 301 can be 
produced as a single diastereoisomer (Scheme 4.10). However, due to time constraints 
we were unable to investigate additional trisubstituted nitroalkenes in the addition 
reaction. 
 
Scheme 4.10 Proposed addition of (S)-273 to tert-butyl-substituted nitroalkene 300. 
Following this, the diastereoselectivity of the conjugate addition reaction was monitored 
over the course of the reaction to determine if reversibility of the reaction (retro-aza-
Michael reaction) or epimerisation of the newly generated chiral centre was having an 
impact on the final ratio of diastereomers of the addition products. As a preliminary 
investigation, the reaction of (S)-273 to ethyl-substituted nitroalkene 289 was carried out 
in CD2Cl2 at 25 °C and monitored by 1H-NMR spectroscopy. Figure 4.6 shows the 
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conversion and diastereoselectivity of the addition reaction plotted against time. Although 
the reaction was not monitored to completion, analysis of the plot shows that conversion 
to addition product 297 increases at a constant rate over the first 5 hours of the reaction, 
whilst the de remains constant at 30%. Taken together, these results indicate that 
reversibility and epimerisation of the chiral centre is not having an impact on the 
diastereoselectivity of the addition reaction. At this stage, no further studies on the 
addition of chiral amines to trisubstituted nitroalkenes were carried out.  
 
 
Figure 4.6 Conversion (blue dots) and de (red dots) vs. time for the addition of (S)-273 to nitroalkene 
289. a Determined by 1H-NMR analysis of the reaction mixture.  
 
4.3.2.4 Modified Route to Oxetane-Containing Dipeptide Building Blocks  
We next explored routes to enantiopure 3-aminooxetane 282 from addition product 277. 
Concomitant reduction of the nitro group and cleavage of the α-methylbenzyl group using 
catalytic hydrogenation conditions gave unprotected 1,2-diamine 302 (Scheme 4.11). 
Treatment of crude 302 with one equivalent of FmocOSu resulted in protection of the less 
sterically hindered amine to yield enantiopure 3-aminooxetane 282 with the 
regiochemistry confirmed using 2D 1H-NMR experiments.  
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Scheme 4.11 Synthesis of enantiopure amino oxetane (R)-282. a Determined by 1H-NMR analysis of the 
crude reaction mixture. b Major diastereoisomer isolated in dr >95:5 as determined by 1H-NMR (see 
Section 6.8). 
The absolute configuration at the newly created centre in 282 was confirmed as (R) by X-
ray crystal structure analysis of 4-bromobenzamide derivative 304 (Scheme 4.12). 
Acylation of 282 with 4-bromobenzoyl chloride 303 gave 304 in excellent yield with 
crystals suitable for X-ray analysis grown from toluene.  
 
Scheme 4.12 Synthesis of amide 304 and X-ray structure. Hydrogen atoms, except at the C-stereocenter, 
are omitted for clarity. 
Following this, the desired (S)-enantiomer 282 was prepared (Scheme 4.13). Addition of 
(R)-273 to nitroalkene 128 produced a 60:40 mixture of diastereoisomers. Isolation of the 
major diastereoisomer using column chromatography gave the addition product (S,R)-
277 in moderate yield. Nitro reduction and cleavage of benzylamine gave 1,2-diamine 
(S)-302 which was Fmoc protected to yield enantiopure 3-aminooxetane (S)-282.  
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Scheme 4.13 Synthesis of enantiopure amino oxetane (S)-282. a Determined by 1H-NMR analysis of the 
crude reaction mixture. b Major diastereoisomer isolated in dr >95:5 as determined by 1H-NMR (see 
Section 6.7). 
With access to both enantiomers of 3-aminooxetane 282, we turned our attention to the 
synthesis of the activated hydroxyester fragment. Initially, we attempted the diazotisation 
of D-alanine to give the corresponding hydroxyacid 306 following a literature procedure 
(Scheme 4.14).140 However, after work-up, no desired product was isolated.  
 
Scheme 4.14 Attempted synthesis of hydroxyacid 306.140 
Following this result, the required hydroxyester fragment was prepared using an 
alternative approach (Scheme 4.15). Cumyl ester (S)-307 was prepared by reaction of L-
lactic acid with imidate 191. Next, inversion of the stereochemistry using Mitsunobu 
reaction conditions yielded diester 308 with (R)-stereochemistry. Hydrolysis of the 
benzoate ester using potassium carbonate in methanol provided the activated 
hydroxyester precursor (R)-307.  
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Scheme 4.15 Synthesis of (R)-307 from L-lactic acid. a Prepared from 2-phenyl-2-propanol 190 and 
trichloroacetonitrile.  
With hydroxyester (R)-307 in hand, we explored the synthesis of triflate 283. Since alkyl 
triflates are extremely reactive electrophiles, it was decided that 283 would be prepared 
immediately prior to the substitution reaction. Hydroxyester (R)-307 was treated with 
triflic anhydride and DIPEA to provide crude triflate 283 which was used immediately 
(Scheme 4.16). An excess of DIPEA was required in the reaction to prevent traces of 
triflic acid promoting cleavage of the cumyl ester. Adopting the conditions developed by 
Carreira and co-workers,47 nucleophilic substitution of triflate 283 with both enantiomers 
of 3-aminooxetane 282 gave the AOx-containing dipeptide blocks (R,S)-255 and (S,S)-255 
in moderate yields. Chiral HPLC analysis confirmed that (R,S)-255 and (S,S)-255 were 
isolated as single diastereoisomers (see Section 6.8), indicating that the substitution 
reaction proceeds exclusively in an SN2 fashion and that no epimerisation arises during 
the synthesis of enantiopure 3-aminooxetanes (R)-282 and (S)-282.  
 
Scheme 4.16 Synthesis of AOx-containing dipeptide building blocks (R,S)-255 and (S,S)-255. a 
Determined by chiral HPLC analysis (see Section 6.8). 
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Following the synthesis of AOx-containing dipeptide blocks (R,S)-255 and (S,S)-255, we 
proposed addition product 299 could be used to prepare enantiopure 3-aminooxetane 308, 
which in turn, could be used to prepare an oxetane-modified valine (VOx) dipeptide 
building block 309 (Scheme 4.17). Due to time constraints and the lower yielding 
synthesis of nitroalkene 293, we did not attempt this chemistry.  
 
Scheme 4.17 Proposed route to VOx-containing dipeptide building block 309. a Determined by 1H-NMR 
analysis of the crude reaction mixture. b Major diastereoisomer isolated in dr >95:5 as determined by 
1H-NMR. c Stereochemistry assigned on the basis of (R,S)-277. 
The results of this investigation have demonstrated that the addition products of α-
methylbenzylamine 273 to oxetane-substituted nitroalkenes can be used to prepare 
enantiopure 3-aminooxetanes. Using this approach, Fmoc-protected enantiopure 3-
aminooxetane (S)-282 was prepared in three steps from oxetan-3-one in an overall yield 
of 22%. This is significantly shorter than the route reported by Carreira and co-workers, 
who prepared Boc-protected enantiopure 3-aminooxetane 66 in twelve steps from Tris 
hydrochloride, in an overall yield of 15% (Chapter 1, Schemes 1.7 and 1.8).47 In addition, 
reaction of enantiopure amines with hydroxyl-cumyl esters can provide oxetane-
containing dipeptide building blocks suitable for solid-phase peptide synthesis (SPPS).  
 
4.3.3 Solid-Phase Synthesis of Oxetane-Modified Peptides 
With access to AOx-containing building block (S,S)-255 established, the required oxetane-
modified pepetides were prepared using the solid-phase methodology described in 
Chapter 3. This portion of work was carried out by Dr Ina Wilkening at the University of 
Warwick. 
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Oxetane-modified peptides were prepared on a Prelude peptide synthesiser (Protein 
Technologies Inc.) using NovaSyn® TGR R resin that had been preloaded with Fmoc-
Tyr(OtBu)-OH using PyBOP, HOBt and DIPEA in DMF. Fmoc deprotection was carried 
out using 20% piperidine in DMF. Couplings were performed with Fmoc-protected 
amino acids using HATU activation with DIPEA in DMF. Two equivalents of oxetane-
containing building blocks 255 and 215 were first deprotected using 2% TFA in CH2Cl2 
to give the crude acid which was dissolved in DMF and manually coupled with resin 
bound peptide using HATU activation with DIPEA in DMF. This process was repeated 
using fresh reagents. N-Terminal acetylation was carried out manually using 
Ac2O:NMM:DMF (5:5:95; v/v/v) at room temperature. Peptide cleavage and 
concomitant side chain deprotection was performed using a cleavage cocktail of 
TFA/H2O/TIS (95:2.5:2.5, v/v/v). For full details, see Section 6.9.  
Using these conditions, parent peptide 248 and three oxetane-modified analogues were 
isolated after purification by reverse-phase HPLC (Table 4.10). Parent peptide 248 was 
isolated in high purity using standard Fmoc/tBu SPPS conditions (Table 4.10, entry 1). 
AOx-containing building block 255 was used to access central AOx-modified analogue 246 
in high purity (Table 4.10, entry 2). The synthesis of N-terminal AOx-modified analogue 
252, using building block 255, gave the oxetane-modified peptide 252 in 76% purity 
along with 16% of an impurity identified as the peptide sequence with deletion of an 
alanine residue (Table 4.10, entry 3). N-Terminal GOx-analogue 254 was prepared in high 
purity using GOx-containing dipeptide building block 215 (Table 4.10, entry 4). During 
the synthesis of the oxetane-modified peptides, no by-products resulting from acetylation 
of the 3-aminooxetane unit were observed during the conditions used for N-terminal 
capping with acetic anhydride. Due to time and material constraints, the central GOx-
modified analogue 253 proposed at the outset of this study was not prepared.  
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Entry Building Block Peptide Sequence Purity (%)e 
1 - 
Ac-KAAAA-KAAAA-KAAAA-KGY-NH2, 248 
Parent 
92 
2 (S,S)-255 
Ac-KAAAA-KAAOxAA-KAAAA-KGY-NH2, 246 
Central AOx 
90 
3 (S,S)-255 
Ac-KAAOxAA-KAAAA-KAAAA-KGY-NH2, 252 
N-Terminal AOx 
76 
4 215 
Ac-KAGOxAA-KAAAA-KAAAA-KGY-NH2, 254 
N-Terminal GOx 
90 
Table 4.10 Solid-phase synthesis of peptides. a Treated with 2% TFA in CH2Cl2 for 2 h to reveal the 
free carboxylic acid from 255 and 215 prior to manual coupling with the resin-bound peptide and 
repeated using fresh reagents. b All deprotections performed at rt for 20 min. c All couplings performed 
at rt for 45 min. d Performed at rt for 20 min and repeated using fresh reagents. e By reverse-phase HPLC 
(at 214 nm). 
Although N-terminal AOx 252 was isolated in 76% purity, LC-MS analysis confirmed the 
impurity was the desired peptide sequence with deletion of an alanine residue indicating 
that the oxetane-containing building block 215 had successfully been incorporated. This 
observation led us to still investigate the secondary structure content of N-terminal AOx 
252 using CD spectroscopy. Attempts to re-synthesise and purify N-terminal AOx 252 to 
a higher level of purity are ongoing.  
These results nicely demonstrate the power of the solid-phase methodology developed in 
Chapter 3. Oxetane-modified peptides, up to 18 residues in length, were rapidly prepared 
using standard Fmoc/tBu SPPS conditions in high purity after purification by reverse-
phase HPLC.   
= NovaSyn® TGR R resin
(AA)m and (AA)n = peptide sequence of m and n amino acids respectively
AAOx = oxetane-modified residue
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4.3.4 Conformational Analysis of Oxetane-Modified Peptides  
Following the synthesis of the required peptides, the impact of oxetane-modification on 
helix structure and stability was determined using circular dichroism (CD) spectroscopy.  
 
4.3.4.1 Methods for Estimating Secondary Structure Content 
There are a number of methods used to estimate the secondary structure content of a 
peptide or protein from analysis of the CD spectrum. The methods used in this study are 
detailed below. 
Method 1 involves analysis of the residual ellipticity at 222 nm ([θ]222) to estimate the 
helical content. Assuming that the mean helix content (fH) is linearly related to the 
observed ellipticity at 222 nm ([θ]obs222) the equation for calculating helical content is: 
𝑓# = ( θ '()*** − θ ,)/( θ /*** − θ ,) (eq 1) 
where the random coil ([θ]C) and infinite helix ([θ]∞222) molar ellipticities are temperature 
dependent based on the equations: 
[θ], = 2220 − 53𝑇 (eq 2) 
[θ]/*** = (−44000 + 250𝑇)(1 − 𝑘/𝑁<) (eq 3) 
where T is the temperature in degrees Celcius, k is the number of non-hydrogen-bonded 
peptide C=O groups in a carboxyamidated peptide and Np is the number of peptide units. 
For this study, a value of k = 3.0 is used. As oxetane-modification involves deletion of an 
amide bond, the value of Np used for the oxetane-modified peptides is 18 compared with 
a value of 19 for the parent peptide system 248.24,141 
Method 2 uses DichroWeb, an online interface to several algorithms that perform 
analysis of the CD data. These algorithms are used to provide a total estimate of all 
secondary structure content. Estimated secondary structure content is determined by 
comparison of the CD data of the sample with a set of reference proteins and peptides 
with known secondary structure content. For this study, DichroWeb analysis was 
performed using Selcon3 algorithms (Ref. set 4) to estimate secondary structure 
content.142,143 
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4.3.4.2 CD Analysis of Oxetane-Modified Peptides  
To begin with, far-UV (250-185 nm) CD spectra were recorded in 10 mM potassium 
phosphate, pH 7.0 at 5 °C. This buffer system ensures that the peptides are soluble and 
stable in solution, and has previously been used in CD analysis of parent peptide 248. 
Figure 4.7 compares the spectra of the oxetane-modified peptides to the spectrum of 
parent peptide 248. Parent peptide 248 shows a characteristic α-helix spectrum with 
minima at ~222 and ~208 nm and a strong positive peak at ~190 nm. The oxetane-
modified peptides are significantly less structured and display typical random coil spectra 
with a maximum at ~217 nm and minimum at ~197 nm. These results suggest that 
oxetane-modification of the central and N-terminal region of an α-helix has a strongly 
helix-destabilising effect under aqueous conditions.  
 
Figure 4.7 Far-UV CD spectra of parent peptide 248 (black line) and the oxetane-modified peptides 246 
(red line), 252 (blue line) and 254 (green line) in 10 mM potassium phosphate, pH 7.0 at 5 °C. 
To quantify the destabilising effect of oxetane-modification, CD spectra of the peptides 
were recorded in 10 mM potassium phosphate buffer, pH 7.0 at 0 °C, with the addition 
of 1.0 M NaCl. The addition of NaCl has been shown to allow a more reliable 
determination of helical content for alanine-based model peptides and is often used for 
quantitative analysis. In addition, the helical value obtained for parent peptide 248 using 
these conditions would allow direct comparison with the value previously reported.24 It 
should be noted that NaCl absorbs strongly below 200 nm which means that this region 
of the spectrum cannot be used for analysis. CD spectra of the peptides in 10 mM 
potassium phosphate buffer, pH 7.0 at 0 °C, with the addition of 1.0 M NaCl are shown 
in Figure 4.8. Under these conditions, parent peptide 248 displays more pronounced α-
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helical character with deep minima at ~222 and ~207 nm. The oxetane-modified peptides 
displayed characteristic random coil spectra. 
 
Figure 4.8 Far-UV CD spectra of parent peptide 248 (black line) and the oxetane-modified peptides 246 
(red line), 252 (blue line) and 254 (green line) in 10 mM potassium phosphate, pH 7.0 at 0 °C, with the 
addition of 1.0 M NaCl. 
The helical contents of the peptides were calculated using Method 1. For parent peptide 
248 this results in a helix content of 58%, which is slightly lower than the reported value 
of 68% (Table 4.11, entry 1).24 Central AOx 246 was calculated to have a helix content of 
4% (Table 4.11, entry 2). The N-terminal AOx 252 and GOx 254 peptides were both 
calculated to have a slightly higher helix content value of 9% (Table 4.11, entries 3 and 
4). Absorption of NaCl below 200 nm prevented analysis of the CD data using 
DichroWeb (Method 2). 
Entry Peptide [θ]222 (deg.cm2.dmol−1)a 𝑓H	(%)	Method	1b 
1 Parent, 248 −20655 58 
2 Central AOx, 246 +487 4 
3 N-Terminal AOx, 252 −1443 9 
4 N-Terminal GOx, 254 −1170 9 
Table 4.11 Estimated helical content of the peptides in 10 mM potassium phosphate, pH 7.0 at 0 °C, 
with the addition of 1.0 M NaCl. a [θ]MRW at 222 nm. b Mean helix content calculated using equations 1-
3 described in Method 1. 
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These results indicate that oxetane-modification has a strongly helix-destabilising effect 
under aqueous conditions. Oxetane-modification in the central region of an α-helix results 
in essentially complete loss of helicity and favours the formation of random-coil 
conformations. Oxetane-modification of the N-terminal region retained a small amount 
of helical structure but predominantly favoured random coil conformations.  
Following these observations, CD spectra of the peptides were recorded in methanol at 0 
°C. Methanol, along with trifluoroethanol, is known to induce helicity in peptides and 
proteins.144 Hence, the oxetane-modified peptides were expected to show an increase in 
helical content. Figure 4.9 compares the spectra of the oxetane-modified peptides to the 
spectra of parent peptide 248. All of the oxetane-modified peptides show a significant 
increase in helical character compared to the spectra recorded in aqueous solution. 
Comparison with parent peptide 248 reveals a destabilising effect of oxetane-
modification in methanol. However, the decrease in helical content caused by oxetane-
modification is more prominent in central AOx 246 than the N-terminal analogues 252 and 
254. Central AOx 246 displays a minimum at ~207 nm accompanied by a shoulder at ~222 
nm with intensities in a ratio R = [θ]222/[θ]208 of ~0.45, in addition to a positive band at 
~195 nm of reduced intensity. These characteristics are suggestive of a 310-helix,145 which 
has been proposed as an intermediate in the folding/unfolding mechanism of α-
helices.146,147 N-Terminal modified analogues 252 and 254 display identical spectra and 
indicate a significant fraction of α-helix.   
 
Figure 4.9 Far-UV CD spectra of parent peptide 248 (black line) and the oxetane-modified peptides 246 
(red line), 252 (blue line) and 254 (green line) MeOH at 0 °C. 
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The helical content of the peptides were calculated using Method 1 and Method 2. The 
values were in good agreement for all peptides and are shown in Table 4.12. Parent 
peptide 248 had a helix content of 56-57% in methanol, which was comparable to the 
value of 58% under aqueous conditions (Table 4.12, entry 1). The helix content of central 
AOx 246 was significantly lower (15-17%) confirming that oxetane-modification in the 
central region results in a strongly helix-destabilising effect (Table 4.12, entry 2). Helix 
content values for N-terminal analogues 252 (33-34%) and 254 (34-37%) confirmed that 
oxetane-modification of the N-terminal region also results in a helix-destabilising effect, 
although to a lesser extent (Table 4.12, entries 3-4). In addition, these values are very 
similar indicating that the α-substituent of the oxetane-modified residue has little impact 
on helix stability when located at the N-terminus in methanol. Further analysis using 
Method 2 indicates that the oxetane-modified peptides show a significant increase in β-
sheet content compared to parent peptide 248, with central AOx 246 displaying a β-sheet 
content of ~30% (Table 4.12). The CD spectrum of a β-sheet is typically characterised by 
a minimum at ~215 nm and a maximum between 190-200 nm. As previous work in our 
group has suggested that oxetane-modification could give rise to turn-like 
conformations,1 it is possible that introduction of an oxetane-modified residue into these 
sequences is promoting turn-like features which result in formation of β-hairpin 
conformations.   
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Entry Peptide [θ]222 (deg.cm2.dmol−1)a 𝑓H (%) Method 1b 𝑓H (%) Method 2c 
1 Parent, 248 −19861 56 57 
2 Central AOx, 246 −4394 17 15 
3 N-Terminal AOx, 252 −10496 33 34 
4 N-Terminal GOx, 254 −10902 34 37 
 
Table 4.12 Estimated secondary structure content of the peptides in MeOH at 0 °C. a [θ]MRW at 222 nm. 
b Calculated using equations 1-3 described in Method 1. c Calculated using DichroWeb algorithms 
(Selcon3, Ref. set 4) as described in Method 2.142,143 
These observations suggest that the oxetane-modified analogues can retain an appreciable 
amount of helical content in methanol. However, comparison with parent peptide 248 
reveals again a helix-destabilising effect of the oxetane-modification, although the 
decrease in helical content is less pronounced than in aqueous solution. Oxetane-
modification in the central region of an α-helix results in significant loss of helicity and 
only a small amount of helix content is retained. In comparison, oxetane-modification of 
the N-terminal region retains a significant fraction of helix content. Additionally, 
DichroWeb analysis (Method 2) indicates an increased preference for the oxetane-
modified peptides to adopt β-sheet conformations in methanol compared to parent peptide 
248, with central AOx 246 displaying a β-sheet content of ~30%.  
Encouraged by these observations, we were interested to further probe the impact of 
oxetane-modification on the secondary structure using 1D and 2D 1H-NMR experiments. 
However, the conditions used to record the CD spectra were not suitable for the desired 
1H-NMR experiments. Therefore, CD spectra of the peptides were recorded in 80% 
methanol in water at 5 °C to confirm the secondary structure content under the conditions 
required for the 1H-NMR experiments (80% MeOD in H2O at 5 °C). CD spectra of the 
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peptides are shown in Figure 4.10. Under these conditions central AOx 246 is significantly 
less structured but still displays a small amount of helical structure. Both N-terminal 
analogues 252 and 254 retain helical structure with AOx analogue 252 displaying a larger 
amount of helical content. Again, parent peptide 248 shows a typical α-helix spectrum. 
 
Figure 4.10 Far-UV CD spectra of parent peptide 248 (black line) and the oxetane-modified peptides 
246 (red line), 252 (blue line) and 254 (green line) in 80% MeOH in H2O at 5 °C. 
Calculated values for helix content using Method 1 and Method 2 were in good 
agreement for the oxetane-modified peptides (Table 4.13, entries 2-4). The helix content 
of central AOx 246 is ~12%, further demonstrating that oxetane-modification in the central 
region has a strongly helix-destabilising effect (Table 4.13, entry 2). N-Terminal AOx 252 
was calculated to have a helix content of 32-34%, compared with a value of 27% for GOx 
analogue 254. In contrast to the results in 100% methanol, there is an appreciable 
difference between the helix content values of N-terminal analogues 252 (32-34%) and 
254 (27%) indicating that the α-substituent of the oxetane-modified residue can have an 
impact on helix stability when located at the N-terminus. There was a significant 
difference between the helix content values calculated for parent peptide 248 (Table 4.13, 
entry 1). However, both values confirmed parent peptide 248 contained a substantial 
amount of helical character (46-56%).  In addition, analysis using Method 2 showed 
again that the oxetane-modified peptides have a preference to form β-sheet conformations 
compared to parent peptide 248, with central AOx 246 displaying a β-sheet content of 
~26%. 
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Entry Peptide [θ]222 (deg.cm2.dmol−1)a 𝑓H (%) Method 1b 𝑓H (%) Method 2c 
1 Parent, 248 −19239 56 46 
2 Central AOx, 246 −2483 12 12 
3 N-Terminal AOx, 252 −10813 34 32 
4 N-Terminal GOx, 254 −8262 27 27 
 
Table 4.13 Estimated secondary structure content of the peptides in 80% MeOH in H2O at 5 °C. a [θ]MRW 
at 222 nm. b Calculated using equations 1-3 described in Method 1. c Calculated using DichroWeb 
algorithms (Selcon3, Ref. set 4) as described in Method 2.142,143 
Comparison of the helix content values obtained in 80% methanol in water at 5 °C with 
those obtained in 100% methanol at 0 °C indicate that no loss of helix content is observed 
for parent peptide 248 and N-terminal AOx 252, and only a small decrease is detected for 
central AOx 246 and N-terminal GOx 254. Based on these observations, it would be of 
interest to record CD in various concentrations of methanol in water, along with other 
helix inducing solvents such as trifluroethanol, in an attempt to maximise the helix 
content of the oxetane-modified peptides. Due to time constraints, further CD analysis of 
the peptides has not been performed.  
1H-NMR analysis and molecular dynamic (MD) simulations are being used to further 
understand the impact of oxetane-modification on the secondary structure content and 
stability of α-helices. This work is being conducted in collaboration with Eleanor 
Jayawant, Dr Ann Dixon and Dr Becky Notman at the University of Warwick, and is 
currently ongoing.  
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4.3.4.3 Conclusions from Circular Dichroism Analysis 
Circular dichroism (CD) analysis of the oxetane-modified peptides in 10 mM potassium 
phosphate gave only random coil structures. In contrast, CD analysis of the  oxetane-
modified peptides in methanol all showed some helical character. Quantification of the 
CD data revealed that introduction of an oxetane-modification at two different positions 
within an alanine-based α-helical peptide has a helix-destabilising effect. There are three 
likely explanations for this: 
1. The oxetane moiety is significantly bulkier in comparison to a carbonyl group, 
which makes it difficult to integrate into the densely packed α-helix.  
2. The change in hybridisation (sp2 to sp3) of the oxetane-modified residue results in 
a higher degree of rotational freedom, which is unfavourable in an α-helix.  
3. Both the hydrogen-bonding acceptor ability of an oxetane and the hydrogen-
bonding donor ability of an amine are weaker than an amide,38,110 which could 
further contribute to the helix-destabilising effect.  
Despite their strong helix-destabilising effect, our results indicate that it is possible to 
incorporate oxetane-modification into the N-terminal region of α-helical structures and 
still retain an appreciable amount of helical content. In addition, the destabilising effect 
of oxetane-modification may be different in α-helices that are already stabilised by side-
chain interactions, or by application of stapling techniques. Therefore, it would be 
worthwhile investigating the impact of oxetane-modification on stabilised α-helices. 
Further analysis of the secondary structure content using DichroWeb revealed a 
preference for the oxetane-modified peptides to adopt β-sheet like conformations. It is 
possible that the higher degree of rotational freedom of the oxetane-modified residue is 
promoting turn-like features which result in formation of β-hairpin conformations. It 
would be of great interest to investigate this observation further by preparing oxetane-
modified analogues of known β-hairpin motifs and determining the impact of oxetane-
modification on the structure and stability of these important types of secondary 
structure.148,149  
 
4.4 Conclusions 
In conclusion, this chapter has described the synthesis and structural analysis of oxetane-
modified analogues of an alanine-based α-helical peptide. The first part of this chapter 
 124 
described efforts towards the synthesis of dipeptide building blocks containing oxetane-
modified residues beyond glycine. These efforts have led to the development of a novel 
route to enantiopure 3-aminooxetane (S)-282 which was used to prepare an AOx-
containing dipeptide building block (S,S)-255 (Scheme 4.18). This route is significantly 
shorter than the approach previously developed by Carreira and co-workers.47  
 
Scheme 4.18 Synthesis of oxetane-modified alanine (AOx) dipeptide building block (S,S)-255. 
Using the solid-phase peptide synthesis (SPPS) methodology described in Chapter 3, 
oxetane-containing dipeptide building blocks 255 and 215 were used to prepare analogues 
of an alanine-based α-helical peptide in which a single alanine residue located in the 
central or N-terminal region was replaced with an oxetane-modified residue. The 
synthesis of these analogues further demonstrates the benefit of the solid-phase 
methodology as oxetane-modified peptides, up to 18 residues in length, can be rapidly 
prepared using standard Fmoc/tBu SPPS conditions in high purity after purification by 
reverse-phase HPLC. 
Circular-dichroism (CD) studies of these peptides revealed that introduction of an 
oxetane-modification at a central and N-terminal position has a helix-destabilising effect. 
Despite this, N-terminal oxetane-modified analogues 252 and 254 retain a considerable 
amount of helical content in methanol. Further analysis of the secondary structure content 
of the oxetane-modified analogues reveals an increase in β-sheet content compared to the 
parent peptide 248. 1H-NMR experiments and molecular dynamic (MD) simulations are 
currently being conducted to further understand the structural basis of the helix-
destabilising effect of oxetane-introduction. 
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Chapter 5: Key Findings and Future Work 
5.1 Key Findings 
This section provides a summary of the key findings reported in Chapters 2-4.  
An efficient two-step sequence to spirocyclic scaffolds related to 2,5-diketopiperazines 
(DKPs) wherein one of the C=O bonds is replaced with an oxetane or azetidine ring has 
been developed. Conjugate addition of α-amino methyl esters to nitroalkenes generated 
from oxetan-3-one or N-Boc-azetidin-3-one gives the spirocyclic precursors. Subsequent, 
reduction of the nitro group with Raney Ni under an atmosphere of hydrogen generates, 
after spontaneous cyclisation of the primary amine, the spirocycles in good overall yield 
(Scheme 5.1). 
 
Scheme 5.1 Synthesis of oxetane- and azetidine-containing spirocycles related to the 2,5-
diketopiperazine framework. 
These rigid scaffolds could be further functionalised by selective alkylation of the amide 
and amine nitrogens as well as by carbonyl reduction to the corresponding piperazine 
(Scheme 5.2).  
 
Scheme 5.2 Further functionalisation of oxetane-containing spirocycles. 
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In collaboration with Dr Andrew Jamieson, methodology for the synthesis of oxetane-
modified peptides (OMPs) using conventional Fmoc/tBu solid-phase peptide synthesis 
(SPPS) techniques has been developed. The approach involves using cumyl-protected 
dipeptide building blocks where the ester can be selectively cleaved with 2% TFA in 
CH2Cl2 to reveal the terminal carboxylic acid. Initially, Fmoc-protected dipeptide 
building blocks in which the oxetane residue is based on glycine were prepared in three 
steps in solution (Scheme 5.3).  
 
Scheme 5.3 Synthesis of dipeptide building blocks containing an oxetane-modified glycine residue. 
A route to enantiopure 3-aminooxetane (S)-282 was developed to access Fmoc-protected 
dipeptide building block (S,S)-255 containing an oxetane-modified alanine residue. The 
key step involves addition of (R)-(+)-α-methylbenzylamine 273 to trisubstituted-
nitroalkene 128 to give a mixture of diastereoisomers, from which the major 
diastereoisomer (S,R)-277 was isolated in dr >95:5 (Scheme 5.4). The key limitation 
being the need to be able to efficiently separate the diastereoisomers as high levels of 
diastereocontrol could not be realised in the conjugate addition step. Although the full 
scope has yet to be explored, preliminary results indicate that dipeptide building blocks 
in which the oxetane residue is based on valine could be prepared using this approach.  
 
Scheme 5.4 Synthesis of dipeptide building block (S,S)-255. 
H
N O
O
O R
FmocOSu
Raney Ni, H2
FmocHN
H
N
O R
O
O
50-78%
FmocHN CO2H
R
FmocHN
R
O
O Ph
Cl3C O
NH
Ph
1. Et2NH
2. O
O2N
40-60%
Ph Ph
70-97%
O2N
7 examples where R = Bn, iPr, CH2OtBu, CH2CO2tBu, (CH2)4NHBoc, -(CH2)3- [Pro], CH3
DIPEA, MeCN
MeO2N
O
H2N Ph
Me
O2N
Me
O
H
N Ph
Me
i. 20% Pd(OH)2, H2
   MeOH
(S,R)-277, 50%
(dr >95:5)
128
FmocHN
Me
O
NH2
(S)-282, 50%
ii. FmocOSu, NaHCO3
    CH2Cl2
(R)-273
TfO
Me
O
O Ph FmocHN
Me
O
H
N
O
O Ph
Me
(S,S)-255, 50%
(dr 99:1)
+
>95% conversion
(dr 60:40)
CH2Cl2
+
SN2
283
 127 
Solution-phase chemistry using oxetane-containing dipeptide building blocks has 
demonstrated that amide couplings can proceed in high yield, without racemisation, and 
without the need to protect the secondary amine of the 3-aminooxetane unit. Hence, 
oxetane-modified peptides can be produced in high purities and acceptable yields using 
conventional Fmoc/tBu SPPS methods. This methodology has been used to prepare 
oxetane-modified peptides up to 18 residues in length, including analogues of Leu- and 
Met-enkephalin, bradykinin, and alanine-based model peptides (Figure 5.1).  
 
 
Figure 5.1 Solid-Phase Synthesis of Oxetane-Modified Peptides 
Preliminary studies regarding the biological properties of oxetane-modified Met- 231 and 
Leu-enkephalin 232 analogues indicate that oxetane modification of the central glycine 
residue has a detrimental impact on the binding affinities towards the δ- and µ-opioid 
receptors. However, a more complete study by Carreira and co-workers has demonstrated 
that oxetane-modified analogues of Leu-enkephalin have improved hydrolytic stability in 
human serum and that two of four analogues retain reasonable affinity towards the δ-
opioid receptor.47  
Circular-dichroism (CD) studies on oxetane-modified alanine-based α-helices have 
revealed that introduction of an oxetane-modification at a central and N-terminal position 
results in a significantly helix-destabilising effect. Despite this, N-terminal oxetane-
modified analogues 252 and 254 retain a considerable amount of helical content in 
methanol at 0 °C (Table 5.1). Further analysis of the secondary structure content revealed 
an increased preference for the oxetane-modified analogues to adopt β-sheet 
conformations compared to the parent peptide 248.  
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Entry Peptide Sequence 𝑓H (%)a 
1 
Ac-KAAAA-KAAAA-KAAAA-KGY-NH2, 248 
Parent 
57 
2 
Ac-KAAAA-KAAOxAA-KAAAA-KGY-NH2, 246 
Central AOx 
15 
3 
Ac-KAAOxAA-KAAAA-KAAAA-KGY-NH2, 252 
N-Terminal AOx 
34 
4 
Ac-KAGOxAA-KAAAA-KAAAA-KGY-NH2, 254 
N-Terminal GOx 
37 
Table 5.1 Estimated helix content of the peptides in MeOH at 0 °C. a Calculated using DichroWeb 
algorithms (Selcon3, Ref. set 4).142,143 
An additional collaboration, with Professor Dave Adams and Dr Andrew Jamieson, has 
also demonstrated that Fmoc-protected oxetane-dipeptides can be used to prepare 
hydrogels. For example, oxetane-based dipeptide 175 is an effective gelator, forming 
hydrogels at a concentration of 3 mg mL−1. Furthermore, 175 is significantly more 
resistant to proteolysis compared to the parent dipeptide 245 (Scheme 5.5). 
 
Scheme 5.5 Enzymatically-stable oxetane-based dipeptide hydrogels.  
 
5.2 Future Work 
It would be of interest to further explore modifications of the oxetane- and azetidine-
containing spirocycles prepared in Chapter 1. For example, routes towards 2-substituted 
oxetan-3-ones and azetidine-3-ones 311 via metalated SAMP/RAMP hydrazones have 
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previously been prepared within our research group.150,151 These substituted-analogues 
could be used to access nitroalkene 312, which in turn could be used to prepare 2-
substituted oxetane- and azetidine-containing spirocycles 314 (Scheme 5.6). 
 
Scheme 5.6 Synthesis of 2-substituted oxetane- and azetidine-containing spirocycles 314. 
Furthermore, the application of β- and 𝛾-amino methyl esters in the conjugate addition 
step could provide access to 7- and 8-membered oxetane- and azetidine-containing 
spirocycles 317 (Scheme 5.7). These additional modifications would further demonstrate 
the utility of these novel scaffolds. 
 
Figure 5.7 Synthesis of 7-membered oxetane- and azetidine-containing spirocycles 317. 
Due to time constraints, we were unable to explore the full potential of the approach 
towards enantiopure 3-aminooxetanes 319. It would be of great interest to further 
investigate the addition of α-methylbenzylamine 273 to a variety of other trisubstituted 
nitroalkenes 24 to determine if additional oxetane-modified residues can be prepared 
using this approach (Scheme 5.8).  
N
X
N
MeO
i. nBuLi or tBuLi
ii. R1X, −78 °C to rt
iii. (CO2H)2
O
X
R1
i. NO2Me, NEt3
ii. MsCl, NEt3
X
O2N
O
H
N CO2Me Raney Ni, H2 HN
NH
X
O
310 311
upto 85% ee
312
313 314
X= O or NBoc
R1
R1
R1
NO2
R2
R2H2N CO2Me
R2
R1O2N
X
H2N CO2Me
O2N
R1
X
H
N CO2Me
X
NH
HN
O
R1
X= O or NBoc
Raney Ni, H2
315 316 317
R2
R3
R3
R2 R2
R3
 130 
 
Scheme 5.8 Route towards oxetane-containing dipeptide building blocks 321 via enantiopure 3-
aminooxetanes 319.  
Alternative routes to enantiopure 3-aminooxetanes 321, such as nitro-Mannich reactions 
also merit investigation. For example, an auxiliary controlled reaction of nitroalkanes 
with imine 322, derived from the condensation of oxetan-3-one and Ellmans’s auxillary 
62,152 could be developed as a novel route towards enantiopure 3-aminooxetanes 319 
(Scheme 5.9). Similar base-promoted diastereoselective additions of nitroalkanes to N-
tert-butylsulfinyl imines have previously been reported in the literature.153,154  
 
Scheme 5.9 Nitro-Mannich approach to enantiopure 3-aminooxetanes 319. 
Having established that introduction of oxetane-modification into α-helices results in 
helix-destabilisation, the impact of oxetane-modification on the structure and stability of 
other secondary structure types warrants investigation. Gellman and co-workers have 
demonstrated that tetrapeptide 324, possessing a D-Pro-D-Ala sequence, readily forms a 
β-hairpin conformation with two intramolecular H-bonds in CD2Cl2 (Scheme 5.10).155 
This sequence offers an excellent experimental template to study the impact of oxetane-
modification on the structure and stability of turn regions. Oxetane-modified analogues 
325 and 326, in which the D-alanine or D-proline residue is substituted for either a GOx, 
D-AOx or L-AOx residue, could be prepared using chemistry described in this thesis 
(Scheme 5.10). The structure and stability of these analogues relative to the native system 
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could then be studied using CD and NMR spectroscopy. These experiments would help 
determine the impact of oxetane-modification within turn regions.  
 
Scheme 5.10 Study of oxetane-modified β-hairpin motifs.155 
Furthermore, it would be of interest to explore the impact of oxetane-modification within 
the strand region of a β-hairpin. Searle and co-workers have demonstrated that 16-mer 
327 is ~50% folded in water and adopts a β-hairpin structure stabilised by the H-bonding 
network depicted in Figure 5.2.156 This sequence is an excellent experimental platform to 
investigate the impact of oxetane-modification on the structure and stability within strand 
regions. Initially, if access to a dipeptide building block in which the oxetane residue is 
based on valine is realised, oxetane-modified analogues 328 and 329, in which the valine 
residues at the i + 4 and i + 13 positions are substituted for a VOx residue, could be 
prepared using the solid-phase methodology described in this thesis. Additional oxetane-
modified analogues could be prepared if access to other oxetane-modified residues is 
realised. The impact of oxetane-modification within the strand region could then be 
explored using CD and NMR spectroscopy. In addition, oxetane-modified analogue 330, 
in which the glycine residue at the i + 8 position is substituted for a GOx residue could be 
prepared to further examine the impact of oxetane-modification within turn regions.  
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Figure 5.2 Study of oxetane-modification within the β-strand region of a hairpin.156 
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Chapter 6: Experimental Section 
6.1 General Details 
Anhydrous solvents were purchased from Sigma-Aldrich or Acros Organics in Sure-
SealTM bottles for use as reaction solvents. All other solvents were reagent grade and used 
as received. Petroleum ether refers to the fraction that boils in the range 40-60 °C. 
Commercially available starting materials were used without purification unless 
otherwise stated. All amino acids are of L-configuration unless otherwise stated. 
Compounds (S)-109,1 (R)-109,1 110,1 126,76 341 and 1781 were prepared following 
previously described literature procedures. Amino methyl esters were free based from the 
corresponding hydrochloride salt following a literature procedure and used 
immediately.77 
Thin layer chromatography was performed on pre-coated aluminium-backed plates 
(Merck Silicagel 60 F254), visualised by UV 254 nm and then stained with 
phosphomolybdic acid (PMA) dip and heated. Flash column chromatography was 
performed using Aldrich 40-63 µm silica gel.  
Nuclear magnetic resonance (NMR) spectra were recorded on Bruker DPX (300 or 400 
MHz), or AV (500 MHz) spectrometers. Chemical shifts (d) are reported in parts per 
million (ppm) relative to the solvent residual peaks (CDCl3 dH: 7.26 ppm, dC: 77.16 ppm; 
CD3OD dH: 3.31, dC 49.00; C6D6 dH: 7.16, dC: 128.06; DMSO-d6 dH: 2.50 ppm, dC 39.52 
ppm). Coupling constants (J) are reported in hertz (Hz). Splitting patterns are abbreviated 
as follows: singlet (s), doublet (d), triplet (t), quartet (q), quintet (quint), septet (sep), 
multiplet (m), broad (b), or combination of these. NMR assignments were deduced using 
1D 13C experiments (APT) and 2D experiments (COSY, HSQC and HMBC). 
Low-resolution mass spectra were recorded on an Agilent Technologies 6130 Quadrupole 
LC-MS instrument. High-resolution mass spectra were recorded using a Bruker MaXis 
Impact. Infrared spectra were recorded with a Bruker ALPHA Platinum ATR apparatus 
and are reported as observed. Optical rotations [𝛼]GH  were measured using an AA-1000 
polarimeter and reported as observed. 
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6.2 General Procedures 
General procedure 1: Synthesis of oxetane containing nitro amino esters 
 
Oxetan-3-one (1.0 equiv), nitromethane (1.4 equiv) and triethylamine (0.2 equiv) were 
stirred at room temperature for 60 min. CH2Cl2 (0.25 M) was added and the reaction 
mixture cooled to –78 ˚C. Triethylamine (2.0 equiv) was added followed by the dropwise 
addition of a solution of methanesulfonyl chloride (1.0 equiv) in CH2Cl2 (1.0 M). The 
reaction mixture was left to stir at –78 ˚C for 90 min. Meanwhile, to a solution of amino 
ester hydrochloride (2.0 equiv) in CH2Cl2 (0.25 M) was added triethylamine (2.0 equiv) 
and this mixture was stirred at room temperature for 10 min. This solution was added to 
the oxetane mixture via syringe at –78 ˚C. The reaction mixture was allowed to warm to 
room temperature and stirred for 16 h. A saturated solution of NH4Cl (8 mL/mmol) was 
added to the reaction mixture and stirred for 10 min. The layers were separated and the 
aqueous extracted with CH2Cl2 (2 x 10 mL/mmol) and EtOAc (2 x 10 mL/mmol). The 
combined organics were washed with saturated NaHCO3 (2 x 8 mL/mmol) then brine (4 
mL/mmol), dried (MgSO4), filtered and concentrated under reduced pressure, and the 
products purified by column chromatography. 
 
General Procedure 2: Synthesis of oxetane nitroalkenes 
 
The synthesis of oxetane nitroalkenes were adapted from procedures originally published 
by Carreira74 and Ellman.75  
Oxetan-3-one (1.3 equiv) and nitroalkane (1.0 equiv) were cooled to 0 °C. Triethylamine 
(0.2 equiv) was added and the reaction mixture stirred at 0 °C for 30 min and then at room 
temperature for 90 min. THF (0.1 M) was added and the reaction cooled to −78 °C. 
Triethylamine (2.0 equiv) was added followed by the dropwise addition of 
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methanesulfonyl chloride (1.1 equiv). The reaction mixture was left to stir at −78 °C for 
90 min, after which the dry-ice bath was removed, and the reaction mixture stirred for 60 
min. The reaction mixture was filtered through a plug of silica gel eluting with 25% 
EtOAc in petroleum ether. The eluent was concentrated under reduced pressure and the 
products purified by column chromatography.  
 
General procedure 3: Synthesis of nitro amino esters from trisubstituted nitroalkenes 
 
The nitroalkene (1.0 equiv) was dissolved in THF (0.1 M). Free amino ester (2.0 equiv) 
in THF (0.25 M) was added and the reaction mixture stirred at room temperature for the 
time stated. The reaction mixture was concentrated under reduced pressure to give a crude 
product which was purified by column chromatography or recrystallization. 
 
General procedure 4: Nitro reduction and cyclisation 
 
The substrate (1.0 equiv) and Raney Ni (1.0 mL/mmol, slurry in H2O) in MeOH (0.1 M) 
were stirred at room temperature under an atmosphere of H2 (balloon) for 16 h. The 
reaction mixture was filtered through a plug of Celite® eluting with EtOAc. The eluent 
was concentrated under reduced pressure and the crude product purified by column 
chromatography. 
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General procedure 5: Synthesis of azetidine containing nitro amino esters 
 
N-Boc-azetidin-3-one (1.0 equiv) and triethylamine (0.2 equiv) in nitromethane (1.0 M) 
were stirred at room temperature for 60 min. The reaction mixture was concentrated under 
reduced pressure and the resulting material dissolved in CH2Cl2 (0.25 M). The reaction 
mixture was cooled to –78 °C and triethylamine (2.0 equiv) added followed by the 
dropwise addition of methanesulfonyl chloride (1.0 equiv) in CH2Cl2 (1.0 M). The 
reaction mixture was left to stir at –78 °C for 90 min. Meanwhile, to a solution of amino 
ester hydrochloride (2.0 equiv) in CH2Cl2 (0.25 M) was added triethylamine (2.0 equiv) 
and stirred at room temperature for 10 min. This solution was added to the azetidine 
mixture via syringe at –78 °C. The reaction mixture was allowed to reach room 
temperature and left to stir for 16 h. A saturated solution of NH4Cl (8 mL/mmol) was 
added to the reaction mixture and stirred for 10 min. The layers were separated and the 
aqueous extracted with CH2Cl2 (2 x 10 mL/mmol) and EtOAc (2 x 10 mL/mmol). The 
combined organics were washed with saturated NaHCO3 (2 x 8 mL/mmol) and brine (4 
mL/mmol), dried (MgSO4), filtered and concentrated under reduced pressure to give a 
crude product that was purified by flash column chromatography. 
 
General procedure 6: Nitro reduction and Fmoc protection using 1.2 equivalents of 
FmocOSu 
 
To substrate (1.0 equiv) in THF (0.1 M) was added Fmoc N-hydroxysuccinimide ester 
(1.2 equiv), NaHCO3 (3.0 equiv) and Raney Ni (1 mL/mmol, slurry in H2O). The reaction 
mixture was stirred at room temperature under an atmosphere of H2 (balloon) until 
consumption of starting material (MS monitoring). The reaction mixture was filtered 
through a plug of Celite® eluting with EtOAc. The eluent was washed with saturated 
Na2CO3 (3 x 8 mL/mmol) and brine (4 mL/mmol), dried (MgSO4), filtered and 
O
N
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   rt, 1 h
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CH2Cl2, −78 °C to rt, 16 h
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    CH2Cl2, −78 °C, 1.5 h
H
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 137 
concentrated under reduced pressure, and the products purified by column 
chromatography. 
 
General procedure 7: Synthesis of cumyl esters 
 
Cumyl esters were prepared following a modified method of Potier and co-workers.103 To 
sodium hydride (60% dispersion in mineral oil, 0.5 equiv) in Et2O (0.5 M) at 0 °C was 
added freshly distilled 2-phenyl-2-propanol (2.2 equiv) in Et2O (2.0 M) and the reaction 
mixture was stirred at room temperature for 1 h. The reaction mixture was cooled to 0 °C. 
Trichloroacetonitrile (2.0 equiv) was added, the reaction mixture was stirred at room 
temperature for 3 h and then concentrated under reduced pressure. Petroleum ether (4.0 
M) and MeOH (0.5 equiv) were added and this mixture was stirred at room temperature 
for 10 min. The reaction mixture was filtered through a plug of Celite® eluting with 
petroleum ether. The eluent was concentrated under reduced pressure to give the crude 
imidate. To the crude imidate in CH2Cl2 (1.0 M) was added carboxylic acid (1.0 equiv) 
and the reaction mixture was stirred at room temperature for 16 h. The mixture was 
filtered through a plug of Celite® to remove precipitated trichloroacetamide. The crude 
product was concentrated under reduced pressure and purified by column 
chromatography. 
 
General procedure 8: Synthesis of oxetane containing nitro amino cumyl esters 
 
HO Ph
(2.2 equiv)
i. NaH (0.5 equiv)
   Et2O, 0 °C to rt, 1 h
ii. Cl3CCN (2.0 equiv)
    0 °C to rt, 3h
Cl3C O
NH
Ph CH2Cl2, rt, 16 h
X CO2H
R
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X
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O
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X = NHFmoc or OH
O
O O
O2N
O2N
H
N O
O
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RO
i. MeNO2 (2.8 equiv)
   NEt3 (0.4 equiv)
   rt, 1 h
ii. MsCl (2.0 equiv)
    NEt3 (4.0 equiv)
    CH2Cl2, −78 °C, 1.5 h
CH2Cl2, −78 °C to rt
16 h
H2N
R
O
O Ph
FmocHN
R
O
O Ph
50% Et2NH in CH2Cl2
rt, 1 h
(1.0 equiv)
(2.0 equiv)
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N-Fmoc amino cumyl esters (1.0 equiv) in 50% diethylamine in CH2Cl2 (0.5 M) was 
stirred at room temperature for 1 h. The reaction mixture was concentrated under reduced 
pressure and the resulting residue repeatedly dissolved in CH2Cl2 (3 x 10 mL/mmol) and 
concentrated under reduced pressure to give the crude amine. Meanwhile, oxetan-3-one 
(2.0 equiv), nitromethane (2.8 equiv) and triethylamine (0.4 equiv) were stirred at room 
temperature for 1 h. CH2Cl2 (0.25 M) was added and the reaction mixture cooled to −78 
°C. Triethylamine (4.0 equiv) was added followed by the dropwise addition of a solution 
of methanesulfonyl chloride (2.0 equiv) in CH2Cl2 (1.0 M). The reaction mixture was 
stirred at −78 °C for 1.5 h. The crude amine in CH2Cl2 (0.25 M) was added to the oxetane 
mixture via syringe at −78 °C. The reaction mixture was allowed to reach room 
temperature and stirred for 16 h. A saturated solution of NH4Cl (8 mL/mmol) was added 
and stirred for 10 min. The layers were separated and the aqueous extracted with CH2Cl2 
(2 x 10 mL/mmol) and EtOAc (2 x 10 mL/mmol). The combined organics were washed 
with saturated NaHCO3 (2 x 8 mL/mmol) then brine (4 mL/mmol), dried (MgSO4), 
filtered and concentrated under reduced pressure, and the products purified by column 
chromatography. 
 
General procedure 9: Nitro reduction and Fmoc protection using 2.0 equivalents of 
FmocOSu 
 
To substrate (1.0 equiv) in THF (0.1 M) was added Fmoc N-hydroxysuccinimide ester 
(2.0 equiv), NaHCO3 (4.0 equiv) and Raney Ni (1 mL/mmol, slurry in H2O). The reaction 
mixture was stirred at room temperature under an atmosphere of H2 (balloon) until 
consumption of starting material (MS monitoring). The reaction mixture was filtered 
through a plug of Celite® eluting with EtOAc. The eluent was washed with saturated 
Na2CO3 (3 x 8 mL/mmol) and brine (4 mL/mmol), dried (MgSO4), filtered and 
concentrated under reduced pressure, and the products purified by column 
chromatography. 
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General Procedure 10: Cumyl ester deprotection 
 
Substrate (1.0 equiv) in 2% TFA/CH2Cl2 (0.05 M) was stirred at room temperature until 
consumption of the starting material (TLC monitoring), The reaction mixture was 
concentrated under reduced pressure and the resulting residue repeatedly dissolved in 
CH2Cl2 (5 x 20 mL/mmol) and concentrated under reduced pressure to give a crude 
product that was purified by column chromatography.  
 
General procedure 11: Cumyl ester deprotection and C-terminal coupling 
 
Substrate (1.0 equiv) in 2% TFA/CH2Cl2 (0.05 M) was stirred at room temperature until 
consumption of starting material (TLC monitoring). The reaction mixture was 
concentrated under reduced pressure and the resulting residue repeatedly dissolved in 
CH2Cl2 (3 x 10 mL/mmol) and concentrated under reduced pressure. To this crude acid 
in CH2Cl2 (0.1 M) was added D- or L-phenylalanine tert-butyl ester hydrochloride (2.0 
equiv), DIPEA (4.0 equiv) and HCTU (1.0 equiv). The reaction mixture was stirred at 
room temperature for 16 h. The mixture was diluted with EtOAc (100 mL/mmol), washed 
with brine (2 x 50 mL/mmol), 1.0 M HCl (3 x 50 mL/mmol), saturated NaHCO3 (3 x 50 
mL/mmol), brine (25 mL/mmol), dried (MgSO4), filtered and concentrated under reduced 
pressure, and the products purified by column chromatography.  
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6.3 Experimental Procedures and Characterisation 
tert-Butyl [3-(nitromethyl)oxetan-3-yl]-L-valinate 111 
Following general procedure 1, oxetan-3-one (161 µL, 2.51 mmol), 
nitromethane (189 µL, 3.50 mmol) and L-valine tert-butyl ester 
hydrochloride (1.05 g, 5.00 mmol) were combined to give, after column 
chromatography (10-20% EtOAc in petroleum ether), 111 (410 mg, 1.42 mmol, 57%) as 
an orange oil. Rf (15% EtOAc in petroleum ether) 0.27; [𝛂]𝐃𝟐𝟖 –10.9 (c 0.10, CHCl3); 1H-
NMR (500 MHz, CDCl3) d 4.83 (1H, d, J = 13.0 Hz, NO2CHH), 4.76 (1H, d, J = 13.0 
Hz, NO2CHH), 4.64 (1H, d, J = 7.1 Hz, OCHH-Ox), 4.58 (1H, d, J = 7.2 Hz, OCHH-
Ox), 4.52 (1H, d, J = 7.1 Hz, OCHH-Ox), 4.45 (1H, d, J = 7.1 Hz, OCHH-Ox), 3.13 (1H, 
d, J = 5.5 Hz, CHα-Val), 2.55-2.19 (1H, bs, NH), 1.97-1.85 (1H, m, CHβ-Val), 1.46 (9H, 
s, tBu), 0.94 (3H, d, J = 6.7 Hz, CH3-Val), 0.86 (3H, d, J = 6.9 Hz, CH3-Val); 13C-NMR 
(125 MHz, CDCl3) d 174.8 (C=O), 82.0 (C, tBu), 78.9 (NO2CH2 or OCH2-Ox), 78.8 
(NO2CH2 or OCH2-Ox) 78.5 (OCH2-Ox), 61.8 (CH, α-Val), 59.6 (C, Ox), 32.3 (CH, β-
Val), 28.1 (3 x CH3, tBu), 19.4 (CH3, Val), 17.9 (CH3, Val); IR (film) 3333 (NH), 2966, 
2876, 1719 (C=O), 1555, 1146 cm−1; MS (ESI+) m/z 289 [M+H]+, 311 [M+Na]+; HRMS 
(ESI+) Calcd.. for C13H25N2O5 [M+H]+: 289.1758, found 289.1754. 
 
Methyl [3-(nitromethyl)oxetan-3-yl]glycinate 113 
Following general procedure 1, oxetan-3-one (161 µL, 2.51 mmol), 
nitromethane (189 µL, 3.50 mmol) and glycine methyl ester 
hydrochloride (628 mg, 5.00 mmol) were combined to give, after 
column chromatography (30-60% EtOAc in petroleum ether), 113 (282 mg, 1.38 mmol, 
55%) as a yellow oil. Rf (50% EtOAc in petroleum ether) 0.24; 1H-NMR (500 MHz, 
CDCl3) d 4.83 (2H, s, NO2CH2), 4.63 (2H, d, J = 7.5 Hz, 2 x OCHH-Ox), 4.58 (2H, d, J 
= 7.5 Hz, 2 x OCHH-Ox), 3.74 (3H, s, CH3), 3.54 (2H, s, CH2-Gly), 2.56-2.16 (1H, bs, 
NH); 13C-NMR (125 MHz, CDCl3) d 172.3 (C=O), 78.5 (NO2CH2), 78.4 (2 x CH2-Ox), 
59.6 (C, Ox), 52.5 (CH3), 44.7 (CH2-Gly); IR (film) 3338 (NH), 2957, 2883, 1735 (C=O), 
1548, 1208 cm−1; MS (ESI+) m/z 205 [M+H]+, 227 [M+Na]+, 243 [M+K]+; HRMS (ESI+) 
Calcd. for C7H13N2O5 [M+H]+: 205.0819, found 205.0818. 
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Methyl [3-(nitromethyl)oxetan-3-yl]-L-alaninate 114 
Following general procedure 1, oxetan-3-one (129 µL, 2.01 mmol), 
nitromethane (151 µL, 2.79 mmol) and L-alanine methyl ester 
hydrochloride (558 mg, 4.00 mmol) were combined to give, after 
column chromatography (20-40% EtOAc in petroleum ether), 114 (239 mg, 1.10 mmol, 
55%) as a yellow oil. Rf (40% EtOAc in petroleum ether) 0.30; [𝛂]𝐃𝟐𝟗 –2.7 (c 0.10, 
CHCl3); 1H-NMR (400 MHz, CDCl3) δ 4.89 (1H, d, J = 12.8 Hz, NO2CHH), 4.84 (1H, 
d, J = 12.8 Hz, NO2CHH), 4.65 (1H, d, J = 7.2 Hz, OCHH-Ox), 4.62 (1H, d, J = 7.1 Hz, 
OCHH-Ox), 4.54 (1H, d, J = 7.2 Hz, OCHH-Ox), 4.44 (1H, d, J = 7.1 Hz, OCHH-Ox), 
3.73 (3H, s, OCH3), 3.61 (1H, q, J = 7.0 Hz, CHα-Ala), 2.87-2.25 (1H, bs, NH), 1.32 (3H, 
d, J = 7.0 Hz, CH3-Ala); 13C-NMR (125 MHz, CDCl3) δ 176.0 (C=O), 79.1 (OCH2-Ox), 
79.0 (OCH2-Ox), 78.2 (NO2CH2), 59.7 (C, Ox), 52.6 (OCH3), 51.4 (CH, α-Ala), 20.4 
(CH3-Ala); IR (film) 3337 (NH), 2955, 2880, 1731 (C=O), 1553 cm−1; MS (ESI+) m/z 
219 [M+H]+, 241 [M+Na]+; HRMS (ESI+) Calcd. for C8H14N2O5Na [M+Na]+: 241.0795, 
found 241.0797. 
 
Methyl [3-(nitromethyl)oxetan-3-yl]-L-serinate 1151 
Following general procedure 1, oxetan-3-one (161 µL, 2.51 mmol), 
nitromethane (189 µL, 3.50 mmol) and L-serine methyl ester 
hydrochloride (778 mg, 5.00 mmol) were combined to give, after 
column chromatography (50-80% EtOAc in petroleum ether), 115 (321 mg, 1.37 mmol, 
55%) as a yellow oil. In this case, due to poor mass recovery, the aqueous layer was 
further extracted with CH2Cl2 (2 x 30 mL) and EtOAc (3 x 30 mL) after initial extraction 
with CH2Cl2 (2 x 30 mL). Rf (80% EtOAc in petroleum ether) 0.28; 1H-NMR (300 MHz, 
CDCl3) d 4.86 (1H, d, J = 13.2 Hz, NO2CHH), 4.80 (1H, d, J = 13.2 Hz, NO2CHH), 4.66-
4.60 (2H, m, 2 x OCHH-Ox), 4.54 (2H, d, J = 7.2 Hz, 2 x OCHH-Ox), 3.84-3.74 (4H, m, 
CH3, CHHβ-Ser), 3.68-3.57 (2H, m, CHHβ-Ser, CHα-Ser), 2.67 (1H, bs, OH), 2.42 (1H, 
bs, NH); 13C-NMR (75 MHz, CDCl3) d 173.4 (C=O), 78.8 (NO2CH2 or OCH2-Ox), 78.6 
(NO2CH2 or OCH2-Ox), 78.4 (OCH2, Ox), 63.8 (CH2, β-Ser), 59.2 (C, Ox), 57.4 (CH, α-
Ser), 52.9 (CH3); MS (ESI+) m/z 235 [M+H]+, 257 [M+Na]+. Data consistent with that 
reported in literature.1 
 
H
N
NO2
O
α CO2Me
Me
H
N
NO2
O
α CO2Meβ OH
  142 
Methyl [3-(nitromethyl)oxetan-3-yl]-L-phenylalaninate 116 
 Following general procedure 1, oxetan-3-one (160 µL, 2.50 mmol), 
nitromethane (187 µL, 3.50 mmol) and L-phenylalanine methyl ester 
hydrochloride (1.08 g, 5.00 mmol) were combined to give, after column 
chromatography (35% EtOAc in petroleum ether), 116 (399 mg, 1.35 mmol, 54%) as an 
orange oil. Rf (35% EtOAc in petroleum ether) 0.30; [𝛂]𝐃𝟑𝟎 +10.5 (c 0.10, CHCl3); 1H-
NMR (500 MHz, CDCl3) d 7.33-7.27 (2H, m, ArH), 7.27-7.22 (1H, m, ArH), 7.18-7.13 
(2H, m, ArH), 4.79 (1H, d, J = 12.9 Hz, NO2CHH), 4.73 (1H, d, J = 12.9 Hz, NO2CHH), 
4.51 (1H, d, J = 7.1 Hz, OCHH-Ox), 4.38 (1H, d, J = 7.2 Hz, OCHH-Ox), 4.35 (m, 2 x 
OCHH-Ox), 3.76-3.65 (4H, m, CH3 and CHα-Phe), 2.98 (1H, dd, J = 13.4 and 6.0 Hz, 
CHHβ-Phe), 2.86 (1H, dd, J = 13.4 and 7.4 Hz, CHHβ-Phe), 2.36 (1H, bs, NH); 13C-
NMR (125 MHz, CDCl3) d 175.1 (C=O), 136.7 (C, Ar), 129.5 (2 x CH, Ar), 128.7 (2 x 
CH, Ar), 127.2 (CH, Ar), 78.9 (OCH2, Ox), 78.7 (OCH2, Ox), 78.6 (NO2CH2), 59.5 (C, 
Ox), 57.7 (CH, α-Phe), 52.5 (CH3), 40.7 (CH2, β-Phe); IR (film) 3333 (NH), 2953, 2879, 
1731 (C=O), 1552 cm−1; MS (ESI+) m/z 295 [M+H]+, 317 [M+Na]+; HRMS (ESI+) 
Calcd. for C14H18N2O5Na [M+Na]+: 317.1108, found 317.1124. 
 
4-tert-Butyl-1-methyl [3-(nitromethyl)oxetan-3-yl]-L-aspartate 117 
 Following general procedure 1, oxetan-3-one (42 µL, 0.66 mmol), 
nitromethane (49 µL, 0.91 mmol) and L-aspartic acid 4-tert-butyl-1-
methyl ester hydrochloride (314 mg, 1.31 mmol) were combined to 
give, after column chromatography (30-40% EtOAc in petroleum ether), 117 (112 mg, 
0.35 mmol, 54%) as an orange oil. Rf (30% EtOAc in petroleum ether) 0.22; [𝛂]𝐃𝟐𝟗 –1.4 
(c 0.10, CHCl3); 1H-NMR (400 MHz, CDCl3) δ 4.85 (1H, d, J = 13.2 Hz, NO2CHH), 
4.78 (1H, d, J = 13.2 Hz, NO2CHH), 4.61 (1H, d, J = 7.2 Hz, OCHH-Ox), 4.56-4.48 (2H, 
m, OCHH-Ox and OCHH-Ox), 4.42 (1H, d, J = 7.2 Hz, OCHH-Ox), 3.80 (1H, t, J = 6.0 
Hz, CHα-Asp), 3.68 (3H, s, CH3), 2.66-2.51 (2H, m, CH2β-Asp), 1.38 (9H, s, tBu), NH 
not observed; 13C-NMR (125 MHz, CDCl3) δ 174.4 (C=O), 169.8 (C=O), 81.9 (C, tBu), 
79.2 (OCH2, Ox), 78.5 (NO2CH2 or OCH2-Ox), 78.4 (NO2CH2 or OCH2-Ox), 59.6 (C, 
Ox), 52.9 (CH, α-Asp), 52.7 (OCH3), 40.4 (CH2, β-Asp), 28.2 (3 x CH3, tBu); IR (film) 
3342 (NH), 2977, 2884, 1728 (C=O), 1554, 1149 cm−1; MS (ESI+) m/z 341 [M+Na]+, 
357 [M+K]+; HRMS (ESI+) Calcd. for C13H22N2O7Na [M+Na]+: 341.1319, found 
341.1318. 
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Methyl N6-(tert-butoxycarbonyl)-N2-[3-(nitromethyl)oxetan-3-yl]-L-lysinate 118 
Following general procedure 1, oxetan-3-one (113 µL, 1.76 
mmol), nitromethane (131 µL, 2.43 mmol) and Nε-Boc-L-lysine 
methyl ester hydrochloride (1.03 g, 3.47 mmol) were combined 
to give, after column chromatography (40-50% EtOAc in petroleum ether), 118 (353 mg, 
0.94 mmol, 53%) as a yellow oil. Rf (50% EtOAc in petroleum ether) 0.32; [𝛂]𝐃𝟐𝟗 +16.0 
(c 0.10, CHCl3); 1H-NMR (400 MHz, CDCl3) d 4.79 (1H, d, J = 12.9 Hz, NO2CHH), 
4.74 (1H, d, J = 12.9 Hz, NO2CHH), 4.58 (1H, d, J = 7.1 Hz, OCHH-Ox), 4.52 (1H, d, J 
= 7.0 Hz, OCHH-Ox), 4.50-4.39 (2H, m, OCHH-Ox, NH-Boc), 4.35 (1H, d, J = 7.0 Hz, 
OCHH-Ox), 3.65 (3H, s, CH3), 3.43-3.32 (1H, m, CHα-Lys), 3.10-2.94 (2H, m, CH2e-
Lys), 2.22 (1H, d, J = 10.2 Hz, NH-Lys), 1.67-1.10 (15H, m, CH2b-Lys, CH2d-Lys, CH2g-
Lys, tBu); 13C-NMR (125 MHz, CDCl3) d 175.9 (C=O, Lys), 156.1 (C=O, Boc), 79.3 (C, 
tBu), 79.2 (OCH2, Ox), 79.0 (OCH2, Ox), 78.4 (NO2CH2), 59.7 (C, Ox), 55.8 (CH, α-
Lys), 52.5 (CH3), 40.3 (CH2, e-Lys), 34.0 (CH2, b-Lys), 29.9 (CH2, d-Lys), 28.6 (3 x CH3, 
tBu), 22.9 (CH2, g-Lys); IR (film) 3338 (NH), 2952, 2878, 1731 (C=O), 1695 (C=O), 
1554, 1165 cm−1; MS (ESI+) m/z 376 [M+H]+, 398 [M+Na]+; HRMS (ESI+) Calcd. for 
C16H29N3O7Na [M+Na]+: 398.1898, found 398.1906. 
 
Methyl [3-(nitromethyl)oxetan-3-yl]-L-prolinate 119 
Following general procedure 1, oxetan-3-one (230 µL, 3.59 mmol), 
nitromethane (269 µL, 4.98 mmol) and L-proline methyl ester 
hydrochloride (1.18 g, 7.11 mmol) were combined to give, after column 
chromatography (30-40% EtOAc in petroleum ether), 119 (484 mg, 1.98 mmol, 55%) as 
an orange oil. Rf (40% EtOAc in petroleum ether) 0.27; [𝛂]𝐃𝟑𝟏 +16.4 (c 0.10, CHCl3); 1H-
NMR (500 MHz, CDCl3) δ 4.87 (1H, d, J = 12.2 Hz, NO2CHH), 4.84-4.79 (2H, m, 
NO2CHH and OCHH-Ox), 4.77 (1H, d, J = 7.2 Hz, OCHH-Ox), 4.73 (1H, d, J = 7.4 Hz, 
OCHH-Ox), 4.37 (1H, d, J = 7.2 Hz, OCHH-Ox), 3.86 (1H, t, J = 5.6 Hz, CHα-Pro), 3.61 
(3H, s, OCH3), 3.23-3.16 (1H, m, NCHHδ-Pro), 2.80 (1H, dd, J = 15.3 and 7.5 Hz, 
NCHHδ-Pro), 2.02-1.77 (4H, m, CH2β-Pro, CH2𝛾-Pro); 13C-NMR (125 MHz, CDCl3) δ 
175.0 (C=O), 78.6 (NO2CH2), 77.5 (OCH2, Ox), 76.4 (OCH2, Ox), 63.0 (C, Ox), 60.0 
(CH, α-Pro), 52.2 (CH3), 47.8 (CH2, δ-Pro), 30.4 (CH2, β-Pro), 24.1 (CH2, 𝛾-Pro); IR 
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(film) 2954, 2875, 1729 (C=O), 1552 cm−1; MS (ESI+) m/z 245 [M+H]+, 267 [M+Na]+; 
HRMS (ESI+) Calcd. for C10H16N2O5Na [M+Na]+: 267.0951, found 267.0948. 
 
 Methyl (R)-2-[[3-(nitromethyl)oxetan-3-yl]amino]-2-phenylacetate 120 
Following general procedure 1, oxetan-3-one (97 µL, 1.51 mmol), 
nitromethane (113 µL, 2.10 mmol) and (R)-(−)-2-phenylglycine methyl 
ester hydrochloride (605 mg, 3.00 mmol) were combined to give, after 
column chromatography (0-40% EtOAc in petroleum ether), 120 (218 mg, 0.78 mmol, 
52%) as an orange oil. Rf (40% EtOAc in petroleum ether) 0.29; [𝛂]𝐃𝟐𝟓 –78.3 (c 0.24, 
CHCl3); 1H-NMR (500 MHz, CDCl3) d 7.37-7.23 (5H, m, ArH), 4.79 (1H, d, J = 13.1 
Hz, NO2CHH), 4.75 (1H, d, J = 13.0 Hz, NO2CHH), 4.64 (1H, s, CHPh), 4.57 (1H, d, J 
= 7.2 Hz, OCHH-Ox), 4.46 (1H, d, J = 7.2 Hz, OCHH-Ox), 4.42 (1H, d, J = 7.2 Hz, 
OCHH-Ox), 4.26 (1H, d, J = 7.2 Hz, OCHH-Ox), 3.64 (3H, s, CH3), 2.30-1.39 (1H, bs, 
NH); 13C-NMR (125 MHz, CDCl3) d 172.9 (C=O), 138.0 (C, Ar), 129.2 (2 x CH, Ar), 
128.9 (CH, Ar), 127.5 (2 x CH, Ar), 78.8 (OCH2, Ox), 78.7 (OCH2, Ox), 78.5 (NO2CH2), 
60.0 (CH3), 59.5 (C, Ox), 53.1 (CHPh); IR (film) 3339 (NH), 2955, 2881, 1731 (C=O), 
1551, 1029 cm−1; MS (ESI+) m/z 281 [M+H]+, 303 [M+Na]+; HRMS (ESI+) Calcd. for 
C13H16N2O5Na [M+Na]+: 303.0951, found 303.0951. 
 
3-(1-Nitro-2-phenylethylidene)oxetane 3174 
Following general procedure 2, oxetane-3-one (1.04 mL, 16.3 mmol) and 
(2-nitroethyl)benzene 12676 (1.89 g, 12.5 mmol) were combined to give, 
after column chromatography (20-30% EtOAc in petroleum ether), 31 
(1.80 g, 8.75 mmol, 70%) contaminated with its rearrangement product 3-
benzylisoxazole-4-carbaldehyde (~19:1 by 1H-NMR) as a yellow solid. Rf (20% EtOAc 
in petroleum ether) 0.40; 1H-NMR (500 MHz, CDCl3) δ 7.39-7.19 (5H, m, ArH), 5.66-
5.52 (2H, m, OCH2), 4.97-4.85 (2H, m, OCH2), 3.81 (2H, s, CH2Ph); 13C-NMR (125 
MHz, CDCl3) δ 151.3 (C), 140.0 (C), 134.8 (C, Ar), 129.2 (2 x CH, Ar), 129.0 (2 x CH, 
Ar), 127.7 (CH, Ar), 80.0 (OCH2), 75.5 (OCH2), 34.0 (CH2Ph). Data consistent with that 
reported in literature.74 
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3-(1-Nitroethylidene)oxetane 12875 
Following general procedure 2, oxetan-3-one (2.08 mL, 32.5 mmol) and 
nitroethane (1.65 mL, 25.0 mmol) were combined to give, after column 
chromatography (20-30% EtOAc in petroleum ether), 128 (2.78 g, 21.6 
mmol, 86%) as a yellow oil that became a yellow solid upon storage at −20 °C. Rf (20% 
EtOAc in petroleum ether) 0.28; 1H-NMR (500 MHz, CDCl3) δ 5.61-5.53 (2H, m, 
OCH2), 5.36-5.28 (2H, m, OCH2), 2.03 (3H, quint, J = 1.8 Hz, CH3); 13C-NMR (125 
MHz, CDCl3) δ 149.0 (C), 137.5 (C), 79.8 (OCH2), 75.7 (OCH2), 13.1 (CH3). Data 
consistent with that reported in literature.75 
 
Methyl [3-(1-nitro-2-phenylethyl)oxetan-3-yl]glycinate 91 
Following general procedure 3, 31 (357 mg, 1.74 mmol) and 
glycine methyl ester 12977 (311 mg, 3.49 mmol) were reacted for 4 
h. Purification by recrystallization (EtOH) gave 91 (450 mg, 1.53 
mmol, 88%) as white crystals. 1H-NMR (400 MHz, CDCl3) d 7.35-7.21 (5H, m, ArH), 
5.12 (1H, dd, J = 9.8 and 4.5 Hz, NO2CH), 4.65 (1H, d, J = 7.5 Hz, OCHH-Ox), 4.62 
(1H, d, J = 7.5 Hz, OCHH-Ox), 4.51 (1H, d, J = 8.0 Hz, OCHH-Ox), 4.48 (1H, d, J = 8.0 
Hz, OCHH-Ox), 3.78 (3H, s, OCH3), 3.72 (1H, dd, J = 17.3 and 6.0 Hz, CHH-Gly), 3.61 
(1H, dd, J = 17.3 and 6.0 Hz, CHH-Gly), 3.52 (1H, dd, J = 14.6 and 9.8 Hz, CHHPh), 
3.29 (1H, dd, J = 14.6 and 4.5 Hz, CHHPh), 2.47 (1H, br t, J = 5.9 Hz, NH); 13C-NMR 
(100 MHz, CDCl3) d 172.4 (C=O), 135.3 (C, Ar), 129.0 (2 x CH, Ar), 128.8 (2 x CH, 
Ar), 127.7 (CH, Ar), 92.8 (NO2CH), 77.1 (OCH2-Ox), 76.7 (OCH2-Ox), 62.1 (C, Ox), 
52.4 (OCH3), 44.4 (CH2-Gly), 34.6 (CH2Ph); MS (ESI+) m/z 295 [M+H]+, 317 [M+Na]+. 
Data consistent with that reported in literature.45 
 
Methyl [3-(1-nitroethyl)oxetan-3-yl]glycinate 131 
Following general procedure 3, 128 (152 mg, 1.18 mmol) and 
glycine methyl ester 12977 (210 mg, 2.35 mmol) were reacted for 
64 h to give, after column chromatography (40-50% EtOAc in 
petroleum ether), 131 (217 mg, 0.99 mmol, 84%) as a colorless oil. Rf (50% EtOAc in 
petroleum ether) 0.38; 1H-NMR (400 MHz, CDCl3) δ 4.96 (1H, q, J = 6.8 Hz, NO2CH), 
4.66 (1H, d, J = 7.6 Hz, OCHH-Ox), 4.64-4.59 (2H, m, OCH2-Ox), 4.56 (1H, d, J = 7.7 
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Hz, OCHH-Ox), 3.76 (3H, s, OCH3), 3.67 (1H, d, J = 17.2 Hz, CHH-Gly), 3.57 (1H, d, J 
= 17.2 Hz, CHH-Gly), 2.23 (1H, bs, NH), 1.73 (3H, d, J = 6.8 Hz, NO2CHCH3); 13C-
NMR (125 MHz, C6D6) δ 172.1 (C=O), 85.4 (NO2CH), 76.9 (CH2-Ox), 76.2 (CH2-Ox), 
62.1 (C, Ox), 51.5 (OCH3), 44.4 (CH2-Gly), 13.3 (NO2CHCH3); IR (film) 3329 (NH), 
2955, 2887, 1737 (C=O), 1548 cm−1; MS (ESI+) m/z 219 [M+H]+, 241 [M+Na]+; HRMS 
(ESI+) Calcd. for C8H14N2O5Na [M+Na]+: 241.0795, found 241.0799. 
 
Methyl [3-((S)-1-nitroethyl)oxetan-3-yl]-L-valinate and Methyl [3-((R)-1-
nitroethyl)oxetan-3-yl]-L-valinate (50:50 dr) 132 
Following general procedure 3, 128 (137 mg, 1.06 mmol) and L-
valine methyl ester 13077 (279 mg, 2.13 mmol) were reacted for 24 
h to give a crude product which 1H-NMR showed to consist of a 
50:50 mixture of diastereoisomers. Purification by column chromatography (20-30% 
EtOAc in petroleum ether) gave 132 (246 mg, 0.95 mmol, 89%) as a 50:50 mixture of 
diastereoisomers and as a colorless oil. Rf (30% EtOAc in petroleum ether) 0.37, 0.48; 
1H-NMR (500 MHz, CDCl3) d 4.92 (0.5H, q, J = 6.9 Hz, NO2CHCH3), 4.87 (0.5H, q, J 
= 6.9 Hz, NO2CHCH3), 4.61 (0.5H, d, J = 7.6 Hz, OCHH-Ox), 4.59 (0.5H, d, J = 7.7 Hz, 
OCHH-Ox), 4.53-4.48 (1.5H, m, 3 x OCHH-Ox), 4.43 (0.5H, d, J = 7.5 Hz, OCHH-Ox), 
4.40 (0.5H, d, J = 7.6 Hz, OCHH-Ox), 4.36 (0.5H, d, J = 7.6 Hz, OCHH-Ox), 3.70-3.65 
(3H, m, 2 x OCH3), 3.41 (0.5H, dd, J = 10.2 and 5.2 Hz, CHα-Val), 3.36 (0.5H, dd, J = 
10.4 and 5.8 Hz, CHα-Val), 2.26 (0.5H, d, J = 10.2 Hz, NH), 2.06 (0.5H, d, J = 10.3 Hz, 
NH), 1.98-1.90 (0.5H, m, CHβ-Val), 1.90-1.81 (0.5H, m, CHβ-Val), 1.70-1.60 (3H, m, 2 
x NO2CHCH3), 0.88 (1.5H, d, J = 6.7 Hz, CH3-Val), 0.84 (1.5H, d, J = 6.8 Hz, CH3-Val), 
0.82-0.76 (3H, m, 2 x CH3-Val); 13C-NMR (125 MHz, CDCl3) d 176.3 (C=O), 176.2 
(C=O) 87.1 (NO2CH), 85.0 (NO2CH), 78.4 (OCH2-Ox), 77.8 (OCH2-Ox), 77.7 (OCH2-
Ox), 76.8 (OCH2-Ox), 62.4 (C, Ox), 62.2 (C, Ox), 60.8 (OCH3), 60.8 (OCH3), 52.4 (CH, 
α-Val), 52.3 (CH, α-Val), 32.2 (CH, β-Val), 32.3 (CH, β-Val), 19.6 (CH3, Val), 19.4 
(CH3, Val), 18.1 (CH3, Val), 17.8 (CH3, Val), 14.3 (NO2CHCH3), 13.4 (NO2CHCH3); IR 
(film) 3340 (NH), 2959, 2878, 1730 (C=O), 1551 cm−1; MS (ESI+) m/z 261 [M+H], 283 
[M+Na]+; HRMS (ESI+) Calcd. for C11H20N2O5Na [M+Na]+: 283.1264, found 283.1265. 
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(S)-6-Isopropyl-2-oxa-5,8-diazaspiro[3.5]nonan-7-one (S)-112 
Following general procedure 4, (S)-1091 (325 mg, 1.32 mmol) gave, after 
column chromatography (0-10% MeOH in EtOAc), (S)-112 (197 mg, 1.07 
mmol, 81%) as white solid. A crystal suitable for X-ray analysis was grown 
from CHCl3. Rf (10% MeOH in EtOAc) 0.31; mp 153-158 °C; [𝛂]𝐃𝟐𝟓 –118.1 
(c 0.10, CH2Cl2); 1H-NMR (300 MHz, CDCl3) d 6.36 (1H, bs, NHCO), 4.64-4.57 (2H, 
m, OCH2-Ox), 4.50 (1H, d, J = 7.1 Hz, OCHH-Ox), 4.45 (1H, d, J = 7.1 Hz, OCHH-Ox), 
3.65 (1H, dd, J = 11.5, 4.6 Hz, NHCHH), 3.51-3.40 (2H, m, NHCHH, CHα-Val), 2.50-
2.34 (1H, m, CHβ-Val), 1.80 (1H, bs, NH-Val), 0.99 (3H, d, J = 7.3 Hz, CH3-Val), 0.91 
(3H, d, J = 6.8 Hz, CH3-Val); 13C-NMR (75 MHz, CDCl3) d 170.4 (C=O), 81.5 (CH2, 
Ox), 79.3 (CH2, Ox), 59.3 (CH, α-Val), 54.7 (C, Ox), 48.4 (NHCH2), 29.5 (CH, β-Val), 
18.5 (CH3, Val), 15.6 (CH3, Val); IR (film) 3253 (NH), 3106 2965, 2869, 2820, 1649 
(C=O), 1321, 980 cm−1; MS (ESI+) m/z 185 [M+H]+, 207 [M+Na]+; HRMS (ESI+) Calcd. 
for C9H17N2O2 [M+H]+: 185.1285, found 185.1284. 
Crystal Data for C9H16N2O2 (M =184.24 g/mol): orthorhombic, space group P212121 (no. 
19), a = 6.05086(3) Å, b = 9.80036(4) Å, c = 15.94440(7) Å, V = 945.513(7) Å3, Z = 4, 
T = 150(2) K, µ(CuKα) = 0.750 mm-1, Dcalc = 1.294 g/cm3, 20278 reflections measured 
(10.596° ≤ 2Θ ≤ 157.912°), 2044 unique (Rint = 0.0318, Rsigma = 0.0127) which were used 
in all calculations. The final R1 was 0.0347 (I > 2σ(I)) and wR2 was 0.0883 (all data). 
 
(R)-6-Isopropyl-2-oxa-5,8-diazaspiro[3.5]nonan-7-one (R)-112 
Following general procedure 4, (R)-1091 (144 mg, 0.58 mmol) gave, after 
column chromatography (0-10% MeOH in EtOAc), (R)-112 (84 mg, 0.46 
mmol, 78%) as a white solid. mp 163-165 ˚C; [𝛂]𝐃𝟐𝟓 +107.5 (c 0.10, 
CH2Cl2); other data as described for (S)-112. 
 
2-Oxa-5,8-diazaspiro[3.5]nonan-7-one 133 
Following general procedure 4, 113 (189 mg, 0.93 mmol) gave 133 (115 mg, 
0.81 mmol, 87%) as a white solid, which after work-up required no further 
purification. mp 148-150 °C; 1H-NMR (400 MHz, DMSO-D6) d 7.67 (1H, bs, 
NHCO), 4.41 (2H, d, J = 6.1 Hz, 2 x OCHH-Ox), 4.34 (2H, d, J = 6.1 Hz, 2 x 
OCHH-Ox), 3.37 (2H, s, CH2NHCO), 3.24-3.11 (3H, m, CH2-Gly and NH-Gly); 13C-
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NMR (125 MHz, DMSO-D6) d 168.8 (C=O), 79.2 (2 x OCH2, Ox), 54.0 (C, Ox), 48.4 
(CH2NHCO), 45.5 (CH2, Gly); IR (film) 3261 (NH), 3174, 3102, 3051, 2861, 1672, 1422, 
973 cm−1; MS (ESI+) m/z 143 [M+H]+, 165 [M+Na]+; HRMS (ESI+) Calcd. for 
C6H11N2O2 [M+H]+: 143.0815, found 143.0814. 
 
(S)-6-Methyl-2-oxa-5,8-diazaspiro[3.5]nonan-7-one 134 
 Following general procedure 4, 114 (82 mg, 0.37 mmol) gave, after column 
chromatography (0-10% MeOH in EtOAc) and recrystallisation 
(EtOAc/hexane), 134 (47 mg, 0.30 mmol, 80%) as a white solid. Rf (20% 
MeOH in EtOAc) 0.22; mp 156-158 ˚C; [𝛂]𝐃𝟐𝟔 −47.7 (c 0.55, CHCl3); 1H-
NMR (400 MHz, CDCl3) δ 6.00 (1H, bs, NHCO), 4.67 (1H, d, J = 6.4 Hz, OCHH-Ox), 
4.63 (1H, d, J = 6.4 Hz, OCHH-Ox), 4.51 (1H, d, J = 7.0 Hz, OCHH-Ox), 4.47 (1H, d, J 
= 7.0 Hz, OCHH-Ox), 3.72 (1H, dd, J = 11.5, 3.1 Hz, NHCHH), 3.62 (1H, q, J = 6.8 Hz, 
CHα-Ala), 3.55 (1H, d, J = 6.8 Hz, NHCHH), 1.95 (1H, bs, NH-Ala), 1.40 (3H, d, J = 
6.8 Hz, CH3-Ala); 13C-NMR (125 MHz, CDCl3) δ 171.6 (C=O), 81.9 (OCH2, Ox), 80.2 
(CH2, Ox), 55.5 (C, Ox), 51.0 (CH, α-Ala), 49.9 (NHCH2), 18.6 (CH3-Ala); IR (film) 
3341 (NH), 3300 (NH), 2993, 2965, 2928, 2871, 1660 (C=O), 1627, 1312, 1081, 971  
cm−1; MS (ESI+) m/z 157 [M+H]+, 179 [M+Na]+; HRMS (ESI+) Calcd. for C7H12N2O2Na 
[M+Na]+: 179.0791, found 179.0789. 
 
(S)-6-(Hydroxymethyl)-2-oxa-5,8-diazaspiro[3.5]nonan-7-one 135 
Following general procedure 4, 115 (166 mg, 0.71 mmol) gave, after 
column chromatography (20% MeOH in EtOAc), 135 (87 mg, 0.51 mmol, 
71%) as a beige solid. Rf (20% MeOH in EtOAc) 0.16; mp 109-111 
°C;	[𝛂]𝐃𝟐𝟒 −60.8 (c 0.10, MeOH); 1H-NMR (500 MHz, DMSO-D6) d 7.73 
(1H, bs, NHCO), 4.67 (1H, dd, J = 6.5 and 4.7 Hz, OH), 4.51 (1H, d, J = 5.9 Hz, OCHH-
Ox), 4.43 (1H, d, J = 6.3 Hz, OCHH-Ox), 4.39 (1H, d, J = 5.9 Hz, OCHH-Ox), 4.30 (1H, 
d, J = 6.3 Hz, OCHH-Ox), 3.66-3.60 (1H, m, CHHβ-Ser), 3.58-3.52 (1H, m CHHβ-Ser), 
3.47 (1H, dd, J = 11.7, 3.9 Hz, NHCHH), 3.32-3.26 (2H, m, NHCHH, CHα-Ser), 3.10 
(1H, bs, NH); 13C-NMR (125 MHz, DMSO-D6) d 168.6 (C=O), 80.4 (OCH2, Ox), 79.2 
(CH2, Ox), 62.3 (CH2, β-Ser), 56.4 (CH, α-Ser), 54.1 (C, Ox), 48.4 (NHCH2); IR (film) 
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3268 (NH), 2923, 2871, 1649 (C=O), 1320, 970 cm−1; MS (ESI+) m/z 173 [M+H]+, 195 
[M+Na]+; HRMS (ESI+) Calcd. for C7H12N2O3Na [M+Na]+: 195.0740, found 195.0738. 
 
(S)-6-Benzyl-2-oxa-5,8-diazaspiro[3.5]nonan-7-one 136 
Following general procedure 4, 116 (221 mg, 0.75 mmol) gave, after 
column chromatography (0-10% MeOH in EtOAc), 136 (140 mg, 0.60 
mmol, 80%) as a white solid. Rf (10% MeOH in EtOAc) 0.32; 1H-NMR 
(400 MHz, CDCl3) d 7.38-7.32 (2H, m, ArH), 7.31-7.24 (3H, m, ArH), 
6.55 (1H, s, NHCO), 4.57 (1H, d, J = 6.4 Hz, OCHH-Ox), 4.49 (1H, d, J = 6.4 Hz, OCHH-
Ox), 4.41 (1H, d, J = 7.1 Hz, OCHH-Ox), 4.38 (1H, d, J = 7.1 Hz, OCHH-Ox), 3.76-3.64 
(2H, m, CHα-Phe, NHCHH), 3.53 (2H, m, NHCHH, CHHβ-Phe), 2.80 (1H, dd, J = 13.7, 
9.9 Hz, CHHβ-Phe), 1.85 (1H, bs, NH-Phe); 13C-NMR (100 MHz, CDCl3) d 170.8 
(C=O), 137.7 (C, Ar), 129.4 (2 x CH, Ar), 129.0 (2 x CH, Ar), 127.0 (CH, Ar), 81.8 
(OCH2, Ox), 79.9 (OCH2, Ox), 56.2 (CH, α-Phe), 55.2 (C, Ox), 49.4 (NHCH2), 38.5 (CH2, 
β-Phe); MS (ESI+) m/z 233 [M+H]+, 255 [M+Na]+. Data consistent with that reported in 
literature.1 
 
tert-Butyl (S)-2-(7-oxo-2-oxa-5,8-diazaspiro[3.5]nonan-6-yl)acetate 137 
Following general procedure 4, 117 (134 mg, 0.42 mmol) gave, after 
column chromatography (0-10% MeOH in EtOAc), 137 (74 mg, 0.29 
mmol, 69%) as a white solid. Rf (10% MeOH in EtOAc) 0.32; mp 136-
138 °C; [𝛂]𝐃𝟐𝟓 −65.0 (c 0.19, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 
5.84 (1H, bs, NHCO), 4.66 (1H, d, J = 6.2 Hz, OCHH-Ox), 4.56 (1H, d, J = 6.3 Hz, 
OCHH-Ox), 4.47 (1H, d, J = 7.0 Hz, OCHH-Ox), 4.37 (1H, d, J = 7.0 Hz, OCHH-Ox), 
3.71 (1H, dd, J = 9.1, 2.8 Hz, CHα-Asp), 3.67 (1H, dd, J = 11.5, 4.1 Hz, NHCHH), 3.49 
(1H, d, J = 11.5 Hz, NHCHH), 2.95 (1H, dd, J = 17.5, 2.8 Hz, CHHβ-Asp), 2.55 (1H, dd, 
J = 17.5, 9.1 Hz, CHHβ-Asp), 1.40 (9H, s, tBu), [Note: NH-Asp not observed]; 13C-NMR 
(125 MHz, CDCl3) δ 171.6 (C=O), 169.9 (C=O), 81.7 (OCH2, Ox), 79.8 (OCH2, Ox), 
55.3 (C, Ox), 52.1 (CH, α-Asp), 49.5 (NHCH2), 37.8 (CH2, β-Asp), 28.3 (3 x CH3, tBu), 
[Note: C, tBu not observed]; IR (film) 3230 (NH), 2972, 2857, 1721, 1651 (C=O), 1223 
cm−1; MS (ESI+) m/z 279 [M+Na]+; HRMS (ESI+) Calcd. for C12H20N2O4Na [M+Na]+: 
279.1315, found 279.1313. 
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tert-Butyl (S)-[4-(7-oxo-2-oxa-5,8-diazaspiro[3.5]nonan-6-yl)butyl]carbamate 138 
Following general procedure 4, 118 (163 mg, 0.43 mmol) gave, after 
column chromatography (0-10% MeOH in EtOAc, then 10% MeOH 
in EtOAc with 0.5% NEt3), 138 (83 mg, 0.26 mmol, 61%) as a sticky 
white gum. Rf (10% MeOH in EtOAc) 0.20; [𝛂]𝐃𝟐𝟔 –41.7 (c 0.12, 
CH2Cl2); 1H-NMR (500 MHz, CDCl3) d 5.95 (1H, bs, NHCO), 4.63 (1H, d, J = 6.5 Hz, 
OCHH-Ox), 4.60 (1H, d, J = 6.5 Hz, OCHH-Ox), 4.56 (1H, bs, NHBoc), 4.51 (1H, d, J 
= 7.0 Hz, OCHH-Ox), 4.45 (1H, d, J = 7.0 Hz, OCHH-Ox), 3.69 (1H, dd, J = 11.5, 4.1 
Hz, NHCHH), 3.56-3.47 (2H, m, NHCHH, CHα-Lys), 3.20-3.02 (2H, m, CH2e-Lys), 
2.10-1.81 (2H, m, NH-Lys, CHHβ-Lys), 1.78-1.68 (1H, m, CHHβ-Lys), 1.57-1.35 (13H, 
m, CH2d-Lys, CH2g-Lys, tBu); 13C-NMR (125 MHz, CDCl3) d 171.1 (C=O, Lys), 156.2 
(C=O, Boc), 82.0 (OCH2, Ox), 80.1 (OCH2, Ox), 55.4 (C, Ox), 55.1 (CH, α-Lys), 49.5 
(CH2), 40.4 (CH2, e-Lys) 32.2 (CH2, β-Lys), 30.2 (CH2, d-Lys), 28.6 (3 x CH3, tBu), 22.8 
(CH2, g-CH2), [Note: C, tBu not observed]; IR (film) 3297 (NH), 2932, 2867, 1691 
(C=O), 1659 (C=O), 1165, 971 cm−1; MS (ESI+) m/z 314 [M+H]+, 336 [M+Na]+; HRMS 
(ESI+) Calcd. for C15H27N3O4Na [M+Na]+: 336.1894, found 336.1903. 
 
(S)-Hexahydro-1'H-spiro[oxetane-3,4'-pyrrolo[1,2-a]pyrazin]-1'-one 139 
Following general procedure 4, 119 (210 mg, 0.86 mmol) gave, after 
column chromatography (20% MeOH in EtOAc), 139 (107 mg, 0.59 mmol, 
68%) as a white solid. Rf (20% MeOH in EtOAc) 0.19; mp 157-159 °C; [𝛂]𝐃𝟐𝟕 +19.1 (c 0.03, CHCl3); 1H-NMR (400 MHz, CDCl3) d 6.14 (1H, bs, 
NH), 4.76-4.70 (2H, m, 2 x OCHH-Ox), 4.49 (1H, d, J = 6.1 Hz, OCHH-Ox), 4.31 (1H, 
d, J = 6.6 Hz, OCHH-Ox), 3.80-3.68 (2H, m, NHCH2), 3.61-3.54 (1H, m, CHα-Pro), 
2.99-2.91 (1H, m, CHHd-Pro), 2.71 (1H, dd, J = 16.0, 7.9 Hz, CHHd-Pro), 2.31-2.21 (1H, 
m, CHHβ-Pro), 2.07-1.96 (1H, m, CHHβ-Pro), 1.93-1.78 (2H, m, CH2g-Pro); 13C-NMR 
(125 MHz, CDCl3) d 172.9 (C=O), 79.3 (OCH2, Ox), 76.8 (OCH2, Ox), 58.9 (CH, α-Pro), 
57.0 (C, Ox), 46.5 (CH2, d-Pro), 45.6 (NHCH2), 28.0 (CH2, β-Pro), 23.3 (CH2, g-Pro); IR 
(film) 3170, 3092, 3049, 2954, 2883, 1651 (C=O), 976 cm−1; MS (ESI+) m/z 183 [M+H]+, 
205 [M+Na]+; HRMS (ESI+) Calcd. for C9H15N2O2 [M+H]+: 183.1128, found 183.1126. 
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(R)-6-Phenyl-2-oxa-5,8-diazaspiro[3.5]nonan-7-one 140 
Following general procedure 4, 120 (148 mg, 0.53 mmol) gave, after column 
chromatography (0-10% MeOH in EtOAc), 140 (98 mg, 0.45 mmol, 85%) 
as a sticky white gum. Rf (10% MeOH in EtOAc) 0.36; [𝛂]𝐃𝟐𝟔 −52.2 (c 0.11, 
CH2Cl2); 1H-NMR (400 MHz, CDCl3) δ 7.41-7.21 (5H, m, ArH), 6.33 (1H, 
s, NHCO), 4.69 (1H, d, J = 6.4 Hz, OCHH-Ox), 4.62 (1H, d, J = 6.4 Hz, OCHH-Ox), 
4.58 (1H, s, CHPh), 4.44-4.37 (2H, m, OCH2-Ox), 3.70 (1H, dd, J = 11.7 and 3.9 Hz, 
NHCHH), 3.61 (1H, d, J = 11.7 Hz, NHCHH), 2.97-1.99 (1H, bs, NH); 13C-NMR (125 
MHz, CDCl3) δ 169.6 (C=O), 128.9 (2 x CH, Ar), 128.5 (CH, Ar), 128.4 (2 x CH, Ar) 
81.8 (OCH2, Ox), 80.0 (OCH2, Ox), 60.6 (CHPh), 55.7 (C, Ox), 49.4 (NHCH2), [Note: 
C, Ar not observed]; IR (film) 3281 (NH), 2941, 2867, 1662 (C=O), 1307, 969 cm-1; MS 
(ESI+) m/z 219 [M+H]+, 241 [M+Na]+; HRMS (ESI+) Calcd. for C12H14N2O2Na 
[M+Na]+: 241.0947, found 241.0948. 
 
9-Benzyl-2-oxa-5,8-diazaspiro[3.5]nonan-7-one 93 
Following general procedure 4, 91 (36 mg, 0.12 mmol) gave, after column 
chromatography (10% MeOH in EtOAc), 93 (21 mg, 0.09 mmol, 74%) as a 
white solid. Rf (10% MeOH in EtOAc) 0.17; mp 157-160 °C; 1H-NMR (400 
MHz, CDCl3) δ 7.31-7.26 (2H, m, ArH), 7.24-7.19 (1H, m, ArH), 7.15 (2H, 
d, J = 7.0 Hz, ArH), 5.74 (1H, bs, NHCO), 4.63 (1H, d, J = 7.3 H, OCHH-Ox), 4.58 (1H, 
d, J = 6.8 Hz, OCHH-Ox), 4.52 (1H, d, J = 6.8, OCHH-Ox), 4.41 (1H, d, J = 7.3 Hz, 
OCHH-Ox), 3.75 (1H, dt, J = 10.6 and 3.0 Hz, CHCH2Ph), 3.55 (1H, d, J = 17.8 Hz, 
CHH-Gly), 3.49 (1H, d, J = 17.8 Hz, CHH-Gly), 3.03 (1H, dd, J = 13.6 and 3.0 Hz, 
CHHPh), 2.70 (1H, dd, J =13.6 and 10.6 Hz, CHHPh), 2.17 (1H, bs, NH-Gly); 13C-NMR 
(100 MHz, CDCl3) δ 168.4 (C=O), 136.5 (C, Ar), 129.4 (2 x CH, Ar), 129.3 (2 x CH, 
Ar), 127.4 (CH), 80.1 (OCH2, Ox), 77.9 (OCH2, Ox), 58.7 (CH), 58.3 (C, Ox), 45.8 (CH2, 
Gly), 38.1 (CH2Ph); IR (film) 3297 (NH), 2948, 2874, 1657 (C=O), 1494, 1454, 1312 
cm−1; MS (ESI+) m/z 233 [M+H]+, 255 [M+Na]+; HRMS (ESI+) Calcd. for C13H16N2O2 
[M+H]+: 233.1285, found 233.1284. 
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9-Methyl-2-oxa-5,8-diazaspiro[3.5]nonan-7-one 141 
Following general procedure 4, 131 (189 mg, 0.87 mmol) gave, after column 
chromatography (10-20% MeOH in CH2Cl2, 20% MeOH in EtOAc + 1% 
NEt3), 141 (109 mg, 0.70 mmol, 81%) as a white solid. Rf (20% MeOH in 
EtOAc + 1% NEt3) 0.25; mp 145-147 °C; 1H-NMR (500 MHz, CDCl3) δ 
6.82 (1H, bs, NHCO), 4.60 (1H, d, J = 7.0 Hz, OCHH-Ox), 4.55 (1H, d, J = 6.8 Hz, 
OCHH-Ox), 4.51 (1H, d, J = 6.8 Hz, OCHH-Ox), 4.43 (1H, d, J = 7.0 Hz, OCHH-Ox), 
3.72 (1H, qd, J = 6.6 and 2.3 Hz, CHMe), 3.58 (1H, d, J = 17.6 Hz, CHH-Gly), 3.51 (1H, 
d, J = 17.6 Hz, CHH-Gly), 1.96 (1H, bs, NH-Gly), 1.34 (3H, d, J = 6.5 Hz, CH3); 13C-
NMR (125 MHz, CDCl3) δ 169.2 (C=O), 79.8 (OCH2, Ox), 77.5 (OCH2, Ox), 58.1 (C, 
Ox), 52.9 (CH), 45.8 (CH2, Gly), 17.5 (CH3); IR (film) 3307 (NH), 3181, 3063, 2955, 
2884, 1665 (C=O), 1390, 1307,  974 cm−1; MS (ESI+) m/z 157 [M+H]+, 179 [M+Na]+; 
HRMS (ESI+) Calcd. for C7H12N2O2Na [M+Na]+: 179.0791, found 179.0791. 
 
(6S, 9S)- and (6S, 9R)-6-Isopropyl-9-methyl-2-oxa-5,8-diazaspiro[3.5]nonan-7-one 
(50:50 dr) 142 
Following general procedure 4, 132 (227 mg, 0.87 mmol) gave, after 
column chromatography (0-5% MeOH in EtOAc), 142 (133 mg, 0.67 
mmol, 77%) as a colourless oil and as a 50:50 mixture of 
diastereoisomers. Rf (5% MeOH in EtOAc) 0.34; 1H-NMR (500 MHz, 
CDCl3) δ 6.04 (0.5H, bs, NHCO), 5.72 (0.5H, bs, NHCO), 4.70-4.63 (1H, m, OCHH-
Ox), 4.59-4.52 (1H, m, OCHH-Ox), 4.52-4.47 (1H, m, OCHH-Ox), 4.45 (0.5H, d, J = 7.3 
Hz, OCHH-Ox), 4.39 (0.5H, d, J = 7.3 Hz, OCHH-Ox), 3.86-3.77 (0.5H, m, CHMe), 3.55 
(0.5H, q, J = 6.9 Hz, CHMe), 3.51 (0.5H, d, J = 2.8 Hz, CHα-Val), 3.44 (0.5H, d, J = 2.8 
Hz, CHα-Val), 2.53-2.37 (1H, m, CHβ-Val), 1.84 (1H, bs, NH-Val), 1.45 (1.5H, d, J = 
6.7 Hz, NHCHCH3), 1.23 (1.5H, d, J = 6.4 Hz, NHCHCH3), 1.05-0.98 (3H, m, CH3-Val), 
0.94 (1.5H, d, J = 6.7 Hz, CH3-Val), 0.92 (1.5H, d, J = 6.8 Hz, CH3-Val); 13C-NMR (125 
MHz, CDCl3) δ 170.9 (C=O), 170.6 (C=O), 82.0 (OCH2, Ox), 79.4 (OCH2, Ox), 78.9 
(OCH2, Ox), 77.2 (OCH2, Ox), 60.1 (CH, α-Val), 59.9 (CH, α-Val), 58.6 (C, Ox), 58.6 
(C, Ox), 53.4 (NHCHMe), 52.1 (NHCHMe), 30.2 (CH, β-Val), 29.9 (CH, β-Val), 19.3 
(CH3, Val), 19.2 (CH3, Val), 18.1 (NHCHCH3), 17.0 (NHCHCH3), 16.5 (CH3-Val), 16.4 
(CH3-Val); IR (film) 3304 (NH), 2960, 2872, 1654 (C=O), 1310, 973 cm−1; MS (ESI+) 
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m/z 221 [M+Na]+, 419 [2M+Na]+, HRMS (ESI+) Calcd. for C10H18N2O2Na [M+Na]+: 
221.1260, found 221.1264. 
 
tert-Butyl 3-[(2-methoxy-2-oxoethyl)amino]-3-(nitromethyl)azetidine-1-carboxylate 
145 
Following general procedure 5, N-Boc-azetidin-3-one (428 mg, 2.50 
mmol), nitromethane (2.5 mL) and glycine methyl ester hydrochloride 
(628 mg, 5.00 mmol) were combined to give, after column 
chromatography (0-40% EtOAc in petroleum ether), 145 (364 mg, 1.20 mmol, 48%) as a 
yellow solid. Rf (0-40% EtOAc in petroleum ether) 0.26; mp 92-95 °C; 1H-NMR (500 
MHz, CDCl3) δ 4.68 (2H, s, NO2CH2), 4.03-3.89 (2H, m, 2 x NCHH-Az), 3.87 (2H, d, J 
= 9.4 Hz, 2 x NCHH-Az), 3.76 (3H, s, OCH3), 3.48 (2H, s, CH2-Gly), 2.31 (1H, bs, NH), 
1.44 (9H, s, tBu); 13C-NMR (125 MHz, CDCl3) δ 172.0 (C=O, Gly), 156.2 (C=O, Boc), 
80.6 (C, tBu), 78.6 (NO2CH2), 57.2 (2 x NCH2, Az), 54.3 (C, Ox), 52.3 (OCH3), 44.7 
(CH2, Gly), 28.5 (3 x CH3, tBu), [Note: 2 x NCH2, Az assigned using HSQC]; IR (film) 
3339 (NH), 3010, 2979, 2955, 1738 (C=O), 1685 (C=O), 1548, 1406, 1120 cm−1; MS m/z 
(ESI+) 326 [M+Na]+, 342 [M+K]+; HRMS (ESI+) Calcd. for C12H21N3O6Na [M+Na]+: 
326.1323, found 326.1323. 
 
tert-Butyl (S)-3-[(1-methoxy-3-methyl-1-oxobutan-2-yl)amino]-3-(nitromethyl) 
azetidine-1-carboxylate 146 
Following general procedure 5, N-Boc-azetidin-3-one (384 mg, 2.24 
mmol), nitromethane (2.24 mL) and L-valine methyl ester hydrochloride 
(752 mg, 4.49 mmol) were combined to give, after column 
chromatography (20% EtOAc in petroleum ether), 146 (605 mg, 1.75 mmol, 78%) as a 
yellow oil. Rf (20% EtOAc in petroleum ether) 0.29;	[𝛂]𝐃𝟑𝟎 –0.4 (c 0.18, CHCl3); 1H-
NMR (400 MHz, CDCl3) δ 4.69 (1H, d, J = 13.4 Hz, NO2CHH), 4.59 (1H, d, J = 13.4 
Hz, NO2CHH), 4.00-3.88 (1H, m, NCHH-Az), 3.92 (2H, s, NCH2-Az), 3.78-3.68 (4H, m, 
NCHH-Az and OCH3), 3.14-3.04 (1H, m, CHα-Val), 2.27 (1H, bs, NH), 1.98-1.82 (1H, 
m, CHβ-Val), 1.44 (9H, s, tBu), 0.92 (3H, d, J = 6.7 Hz, CH3-Val), 0.88 (3H, d, J = 6.8 
Hz, CH3-Val); 13C-NMR (125 MHz, CDCl3) δ 175.9 (C=O, Val), 156.3 (C=O, Boc), 80.4 
(C, tBu), 78.8 (NO2CH2), 61.4 (CH, α-Val), 57.7 (NCH2, Az), 57.4 (NCH2, Az),  54.3 (C, 
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Ox), 52.4 (OCH3), 32.3 (CH, β-Val), 28.5 (3 x CH3, tBu), 19.3 (CH3, Val), 18.2 (CH3, 
Val), [Note: 2 x NCH2 assigned using HSQC]; IR (film) 3339 (NH), 2972, 2884, 1731 
(C=O), 1697 (C=O), 1556, 1378, 1163 cm−1; MS (ESI+) m/z 346 [M+H]+, 368 [M+Na]+; 
HRMS (ESI+) Calcd. for C15H27N3O6Na [M+Na]+: 368.1792, found 368.1792. 
 
tert-Butyl 7-oxo-2,5,8-triazaspiro[3.5]nonane-2-carboxylate 147 
Following general procedure 4, 145 (286 mg, 0.94 mmol) gave 147 (211 mg, 
0.87 mmol, 93%) as a white solid which after work up required no further 
purification. mp 156-158 °C; 1H-NMR (500 MHz, CDCl3) δ 5.94 (1H, bs, 
NHCO), 3.85 (2H, d, J = 9.1 Hz, 2 x NCHH-Az), 3.82 (2H, d, J = 9.1 Hz, 2 x 
NCHH-Az), 5.59 (2H, s, CH2-Gly), 3.51 (2H, d, J = 1.8 Hz, CH2NHCO), 1.83 (1H, bs, 
NH-Gly), 1.45 (9H, s, tBu); 13C-NMR (125 MHz, CDCl3) 168.5 (C=O, Gly), 156.4 (C=O, 
Boc), 80.3 (C, tBu), 58.1 (2 x NCH2, Az), 50.3 (CH2NHCO), 46.0 (CH2, Gly), 28.5 (3 x 
CH3, tBu), [Note: 2 x NCH2, Az assigned using HSQC and C, Az not assigned]; IR (film) 
3308 (NH), 3246 (NH) 2976, 2930, 2876, 1699 (C=O), 1680 (C=O), 1445, 1322 cm−1; 
MS (ESI+) m/z 264 [M+Na]+, 483 [2M+H]; HRMS (ESI+) Calcd. for C11H19N3O3Na 
[M+Na]+: 264.1319, found 264.1318. 
 
tert-Butyl (S)-6-isopropyl-7-oxo-2,5,8-triazaspiro[3.5]nonane-2-carboxylate 148 
Following general procedure 4, 146 (116 mg, 0.34 mmol) gave, after 
column chromatography (0-5% MeOH in CH2Cl2), 148 (66 mg, 0.23 mmol, 
69%) as a white solid. Rf (5% MeOH in CH2Cl2) 0.20; mp 162-165 °C; [𝛂]𝐃𝟐𝟔 –51.5 (c 0.28, CHCl3); 1H-NMR (400 MHz, CDCl3) δ 6.16 (1H, bs, 
NHCO), 3.89 (1H, d, J = 8.7 Hz, NCHH-Az), 3.86-3.78 (2H, m, NCHH-Az and NCHH-
Az), 3.75 (1H, d, J = 9.4 Hz, NCHH-Az), 3.52-3.42 (2H, m, CHα-Val and NHCHH), 3.39 
(1H, dd, J = 11.4 and 4.2 Hz, NHCHH), 2.53-2.37 (1H, m, CHβ-Val), 1.69 (1H, bs, NH), 
1.44 (9H, s, tBu), 0.99 (3H, d, J = 7.1 Hz, CH3-Val), 0.92 (3H, d, J = 6.7 Hz, CH3-Val); 
13C-NMR (125 MHz, CDCl3) δ 171.1 (C=O, Val), 156.5 (C=O, Boc), 80.2 (C, tBu), 60.12 
(CH, α-Val), 59.3 (NCH2, Az), 58.3 (NCH2, Az) 50.6 (C, Ox), 49.9 (NHCH2), 30.1 (CH, 
β-Val), 28.5 (3 x CH3, tBu), 19.2 (CH3, Val), 16.4 (CH3, Val) [Note: 2 x NCH2 assigned 
using HSQC]; IR (film) 3283 (NH), 3261 (NH), 2963, 2873, 1691 (C=O), 1652 (C=O), 
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1403, 1171, 1121 cm−1; MS (ESI+) m/z 284 [M+H]+, 306 [M+Na]+; HRMS (ESI+) Calcd. 
for C14H25N3O3Na [M+Na]+: 306.1788, found 306.1791. 
 
(S)-5-Benzyl-6-methyl-2-oxa-5,8-diazaspiro[3.5]nonan-7-one 156 
134 (84 mg, 0.54 mmol), Na2CO3 (399 mg, 3.76 mmol), NaI (202 mg, 1.35 
mmol) and benzyl bromide (161 µL, 1.35 mmol) in MeCN (5 mL) were 
stirred at reflux for 3 h. On cooling to room temperature, the mixture was 
poured in water (10 mL) and extracted with EtOAc (3 x 10 mL). The 
combined organics were washed with brine (1 mL), dried (MgSO4), filtered and 
concentrated under reduced pressure. Purification by column chromatography (0-5% 
MeOH in CH2Cl2) gave 156 (101 mg, 0.41 mmol, 76%) as a white solid. Rf (5% MeOH 
in CH2Cl2) 0.38; mp 150-152 °C; [𝛂]𝐃𝟐𝟔 −31.7 (c 0.24, CH2Cl2); 1H-NMR (500 MHz, 
CDCl3) δ 7.40-7.35 (2H, m, ArH), 7.35-7.30 (2H, m, ArH), 7.29-7.23 (1H, m, ArH), 6.27 
(1H, bs, NH), 4.83 (1H, d, J = 6.3 Hz, OCHH-Ox), 4.74 (1H, d, J = 6.3 Hz, OCHH-Ox), 
4.33 (1H, d, J = 6.2 Hz, OCHH-Ox), 4.28 (1H, d, J = 6.3 Hz, OCHH-Ox), 3.95-3.80 (3H, 
m, NHCH2 and CHHPh), 3.60 (1H, d, J = 14.8 Hz, CHHPh), 3.33 (1H, q, J = 7.3 Hz, CH 
α-Ala), 1.25 (3H, d, J = 7.3 Hz, CH3, Ala); 13C-NMR (125 MHz, CDCl3) δ 172.7 (C=O), 
139.1 (C, Ar), 128.7 (2 x CH, Ar), 128.0 (2 x CH, Ar), 127.5 (CH, Ar), 79.5 (OCH2, Ox), 
78.5 (OCH2, Ox), 58.6 (C, Ox), 57.2 (CH, α-Ala), 52.9 (CH2Ph), 47.3 (NHCH2), 19.0 
(CH3, Ala); IR (film) 3186 (NH), 3051, 2985, 2947, 2868, 1662 (C=O), 1492, 1363, 
1329, 979 cm-1; MS (ESI+) m/z 247 [M+H]+, 269 [M+Na]+; HRMS (ESI+) Calcd. for 
C14H19N2O2 [M+H]+: 247.1441, found 247.1442. 
 
(S)-8-Benzyl-6-methyl-2-oxa-5,8-diazaspiro[3.5]nonan-7-one 157 
134 (126 mg, 0.81 mmol) was dissolved in DMF (3 mL) and cooled to 0 
˚C. NaH (60% in mineral oil, 34 mg, 0.85 mmol) was added and the 
reaction mixture allowed to reach room temperature and stirred for 30 min, 
whereupon benzyl bromide (101 µL, 0.85 mmol) was added. After stirring 
for a further 20 h, the mixture was poured into brine (10 mL) and extracted with EtOAc 
(3 x 20 mL). The combined organic extracts were dried (MgSO4), filtered and 
concentrated under reduced pressure. Purification by column chromatography (0-5% 
MeOH in CH2Cl2) gave 157 (135 mg, 0.55 mmol, 68%) as a colourless oil. Rf (5% MeOH 
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in CH2Cl2) 0.27;	[𝛂]𝐃𝟐𝟔 −56.3 (c 0.12, CH2Cl2); 1H-NMR (400 MHz, CDCl3) δ 7.40-7.20 
(5H, m, ArH), 4.81 (1H, d, J = 14.5 Hz, CHHPh), 4.60 (1H, d, J = 6.3 Hz, OCHH-Ox), 
4.44 (1H, d, J = 7.0 Hz, OCHH-Ox), 4.42-4.31 (3H, m, CHHPh and 2 x OCHH-Ox), 3.69 
(1H, q, J = 6.5 Hz, CHα-Ala), 3.55 (1H, d, J = 11.9 Hz, NCHH), 3.44 (1H, d, J = 11.9 
Hz, NCHH), 1.97 (1H, bs, NH), 1.45 (3H, d, J = 6.7 Hz, CH3-Ala); 13C-NMR (125 MHz, 
CDCl3) δ 169.7 (C=O), 136.6 (C, Ar), 129.0 (2 x CH, Ar), 128.3 (2 x CH, Ar), 127.9 (CH, 
Ar), 81.9 (OCH2, Ox), 80.3 (OCH2, Ox), 55.6 (C, Ox), 53.8 (NCH2), 51.4 (CH, α-Ala), 
50.1 (CH2Ph), 19.3 (CH3, Ala); IR (film) 3276 (NH), 2933, 2868, 1633 (C=O), 1494, 
1452, 1293, 972 cm−1; MS (ESI+) m/z 247 [M+H]+, 269 [M+Na]+; HRMS (ESI+) Calcd. 
for C14H19N2O2 [M+H]+: 247.1441, found 247.1441. 
 
(S)-5-Benzyl-6-methyl-2-oxa-5,8-diazaspiro[3.5]nonane-7-thione 165 
 To a solution of 156 (155 mg, 0.63 mmol) in THF (4 mL) was added a 
suspension of Lawesson’s reagent (125 mg, 0.31 mmol) in THF (15 mL). 
The reaction mixture was stirred at room temperature for 16 h and then at 
reflux for 4 h. The mixture was allowed to cool to room temperature and 
concentrated under reduced pressure. Purification by column chromatography (0-5% 
MeOH in CH2Cl2) gave 165 (131 mg, 0.50 mmol, 79%) as a yellow solid. Rf (5% MeOH 
in CH2Cl2) 0.30; mp 189-191 ˚C; [𝛂]𝐃𝟐𝟕 +2.1 (c 0.11, CH2Cl2); 1H-NMR (400 MHz, 
CDCl3) δ 8.09 (1H, bs, NHCS), 7.33-7.19 (5H, m, ArH), 4.79-7.74 (2H, m, 2 X OCHH-
Ox), 4.27-4.18 (2H, m, 2 x OCHH-Ox), 3.87 (1H, dd, J = 13.6 and 1.9 Hz, NHCHH), 
3.77 (1H, d, J = 13.1 Hz, NHCHH), 3.73-3.61 (2H, m, CHα-Ala and CHHPh), 3.47 (1H, 
d, J = 14.2 Hz, CHHPh), 1.33 (3H, d, J = 7.3 Hz, CH3-Ala); 13C-NMR (125 MHz, CDCl3) 
δ 206.5 (C=S), 138.0 (C, Ar), 128.8 (2 x CH, Ar), 128.3 (2 x CH, Ar), 127.8 (CH, Ar), 
80.4 (OCH2, Ox), 79.0 (OCH2, Ox), 63.1 (CH, α-Ala), 57.5 (C, Ox), 53.1 (CH2Ph), 48.3 
(NHCH2), 22.9 (CH3, Ala); IR (film) 3145 (NH), 3066, 3024, 2981, 2934, 2864, 1568 
(C=S), 1336, 980 cm−1; MS (ESI+) m/z 263 [M+H]+, 285 [M+Na]+; HRMS (ESI+) Calcd. 
for C14H18N2OSNa [M+Na]+: 285.1032, found 285.1033. 
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(S)-5-Benzyl-6-methyl-2-oxa-5,8-diazaspiro[3.5]nonane 166 
To a suspension of 165 (50 mg, 0.19 mmol) in MeOH (2 mL) was added 
Raney Ni (slurry in H2O, 0.5 mL). The reaction mixture was stirred at reflux 
for 3 h. On cooling to room temperature, the mixture was filtered through a 
plug of Celite® eluting with EtOAc and the eluent concentrated under reduced pressure. 
Purification by column chromatography (10-20% MeOH in CH2Cl2) gave 166 (29 mg, 
0.13 mmol, 68%) as a yellow oil. Rf (10% MeOH in CH2Cl2) 0.28; [𝛂]𝐃𝟐𝟔 +29.3 (c 0.03, 
CHCl3); 1H-NMR (500 MHz, CDCl3) δ 7.39 (2H, d, J = 7.2 Hz, ArH), 7.31 (2H, t, J = 
7.6 Hz, ArH), 7.25-7.19 (1H, m, ArH), 4.81 (1H, d, J = 6.5 Hz, OCHH-Ox), 4.60 (1H, d, 
J = 6.8 Hz, OCHH-Ox), 4.46 (1H, d, J = 6.6 Hz, OCHH-Ox), 4.31 (1H, d, J = 6.8 Hz, 
OCHH-Ox), 4.18 (1H, d, J = 16.4 Hz, CHHPh), 3.89 (1H, d, J = 16.4 Hz, CHHPh), 3.30 
(1H, d, J = 12.0 Hz, NHCHH), 3.19 (1H, d, J = 12.0 Hz, NHCHH), 2.90 (1H, dd, J = 
12.0, 2.9 Hz, CHHCHMe), 2.87-2.71 (2H, m, CHMe, NH), 2.67 (1H, dd, J = 12.0, 7.5 
Hz, CHHCHMe), 0.90 (3H, d, J = 6.5 Hz, CH3); 13C-NMR (125 MHz, CDCl3) δ 142.0 
(C, Ar), 128.4 (2 x CH, Ar), 127.2 (2 x CH, Ar), 126.7 (CH, Ar), 78.8 (OCH2-Ox), 78.6 
(OCH2-Ox), 60.8 (C, Ox), 53.2 (NHCH2), 52.8 (CHMe), 50.8 (CH2Ph or CH2CHMe), 
50.7 (CH2Ph or CH2CHMe), 16.9 (CH3); IR (film) 3307 (NH), 3059, 3026, 2937, 2872, 
2814, 1493, 1452, 973 cm−1; MS (ESI+) m/z 233 [M+H]+; HRMS (ESI+) Calcd. for 
C14H21N2O [M+H]+: 233.1648, found 233.1650. 
 
Fmoc-GOx-Phe-OBn 174 
Following general procedure 6, 341 (1.24 g, 3.34 mmol) gave, 
after column chromatography (5-10% EtOAc in CH2Cl2), 174 
(1.30 g, 2.32 mmol, 69%) as a sticky white gum. Rf (5% EtOAc 
in CH2Cl2) 0.21; [𝜶]𝑫𝟐𝟗 –3.8 (c 0.144, CHCl3) 1H-NMR (500 MHz, CDCl3) δ 7.78 (2H, 
d, J = 7.5 Hz, ArH-Fmoc), 7.63-7.55 (2H, m, ArH-Fmoc), 7.42 (2H, t, J = 7.4 Hz, ArH-
Fmoc), 7.39-7.28 (7H, m, ArH) 7.27-7.21 (2H, m, ArH), 7.21-7.11 (3H, m, ArH), 5.15 
(1H, d, J = 12.1 Hz, OCHHPh), 5.11(1H, d, J = 12.1 Hz, OCHHPh), 4.80-4.69 (1H, m, 
NH-GOx), 4.39 (2H, d, J = 6.9 Hz, CH2-Fmoc), 4.29-4.18 (3H, m, CH-Fmoc and 2 x 
OCHH-Ox), 4.15 (1H, d, J = 6.6 Hz, OCHH-Ox), 4.10 (1H, d, J = 6.4 Hz, OCHH-Ox), 
3.53 (1H, dd, J = 8.9, 4.9 Hz, CHα-Phe), 3.47-3.30 (2H, m, CH2-GOx), 13.03 (1H, dd, J 
= 13.4, 4.9 Hz, CHHβ-Phe), 2.75 (1H, dd, J = 13.4, 8.9 Hz, CHHβ-Phe), 2.08 (1H, bs, 
NH-Phe); 13C-NMR (125 MHz, CDCl3) δ 175.3 (C=O, Phe), 156.9 (C=O, Fmoc), 144.1 
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(C, Ar-Fmoc), 144.0 (C, Ar-Fmoc), 141.5 (2 x C, Ar-Fmoc) 137.2 (C, Ar), 135.2 (C, Ar), 
129.4 (2 x CH, Ar), 128.84 (CH, Ar), 128.83 (CH, Ar), 128.79 (2 x CH, Ar), 128.76 (CH, 
Ar), 127.8 (2 x CH, Ar), 127.3 (CH, Ar), 127.2 (2 x CH, Ar), 125.21 (CH, Ar), 125.18 
(CH, Ar), 120.1 (2 x CH, Ar), 79.9 (OCH2, Ox), 79.4 (OCH2, Ox), 67.5 (CH2, OCH2Ph), 
66.8 (CH2, Fmoc), 59.4 (C, Ox), 57.5 (CHα, Phe), 47.4 (CH, Fmoc), 44.9 (CH2, GOx), 
40.7 (CH2β, Phe) [Note: 2 x CH, Ar not assigned]; IR (film) 3408 (NH), 3332 (NH), 
3063, 3030, 2948, 2872, 1719 (C=O), 1512, 1496, 1450, 1224, 1152 cm–1; MS (ESI+) 
m/z 563 [M+H]+, 585 [M+Na]+; HRMS (ESI+) Calcd. for C35H34N2O5Na [M+Na]+: 
585.2360, found 585.2361.  
 
Fmoc-GOx-Gly-OBn 179 
Following general procedure 6, 1781 (1.19 g, 4.23 mmol) gave, 
after column chromatography (30% EtOAc in CH2Cl2), 179 
(1.50 g, 3.16 mmol, 75%) as a white solid. Rf (30% EtOAc in 
CH2Cl2) 0.36; mp 128-130 °C; 1-H-NMR (500 MHz, CDCl3) d 7.76 (2H, d, J = 7.6 Hz, 
ArH-Fmoc), 7.60 (2H, d, J = 7.4 Hz, ArH-Fmoc), 7.45-7.28 (9H, m, ArH), 5.36-5.24 (1H, 
m, NH-GOx), 5.19 (2H, s, CH2-Bn), 4.55-4.17 (7H, m, CHCH2-Fmoc and 2 x OCH2-Ox), 
3.62-3.35 (4H, m, CH2-Gly and CH2-GOx), 2.10 (1H, bs, NH-Gly); 13C-NMR (125 MHz, 
CDCl3) d 172.5 (C=O, Gly), 157.0 (C=O, Fmoc), 144.0 (2 x C, Ar-Fmoc), 141.5 (2 x C, 
Ar-Fmoc), 135.3 (C, Ar), 128.9 (2 x CH, Ar), 128.8 (CH, Ar), 128.7 (2 x CH, Ar), 127.8 
(2 x CH, Ar), 127.2 (2 x CH, Ar), 125.2 (2 x CH, Ar), 120.1 (2 x CH, Ar), 79.3 (2 x 
OCH2, Ox), 67.3 (CH2, Bn), 67.0 (CH2, Fmoc), 59.7 (C, Ox), 47.4 (CH, Fmoc), 45.1 
(CH2, Gly), 44.9 (CH2, GOx); IR (film) 3281 (NH), 3246 (NH), 3063, 2987, 2952, 2887, 
1742 (C=O), 1721 (C=O), 1560, 1442, 1394 cm–1; MS (ESI+) m/z 473 [M+H]+, 495 
[M+Na]+; HRMS (ESI+) Calcd. for C28H29N2O5 [M+H]+: 473.2071, found 473.2072. 
 
Fmoc-GOx-Val-OBn 180 
Following general procedure 6, 1101 (873 mg, 2.71 mmol) 
gave, after column chromatography (5-10% EtOAc in 
CH2Cl2), 180 (519 mg, 1.01 mmol, 37%) as a colourless oil. Rf 
(5% EtOAc in CH2Cl2) 0.25; [𝛂]𝐃𝟐𝟎 −7.4 (c 0.45, CHCl3); 1H-NMR (500 MHz, CDCl3) d 
7.77 (2H, d, J = 7.5 Hz, ArH-Fmoc), 7.60 (2H, J = 7.5 Hz, ArH-Fmoc), 7.46-7.28 (9H, 
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m, ArH), 5.24-5.15 (2H, m, NH-GOx and CHH-Bn), 5.13 (1H, d, J = 12.0 Hz, CHH-Bn), 
4.55-4.10 (7H, m, CHCH2Fmoc and 2 x OCH2-Ox), 3.66 (1H, dd, J = 13.7, 5.6 Hz, CHH-
GOx), 3.43 (1H, dd, J = 13.7 and 5.0 Hz, CHH-GOx), 3.14 (1H, d, J = 5.3 Hz, CHα-Val), 
2.15-1.87 (2H, m, NH-Val and CHβ-Val), 0.96 (3H, d, J = 6.7 Hz, CH3-Val), 0.90 (3H, 
d, J = 6.7 Hz, CH3-Val); 13C-NMR (125 MHz, CDCl3) d 176.0 (C=O, Val), 156.9 (C=O, 
Fmoc), 144.1 (C, Ar-Fmoc), 144.0 (C, Ar-Fmoc), 141.5 (2 x C, Ar-Fmoc), 135.3 (C, Ar), 
128.83 (2 x CH, Ar), 128.80 (3 x CH, Ar), 127.8 (2 x CH, Ar), 127.2 (2 x CH, Ar), 125.2 
(2 x CH, Ar), 120.1 (2 x CH, Ar), 79.7 (OCH2, Ox), 79.6 (OCH2, Ox), 67.3 (CH2, Bn), 
67.0 (CH2, Fmoc), 61.1 (CH, α-Val), 59.5 (C, Ox), 47.4 (CH, Fmoc), 45.4 (CH2, GOx), 
32.1 (CH, β-Val), 19.6 (CH3, Val), 18.1 (CH3, Val); IR (film) 3313 (NH), 2963, 2900, 
2879, 1720 (C=O), 1450, 1235, 1145 cm–1; MS (ESI+) m/z 515 [M+H]+, 537 [M+Na]+; 
HRMS (ESI+) Calcd. for C31H34N2O5Na [M+Na]+: 537.2360, found 537.2359. 
 
Fmoc-GOx-Phe-OMe 186 
Following general procedure 6, 116 (497 mg, 1.69 mmol) gave, 
after column chromatography (40% EtOAc in petroleum ether), 
186 (717 mg, 1.47 mmol, 87%) as sticky white gum. Rf (50% 
EtOAc in petroleum ether) 0.32; [𝜶]𝑫𝟐𝟗 –21.3 (c 0.075, CHCl3) 1H-NMR (500 MHz, 
CDCl3) δ 7.78 (2H, d, J = 7.5 Hz, ArH-Fmoc), 7.59 (2H, dd, J = 7.2, 3.4 Hz, ArH-Fmoc), 
7.42 (2H, t, J = 7.4 Hz, ArH-Fmoc), 7.34 (2H, t, J = 7.4 Hz, ArH-Fmoc), 7.29-7.23 (2H, 
m, ArH-Phe), 7.22-7.13 (3H, m, ArH-Phe), 4.90-4.66 (1H, m, NH-GOx), 4.39 (2H, d, J = 
6.9 Hz, CH2-Fmoc), 4.30-4.09 (5H, m, CH-Fmoc and 2 x OCH2-Ox), 3.72 (3H, s, OCH3), 
3.55-3.32 (3H, m, CHα-Phe and CH2-GOx), 3.03 (1H, dd, J = 13.4, 4.5 Hz, CHHb-Phe), 
2.74 (1H, dd, J = 13.3, 9.3 Hz, CHHb-Phe), 2.05 (1H, bs, NH-Phe); 13C-NMR (125 MHz, 
CDCl3) δ 175.9 (C=O, Phe), 156.9 (C=O, Fmoc), 144.1 (C, Ar-Fmoc), 144.0 (C, Ar-
Fmoc), 141.5 (2 x C, Ar-Fmoc), 137.3 (C, Ar-Phe), 129.4 (2 x CH, Ar), 128.8 (2 x CH, 
Ar), 127.8 (2 x CH, Ar), 127.3 (CH, Ar), 127.2 (2 x CH, Ar), 125.2 (2 x CH, Ar), 120.1 
(2 x CH, Ar), 80.0 (OCH2, Ox), 79.4 (OCH2, Ox), 66.8 (CH2, Fmoc), 59.4 (C, Ox), 57.4 
(CH, Fmoc), 52.6 (CH3), 47.4 (CHα, Phe), 44.9 (CH2, GOx), 40.7 (CH2b-Phe); IR (film) 
3406 (NH), 3333 (NH), 2949, 2879, 1718 (C=O), 1511, 1449, 1222 cm–1; MS (ESI+) m/z 
487 [M+H]+, 509 [M+Na]+; HRMS (ESI+) Calcd. for C29H30N2O5Na [M+Na]+: 
509.2047, found 509.2045.  
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Fmoc-Phe-ODmb 189 
Fmoc-Phe-OH (3.87 g, 10.0 mmol), DCC (2.27 g, 11.0 
mmol) and DMAP (122 mg, 1.00 mmol) were combined in 
CH2Cl2 (40 mL). The reaction mixture was cooled to 0 °C 
and 2,4-dimethoxybenzyl alcohol (2.02 g, 12.0 mmol) was added. The mixture was 
warmed to room temperature and stirred for 16 h. The reaction mixture was filtered and 
the eluent washed with saturated NaHCO3 (40 mL) and brine (20 mL), dried (MgSO4), 
filtered and concentrated under reduced pressure to give a crude product. Purification by 
flash column chromatography (20% EtOAc in petroleum ether) gave 189 (2.28 g, 7.96 
mmol, 80%) as a sticky white gum. Rf (20% EtOAc in petroleum ether) 0.33; [𝜶]𝑫𝟐𝟗 –9.4 
(c 0.168, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 7.77 (2H, d, J = 7.5 Hz, ArH), 7.63-
7.50 (2H, m, ArH), 7.44-7.35 (2H, m, ArH), 7.35-7.28 (2H, m, ArH), 7.28-7.11 (4H, m, 
ArH), 7.09-6.91 (2H, m, ArH), 6.53-6.38 (2H, m, ArH-3, ArH-5), 5.30 (1H, d, J = 8.2 
Hz, NH), 5.21 (1H, d, J = 11.7 Hz, CHH-Dmb), 5.12 (1H, d, J = 11.7 Hz, CHH-Dmb), 
4.75-4.65 (1H, m, CHα-Phe), 4.47-4.27 (2H, m, CH2-Fmoc), 4.20 (0.85H, t, J = 7.1 Hz, 
major rotamer CH-Fmoc), 4.14-4.04 (0.15H, minor rotamer CH-Fmoc), 3.88- 3.70 (6H, 
m, 2 x OCH3), 3.15 (0.85H, dd, J = 13.9, 5.6 Hz, major rotamer CHHβ-Phe), 3.11 (0.85H, 
dd, J = 13.8, 5.5 Hz, major rotamer CHHβ-Phe) 2.94-2.81 (0.30H, m, minor rotamer 
CH2β-Phe); 13C-NMR (125 MHz, CDCl3) δ 171.6 (C=O, Phe), 161.7 (C, Ar-4), 159.3 
(C, Ar-2), 155.6 (C=O, Fmoc), 144.0 (C, Ar-Fmoc), 143.9 (C, Ar-Fmoc), 141.4 (2 x C, 
Ar-Fmoc), 135.9 (C, Ar-Phe), 132.1 (CH, Ar-6), 129.6 (2 x CH, Ar), 128.6 (2 x CH, Ar), 
127.8 (2 x CH, Ar), 127.2 (2 x CH, Ar), 127.1 (CH, Ar), 125.3 (CH, Ar), 125.2 (CH, Ar), 
120.09 (CH, Ar), 120.08 (CH, Ar), 116.0 (C, Ar-1), 104.2 (CH, Ar-3 or Ar-5), 98.7 (CH, 
Ar-3 or Ar-5), 67.0 (CH2, Fmoc), 63.1 (CH2, Dmb), 55.5 (2 x OCH3), 54.8 (CH, α-Phe), 
47.3 (CH, Fmoc), 38.2 (CH2, β-Phe); IR (film): 3320 (NH), 3063, 3003, 2938, 2835, 1720 
(C=O), 1688 (C=O), 1524, 1508, 1206 cm–1; MS (ESI+) m/z 560 [M+Na]+, 576 [M+K]+; 
HRMS (ESI+) Calcd. for C33H31NO6Na [M+Na]+: 560.2044, found 560.2040. 
 
2,4-Dimethoxybenzyl [3-(nitromethyl)oxetan-3-yl]-L-phenylalaninate 193 
To 189 (702 mg, 1.31 mmol) in CH2Cl2 (12 mL) was added 
diethylamine (2 mL) and the reaction mixture stirred at room 
temperature for 4 h. The reaction mixture was concentrated 
under reduced pressure and the resulting residue repeatedly dissolved in CH2Cl2 (3 x 10 
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mL) and concentrated under reduced pressure to give the crude amine. Meanwhile, 
oxetan-3-one (42 µL, 0.66 mmol), nitromethane (49 µL, 0.92 mmol) and triethylamine 
(18 µL, 0.13 mmol) were stirred at room temperature for 1 h. CH2Cl2 (3 mL) was added 
and the reaction mixture cooled to −78 °C. Triethylamine (183 µL, 1.32 mmol) was added 
followed by the dropwise addition of a solution of methanesulfonyl chloride (51 µL, 0.66 
mmol) in CH2Cl2 (1 ml). The reaction mixture was left to stir at −78 °C for 1.5 h. The 
crude amine was dissolved in CH2Cl2 (6 mL) and added to the oxetane mixture via syringe 
at −78 °C. The reaction mixture was allowed to reach room temperature and stirred for 
16 h. A saturated solution of NH4Cl (6 mL) was added to the reaction mixture and stirred 
for 10 min. The layers were separated and the aqueous layer extracted with CH2Cl2 (2 x 
10 mL) and EtOAc (2 x 10 mL). The combined organics were washed with saturated 
NaHCO3 (6 mL) and brine (4 mL), dried (MgSO4), filtered and concentrated under 
reduced pressure. The crude product was purified by flash column chromatography (20% 
EtOAc in petroleum ether) to give 193 (172 mg, 0.40 mmol, 61%) as a yellow oil. Rf 
(30% EtOAc in petroleum ether) 0.25;	[𝜶]𝑫𝟐𝟗 –7.6 (c 0.142, CHCl3); 1H-NMR (500 MHz, 
CDCl3) δ 7.28-7.19 (3H, m, ArH-Phe), 7.15 (1H, d, J = 7.9 Hz, ArH-6), 7.13-7.09 (2H, 
m, ArH-Phe), 6.50-6.43 (2H, m, ArH-3, ArH-5), 5.11 (1H, d, J = 11.6 Hz, CHHAr), 5.03 
(1H, d, J = 11.6 Hz, CHHAr), 4.77 (1H, d, J = 12.7 Hz, NO2CHH), 4.71 (1H, d, J = 12.8 
Hz, NO2CHH), 4.50 (1H, d, J = 7.1 Hz, OCHH-Ox), 4.41-4.34 (2H, m, OCHH-Ox and 
OCHH-Ox), 4.25 (1H, d, J = 7.1 Hz, OCHH-Ox), 3.82 (3H, s, OCH3), 3.81 (3H, s, OCH3), 
3.73-3.65 (1H, m, CHα-Phe), 2.95 (1H, dd, J = 13.3, 6.2 Hz, CHHβ-Phe), 2.85 (1H, dd, 
J = 13.3, 7.1 Hz, CHHβ-Phe), 2.34 (1H, bs, NH) ppm; 13C-NMR (125 MHz, CDCl3) δ 
174.7 (C=O), 161.8 (C, Ar-4), 159.3 (C, Ar-2), 136.7 (C, Ar-Phe), 132.2 (CH, Ar-6), 
129.6 (2 x CH, Ar-Phe), 128.5 (2 x CH, Ar-Phe), 127.0 (CH, Ar-Phe), 115.9 (C, Ar-1), 
104.2 (CH, Ar-5), 98.7 (CH, Ar-3), 78.9 (OCH2, Ox), 78.8 (OCH2, Ox), 78.4 (NO2CH2), 
63.0 (CH2, Dmb), 59.6 (C, Ox), 57.6 (CH, α-Phe), 55.57 (OCH3), 55.56 (OCH3), 40.6 
(CH2, b-Phe); IR (film): 3326 (NH), 2959, 2884, 2838, 1726 (C=O), 1552, 1207, 1157 
cm–1; MS (ESI+) m/z = 453 [M+Na]+, 883 [2M+Na]+; HRMS (ESI+) Calcd. for 
C22H26N2O7Na [M+Na]+: 453.1632, found 453.1633. 
 
Fmoc-GOx-Phe-ODmb 195  
Following general procedure 6, 193 (139 mg, 0.32 
mmol) gave, after column chromatography (30-40% FmocHN
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EtOAc in petroleum ether), 195 (125 mg, 0.20 mmol, 63%) as a colourless oil. Rf (40% 
EtOAc in petroleum ether) 0.25; [𝜶]𝑫𝟐𝟗 –4.7 (c 0.143, CHCl3); 1H-NMR (500 MHz, 
CDCl3) δ 7.77 (2H, d, J = 7.5 Hz, ArH), 7.61-7.54 (2H, m, ArH), 7.41 (2H, t, J = 7.4 Hz, 
ArH), 7.33 (2H, t, J = 7.4 Hz, ArH), 7.27-7.11 (6H, m, ArH), 6.50-6.41 (2H, m, ArH-3, 
ArH-5), 5.17 (1H, d, J = 11.6 Hz, CHH-Dmb), 5.08 (1H, d, J = 11.6 Hz, CHH-Dmb), 
4.81-4.69 (1H, m, NH-Fmoc), 4.37 (2H, d, J = 6.9 Hz, CH2-Fmoc), 4.25 (1H, d, J = 6.6 
Hz, OCHH-Ox), 4.23-4.17 (2H, m, CH-Fmoc and OCHH-Ox), 4.15 (1H, d, J = 6.5 Hz, 
OCHH-Ox), 4.11 (1H, d, J = 6.3 Hz, OCHH-Ox), 3.81 (6H, s, 2 x OCH3), 3.51-3.26 (3H, 
m, CH2-GOx, CHα-Phe), 3.02 (1H, dd, J = 13.4, 4.3 Hz, CHHβ-Phe), 2.72 (1H, dd, J = 
13.4, 9.2 Hz, CHHβ-Phe), 2.06 (1H, bs, NH-Phe); 13C-NMR (125 MHz, CDCl3) δ 175.5 
(C=O), 161.8 (C, Ar-4), 159.3 (C, Ar-2), 156.9 (C=O, Fmoc), 144.2 (C, Ar-Fmoc), 144.1 
(C, Ar-Fmoc), 141.5 (2 x C, Ar-Fmoc), 137.4 (C, Ar-Phe), 132.1 (CH, Ar-6), 129.5 (2 x 
CH, Ar), 128.7 (2 x CH, Ar), 127.8 (2 x CH, Ar), 127.2 (2 x CH, Ar), 125.25 (CH, Ar), 
125.21 (CH, Ar), 120.1 (2 x CH, Ar), 115.9 (C, Ar-1), 104.2 (CH, Ar-5), 98.7 (CH, Ar-
3), 80.0 (OCH2, Ox), 79.4 (OCH2, Ox), 66.8 (CH2, Fmoc), 63.1 (CH2, Dmb), 59.4 (C, 
Ox), 57.5 (CH, a-Phe), 55.6 (2 x OCH3), 47.4 (CH, Fmoc), 44.8 (CH2, GOx), 40.6 (CH2, 
b-Phe); IR (film) 3320 (NH), 2972, 2932, 2890, 1725 (C=O), 1689 (C=O), 1207, 1086, 
1044 cm–1; MS (ESI+) m/z 623 [M+H]+, 645 [M+Na]+; HRMS (ESI+) Calcd. for 
C37H38N2O7Na [M+Na]+: 645.2571, found 645.2576. 
 
Fmoc-Phe-OCumyl 192 
Following general procedure 7, Fmoc-Phe-OH (5.51 g, 40.5 mmol) 
gave, after column chromatography (0-20% EtOAc in petroleum 
ether), 192 (9.02 g, 17.8 mmol, 97%) contaminated with traces of 
2-phenyl-2-propanol (~19:1 by 1H-NMR) as a white solid. Rf (15% EtOAc in petroleum 
ether) 0.29; mp 86-90 °C; [𝜶]𝑫𝟐𝟓 +3.1 (c 0.144, CHCl3); 1H-NMR (500 MHz, CDCl3) d 
7.76 (2H, d, J = 7.6 Hz, ArH-Fmoc), 7.57-7.51 (2H, m, ArH-Fmoc), 7.39 (2H, t, J = 7.5 
Hz, ArH-Fmoc), 7.33-7.22 (10H, m, ArH), 7.17 (2H, d, J = 7.0 Hz, ArH), 5.22 (0.9H, d, 
J = 8.1 Hz, major rotamer NH), 4.96-4.83 (0.1H, m, minor rotamer NH), 4.65 (0.9H, m, 
major rotamer CHa-Phe), 4.54-4.45 (0.1 H, m, minor rotamer CHH-Fmoc), 4.40 (1H, dd, 
J = 10.6, 7.3 Hz, CHH-Fmoc), 4.36-4.25 (1H, m, minor rotamer CHa-Phe, major rotamer 
CHH-Fmoc), 4.18 (1H, t, J = 7.1 Hz, CH-Fmoc), 3.17 (0.9H, dd, J = 13.9, 6.2 Hz, major 
rotamer CHHb-Phe), 3.10 (0.9H, dd, J = 13.9, 6.2 Hz, major rotamer CHHb-Phe), 2.97-
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2.80 (0.2H, m, minor rotamer CH2b-Phe), 1.76 (3H, s, CH3-cumyl), 1.74 (3H, s, CH3-
cumyl); 13C-NMR (125 MHz, CDCl3) d 170.3 (C=O, Phe), 155.7 (C=O, Fmoc), 145.0 
(C, Ar-cumyl), 144.0 (C, Ar-Fmoc), 143.9 (C, Ar-Fmoc), 141.4 (2 x C, Ar-Fmoc) 136.1 
(C, Ar-Phe), 129.7 (2 x CH, Ar), 128.6 (2 x CH, Ar), 128.5 (2 x CH, Ar), 127.8 (2 x CH, 
Ar), 127.5 (CH, Ar), 127.2 (3 x CH, Ar), 125.3 (CH, Ar), 125.2 (CH, Ar), 124.5 (2 x CH, 
Ar), 120.11 (CH, Ar), 120.10 (CH, Ar), 83.7 (C, cumyl), 67.1 (CH2, Fmoc), 55.2 (CH, a-
Phe), 47.3 (CH, Fmoc), 38.5 (CH2, b-Phe), 28.8 (CH3, cumyl), 28.0 (CH3, cumyl); IR 
(film) 3396 (NH), 3241, 3018, 2980, 2924, 1708 (C=O), 1519, 1341, 1239, 985 cm-1; MS 
(ESI+) m/z 528 [M+Na]+; HRMS (ESI+) Calcd. for C33H31NO4Na [M+Na]+: 528.2145, 
found 528.2139.  
 
Fmoc-Val-OCumyl 197 
Following general procedure 7, Fmoc-Val-OH (3.39 g, 10.0 mmol) 
gave, after column chromatography (0-30% EtOAc in petroleum 
ether), 197 (3.33 g, 7.27 mmol, 73%) as a colourless oil. Rf (10% 
EtOAc in petroleum ether) 0.19;	[𝜶]𝑫𝟐𝟗 –16.8 (c 0.076, CHCl3); 1H-NMR (500 MHz, 
CDCl3) d 7.76 (2H, d, J = 7.5 Hz, ArH-Fmoc), 7.58 (2H, d, J = 7.4 Hz, ArH-Fmoc), 7.45-
7.22 (9H, m, ArH), 5.25 (0.9H, d, J = 9.0 Hz, major rotamer NH), 5.01-4.82 (0.1H, m, 
minor rotamer NH), 4.55-4.27 (2.9H, m, major rotamer CHa-Val, CHH-Fmoc, major 
rotamer CHH-Fmoc, minor rotamer CH-Fmoc), 4.27-4.17 (1H, m, minor rotamer CHH-
Fmoc, major rotamer CH-Fmoc) 4.02-3.86 (0.1H, m, minor rotamer CHa-Val), 2.33-2.20 
(0.9H, m, major rotamer CHb-Val), 2.10-1.98 (0.1 H, m, minor rotamer CHb-Val), 1.82 
(3H, s, CH3-cumyl), 1.81 (3H, s, CH3-cumyl), 1.00 (2.7H, d, J = 6.8 Hz, major rotamer 
CH3-Val), 0.90 (3.3H, m, minor rotamer CH3-Val, CH3-Val); 13C-NMR (125 MHz, 
CDCl3) d 170.8 (C=O, cumyl), 156.4 (C=O, Fmoc), 145.1 (C, Ar-cumyl), 144.1 (C, Ar-
Fmoc), 144.0 (C, Ar-Fmoc), 141.4 (2 x C, Ar-Fmoc), 128.5 (2 x CH, Ar), 127.8 (2 x CH, 
Ar), 127.5 (CH, Ar), 127.2 (2 x CH, Ar), 125.28 (CH, Ar), 125.25 (CH, Ar), 124.5 (2 x 
CH, Ar), 120.11 (CH, Ar), 120.10 (CH, Ar), 83.3 (C, cumyl), 67.1 (CH2, Fmoc), 59.3 
(CH, a-Val), 47.3 (CH, Fmoc), 31.5 (CH, b-Val), 28.6 (CH3, cumyl), 28.4 (CH3, cumyl), 
19.3 (CH3, Val), 17.4 (CH3, Val); IR (film) 3353 (NH), 3064, 2965, 2874, 1707 (C=O), 
1509, 1448, 1202, 1092, 1077, 1029 cm-1; MS (ESI+) m/z 480 [M+Na]+, 496 [M+K]+; 
HRMS (ESI+) Calcd. for C29H31NO4Na [M+Na]+: 480.2145, found 480.2140.  
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Fmoc-Ser(tBu)-OCumyl 198 
Following general procedure 7, Fmoc-Ser(OtBu)-OH (2.77 g, 7.23 
mmol) gave, after column chromatography (0-15% EtOAc in 
petroleum ether), 198 (2.79 g, 5.56 mmol, 77%) contaminated with 
traces of 2-phenyl-2-propanol (~9:1 by 1H-NMR) as a colourless oil. Rf (10% EtOAc in 
petroleum ether) 0.30; [𝜶]𝑫𝟐𝟓 –5.0 (c 0.06, CHCl3); 1H-NMR (500 MHz, CDCl3) d 7.76 
(2H, d, J = 7.6 Hz, ArH), 7.64-7.54 (2H, m, ArH), 7.45-7.20 (9H, m, ArH), 5.63 (0.85H, 
d, J = 8.8 Hz, major rotamer NH), 5.35 (0.15H, d, J = 8.6 Hz, minor rotamer NH), 4.56-
4.18 (4H, m, CHa-Ser, CHCH2-Fmoc), 3.93 (0.85H, dd, J = 8.8, 2.5 Hz, major rotamer 
CHHb-Ser), 3.83-3.76 (0.15H, m, minor rotamer CHHb-Ser), 3.63 (0.85H, dd, J = 8.8, 
3.0 Hz, major rotamer CHHb-Ser), 3.53-3.43 (0.15H, m, minor rotamer CHHb-Ser), 
1.84-1.73 (6H, m, 2 x CH3-cumyl), 1.20 (7.65H, s, major rotamer tBu), 1.17 (1.35H, bs, 
minor rotamer tBu); 13C-NMR (125 MHz, CDCl3) d 169.2 (C=O, Ser), 156.2 (C=O, 
Fmoc), 145.4 (C, Ar-cumyl), 144.1 (C, Ar-Fmoc), 144.0 (C, Ar-Fmoc), 141.4 (2 x C, Ar-
Fmoc), 128.4 (2 x CH, Ar), 127.8 (2 x CH, Ar), 127.21 (2 x CH, Ar), 127.18 (CH, Ar), 
125.3 (2 x CH, Ar), 124.5 (2 x CH, Ar), 120.1 (2 x CH, Ar), 83.4 (C, cumyl), 73.5 (C, 
tBu), 67.2 (CH2, Fmoc), 62.5 (CH2, b-Ser), 55.1 (CH, a-Ser), 47.3 (CH, Fmoc), 28.9 
(CH3, cumyl), 28.6 (CH3, cumyl), 27.6 (3 x CH3, tBu); IR (film) 3315 (NH), 3065, 2975, 
2934, 2876, 1723 (C=O), 1500, 1199, 1102, 1107, 1060 cm–1; MS (ESI+) m/z 524 
[M+Na]+; HRMS (ESI+) Calcd. for C31H35NO5Na [M+Na]+: 524.2407, found 524.2405.  
 
Fmoc-Asp(tBu)-OCumyl 199 
Following general procedure 7, Fmoc-Asp(tBu)-OH (4.27 g, 10.4 
mmol) gave, after column chromatography (10-15% EtOAc in 
petroleum ether), 199 (4.01 g, 7.56 mmol, 73%) contaminated with 
traces of 2-phenyl-2-propanol (~9:1 by 1H-NMR) as a colourless oil. Rf (10% EtOAc in 
petroleum ether) 0.24; [𝜶]𝑫𝟐𝟓 +14.2 (c 0.088, CHCl3); 1H-NMR (500 MHz, CDCl3) d 7.76 
(2H, d, J = 7.5 Hz, ArH), 7.59 (2H, d, J = 7.5 Hz, ArH), 7.44-7.22 (9H, m, ArH), 5.83 
(0.9H, d, J = 8.6 Hz, major rotamer NH), 5.46 (0.1H, bs, minor rotamer NH), 4.57 (0.9H, 
dt, J = 8.7, 4.4 Hz, major rotamer CHa-Asp), 4.51-4.29 (2.1H, m, minor rotamer CHa-
Asp, CH2-Fmoc), 4.28-4.18 (1H, m, CH-Fmoc), 2.97 (0.9H, dd, J = 17.0, 4.4 Hz, major 
rotamer CHHb-Asp), 2.84-2.73 (1H, m, minor rotamer CHHb-Asp, major rotamer 
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CHHb-Asp), 2.63-2.49 (0.1H, m, CHHb-Asp), 1.82 (3H, s, CH3-cumyl), 1.78 (3H, s, 
CH3-cumyl), 1.46 (9H, s, tBu); 13C-NMR (125 MHz, CDCl3) d 170.3 (C=O, CO2tBu), 
169.5 (C=O, Asp), 156.1 (C=O, Fmoc), 145.2 (C, Ar-cumyl), 144.0 (C, Ar-Fmoc), 143.9 
(C, Ar-Fmoc), 141.4 (2 x C, Ar-Fmoc), 128.4 (2 x CH, Ar), 127.8 (2 x CH, Ar), 127.4 
(CH, Ar), 127.19 (CH, Ar), 127.16 (CH, Ar), 125.31 (CH, Ar), 125.28 (CH, Ar), 124.4 
(2 x CH, Ar), 120.1 (2 x CH, Ar), 83.7 (C, cumyl), 81.9 (C, tBu), 67.3 (CH2, Fmoc), 51.1 
(CH, a-Asp), 47.2 (CH, Fmoc), 37.9 (CH2, b-Asp), 28.8 (CH3, cumyl), 28.2 (3 x CH3, 
tBu), 28.1 (CH3, cumyl); IR (film) 3437 (NH), 3064, 2978, 2936, 1721 (C=O), 1498, 
1366, 1214, 1136, 1030 cm–1; MS (ESI+) m/z 552 [M+Na]+, 568 [M+K]+; HRMS (ESI+) 
Calcd. for C32H35NO6Na [M+Na]+: 552.2357, found 552.2358. 
 
Fmoc-Lys(Boc)-OCumyl 200 
Following general procedure 7, Fmoc-Lys(Boc)-OH (2.53 g, 
5.40 mmol) gave, after column chromatography (0-10% EtOAc 
in CH2Cl2), 200 (2.22 g, 3.78 mmol, 70%) as a white solid. mp 
56-59 °C; [𝜶]𝑫𝟐𝟓 +2.0 (c 0.15, CHCl3); 1H-NMR (CDCl3, 500 MHz) d 7.78 (2H, d, J = 
7.6, ArH-Fmoc), 7.60 (2H, d, J = 7.4 Hz, ArH-Fmoc), 7.46-7.24 (9H, m, ArH), 5.34 (1H, 
d, J = 7.5 Hz, NH-Fmoc), 4.66-4.46 (1H, m, NH-Boc), 4.46-4.28 (3H, m, CH2-Fmoc and 
CHa-Lys), 4.27-4.19 (1H, m, CH-Fmoc), 3.23-3.00 (2H, m, CH2e-Lys), 1.99-1.89 (1H, 
m, CHHb-Lys), 1.83 (3H, s, CH3-cumyl), 1.82 (3H, s, CH3-cumyl), 1.78-1.67 (1H, m, 
CHHb-Lys), 1.60-1.29 (13H, m, CH2g-Lys, CH2d-Lys and tBu); 13C-NMR (CDCl3, 125 
MHz) d 171.1 (C=O, cumyl), 156.2 (C=O), 156.1 (C=O), 145.0 (C, Ar), 144.1 (C, Ar), 
143.9 (C, Ar), 141.4 (2 x C, Ar), 128.5 (2 x CH, Ar), 127.8 (2 x CH, Ar), 127.5 (CH, Ar), 
127.2 (2 x CH, Ar), 125.3 (2 x CH, Ar), 124.4 (2 x CH, Ar) 120.11 (CH, Ar), 120.10 (CH, 
Ar), 83.4 (C, cumyl), 79.3 (C, tBu), 67.1 (CH2, Fmoc), 54.2 (CHa, Lys), 47.3 (CH, Fmoc), 
40.4 (CH2e-Lys), 32.5 (CH2b, Lys), 29.8 (CH2d-Lys), 28.7 (CH3, cumyl), 28.6 (3 x CH3, 
tBu), 28.4 (CH3, cumyl), 22.4 (CH2g-Lys); IR (film) 3343 (NH), 2976, 2932, 2865, 1689 
(C=O), 1511, 1247, 1165, 1136 cm–1; MS (ESI+) m/z 609 [M+Na]+; HRMS (ESI+) 
Calcd. for C35H42N2O6Na [M+Na]+: 609.2935, found 609.2933. 
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Fmoc-Ala-OCumyl 202 
Following general procedure 7, Fmoc-Ala-OH (3.27 g, 10.5 mmol) 
gave, after repeat column chromatography (10-20% EtOAc in 
petroleum ether; 10-15% EtOAc in petroleum ether), 202 (3.24 g, 
7.55 mmol, 42%) as a colourless oil. Rf (15% EtOAc in petroleum ether) 0.37; [𝛂]𝐃𝟐𝟐 
+10.8 (c 0.20, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 7.75 (2H, d, J = 7.5 Hz, ArH-
Fmoc), 7.57 (2H, d, J = 7.4 Hz, ArH-Fmoc), 7.44-7.22 (9H, m, ArH), 5.33 (0.9 H, d, J = 
7.3 Hz, major rotamer NH), 5.00 (0.1 H, bs, minor rotamer NH), 4.54-4.29 (3H, m, CH2-
Fmoc, CHa-Ala), 4.28-4.15 (1H, m, CH-Fmoc), 1.82 (3H, s, CH3-cumyl), 1.78 (3H, s, 
CH3-cumyl), 1.46 (2.7H, d, J = 7.1 Hz, major diastereoisomer CH3-Ala), 1.38-1.30 (0.3H, 
m, minor diastereoisomer CH3-Ala); 13C-NMR (125 MHz, CDCl3) δ 171.7 (C=O, Ala), 
155.7 (C=O, Fmoc), 145.2 (C, Ar-Ph), 144.1 (C, Ar-Fmoc), 144.0 (C, Ar-Fmoc), 141.3 
(2 x C, Ar-Fmoc), 128.5 (2 x CH, Ar), 127.8 (2 x CH, Ar), 127.5 (CH, Ar), 127.2 (2 x 
CH, Ar), 125.3 (2 x CH, Ar), 124.4 (2 x CH, Ar), 120.1 (2 x CH, Ar), 83.3 (C, cumyl), 
67.1 (CH2, Fmoc), 50.2 (CH, a-Ala), 47.3 (CH, Fmoc), 28.9 (CH3, cumyl), 28.2 (CH3, 
cumyl), 19.0 (CH3, Ala); IR (film) 3332 (NH), 3064, 2981, 2944, 1701 (C=O), 1512, 
1448, 1213, 1071 cm−1; MS (ESI+) m/z 452 [M+Na]+, 468 [M+K]+; HRMS (ESI+) Calcd. 
for C27H27NO4Na [M+Na]+: 452.1832, found 452.1829. 
 
H-Pro-OCumyl 203 
To sodium hydride (60% dispersion in mineral oil, 82 mg, 2.05 mmol) in 
Et2O (2 mL) at 0 °C was added 2-phenyl-2-propanol (1.23 g, 4.11 mmol) 
in Et2O (2 mL) then stirred at room temperature for 1 h. The reaction 
mixture was cooled to 0 °C, trichloroacetonitrile (824 µL, 8.22 mmol) added and stirred 
at room temperature for 3 h. The reaction mixture was concentrated under reduced 
pressure. Petroleum ether (2 mL) and MeOH (83 µL, 2.05 mmol) were added and stirred 
at room temperature for 10 min. The reaction mixture was filtered through a plug of 
Celite® eluting with petroleum ether. The eluent was concentrated under reduced pressure 
to give the crude imidate. To the crude imidate in CH2Cl2 (8 mL) was added Fmoc-Pro-
OH (1.39 g, 4.11 mmol) and the reaction mixture stirred at room temperature for 16 h. 
The mixture was filtered through a plug of Celite® and the eluent concentrated under 
reduced pressure to give a cream oil. The crude product was stirred in 50% diethylamine 
in CH2Cl2 (8 mL) for 1 h then concentrated under reduced pressure. CH2Cl2 was added 
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and concentrated under reduced pressure (repeated x3, to remove trace diethylamine) to 
give the crude amine, which was purified by column chromatography (0-7% MeOH in 
CH2Cl2) to give 203 (681 mg, 2.92 mmol, 71%) as a yellow oil. Rf (10% MeOH in 
CH2Cl2) 0.35; [𝜶]𝑫𝟐𝟓 –13.5 (c 0.122, CHCl3); 1H-NMR (CDCl3, 500 MHz) d 7.40-7.30 
(4H, m, ArH), 7.29-7.23 (1H, m, ArH), 3.75 (1H, dd, J = 8.5 and 5.8 Hz, CHa-Pro), 3.09-
3.00 (1H, m, CHHd-Pro), 2.92-2.84 (1H, m, CHHd-Pro), 2.41-2.11 (2H, m, NH and 
CHHb-Pro), 1.94-1.83 (1H, m, CHHb-Pro), 1.83-1.64 (8H, m, 2 x CH3-cumyl and CH2g-
Pro); 13C-NMR (CDCl3, 500 MHz) d 174.0 (C=O), 145.6 (C, Ar), 128.5 (2 x CH, Ar), 
127.3 (CH, Ar), 124.3 (2 x CH, Ar), 82.3 (C, cumyl), 60.5 (CHa, Pro), 47.1 (CH2d, Pro), 
30.4 (CH2b, Pro), 28.9 (CH3, cumyl), 28.4 (CH3, cumyl), 25.6 (CH2g, Pro); IR (film) 
3335 (NH), 3061, 2977, 2872, 1730 (C=O), 1213, 1199, 1136, 1100 cm–1; MS m/z (ESI+) 
467 [2M+H]+; HRMS (ESI+) Calcd. for C14H19NO2Na [M+Na]+: 256.1308, found 
256.1304. 
 
2-Phenylpropan-2-yl [3-(nitromethyl)oxetan-3-yl]-L-phenylalaninate 193 
Following general procedure 8, 192 (915 mg, 1.81 mmol), oxetan-3-
one (232 µL, 3.62 mmol) and nitromethane (274 µL, 5.07 mmol) 
were combined to give, after column chromatography (20-30% 
EtOAc in petroleum ether), 193 (408 mg, 1.02 mmol, 57%) as an orange solid. 
Increased scale: 192 (5.85 g, 11.6 mmol) was stirred in 50% diethylamine in CH2Cl2 (24 
mL) at room temperature for 1 h. The reaction mixture was concentrated under reduced 
pressure. CH2Cl2 (3 x 20 mL) was added and concentrated under reduced pressure (to 
remove trace diethylamine) to give the crude amine. Meanwhile, to oxetan-3-one (1.48 
mL, 23.1 mmol) at 0 °C was added nitromethane (1.75 mL, 32.4 mmol) and triethylamine 
(0.65 mL, 4.63 mmol). The reaction mixture was stirred at 0 °C for 0.5 h, then at room 
temperature for 1 h. CH2Cl2 (100 mL) was added and the reaction mixture cooled to −78 
°C. Triethylamine (6.45 mL, 46.3 mmol) was added followed by the dropwise addition 
of a solution of methanesulfonyl chloride (1.79 mL, 23.1 mmol) in CH2Cl2 (23 mL). The 
reaction mixture was stirred at −78 °C for 2 h. The crude amine in CH2Cl2 (50 mL) was 
added to the oxetane mixture via syringe at −78 °C. The reaction mixture was allowed to 
reach room temperature and stirred for 16 h. The reaction mixture was poured into a 
saturated solution of NH4Cl (100 mL) and stirred at room temperature for 10 min. The 
layers were separated and the aqueous extracted with CH2Cl2 (2 x 125 mL) and EtOAc 
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(2 x 125 mL). The combined organics were washed with saturated NaHCO3 (2 x 100 mL) 
and brine (50 mL), dried (MgSO4), filtered and concentrated under reduced pressure. 
Purification by column chromatography (20-25% EtOAc in petroleum ether) gave 193 
(2.75 g, 6.90 mmol, 60%) as an orange solid. Rf (20% EtOAc in petroleum ether) 0.24; 
mp 76-79 °C; [𝜶]𝑫𝟐𝟓 +6.5 (c 0.1, CHCl3); 1H-NMR (500 MHz, CDCl3) d 7.34-7.27 (4H, 
m, ArH), 7.27-7.22 (4H, m, ArH), 7.20 (2H, d, J = 7.0, ArH), 4.73 (1H, d, J = 12.7 Hz, 
NO2CHH), 4.66 (1H, d, J = 12.7 Hz, NO2CHH), 4.46 (1H, d, J = 7.2 Hz, OCHH-Ox), 
4.33 (1H, d, J = 7.2 Hz, OCHH-Ox), 4.29 (1H, d, J = 7.2 Hz, OCHH-Ox), 4.26 (1H, d, J 
= 7.2 Hz, OCHH-Ox), 3.71 (1H, m, CHa-Phe), 2.99 (1H, J = 13.4, 6.1 Hz, CHHb-Phe), 
2.83 (1H, J = 13.4, 7.6 Hz, CHHb-Phe), 2.33 (1H, d, J = 9.4 Hz, NH), 1.76 (3H, s, CH3-
cumyl), 1.71 (3H, s, CH3-cumyl); 13C-NMR (125 MHz, CDCl3) d 173.4 (C=O), 144.8 
(C, Ar-cumyl), 137.0 (C, Ar-Phe), 129.6 (2 x CH, Ar), 128.6 (2 x CH, Ar), 128.5 (2 x 
CH, Ar), 127.6 (CH, Ar), 127.1 (CH, Ar), 124.5 (2 x CH, Ar), 83.3 (C, cumyl), 79.0 
(NO2CH2), 78.8 (OCH2, Ox), 78.7 (OCH2, Ox), 59.5 (C, Ox), 58.0 (CH, a-Phe), 40.9 
(CH2, b-Phe), 28.7 (CH3, cumyl), 27.6 (CH3, cumyl); IR (film) 3348 (NH), 3243, 3067, 
3030, 2978, 1727 (C=O), 1694, 1546, 1381, 1233, 1194, 1133, 980 cm–1; MS (ESI+) m/z 
421 [M+Na]+; HRMS (ESI+) Calcd. for C22H26N2O5Na [M+Na]+: 421.1734, found 
421.1736. 
 
2-Phenylpropan-2-yl [3-(nitromethyl)oxetan-3-yl]-L-valinate 204 
Following general procedure 8, 197 (1.81 g, 3.96 mmol), oxetan-3-
one (507 µL, 7.91 mmol) and nitromethane (593 µL, 11.1 mmol) 
were combined to give, after column chromatography (15-20% 
EtOAc in petroleum ether), 204 (763 mg, 2.18 mmol, 55%) as a yellow solid. Rf (20% 
EtOAc in petroleum ether) 0.32; mp 82-85 °C; [𝜶]𝑫𝟐𝟓 -21.6 (c 0.058, CHCl3); 1H-NMR 
(500 MHz, CDCl3) d 7.41-7.31 (4H, m, ArH), 7.29-7.24 (1H, m, ArH), 4.78 (1H, d, J = 
12.7 Hz, NO2CHH), 4.67 (1H, d, J = 12.8 Hz, NO2CHH), 4.57 (1H, d, J = 7.2 Hz, OCHH-
Ox), 4.48 (1H, d, J = 7.2 Hz, OCHH-Ox), 4.45 (1H, d, J = 7.2 Hz, OCHH-Ox), 4.43 (1H, 
d, J = 7.2 Hz, OCHH-Ox), 3.30 (1H, bs, CHa-Val), 2.22 (1H, bs, NH), 2.12-2.01 (1H, 
m, CHb-Val), 1.82 (3H, s, CH3-cumyl), 1.79 (3H, s, CH3-cumyl), 0.97 (3H, d, J = 6.8 Hz, 
CH3-Val), 0.81 (3H, d, J = 6.9 Hz, CH3-Val); 13C-NMR (125 MHz, CDCl3) d 174.2 
(C=O), 145.0 (C, Ar), 128.5 (2 x CH, Ar), 127.6 (CH, Ar), 124.6 (2 x CH, Ar), 83.0 (C, 
cumyl), 79.3 (NO2CH2), 78.8 (OCH2), 78.6 (OCH2), 61.2 (CH, a-Val), 59.6 (C, Ox), 32.1 
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(CH, b-Val), 28.6 (CH3, cumyl), 27.9 (CH3, cumyl), 19.8 (CH3, Val), 17.3 (CH3, Val); 
IR (film) 3339 (NH), 2981, 2957, 2932, 2881, 1717 (C=O), 1548, 1312, 1202, 1133, 952 
cm–1; MS (ESI+) m/z 373 [M+Na]+, 389 [M+K]+; HRMS (ESI+) Calcd. for 
C18H26N2O5Na [M+Na]+: 373.1734, found 373.1730. 
 
2-Phenylpropan-2-yl O-(tert-butyl)-N-[3-(nitromethyl)oxetan-3-yl]-L-serinate 205 
Following general procedure 8, 198 (301 mg, 0.60 mmol), oxetan-3-
one (77 µL, 1.20 mmol) and nitromethane (91 µL, 1.68 mmol) were 
combined to give, after column chromatography (25% EtOAc in 
petroleum ether), 205 (127 mg, 0.32 mmol, 54%) as a yellow oil. Rf (25% EtOAc in 
petroleum ether) 0.30; [𝜶]𝑫𝟐𝟓 –7.0 (c 0.104, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 7.44-
7.38 (2H, m, ArH), 7.38-7.32 (2H, m, ArH), 7.31-7.23 (1H, m, ArH), 4.84 (2H, s, 
NO2CH2), 4.64 (1H, d, J = 7.1 Hz, OCHH-Ox), 4.56 (2H, s, OCH2-Ox), 4.45 (1H, d, J = 
7.1 Hz, OCHH-Ox), 3.67-3.60 (2H, m, CHa-Ser, CHHb-Ser), 3.54 (1H, dd, J = 10.2 and 
6.7 Hz, CHHb-Ser), 2.59 (1H, bs, NH), 1.82 (3H, s, CH3-cumyl), 1.80 (3H, s, CH3-
cumyl), 1.20 (9H, s, tBu); 13C-NMR (125 MHz, CDCl3) δ 172.1 (C=O), 145.2 (C, Ar), 
128.4 (2 x CH, Ar), 127.4 (CH, Ar), 124.5 (2 x CH, Ar), 83.2 (C, cumyl), 79.4 (OCH2, 
Ox), 79.2 (OCH2, Ox), 78.8 (NO2CH2), 73.6 (C, tBu), 64.3 (CH2, b-Ser), 59.6 (C, Ox), 
57.1 (CH, a-Ser), 28.7 (CH3-cumyl), 28.3 (CH3-cumyl), 27.5 (3 x CH3, tBu); IR (film) 
3339 (NH), 2979, 2935, 2882, 1724 (C=O), 1554, 1367, 1272, 1133, 1077, 977 cm–1; MS 
(ESI+) m/z 417 [M+Na]+; HRMS (ESI+) Calcd. for C20H30N2O6Na [M+Na]+: 417.1996, 
found 417.2002. 
 
4-(tert-Butyl) 1-(2-phenylpropan-2-yl) [3-(nitromethyl)oxetan-3-yl]-L-aspartate 206 
Following general procedure 8, 199 (577 mg, 1.09 mmol), oxetan-3-
one (140 µL, 2.18 mmol) and nitromethane (165 µL, 3.05 mmol) 
were combined to give, after column chromatography (0-30% 
EtOAc in petroleum ether), 206 (184 mg, 0.43 mmol, 40%) as a yellow oil. Rf (30% 
EtOAc in petroleum ether) 0.38; [𝜶]𝑫𝟐𝟓 –12.2 (c 0.074, CHCl3); 1H-NMR (500 MHz, 
CDCl3) d 7.37-7.31 (4H, m, ArH), 7.29-7.23 (1H, m, ArH), 4.81 (1H, d, J = 12.9 Hz, 
NO2CHH), 4.72 (1H, d, J = 12.9 Hz, NO2CHH), 4.65 (1H, d, J = 7.2 Hz, OCHH-Ox), 
4.50 (1H, d, J = 7.4 Hz, OCHH-Ox), 4.48-4.42 (2H, m, 2 x OCHH-Ox), 3.92-3.81 (1H, 
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m, CHa-Asp), 2.68 (1H, dd, J = 15.9 and 4.6 Hz, CHHb-Asp), 2.59 (1H, bs, NH), 2.54 
(1H, dd, J = 15.9 and 7.9 Hz, CHHb-Asp), 1.79 (3H, s, CH3-cumyl), 1.78 (3H, s, CH3-
cumyl), 1.45 (9H, s, tBu); 13C-NMR (125 MHz, CDCl3) d 172.7 (C=O, Asp), 170.0 (C=O, 
CO2tBu), 144.9 (C, Ar), 128.5 (2 x CH, Ar), 127.6 (CH, Ar), 124.4 (2 x CH, Ar), 83.5 (C, 
cumyl), 81.7 (C, tBu), 79.1 (NO2CH2), 78.9 (OCH2-Ox), 78.4 (OCH2-Ox), 59.5 (C, Ox), 
53.3 (CH, a-Asp), 40.5 (CH2, b-Asp), 28.5 (CH3-cumyl), 28.2 (4 x CH3, cumyl and tBu); 
IR (film) 3300 (NH), 3006, 2985, 2933, 2875, 1733 (C=O), 1716 (C=O), 1549, 1364, 
1342, 1135, 942 cm–1; MS (ESI+) m/z 445 [M+Na]+, 461 [M+K]+; HRMS (ESI+) Calcd. 
for C21H30N2O7Na [M+Na]+: 445.1945, found 445.1951. 
 
2-Phenylpropan-2-yl N6-(tert-butoxycarbonyl)-N2-[3-(nitromethyl)oxetan-3-yl]-L-
lysinate 207 
Following general procedure 8, 200 (186 mg, 0.32 mmol), 
oxetan-3-one (41 µL, 0.64 mmol) and nitromethane (48 µL, 0.90 
mmol) were combined to give, after column chromatography 
(40% EtOAc in petroleum ether), 207 (85 g, 0.18 mmol, 56%) as a yellow oil. Rf (30% 
EtOAc in petroleum ether) 0.32; [𝜶]𝑫𝟐𝟓 +10.5 (c 0.038, CHCl3); 1H-NMR (500 MHz, 
CDCl3) d 7.38-7.32 (4H, m, ArH), 7.30-7.24 (1H, m, ArH), 4.78 (1H, d, J = 12.7 Hz, 
NO2CHH), 4.73 (1H, d, J = 12.7 Hz, NO2CHH), 4.58-4.48 (3H, m, 2 x OCHH-Ox, NH-
Boc), 4.45 (1H, d, J = 7.2 Hz, OCHH-Ox), 4.37 (1H, d, J = 6.9 Hz, OCHH-Ox), 3.49-
3.36 (1H, m, CHa-Lys), 3.18-3.00 (2H, m, CH2e-Lys), 2.32-2.19 (1H, m, NH-Lys), 1.80 
(3H, s, CH3-cumyl), 1.79 (3H, s, CH3-cumyl), 1.75-1.65 (1H, m, CHHb-Lys), 1.54-1.41 
(12H, m, CHHb-Lys, CH2d-Lys, tBu), 1.41-1.28 (2H, m, CH2g-Lys); 13C-NMR (125 
MHz, CDCl3) d 174.2 (C=O, Lys), 156.1 (C=O, Boc), 144.8 (C, Ar), 128.5 (2 x CH, Ar), 
127.7 (CH, Ar), 124.5 (2 x CH, Ar), 83.1 (C, cumyl), 79.4 (C, tBu) 79.0 (OCH2-Ox or 
NO2CH2), 78.94 (OCH2-Ox or NO2CH2), 78.86 (CH2, OCH2), 59.7 (C, Ox), 56.2 (CH, a-
Lys), 40.4 (CH2, e-Lys), 34.2 (CH2, b-Lys), 29.9 (CH2, d-Lys), 28.6 (3 x CH3, tBu), 28.5 
(CH3, cumyl), 28.1 (CH3, cumyl), 22.9 (CH2, g-Lys) [NOTE: 79.4 (C, tBu) assigned using 
HMBC]; IR (film) 3341 (NH), 2977, 2935, 2876, 1699 (C=O), 1554, 1510, 1365, 1248, 
1167, 1133, 979 cm–1; MS (ESI+) m/z 480 [M+H]+, 502 [M+Na]+; HRMS (ESI+) Calcd. 
for C24H37N3O7Na [M+Na]+: 502.2524, found 502.2527. 
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2-Phenylpropan-2-yl [3-(nitromethyl)oxetan-3-yl]-L-prolinate 208 
Oxetan-3-one (365 µL, 5.70 mmol), nitromethane (427 µL, 7.98 
mmol) and triethylamine (159 µL, 1.14 mmol) were stirred at room 
temperature for 1 h. CH2Cl2 (23 mL) was added and the reaction 
mixture cooled to −78 °C. Triethylamine (1.59 mL, 11.4 mmol) was added followed by 
the dropwise addition of a solution of methanesulfonyl chloride (441 µL, 5.70 mmol) in 
CH2Cl2 (6 mL). The reaction mixture was stirred at −78 °C for 1.5 h. H-Pro-Cumyl 203 
(665 mg, 2.85 mmol) in CH2Cl2 (11 mL) was added to the oxetane mixture via syringe at 
−78 °C. The reaction mixture was allowed to reach room temperature and stirred for 16 
h. A saturated solution of NH4Cl (50 mL) was added and the reaction mixture stirred at 
room temperature for 10 min. The layers were separated and the aqueous extracted with 
CH2Cl2 (2 x 60 mL) and EtOAc (2 x 60 mL). The combined organics were washed with 
saturated NaHCO3 (50 mL) and brine (25 mL), dried (MgSO4), filtered and concentrated 
under reduced pressure. Purification by column chromatography (30-40% EtOAc in 
petroleum ether) gave 208 (554 mg, 1.59 mmol, 56%) as a yellow oil. Rf (30% EtOAc in 
petroleum ether) 0.32; [𝜶]𝑫𝟐𝟓 –6.8 (c 0.112, CHCl3); 1H-NMR (CDCl3, 500 MHz) d 7.37-
7.30 (4H, m, ArH), 7.28-7.21 (1H, m, ArH), 4.96-4.90 (2H, m, NO2CHH and OCHH), 
4.87-4.81 (2H, m, NO2CHH and OCHH), 4.79 (1H, d, J = 7.2 Hz, OCHH), 4.32 (1H, d, 
J = 7.2 Hz, OCHH), 3.97 (1H, dd, J = 7.7 and 3.5 Hz, CHa-Pro), 3.26 (1H, td, J = 7.8 
and 3.5 Hz, CHHd-Pro), 2.74 (1H, dd, J = 8.0 and 7.5 Hz, CHHd-Pro), 2.01-1.82 (4H, m, 
CH2b-Pro and CH2g-Pro), 1.77 (3H, s, CH3-cumyl), 1.75 (3H, s, CH3-cumyl); 13C-NMR 
(CDCl3, 125 MHz) d 173.1 (C=O), 145.4 (C, Ar), 128.5 (2 x CH, Ar), 127.3 (CH, Ar), 
124.3 (2 x CH, Ar), 82.3 (C, cumyl), 78.8 (NO2CH2 or CH2, Ox), 78.1 (NO2CH2 or CH2, 
Ox), 76.3 (CH2, Ox), 63.1 (C, Ox), 60.8 (CHa, Pro), 47.8 (CH2d, Pro), 30.3 (CH2b, Pro), 
28.6 (CH3, cumyl), 28.3 (CH3, cumyl), 24.2 (CH2g, Pro); IR (film) 2978, 2878, 1725 
(C=O), 1550, 1348, 1133, 981 cm–1; MS m/z (ESI+) 371 [M+Na]+, 387 [M+K]+; HRMS 
(ESI+) Calcd. for C18H24N2O5Na [M+Na]+: 371.1577, found 371.1578. 
 
2-Phenylpropan-2-yl (3-(nitromethyl)oxetan-3-yl)-L-alaninate 209 
Following general procedure 8, 202 (1.77 g, 4.12 mmol), oxetan-3-
one (528 µL, 8.24 mmol) and nitromethane (625 µL, 11.5 mmol) 
were combined to give, after repeat column chromatography (25-
30% EtOAc in petroleum ether; 0-10% EtOAc in CH2Cl2), 209 (730 mg, 2.26 mmol, 
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55%) as a colourless oil. Rf (5% EtOAc in CH2Cl2) 0.40; [𝛂]𝐃𝟐𝟐 +19.4 (c 0.10, CHCl3) 
1H-NMR (500 MHz, CDCl3) δ 7.38-7.31 (4H, m, ArH), 7.30-7.24 (1H, m, ArH), 4.81 
(1H, d, J = 12.6 Hz, NO2CHH), 4.76 (1H, d, J = 12.6 Hz, NO2CHH), 4.60-4.55 (2H, m, 
2 x OCHH-Ox), 4.49 (1H, d, J = 7.1 Hz, OCHH-Ox), 4.38 (1H, d, J = 7.0 Hz, OCHH-
Ox), 3.57 (1H, q, J = 7.0 Hz, CHa-Ala), 1.83-1.80 (1H, m, NH), 1.79 (6H, s, 2 x CH3-
cumyl), 1.32 (3H, d, J = 7.0 Hz, CH3-Ala); 13C-NMR (125 MHz, CDCl3) δ 174.5 (C=O, 
Ala), 145.0 (C, Ar), 128.5 (2 x CH, Ar), 127.6 (CH, Ar), 124.4 (2 x CH, Ar), 82.9 (C, 
cumyl), 79.1 (OCH2, Ox), 79.0 (OCH2, Ox), 78.8 (NO2CH2), 59.8 (C, Ox), 51.9 (CH, a-
Ala), 28.39 (CH3, cumyl), 28.37 (CH3, cumyl), 20.7 (CH3, Ala); IR (film) 3338 (NH), 
2954, 2929, 1717 (C=O), 1550, 1303, 1130, 960 cm−1; MS (ESI+) m/z 345 [M+Na]+, 361 
[M+K]+; HRMS (ESI+) Calcd. for C16H22N2O5Na [M+Na]+: 345.1421, found 345.1423. 
 
Fmoc-GOx-Phe-OCumyl 196 
Following general procedure 9, 193 (378 mg, 0.95 mmol) 
gave, after column chromatography (10% EtOAc in 
CH2Cl2), 196 (324 mg, 0.55 mmol, 58%) as a white solid. Rf 
(5% EtOAc in CH2Cl2) 0.24; mp 55-59 °C; [𝜶]𝑫𝟐𝟏 +7.5 (c 0.1, CHCl3); 1H-NMR (500 
MHz, CDCl3) d 7.78 (2H, d, J = 7.6 Hz, ArH-Fmoc), 7.57 (2H, t, J = 7.4 Hz, ArH-Fmoc), 
7.45-7.38 (2H, m, ArH), 7.36-7.14 (12H, m, ArH), 4.76-4.64 (1H, m, NH-GOx), 4.46-4.30 
(2H, m, CH2-Fmoc), 4.28-4.15 (3H, m, CH-Fmoc and 2 x OCHH-Ox), 4.13 (2H, d, J = 
6.5 Hz, 2 x OCHH-Ox), 3.52-3.28 (3H, m, CHa-Phe and CH2-GOx), 3.08 (1H, dd, J = 
13.3, 4.6 Hz, CHHb-Phe), 2.69 (1H, dd, J = 13.2, 9.5 Hz, CHHb-Phe), 2.02 (1H, bs, NH-
Phe), 1.79 (3H, s, CH3, cumyl), 1.76 (3H, s, CH3, cumyl); 13C-NMR (125 MHz, CDCl3) 
d 174.2 (C=O, Phe), 156.9 (C=O, Fmoc), 144.9 (C, Ar-cumyl), 144.12 (C, Ar-Fmoc), 
144.07 (C, Ar-Fmoc), 141.47 (C, Ar-Fmoc), 141.46 (C, Ar-Fmoc), 137.5 (C, Ar-Phe), 
129.6 (2 x CH, Ar), 128.7 (2 x CH, Ar), 128.5 (2 x CH, Ar), 127.8 (2 x CH, Ar), 127.6 
(CH, Ar), 127.23 (CH, Ar), 127.16 (2 x CH, Ar), 125.2 (2 x CH, Ar), 124.5 (2 x CH, Ar), 
120.1 (2 x CH, Ar), 83.2 (C, cumyl), 79.9 (OCH2, Ox), 79.4 (OCH2, Ox), 66.7 (CH2, 
Fmoc), 59.4 (C, Ox), 57.9 (CH, a-Phe), 47.4 (CH, Fmoc), 45.1 (CH2, GOx), 40.8 (CH2, 
b-Phe), 28.7 (CH3, cumyl), 27.9 (CH3, cumyl); IR (film) 3335 (NH), 3063, 3026, 2943, 
2871, 1717 (C=O), 1218, 1131, 970 cm–1; MS (ESI+) m/z 613 [M+Na]+; HRMS (ESI+) 
Calcd. for C37H38N2O5Na [M+Na]+: 613.2673, found 613.2670. 
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Fmoc-GOx-Val-OCumyl 210 
Following general procedure 9, 204 (221 mg, 0.63 mmol) 
gave, after column chromatography (5-10% EtOAc in 
CH2Cl2), 210 (258 mg, 0.48 mmol, 76%) as a white solid. Rf 
(5% EtOAc in CH2Cl2) 0.30; mp 82-84 °C; [𝜶]𝑫𝟐𝟏 +9.4 (c, 0.064, CHCl3); 1H-NMR (500 
MHz, CDCl3) d 7.76 (2H, d, J = 7.6 Hz, ArH-Fmoc), 7.66-7.52 (2H, m, ArH-Fmoc), 7.44-
7.36 (4H, m, ArH), 7.36-7.27 (4H, m, ArH), 7.27-7.22 (1H, m, ArH), 5.21 (0.9H, bs, 
major rotamer NH-GOx), 4.49 (0.1H, bs, minor rotamer NH-GOx), 4.56-4.04 (7H, m, 2 x 
OCH2-Ox, CHCH2-Fmoc), 3.70 (0.9H, dd, J = 13.7, 6.3 Hz, major rotamer CHH-GOx), 
3.62-3.51 (0.1H, m, minor rotamer CHH-GOx) 3.35 (1H, dd, J = 13.7 and 4.7 Hz, CHH-
GOx), 3.14 (1H, d, J = 4.3 Hz, CHa-Val), 2.15-2.03 (1H, m, CHb-Val), 2.03-1.88 (1H, 
m, NH-Val), 1.83 (3H, s, CH3-cumyl), 1.79 (3H, s, CH3-cumyl), 1.03 (3H, d, J = 6.7, 
CH3-Val), 0.86 (3H, d, J = 6.8 Hz, CH3-Val); 13C-NMR (125 MHz, CDCl3) d 174.9 
(C=O, cumyl), 156.9 (C=O, Fmoc), 145.0 (C, Ar-cumyl), 144.1 (C, Ar-Fmoc), 144.0 (C, 
Ar-Fmoc), 141.4 (2 x C, Ar-Fmoc), 128.4 (2 x CH, Ar), 127.8 (2 x CH, Ar), 127.6 (CH, 
Ar), 127.2 (2 x CH, Ar), 125.3 (2 x CH, Ar), 124.6 (2 x CH, Ar), 120.1 (2 x CH, Ar), 82.9 
(C, cumyl), 79.7 (OCH2, Ox), 79.5 (OCH2, Ox), 67.0 (CH2, Fmoc), 61.0 (CH, a-Val), 
59.5 (C, Ox) 47.4 (CH, Fmoc), 45.8 (CH2, GOx), 32.0 (CH, b-Val), 28.7 (CH3, cumyl), 
27.9 (CH3, cumyl), 20.0 (CH3, Val), 17.4 (CH3, Val); IR (film) 3339 (NH), 2981, 2958, 
2932, 2879, 1717 (C=O), 1548, 1270, 1202, 1160, 985 cm–1; MS (ESI+) m/z 543 [M+H]+, 
565 [M+Na]+; HRMS (ESI+) Calcd. for C33H38N2O5Na [M+Na]+: 565.2673, found 
565.2667.  
 
Fmoc-GOx-Ser(tBu)-OCumyl 211 
Following general procedure 9, 205 (220 mg, 0.56 mmol) 
gave, after column chromatography (10-20% EtOAc in 
CH2Cl2), 211 (255 mg, 0.43 mmol, 78%) as a white solid. Rf 
(10% EtOAc in CH2Cl2) 0.28; mp 53-57 °C; [𝜶]𝑫𝟐𝟏 +10.0 (c 0.1, CHCl3); 1H-NMR (500 
MHz, CDCl3) δ 7.78 (2H, d, J = 7.5 Hz, ArH-Fmoc), 7.62-7.60 (2H, m, ArH-Fmoc), 7.47-
7.22 (9H, m, ArH), 5.69-5.55 (1H, m, NH-GOx), 4.53-4.12 (7H, m, CHCH2-Fmoc, 2 x 
OCH2-Ox), 3.69-3.48 (4H, m, CH2-GOx and CH2b-Ser), 3.46-3.36 (1H, m, CHa-Ser), 
2.35 (1H, bs, NH-Ser), 1.84 (3H, s, CH3, cumyl), 1.81 (3H, s, CH3, cumyl), 1.23 (9H, s, 
tBu); 13C-NMR (125 MHz, CDCl3) δ 172.5 (C=O, Ser), 157.0 (C=O, Fmoc), 145.1 (C, 
FmocHN
H
N α O
O
O β
Ph
FmocHN
H
N α O
O
O β OtBu
Ph
  174 
Ar-cumyl), 144.1 (2 x C, Ar-Fmoc), 141.4 (2 x C, Ar-Fmoc), 128.4 (2 x CH, Ar), 127.7 
(2 x CH, Ar), 127.4 (CH, Ar), 127.1 (2 x CH, Fmoc), 125.2 (2 x CH, Ar), 124.4 (2 x CH, 
Ar), 120.0 (2 x CH, Ar), 83.3 (C, cumyl), 80.5 (OCH2, Ox), 80.1 (OCH2, Ox), 73.8 (C, 
tBu), 66.8 (CH2, Fmoc), 64.1 (CH2, b-Ser), 59.5 (C, Ox), 57.1 (CH, a-Ser), 47.4 (CH, 
Fmoc), 45.1 (CH2, GOx), 28.8 (CH3, cumyl), 28.2 (CH3, cumyl), 27.5 (3 x CH3, tBu); IR 
(film) 3331 (NH), 2974, 2873, 1720 (C=O), 1518, 1449, 1233, 1134, 1077, 972 cm–1; MS 
(ESI+) m/z 587 [M+H]+, 609 [M+Na]+; HRMS (ESI+) Calcd. for C35H42N2O6Na 
[M+Na]+: 609.2935, found 609.2938. 
 
Fmoc-GOx-Asp(tBu)-OCumyl 212  
Following general procedure 9, 206 (161 mg, 0.38 mmol) 
gave, after column chromatography (10% EtOAc in 
CH2Cl2), 212 (180 mg, 0.29 mmol, 77%) as a white solid. Rf 
(5% EtOAc in CH2Cl2) 0.30; mp 52-54 °C; [𝜶]𝑫𝟐𝟏 +23.1 (c 0.078, CHCl3); 1H-NMR (500 
MHz, CDCl3) d 7.78 (2H, d, J = 7.5 Hz, ArH-Fmoc), 7.66 (1H, d, J = 7.4 Hz, ArH-Fmoc), 
7.63 (1H, d, J = 7.4 Hz, ArH-Fmoc), 7.45-7.39 (2H, m, ArH-Fmoc), 7.39-7.25 (7H, m, 
ArH), 5.78-5.65 (1H, m, NH-Fmoc), 4.45 (1H, d, J = 6.5 Hz, CHH-Ox), 4.43-4.28 (4H, 
m, CH2-Ox and CH2-Fmoc), 4.26-4.16 (2H, CHH-Ox and CH-Fmoc), 3.82-3.68 (2H, m, 
CHH-GOx and CHa-Asp), 3.63 (1H, dd, J = 14.0 and 4.4 Hz, CHH-GOx), 2.69 (1H, dd, J 
= 15.9 and 3.4 Hz, CHHb-Asp), 2.48 (1H, dd, J = 15.9 and 9.6 Hz, CHHb-Asp), 2.21 
(1H, bs, NH-Asp), 1.82 (3H, s, CH3-cumyl), 1.81 (3H, s, CH3-cumyl), 1.50 (9H, s, tBu); 
13C-NMR (125 MHz, CDCl3) d 173.3 (C=O, Asp), 170.6 (C=O, CO2tBu), 157.2 (C=O, 
Fmoc), 144.8 (C, Ar-cumyl), 144.2 (C, Ar-Fmoc), 144.1 (C, Ar-Fmoc), 141.43 (C, Ar-
Fmoc), 141.41 (C, Ar-Fmoc), 128.6 (2 x CH, Ar), 127.8 (2 x CH, Ar), 127.6 (CH, Ar), 
127.2 (CH, Ar), 125.4 (CH, Ar), 125.3 (CH, Ar), 124.4 (2 x CH, Ar), 120.1 (2 x CH, Ar), 
83.4 (C, cumyl), 82.0 (C, tBu), 80.2 (OCH2, Ox), 79.8 (OCH2, Ox), 67.0 (CH2, Fmoc), 
59.5 (C, Ox), 52.9 (CH, a-Asp), 47.4 (CH, Fmoc), 44.9 (CH2, GOx), 40.1 (CH2, b-Asp), 
28.6 (CH3, cumyl), 28.24 (3 x CH3, tBu), 28.19 (CH3, cumyl); IR (film) 3339 (NH), 2977, 
2936, 2873, 1715 (C=O), 1518, 1239, 1132, 971 cm–1; MS (ESI+) m/z 615 [M+H]+, 637 
[M+Na]+; HRMS (ESI+) Calcd. for C36H42N2O7Na [M+Na]+: 637.2884, found 637.2890. 
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Fmoc-GOx-Lys(Boc)-OCumyl 213 
 Following general procedure 9, 207 (614 mg, 1.28 
mmol) gave, after column chromatography (30-50% 
EtOAc in CH2Cl2), 213 (610 mg, 0.91 mmol, 71%) as a 
white solid. Rf (30% EtOAc in CH2Cl2) 0.38; mp 55-57 °C; [𝜶]𝑫𝟐𝟏 +6.7 (c 0.09, CHCl3); 
1H-NMR (500 MHz, CDCl3) d 7.76 (2H, d, J = 7.5 Hz, ArH-Fmoc), 7.61-7.54 (2H, m, 
ArH), 7.43-7.37 (2H, m, ArH), 7.37-7.27 (6H, m, ArH), 7.27-7.22 (1H, m, ArH), 5.43-
5.10 (0.85H, m, major rotamer NH-GOx), 5.06-4.83 (0.15H, m, minor rotamer NH-GOx), 
4.68-4.03 (8H, m, NH-Boc, 2 x OCH2-Ox, CHCH2-Fmoc), 3.70 (0.85H, dd, J = 13.7 and 
6.4 Hz, major rotamer CHH-GOx), 3.60 (0.15H, m, minor rotamer CHH-GOx), 3.36 (1H, 
dd, J = 13.8 Hz and 4.6 Hz, CHH-GOx), 3.33-3.22 (1H, m, CHa-Lys), 3.19-3.00 (2H, m, 
CH2e-Lys), 2.04-1.90 (1H, bs, NH-Lys), 1.80 (3H, s, CH3-cumyl), 1.78 (3H, s, CH3-
cumyl), 1.76-1.67 (1H, m, CHHb-Lys), 1.63-1.32 (14H, m, CHHb-Lys, CH2g-Lys, CH2d-
Lys and tBu); 13C-NMR (125 MHz, CDCl3) d 175.0 (C=O, cumyl), 157.0 (C=O, Fmoc), 
156.1 (C=O, Boc), 144.9 (C, Ar), 144.1 (C, Ar), 144.0 (C, Ar), 141.4 (2 x C, Ar), 128.5 
(2 x CH, Ar), 127.8 (2 x CH, Ar), 127.6 (CH, Ar), 127.2 (2 x CH, Ar), 125.3 (2 x CH, 
Ar), 124.5 (2 x CH, Ar), 120.1 (2 x CH, Ar), 82.9 (C, cumyl), 79.9 (OCH2, Ox), 79.6 
(OCH2, Ox), 79.3 (C, tBu), 67.0 (CH2, Fmoc), 59.6 (C, Ox), 56.0 (CHa-Lys), 47.4 (CH, 
Fmoc), 45.7 (CH2, GOx), 40.4 (CH2e-Lys), 34.2 (CH2b-Lys), 30.0 (CH2g-Lys or CH2d-
Lys) 28.6 (3 x CH3, tBu), 28.5 (CH3, cumyl), 28.2 (CH3, cumyl) 23.1 (CH2g-Lys or CH2d-
Lys); IR (film): 3329 (NH), 2973, 2938, 2869, 1702 (C=O), 1511, 1478, 1449, 1365, 
1244, 1167, 1132, 1101, 974 cm–1; MS (ESI+) m/z 672 [M+H]+, 694 [M+Na]+; HRMS 
(ESI+) Calcd. for C39H49N3O7Na [M+Na]+: 694.3463, found 694.3457.  
 
Fmoc-GOx-Ala-OCumyl 215 
 Following general procedure 9, 209 (551 mg, 1.71 mmol) 
gave, after column chromatography (15-20% EtOAc in 
CH2Cl2), 215 (498 mg, 0.97 mmol, 57%) as a sticky white 
gum. Rf (20% EtOAc in CH2Cl2) 0.31; [𝛂]𝐃𝟐𝟐 −0.5 (c 0.30, CHCl3);  1H-NMR (500 MHz, 
CDCl3) δ 7.76 (2H, d, J = 7.5 Hz, ArH-Fmoc), 7.64-7.53 (2H, m, ArH-Fmoc), 7.40 (2H, 
t, J = 7.4 Hz, ArH-Fmoc), 7.37-7.27 (6H, m, ArH), 7.27-7.21 (1H, m, ArH), 5.37-5.16 
(0.85H, m, major rotamer NH-GOx), 5.04-4.95 (0.15H, m, minor rotamer NH-GOx), 4.59-
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4.13 (7H, m, 2 x OCH2-Ox, CH2CH-Fmoc), 3.71 (0.85H, dd, J = 13.7, 6.4 Hz, major 
rotamer CHH-GOx), 3.61-3.50 (0.15H, m, minor rotamer CHH-GOx), 3.50-3.33 (2H, m, 
CHH-GOx, CHa-Ala), 2.02 (1H, bs, NH-Ala), 1.79 (3H, s, CH3-cumyl), 1.78 (3H, s, CH3-
cumyl), 1.35 (3H, d, J = 7.0 Hz, CH3-Ala); 13C-NMR (125 MHz, CDCl3) δ 175.2 (C=O, 
Ala), 157.0 (C=O, Fmoc), 145.0 (C, Ar-Ph), 144.1 (C, Ar-Fmoc), 144.0 (C, Ar-Fmoc), 
141.4 (2 x C, Ar-Fmoc), 128.5 (2 x CH, Ar), 127.8 (2 x CH, Ar), 127.5 (CH, Ar), 127.2 
(2 x CH, Ar), 125.3 (2 x CH, Ar), 124.3 (2 x CH, Ar), 120.1 (2 x CH, Ar), 82.8 (C, cumyl), 
80.1 (OCH2, Ox), 79.8 (OCH2, Ox), 67.3 (CH2, Fmoc), 59.5 (C, Ox), 51.7 (CH, a-Ala), 
47.4 (CH, Fmoc), 45.4 (CH2, GOx), 28.6 (CH3, cumyl), 28.5 (CH3, cumyl), 20.9 (CH3, 
Ala); IR (film) 3327 (NH), 3064, 2977, 2938, 2873, 1717 (C=O), 1517, 1448, 1240, 1130, 
972 cm−1; MS (ESI+) m/z 515 [M+H]+, 537 [M+Na]+; HRMS (ESI+) Calcd. for 
C31H34N2O5Na [M+Na]+: 537.2360, found 537.2360. 
 
Fmoc-GOx-Pro-OCumyl 214  
Following general procedure 9, 208 (515 mg, 1.48 mmol) 
gave, after column chromatography (5-10% EtOAc in 
CH2Cl2), 214 (403 mg, 0.75 mmol, 50%) as a white solid. Rf 
(10% EtOAc in CH2Cl2) 0.45; mp 50-53 °C; [𝜶]𝑫𝟐𝟏 +22.4 (c 0.078, CHCl3); 1H-NMR 
(500 MHz, CDCl3) d 7.75 (2H, d, J = 7.1 Hz, ArH-Fmoc), 7.64-7.55 (2H, m, ArH-Fmoc), 
7.42-7.36 (2H, m, ArH-Fmoc), 7.36-7.19 (7H, m, ArH), 5.82-5.71 (0.9H, m, major 
rotamer NH-GOx), 5.45-5.32 (0.1H, m, minor rotamer NH-GOx), 4.72 (1H, d, J = 6.7 Hz, 
OCHH-Ox), 4.59 (1H, d, J = 6.9 Hz, OCHH-Ox), 4.51-4.22 (4H, m, CH2-Fmoc, 2 x 
OCHH-Ox), 4.22-4.11 (1H, m, CH-Fmoc), 3.79 (1H, dd, J = 9.4, 3.9 Hz, CHa-Pro), 3.67 
(1H, dd, J = 13.3, 4.0 Hz, CHH-GOx), 3.54 (1H, dd, J = 13.1, 5.1 Hz, CHH-GOx), 3.23-
3.06 (1H, m, CHHd-Pro), 2.81 (0.9H, q, J = 7.9 Hz, major rotamer CHHd-Pro) 2.75-2.61 
(0.1 H, m, minor rotamer CHHd-Pro), 2.26-2.10 (1H, m, CHHb-Pro), 2.09-1.98 (1H, m, 
CHHb-Pro), 1.98-1.83 (2H, m, CH2g-Pro), 1.770 (3H, s, CH3-cumyl), 1.765 (3H, s, CH3-
cumyl); 13C-NMR (125 MHz, CDCl3) d 174.1 (C=O, Pro), 145.3 (C, Ar-Ph), 144.2 (2 x 
C, Ar-Fmoc), 141.1 (2 x C, Ar-Fmoc), 128.5 (2 x CH, Ar), 127.7 (2 x CH, Ar), 127.4 
(CH, Ar), 127.2 (2 x CH, Ar), 125.4 (2 x CH, Ar), 124.3 (2 x CH, Ar), 120.0 (2 x CH, 
Ar), 82.4 (C, cumyl), 77.6 (OCH2, Ox), 76.9 (OCH2, Ox), 66.9 (CH2, Fmoc), 62.2 (C, 
Ox), 60.5 (CH, a-Pro), 48.4 (CH2, d-Pro), 47.4 (CH, Fmoc), 47.0 (CH2, GOx), 31.1 (CH2, 
b-Pro), 28.6 (CH3, cumyl), 28.4 (CH3, cumyl), 24.7 (CH2, g-Pro) (NOTE: C=O, Fmoc not 
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observed); IR (film) 3342 (NH), 2947, 2873, 1717 (C=O), 1509, 1465, 1272, 1131, 1100, 
979 cm–1; MS (ESI+) m/z 541 [M+H]+, 563 [M+Na]+; HRMS (ESI+) Calcd. for 
C33H36N2O5Na [M+Na]+: 563.2516, found 563.2521. 
 
Fmoc-GOx-Phe-OH 75 
196 (376 mg, 0.62 mmol) in 2% TFA/CH2Cl2 (13 mL) was 
stirred at room temperature until consumption of starting 
material (TLC monitoring). The reaction mixture was 
concentrated under reduced pressure and the resulting residue repeatedly dissolved in 
CH2Cl2 (5 x 15 mL) and concentrated under reduced pressure. To the crude acid was 
added Et2O (40 mL) and the suspension vigorously stirred at 0 °C for 15 min. The 
precipitate was collected by vacuum filtration and washed with ice cold Et2O to give 75 
(178 mg, 0.38 mmol, 61%) as a white solid. mp 183-186 °C; 1H-NMR (500 MHz, 
DMSO-d6) δ 7.90 (2H, d, J = 7.6 Hz, ArH-Fmoc), 7.70 (2H, d, J = 7.4 Hz, ArH-Fmoc), 
7.42 (2H, t, J = 7.4 Hz, ArH-Fmoc), 7.34 (2H, t, J = 7.4 Hz, ArH-Fmoc), 7.30-7.10 (6H, 
m, ArH-Phe and NH-GOx), 4.40-4.31 (2H, m, CH2-Fmoc), 4.31-4.18 (4H, m, CH-Fmoc, 
OCH2-Ox and OCHH-Ox), 4.12 (1H, d, J = 6.2 Hz, OCHH-Ox), 3.82-3.61 (1H, m, CHα-
Phe), 3.53-3.14 (2H, m, CH2-GOx, overlapping with H2O signal), 2.87 (1H, dd, J = 13.3, 
6.8 Hz, CHHb-Phe), 2.77 (1H, dd, J = 13.0, 7.0 Hz, CHHb-Phe) [Note: NH-Phe and 
CO2H not assigned]; 13C-NMR (125 MHz, DMSO-d6) δ 176.0 (C=O, Phe), 156.9 (C=O, 
Fmoc), 143.9 (C, Ar-Fmoc), 143.8 (C, Ar-Fmoc), 140.7 (2 x C, Ar-Fmoc), 137.8 (C, Ar-
Phe), 129.3 (2 x CH, Ar), 128.0 (2 x CH, Ar), 127.6 (2 x CH, Ar), 127.1 (2 x CH, Ar), 
126.3 (CH, Ar), 125.1 (2 x CH, Ar), 120.1 (2 x CH, Ar), 78.08 (OCH2, Ox), 77.98 (OCH2, 
Ox), 65.5 (CH2, Fmoc), 59.8 (C, Ox), 56.9 (CH, α-Phe), 46.7 (CH, Fmoc), 44.4 (CH2, 
GOx), 39.5 (CH2, b-Phe) [Note: C=O-Phe assigned using HMBC and CH2b-Phe assigned 
using HSQC]; MS (ESI+) m/z 473 [M+H]+, 495 [M+Na]+, 511 [M+K]+, 967 [2M+Na]+; 
IR (film): 3410 (NH), 3063, 2884, 1702 (C=O), 1625 (C=O), 1524, 1225, 993 cm–1; MS 
(ESI–) 471 [M-H]–, 585 [M+TFA-H]–, 943 [2M-H]–; HRMS (ESI+) Calcd. for 
C28H28N2O5Na [M+Na]+: 495.1890, found 495.1891; HRMS (ESI–) Calcd. for 
C28H27N2O5 [M-H]–: 471.1925, found 471.1925. NOTE: No optical rotation recorded as 
compound insoluble in suitable solvents. 
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Fmoc-GOx-Val-OH 182 
Following general procedure 10, 210 (446 mg, 0.82 mmol) was 
treated with 2% TFA/CH2Cl2 (16 mL) to give, after column 
chromatography (0-10% MeOH in CH2Cl2), 182 (329 mg, 0.77 
mmol, 94%) as a white solid. Rf (10% MeOH in CH2Cl2) 0.32; mp 103-107 °C; [𝜶]𝑫𝟐𝟒 
+2.0 (c 0.60, CHCl3); 1H-NMR (500 MHz, MeOD) δ 7.80 (2H, d, J = 7.5 Hz, ArH-
Fmoc), 7.65 (2H, d, J = 7.4 Hz, ArH-Fmoc), 7.39 (2H, t, J = 7.4 Hz, ArH-Fmoc), 7.31 
(2H, t, J = 7.4 Hz, ArH-Fmoc), 4.69 (1H, d, J = 7.2 Hz, OCHH-Ox), 4.59 (1H, d, J = 7.3 
Hz, OCHH-Ox), 4.48 (1H, d, J = 7.3, OCHH-Ox), 4.46-4.35 (3H, m, OCHH-Ox and 
CH2-Fmoc), 4.23 (1H, t, J = 6.6 Hz, CH-Fmoc), 3.74 (1H, d, J = 4.0 Hz, CHα-Val), 3.70 
(1H, d, J = 14.9 Hz, CHH-GOx), 3.60 (1H, d, J = 14.8 Hz, CHH-GOx), 2.19-2.04 (1H, m, 
CHb-Val), 1.06 (3H, d, J = 6.9 Hz, CH3-Val), 1.02 (3H, d, J = 6.8 Hz, CH3-Val); 13C-
NMR (125 MHz, MeOD) δ 174.9 (C=O, Val), 159.7 (C=O, Fmoc), 145.3 (C, Ar-Fmoc), 
145.2 (C, Ar-Fmoc), 142.6 (2 x C, Ar-Fmoc), 128.8 (2 x CH, Ar-Fmoc), 128.2 (2 x CH, 
Ar-Fmoc), 126.13 (CH, Ar-Fmoc), 126.11 (CH, Ar-Fmoc), 121.0 (2 x CH, Ar-Fmoc), 
78.03 (OCH2-Ox), 78.00 (OCH2-Ox), 68.1 (CH2-Fmoc), 63.0 (CH, α-Val), 62.7 (C, Ox), 
48.4 (CH, Fmoc), 45.1 (CH2, GOx), 32.1 (CH, b-Val), 18.9 (CH3, Val), 18.5 (CH3, Val); 
IR (film): 3304 (NH), 3040, 2966, 2882, 2882, 1671 (C=O), 1250, 1181, 1134 cm–1; MS 
(ESI+) m/z 447 [M+Na]+, 871 [2M+Na]+; MS (ESI–) m/z 423[M-H]–, 847 [2M-H]–; 
HRMS (ESI+) Calcd. for C24H28N2O5Na [M+Na]+: 447.1890, found 447.1879. 
Compound previously prepared by Carreira and co-workers via an alternative route.46 
 
Fmoc-GOx-Ser(tBu)-OH 216 
Following general procedure 10, 211 (472 mg, 0.80 mmol) was 
treated with 2% TFA in CH2Cl2 (16 mL) to give, after column 
chromatography (0-10 % MeOH in CH2Cl2), 216 (306 mg, 0.65 
mmol, 82%) as a beige solid. Rf (10% MeOH in CH2Cl2) 0.23; mp 112-115 °C; [𝛂]𝐃𝟐𝟐 
−2.4 (c 0.35, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 7.79 (2H, d, J = 7.6 Hz, ArH-Fmoc), 
7.65 (2H, d, J = 7.5 Hz, ArH-Fmoc), 7.38 (2H, t, J = 7.5 Hz, ArH-Fmoc), 7.30 (2H, t, J 
= 7.4 Hz, ArH-Fmoc), 4.69-4.51 (2H, m, 2 x OCHH-Ox), 4.51-4.06 (5H, m, 2 x OCHH-
Ox, CHCH2-Fmoc), 3.88-3.43 (5H, m, CH2-GOx, CHα-Ser, CH2β-Ser), 1.18 (9H, s, tBu); 
13C-NMR (125 MHz, MeOD) δ 159.4 (C=O, Fmoc), 145.3 (C, Ar-Fmoc), 145.2 (C, Ar-
Fmoc), 142.7 (2 x C, Ar-Fmoc), 128.8 (2 x CH, Ar-Fmoc), 128.2 (2 x CH, Ar-Fmoc), 
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126.14 (CH, Ar-Fmoc), 126.11 (CH, Ar-Fmoc), 120.9 (2 x CH, Ar-Fmoc), 79.1 (OCH2, 
Ox), 78.8 (OCH2, Ox), 75.0 (C, tBu), 67.9 (CH2, Fmoc), 63.7 (C, Ox), 62.1 (CH2, β-Ser), 
59.6 (CH, α-Ser), 48.5 (CH, Fmoc), 45.0 (CH2, GOx), 27.7 (3 x CH3, tBu) [Note: C=O, 
Ser not observed]; IR (film) 3316 (NH), 3036, 2971, 2878, 1716 (C=O), 1642, 1523, 
1476, 1239, 1188, 1076 cm−1; MS (ESI+) m/z 469 [M+H]+, 491 [M+Na]+, 507 [M+K]+; 
HRMS (ESI+) Calcd. for C26H32N2O6Na [M+Na]+: 491.2153, found 491.2155. 
 
Fmoc-GOx-Val-Phe-OtBu (S,S)-219 
Following general procedure 11, 210 (125 mg, 0.23 
mmol) was treated with 2% TFA/CH2Cl2 (4.6 mL). The 
crude acid was coupled with L-phenylalanine tert-butyl 
ester hydrochloride (119 mg, 0.46 mmol) to give, after column chromatography (0-3% 
MeOH in CH2Cl), (S,S)-219 (114 mg, 0.18 mmol, 79%) as a white solid. Rf (3% MeOH 
in CH2Cl2) 0.24; mp 73-77 °C; [𝜶]𝑫𝟐𝟓 –12.5 (c 0.048, CHCl3); 1H-NMR (500 MHz, 
CDCl3) d 7.76 (2H, d, J = 7.5 Hz, ArH), 7.62 (2H, d, J = 7.3 Hz, ArH), 7.43-7.36 (2H, m, 
ArH), 7.36-7.18 (6H, m, ArH, NH-Phe), 7.15 (2H, d, J = 7.2 Hz, ArH), 6.06-5.94 (1H, 
m, NH-GOx), 4.81-4.71 (1H, m, CHa-Phe) 4.50-4.26 (6H, m, 2 x OCH2, CH2-Fmoc), 
4.25-4.16 (1H, m, CH-Fmoc), 3.69 (1H, dd, J = 14.2, 7.1 Hz, CHH-GOx), 3.32 (1H, dd, J 
= 14.2, 4.6 Hz, CHH-GOx), 3.11 (1H, dd, J = 14.0, 5.8 Hz, CHHb-Phe), 3.04 (1H, d, J = 
4.1 Hz, CHa-Val), 2.93 (1H, dd, J = 13.9 Hz, 8.2 Hz, CHHb-Phe), 2.06-1.93 (1H, m, 
CHb-Val), 1.86 (1H, bs, NH-Val), 1.41 (9H, s, tBu), 0.90 (3H, d, J = 6.8 Hz, CH3-Val), 
0.77 (3H, d, J = 6.8 Hz, CH3-Val); 13C-NMR (125 MHz, CDCl3) d 174.1 (C=O, Val), 
171.9 (C=O, Phe), 157.7 (C=O, Fmoc), 144.1 (C, Ar-Fmoc), 144.0 (C, Ar-Fmoc), 141.4 
(2 x C, Ar-Fmoc), 136.3 (C, Ar-Phe), 129.3 (2 x CH, Ar), 128.7 (2 x CH, Ar), 127.8 (2 x 
CH, Ar), 127.22 (CH, Ar), 127.19 (2 x CH, Ar), 125.3 (2 x CH, Ar), 120.1 (2 x CH, Ar), 
82.9 (C, tBu), 79.4 (OCH2, Ox), 79.0 (OCH2, Ox), 67.2 (CH2, Fmoc), 62.7 (CH, a-Val), 
60.8 (C, Ox), 53.3 (CH, a-Phe), 47.4 (CH, Fmoc), 46.3 (CH2, GOx), 38.5 (CH2, b-Phe), 
32.0 (CH, b-Val), 28.1 (3 x CH3, tBu), 19.7 (CH3, Val), 17.9 (CH3, Val); IR (film) 3325 
(NH), 3295 (NH), 2970, 2956, 2940, 2929, 2903, 2868, 1713 (C=O), 1657 (C=O), 1650 
(C=O), 1512, 1502, 1240, 1152, 973 cm–1; MS (ESI+) m/z 628 [M+H]+, 650 [M+Na]+; 
HRMS (ESI+) Calcd. for C37H45N3O6Na [M+Na]+: 650.3201, found 650.3201.  
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Fmoc-GOx-Val-D-Phe-OtBu (S,R)-219 
Following general procedure 11, 210 (114 mg, 0.21 
mmol) was treated with 2% TFA/CH2Cl2 (4.2 mL). The 
crude acid was coupled with D-phenylalanine tert-butyl 
ester hydrochloride (108 mg, 0.42 mmol) to give, after column chromatography (0-3% 
MeOH in CH2Cl), (S,R)-219 (105 mg, 0.17 mmol, 80%) as a white solid. Rf (3% MeOH 
in CH2Cl2) 0.15; mp 77-81 °C; [𝜶]𝑫𝟐𝟓 –9.8 (c 0.066, CHCl3); 1H-NMR (CDCl3) d 7.77 
(2H, d, J = 7.5 Hz, ArH-Fmoc), 7.60 (2H, d, J = 7.5 Hz, ArH-Fmoc), 7.42-7.37 (2H, m, 
ArH), 7.34-7.29 (2H, m, ArH), 7.28-7.19 (3H, m, ArH), 7.13 (2H, d, J = 7.1 Hz, ArH), 
6.72 (1H, d, J = 7.5 Hz, NH-Phe), 5.20-5.13 (1H, m, NH-GOx), 4.79-4.70 (1H, m, CHa-
Phe), 4.54-4.31 (3H, m, CH2-Fmoc, OCHH-Ox), 4.31-4.14 (3H, m, OCHH-Ox, OCHH-
Ox, CH-Fmoc), 4.01 (1H, d, J = 6.7 Hz, OCHH-Ox), 3.56 (1H, dd, J = 13.9, 6.3 Hz, 
CHH-GOx), 3.36 (1H, dd, J = 14.0, 5.1 Hz, CHH-GOx), 3.14 (1H, dd, J = 14.2, 5.9 Hz, 
CHHb-Phe), 3.10-3.02 (1H, m, CHa-Val), 2.96 (1H, dd, J = 14.1, 7.8 Hz, CHHb-Phe), 
2.08-1.85 (2H, m, CHb-Val, NH-Val), 1.42 (9H, s, tBu), 0.90 (3H, d, J = 6.7 Hz, CH3-
Val), 0.85 (3H, d, J = 6.7 Hz, CH3-Val); 13C-NMR (125 MHz, CDCl3) d 174.5 (C=O, 
Val), 170.9 (C=O, Phe), 157.2 (C=O, Fmoc), 144.0 (2 x C, Ar-Fmoc), 141.5 (2 x C, Ar-
Fmoc), 136.3 (C, Ar-Phe), 129.3 (2 x CH, Ar), 128.7 (2 x CH, Ar), 127.9 (2 x CH, Ar), 
127.2 (3 x CH, Ar), 125.2 (2 x CH, Ar), 120.2 (2 x CH, Ar), 82.6 (C, tBu), 78.9 (OCH2, 
Ox), 78.7 (OCH2, Ox), 67.1 (CH2, Fmoc), 62.0 (CH, a-Val), 60.0 (C, Ox), 53.4 (CH, a-
Phe), 47.4 (CH, Fmoc), 46.4 (CH2, GOx), 38.1 (CH2, b-Phe), 32.1 (CH, b-Val), 28.1 (3 x 
CH3, tBu), 19.8 (CH3, Val), 17.7 (CH3, Val); IR (film) 3325 (NH), 2959, 2876, 1720 
(C=O), 1651 (C=O), 1513, 1239, 1150, 975 cm–1; MS (ESI+) m/z 628 [M+H]+, 650 
[M+Na]+; HRMS (ESI+) Calcd. for C37H45N3O6 Na [M+Na]+: 650.3201, found 
650.3199. 
 
Fmoc-GOx-Lys(Boc)-Phe-OtBu 220 
Following general procedure 11, 213 (104 mg, 0.15 
mmol) was treated with 2% TFA/CH2Cl2 (3 mL). The 
crude acid was coupled with L-phenylalanine tert-butyl 
ester hydrochloride (80 mg, 0.31 mmol) to give, after 
column chromatography (0-3% MeOH in CH2Cl2), 220 (93 mg, 0.12 mmol, 79%) as a 
white solid. Rf (3% MeOH in CH2Cl2); 0.20; mp 72-75 °C; [𝜶]𝑫𝟐𝟓 +9.2 (c 0.06, CHCl3); 
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1H-NMR (500 MHz, CDCl3) d 7.76 (2H, d, J = 7.5 Hz, ArH), 7.63 (2H, d, J = 7.4 Hz, 
ArH), 7.55-7.46 (1H, m, NH-Phe), 7.42-7.37 (2H, m, ArH), 7.36-7.18 (5H, m, ArH), 7.15 
(2H, d, J = 7.0 Hz, ArH), 6.12 (1H, bs, NH-GOx), 4.76 (1H, dt, J = 8.3 and 5.9, CHa-
Phe), 4.58 (1H, bs, NH-Boc), 4.50-4.25 (6H, m, 2 x OCH2-Ox, CH2-Fmoc), 4.25-4.17 
(1H, m, CH-Fmoc), 3.70 (1H, dd, J = 14.2 and 7.1 Hz, CHH-GOx), 3.29 (1H, dd, J = 14.1 
and 4.2 Hz, CHH-GOx), 3.20-2.98 (4H, m, CHa-Lys, CH2e-Lys and CHHb-Phe), 2.93 
(1H, dd, J = 13.9 and 8.2 Hz, CHHb-Phe), 1.92 (1H, bs, NH-Lys), 1.59-1.35 (21H, m, 
CH2b-Lys, CHHd-Lys and 2 x tBu), 1.31-1.13 (3H, m, CHHd-Lys and CH2g-Lys); 13C-
NMR (125 MHz, CDCl3) d 174.5 (C=O, Lys), 171.8 (C=O, Phe), 157.7 (C=O, Fmoc), 
156.3 (C=O, Boc), 144.2 (C, Ar-Fmoc), 144.0 (C, Ar-Fmoc), 141.4 (2 x C, Ar-Fmoc), 
136.3 (C, Ar-Phe), 129.4 (2 x CH, Ar), 128.6 (2 x CH, Ar), 127.8 (2 x CH, Ar), 127.21 
(CH, Ar), 127.16 (2 x CH, Ar), 125.4 (CH, Ar), 125.3 (CH, Ar), 120.1 (2 x CH, Ar), 82.9 
(C, tBu), 79.4 (overlapping signals: OCH2, Ox and C, tBu), 79.2 (OCH2, Ox), 67.2 (CH2, 
Fmoc), 60.9 (C, Ox), 57.4 (CH, a-Lys), 53.1 (CH, a-Phe), 47.4 (CH, Fmoc), 45.9 (CH2, 
GOx), 39.8 (CH2, e-Lys), 38.4 (CH2, b-Phe), 34.1 (CH2, b-Lys), 30.0 (CH2, d-Lys), 28.6 
(3 x CH3, tBu), 28.1 (3 x CH3, tBu), 22.6 (CH2, g-Lys); IR (film) 3322 (NH), 2973, 2930, 
2865, 1881, 1706 (C=O), 1513, 1244, 1153 cm–1; MS (ESI+) m/z 757 [M+H]+, 779 
[M+Na]+; HRMS (ESI+) Calcd. for C43H56N4O8Na [M+Na]+: 779.3990, found 779.3987. 
 
Boc-Gly-GOx-Phe-OCumyl 221 
196 (234 mg, 0.40 mmol) in 50% diethylamine in 
CH2Cl2 (2 mL) was stirred at room temperature for 1 h. 
The reaction mixture was concentrated under reduced 
pressure and the resulting residue repeatedly dissolved in CH2Cl2 (3 x 5 mL) and 
concentrated under reduced pressure to give the crude amine. The crude amine was 
dissolved in CH2Cl2 (4 mL) and Boc-Gly-OH (277 mg, 1.58 mmol), DIPEA (552 µL, 
3.17 mmol) and HCTU (654 mg, 1.58 mmol) added. The reaction mixture was stirred at 
room temperature for 16 h. The reaction mixture was concentrated under reduced pressure 
and dissolved in EtOAc (50 mL). The organics were washed with brine (3 x 10 mL), 
saturated NaHCO3 (2 x 10 mL) and brine (5 mL), dried (MgSO4), filtered and 
concentrated under reduced pressure. The crude material was purified by flash column 
chromatography (40-67% EtOAc in CH2Cl2) to give 221 (137 mg, 0.26 mmol, 65%) as a 
colourless oil. Rf (40% EtOAc in CH2Cl2) 0.31; [𝜶]𝑫𝟐𝟗 –3.5 (c 0.092, CHCl3); 1H-NMR 
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(500 MHz, CDCl3) d 7.39-7.29 (7H, m, ArH), 7.29-7.22 (3H, m, ArH), 5.75-5.63 (1H, m, 
NH-GOx), 4.85 (1H, bs, NH-Gly), 4.19 (1H, d, J = 6.5 Hz, OCHH-Ox), 4.16 (1H, d, J = 
6.5 Hz, OCHH-Ox), 4.09 (1H, d, J = 6.6 Hz, OCHH), 4.07 (1H, d, J = 6.7 Hz, OCHH), 
3.57-3.36 (5H, m, CH2-GOx, CH2-Gly, CHa-Phe), 3.08 (1H, dd, J = 10.7, 3.6 Hz, CHHb-
Phe), 2.65 (1H, dd, J = 10.7, 7.7 Hz, CHHb-Phe), 2.02 (1H, bs, NH-Phe), 1.80 (3H, s, 
CH3-cumyl), 1.74 (3H, s, CH3-cumyl), 1.42 (9H, s, tBu); 13C-NMR (125 MHz, CDCl3) d 
174.2 (C=O, Phe), 169.5 (C=O, Gly), 144.7 (C, Ar-cumyl), 137.6 (C, Ar-Phe), 129.6 (2 
x CH, Ar), 128.7 (2 x CH, Ar), 128.4 (2 x CH, Ar), 127.5 (CH, Ar), 127.1 (CH, Ar), 124.4 
(2 x CH, Ar), 83.3 (C, cumyl), 79.9 (overlapping signals OCH2, Ox and C, tBu), 79.5 
(OCH2, Ox), 59.0 (C, Ox), 57.7 (CH, a-Phe), 43.8 (CH2, Gly), 42.8 (CH2, GOx), 40.6 
(CH2, b-Phe), 28.9 (CH3, cumyl), 28.3 (3 x CH3, tBu), 27.4 (CH3, cumyl) [NOTE: C=O, 
Boc not observed]; IR (film) 3321 (NH), 2978, 2932, 2873, 1716 (C=O), 1674 (C=O), 
1496, 1366, 1272, 1248, 1165, 1134, 1101, 974 cm–1; MS (ESI+) m/z 526 [M+H]+, 548 
[M+Na]+, 564 [M+K]+; HRMS (ESI+) Calcd. for C29H39N3O6Na [M+Na]: 548.2731, 
found 548.2735. 
 
2-Phenylpropan-2-yl [3-((S)-1-nitroethyl)oxetan-3-yl]-L-alaninate and 2-
Phenylpropan-2-yl [3-((R)-1-nitroethyl)oxetan-3-yl]-L-alaninate (dr 55:45) 257 
202 (976 mg, 2.27 mmol) in 50% diethylamine in CH2Cl2 (5 mL) 
was stirred at room temperature for 1 h. The reaction mixture 
was concentrated under reduced pressure and the resulting 
residue repeatedly dissolved in CH2Cl2 (3 x 20 mL) and concentrated under reduced 
pressure to give the crude amine. To the crude amine in CH2Cl2 (7.5 mL) was added 128 
(196 mg, 1.51 mmol) in CH2Cl2 (7.5 mL). The reaction mixture was stirred at room 
temperature until consumption of the nitroalkene (1H-NMR monitoring, 8 h) and then 
concentrated under reduced pressure to give a crude product which 1H-NMR showed to 
consist of a 50:50 mixture of diastereoisomers. Purification by column chromatography 
(10-20% EtOAc in petroleum ether) gave 257 (436 mg, 1.30 mmol, 86%) as a 55:45 
mixture of diastereoisomers and as a colourless oil. Rf (20% EtOAc in petroleum ether) 
0.29; 1H-NMR (500 MHz, CDCl3) δ 7.40-7.30 (4H, m, ArH), 7.30-7.22 (1H, m, ArH), 
4.97-4.86 (1H, m, NO2CH), 4.61-4.57 (1.55H, m, 2 x major diastereoisomer OCHH-Ox 
and minor diastereoisomer OCHH-Ox), 4.55 (1H, d, J = 7.5 Hz, OCHH-Ox), 4.48 (0.45H, 
d, J = 7.6 Hz, minor diastereoisomer OCHH-Ox), 4.45 (0.45H, d, J = 7.6 Hz, minor 
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diastereoisomer OCHH-Ox), 4.41 (0.55 H, d, J = 7.8 Hz, major diastereoisomer OCHH-
Ox), 3.79-3.69 (0.45H, m, minor diastereoisomer CHα-Ala), 3.68-3.57 (0.55H, m, major 
diastereoisomer CHα-Ala), 2.36 (0.45H, bs, minor diastereoisomer NH), 2.19 (0.55H, bs, 
major diastereoisomer NH), 1.81-1.77 (6H, m, 2 x CH3-cumyl), 1.68 (1.35H, d, J = 7.1 
Hz, minor diastereoisomer NO2CHCH3), 1.67 (1.65H, d, J = 7.0 Hz, major 
diastereoisomer NO2CHCH3), 1.34 (1.35H, d, J = 7.1 Hz, minor diastereoisomer CH3-
Ala), 1.32 (1.65H, d, J = 7.1 Hz, major diastereoisomer CH3-Ala); 13C-NMR (125 MHz, 
CDCl3) δ 174.9 (C=O), 174.7 (C=O), 145.1 (C, Ar), 128.52 (2 x CH, Ar), 128.5 (2 x CH, 
Ar), 127.53 (CH, Ar), 127.48 (CH, Ar), 124.39 (2 x CH, Ar), 124.37 (2 x CH, Ar), 86.9 
(NO2CH), 85.3 (NO2CH), 82.83 (C, cumyl), 82.78 (C, cumyl), 78.2 (OCH2, Ox), 77.9 
(OCH2, Ox), 77.8 (OCH2, Ox), 76.9 (OCH2, Ox), 62.6 (C, Ox), 62.2 (C, Ox), 51.9 (CH, 
α-Ala), 51.7 (CH, α-Ala), 28.52 (CH3, cumyl), 28.47 (CH3, cumyl), 28.45 (CH3, cumyl), 
28.3 (CH3, cumyl), 21.3 (CH3, NO2CHCH3), 21.0 (CH3, NO2CHCH3), 14.0 (CH3, Ala), 
13.5 (CH3, Ala); IR (film) 3342 (NH), 2981, 2937, 2883, 1730 (C=O), 1549, 1448, 1366, 
1271, 1132, 1101 cm−1; MS (ESI+) m/z 359 [M+Na]+; HRMS (ESI+) Calcd. for 
C17H24N2O5Na [M+Na]+: 359.1577, found 359.1571. 
 
Fmoc-L-AOx-Ala-OCumyl and Fmoc-D-AOx-Ala-OCumyl (dr 58:42) (±,S)-255 
Following general procedure 9, 257 (377 mg, 1.12 mmol, dr 
55:45) gave, after column chromatography (5-20% EtOAc in 
CH2Cl2), (±,S)-255 (467 mg, 0.88 mmol, 79%) as a white 
solid which HPLC analysis showed to consist of a 58:42 mixture of diastereoisomers. Rf 
(15% EtOAc in CH2Cl2) 0.47; 1H-NMR (500 MHz, CDCl3) δ 7.76 (2H, d, J = 7.6 Hz, 
ArH-Fmoc), 7.63-7.54 (2H, m, ArH-Fmoc), 7.45-7.20 (9H, m, ArH), 5.69-4.91 (1H, m, 
NH-AOx), 4.78-4.02 (8H, m, CHCH2-Fmoc, CHα-AOx, 2 x OCH2-Ox), 4.01-3.63 (1H, m, 
CHα-Ala), 1.82 (3H, s, CH3-cumyl), 1.79 (1.8H, s, major diastereoisomer CH3-cumyl), 
1.78 (1.2H, s, minor diastereoisomer CH3-cumyl), 1.38 (3H, d, J = 6.9 Hz, CH3-Ala), 
1.23-0.90 (3H, m, CH3-AOx); 13C-NMR (125 MHz, CDCl3) δ 175.6 (2 x C=O, Ala), 156.5 
(C=O, Fmoc), 156.3 (C=O, Fmoc), 145.17 (C, Ar-cumyl), 145.15 (C, Ar-cumyl), 144.12 
(C, Ar-Fmoc), 144.09 (C, Ar-Fmoc), 144.06 (C, Ar-Fmoc), 141.5 (C, Ar-Fmoc), 128.53 
(CH, Ar), 128.48 (CH, Ar), 127.82 (CH, Ar), 127.79 (CH, Ar), 127.49 (CH, Ar), 127.47 
(CH, Ar), 127.2 (CH, Ar), 125.36 (CH, Ar), 125.27 (CH, Ar), 125.19 (CH, Ar), 124.4 
(CH, Ar), 124.3 (CH, Ar), 120.12 (CH, Ar), 120.08 (CH, Ar), 82.80 (C, cumyl), 82.78 
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(C, cumyl), 79.1 (OCH2, Ox), 79.0 (OCH2, Ox), 78.9 (OCH2, Ox), 77.9 (OCH2, Ox), 66.8 
(CH2, Fmoc), 66.7 (CH2, Fmoc), 62.5 (C, Ox), 62.4 (C, Ox), 52.1 (CH, α-Ala), 52.0 (CH, 
Fmoc or α-AOx), 51.2 (CH, α-Ala), 47.5 (CH, Fmoc or α-AOx), 47.4 (CH, Fmoc), 28.8 
(CH3, cumyl), 28.2 (CH3, cumyl), 28.1 (CH3, cumyl), 21.7 (CH3, Ala), 20.8 (CH3, Ala), 
14.9 (CH3, AOx), 14.6 (CH3, AOx);  IR (film) 3330 (NH), 2976, 2940, 2875, 1718 (C=O), 
1496, 1448, 1241, 1132, 1101 cm−1; MS (ESI+) m/z 529 [M+H]+, 551 [M+Na]+; HRMS 
(ESI+) Calcd. for C32H36N2O5Na [M+Na]+: 551.2516, found 551.2515; HPLC (Chiralcel 
OD-H (0.46 cm x 25 cm, 5 µm), 20% isopropanol in hexane, 25 °C, 1.0 mL/min, 𝜆 = 254 
nm) tR = 54 min (major), 93 min (minor). 
 
3-((R)-1-Nitroethyl)-N-((S)-1-phenylethyl)oxetan-3-amine (R,S)-277 
To 128 (100 mg, 0.77 mmol) in CH2Cl2 (8.0 mL) was added (S)-(−)-
a-methylbenzylamine (120 µL, 0.93 mmol) and the reaction mixture 
stirred at room temperature for 16 h. The reaction mixture was 
concentrated under reduced pressure to give a crude product which 1H-NMR showed to 
consist of 60:40 mixture of diastereoisomers. Purification by column chromatography 
(12.5% EtOAc in petroleum ether) gave the major diastereoisomer (R,S)-277 (108 mg, 
0.43 mmol, 56%, dr >95:5) as a white solid. Rf (20% EtOAc in petroleum ether) 0.29; 
mp 76-79 °C; [𝜶]𝑫𝟏𝟖 −10.3 (c 0.60, CHCl3); 1H-NMR (500 MHz, CDCl3) d 7.39-7.29 
(4H, m, ArH), 7.28-7.21 (1H, m, ArH), 5.05 (1H, q, J = 6.9 Hz, NO2CH), 4.53 (1H, d, J 
= 7.2 Hz, OCHH-Ox), 4.43 (1H, d, J = 7.6 Hz, OCHH-Ox), 4.41 (1H, d, J = 7.6 Hz, 
OCHH-Ox), 4.30-4.22 (2H, m, OCHH-Ox and NHCH), 1.84 (1H, bs, NH), 1.73 (3H, d, 
J = 6.9 Hz, NO2CHCH3), 1.37 (3H, d, J = 6.7 Hz, NHCHCH3); 13C-NMR (125 MHz, 
CDCl3) d 146.7 (C, Ar), 128.9 (2 x CH, Ar), 127.4 (CH, Ar), 126.3 (2 x CH, Ar), 86.2 
(CH, NO2CH), 77.8 (OCH2, Ox), 76.9 (OCH2, Ox), 62.4 (C, Ox), 52.7 (CH, NHCH), 26.3 
(CH3, NO2CHCH3), 14.4 (CH3, NHCHCH3); IR (film) 3330 (NH), 2977, 2968, 2925, 
2881, 1546, 1389, 1289, 974 cm−1; MS (ESI+) m/z 251 [M+H], 273 [M+Na]+, 289 
[M+K]+; HRMS (ESI+) Calcd. for C13H19N2O3 [M+H]+: 251.1390, found 251.1397. 
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3-((S)-1-Nitroethyl)-N-((R)-1-phenylethyl)oxetan-3-amine (S,R)-277 
To 128 (1.06 g, 8.17 mmol) in CH2Cl2 (82 mL) was added (R)-(+)-a-
methylbenzylamine (1.25 mL, 9.81 mmol) and the reaction mixture 
stirred at room temperature for 16 h. The reaction mixture was 
concentrated under reduced pressure to give a crude product which 1H-NMR showed to 
consist of 60:40 mixture of diastereoisomers. Purification by column chromatography 
(10-15% EtOAc in petroleum ether) gave the major diastereoisomer (S,R)-277 (1.03 g, 
4.12 mmol, 50%, dr >95:5) as a white solid. mp 71-74 °C; [𝛂]𝐃𝟏𝟗 +7.9 (c 0.19, CHCl3); 
other data as described for (R,S)-277.  
 
3-(1-nitropropylidene)oxetane 28975 
Following general procedure 2, oxetan-3-one (883 µL, 13 mmol) and 1-
nitropropane (893 µL, 10 mmol) were combined to give, after column 
chromatography (15-20% EtOAc in petroleum ether), 289 (679 mg, 4.74 
mmol, 47%) as a colourless oil. Rf (20% EtOAc in petroleum ether) 0.24; 1H-NMR (500 
MHz, CDCl3) δ 5.62-5.54 (2H, m, OCH2-Ox), 5.39-5.32 (2H, m, OCH2-Ox), 2.45 (2H, 
q, J = 7.4 Hz, CH2CH3), 1.15 (3H, t, J = 7.4 Hz, CH2CH3); 13C-NMR (125 MHz, CDCl3) 
δ 148.7 (C), 142.7 (C), 79.9 (OCH2-Ox), 75.7 (OCH2-Ox), 21.3 (CH2), 11.7 (CH3). Data 
consistent with that reported in literature.75 
 
3-(2-Methyl-1-nitropropyl)oxetan-3-ol 292 
1-Iodo-2-methylpropane (2.30 mL, 20.0 mmol) in Et2O (50 mL) was added 
dropwise via an addition funnel to a suspension of silver nitrite (4.00 g, 
26.0 mmol) in Et2O (50 mL) at 0 °C. The reaction flask was wrapped in 
aluminium foil to protect the reaction from light. The reaction mixture was allowed to 
reach room temperature and stirred for 3 d. A further amount of silver nitrite (1.54 g, 10.0 
mmol) was added and the reaction mixture stirred at room temperature for 3 d. The 
reaction mixture was filtered through Celite® eluting with Et2O and the eluent 
concentrated under reduced pressure (Note: rotary evaporator water bath cooled to 0 °C) 
to give crude 2-methyl-1-nitropropane which was used immediately without further 
purification. 
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To crude 2-methyl-1-nitropropane was added oxetan-3-one (4.0 mL, 5.0 M) and 
triethylamine (558 µL, 4.00 mmol) and the reaction mixture stirred at 60 °C for 4 d. The 
reaction mixture was concentrated under reduced pressure and the crude material purified 
by column chromatography (20% EtOAc in petroleum ether) to give 292 (680 mg, 3.88 
mmol, 19%) as a white solid. Rf (20% EtOAc in petroleum ether) 0.29; mp 74-77 °C; 
1H-NMR (500 MHz CDCl3) δ 4.75 (1H, d, J = 9.9 Hz, NO2CH), 4.67 (1H, d, J = 7.2 Hz, 
OCHH-Ox), 4.58 (1H, d, J = 7.2 Hz, OCHH-Ox), 4.54 (1H, d, J = 7.2 Hz, OCHH-Ox), 
4.51 (1H, d, J = 7.2 Hz, OCHH-Ox), 3.48 (1H, s, OH), 2.55-2.42 (1H, m, CH-iPr), 1.05 
(3H, d, J = 6.6 Hz, CH3), 0.99 (3H, d, J = 6.9 Hz, CH3); 13C-NMR (125 MHz, CDCl3) δ 
97.7 (CH, NO2CH), 82.6 (OCH2, Ox), 82.1 (OCH2, Ox), 74.2 (C, Ox), 30.1 (CH, iPr), 
19.8 (CH3), 18.9 (CH3); IR (film) 3346 (OH), 2978, 2962, 2923, 2890, 2854, 1545, 1536, 
1299, 1246, 981 cm−1; HRMS (ESI+) Calcd. for C7H13NO4Na [M+Na]+: 198.0737, found 
198.0736. 
  
3-(2-Methyl-1-nitropropylidene)oxetane 293 
292 (580 mg, 3.31 mmol) in CH2Cl2 (33 mL) was cooled to −78 °C. 
Triethylamine (969 µL, 6.95 mmol) was added followed by the dropwise 
addition of a solution of methanesulfonyl chloride (282 µL, 3.64 mmol) in 
CH2Cl2 (4 mL). The reaction mixture was stirred at −78 °C for 90 min, after which the 
dry-ice bath was removed, and the reaction mixture stirred for 60 min. The reaction 
mixture was filtered through a plug of silica eluting with 25% EtOAc in petroleum ether 
and the eluent concentrated under reduced pressure. Purification by column 
chromatography (15-20% EtOAc in petroleum ether) gave 293 (188 mg, 1.20 mmol, 
36%) as a yellow oil. Rf (20% EtOAc in petroleum ether) 0.41; 1H-NMR (500 MHz, 
CDCl3) δ 5.58 (2H, t, J = 3.7 Hz, OCH2-Ox), 5.44 (2H, t, J = 3.7 Hz, OCH2-Ox), 3.10 
(1H, sep, J = 7.0 Hz, CH), 1.17 (6H, d, J = 7.0 Hz, 2 x CH3); 13C-NMR (125 MHz, 
CDCl3) δ 148.3 (C), 146.5 (C), 80.6 (OCH2, Ox), 75.8 (OCH2, Ox), 28.9 (CH), 20.0 (2 x 
CH3). Data consistent with that reported in literature.75 
 
3-((R)-2-Methyl-1-nitropropyl)-N-((S)-1-phenylethyl)oxetan-3-amine 299 
293 (57 mg, 0.36 mmol) in n-hexane (4.0 mL) was cooled to −20 °C. 
(S)-(−)-α-Methylbenzylamine (56 µL, 0.43 mmol) was added and the O2N
H
N Ph
O Me
O2N
O
  187 
reaction mixture stirred for 16 h by which time the cooling bath had reached room 
temperature. The reaction mixture was concentrated under reduced pressure to give a 
crude product which 1H-NMR showed to consist of a 85:15 mixture of diastereoisomers. 
Purification by column chromatography (10% EtOAc in petroleum ether) gave the major 
diastereoisomer 299 (71 mg, 0.26 mmol, 71%, dr >95:5) as a colourless oil. Rf (10% 
EtOAc in petroleum ether) 0.34; [𝛂]𝐃𝟐𝟓 −16.7 (c 0.46, CHCl3); 1H-NMR (500 MHz, 
CDCl3) δ 7.46 (2H, d, J = 7.6 Hz, ArH), 7.35-7.29 (2H, m, ArH), 7.23 (1H, t, J = 7.3 Hz, 
ArH), 4.83 (1H, d, J = 7.2 Hz, OCHH-Ox), 4.74 (1H, d, J = 10.1 Hz, NO2CH), 4.55-4.47 
(2H, m, OCHH-Ox, NHCH), 4.38 (1H, d, J = 7.6 Hz, OCHH-Ox), 4.19 (1H, d, J = 7.6 
Hz, OCHH-Ox), 2.73 (1H, dsep, J = 10.1, 6.7 Hz, CH- iPr), 2.36 (1H, bs, NH), 1.42 (3H, 
d, J = 6.8 Hz, NHCHCH3), 1.02 (3H, d, J = 6.6 Hz, CH3-iPr), 0.84 (3H, d, J = 6.8 Hz, 
CH3- iPr); 13C-NMR (125 MHz, CDCl3) δ 148.2 (C, Ar), 128.7 (2 x CH, Ar), 127.0 (CH, 
Ar), 126.4 (2 x CH, Ar), 100.2 (CH, NO2CH), 78.4 (OCH2, Ox), 77.6 (OCH2, Ox), 61.9 
(C, Ox), 52.3 (CH, NHCH), 29.5 (CH, iPr), 27.3 (CH3, NHCHCH3), 20.0 (CH3, iPr), 18.9 
(CH3, iPr); IR (film) 3361 (NH), 3029, 2966, 2877, 1547, 1466, 1370, 992 cm−1; MS 
(ESI+) m/z 301 [M+Na]+; HRMS (ESI+) Calcd. for C15H22N2O3Na [M+Na]+: 301.1523, 
found 301.1517.  
 
Fmoc-D-AOx-NH2 (R)-282 
To (R,S)-277 (531 mg, 2.12 mmol) in MeOH (21 mL) was added 20% 
Pd(OH)2/C (212 mg). The reaction mixture was stirred under an 
atmosphere of H2 (balloon) at room temperature for 4 d. The reaction 
mixture was filtered through a plug of Celite® eluting with MeOH and the eluent 
concentrated under reduced pressure to give the crude diamine. To the crude diamine was 
added CH2Cl2 (10 mL), NaHCO3 (356 mg, 4.24 mmol) and Fmoc N-hydroxysuccinimide 
ester (715 mg, 2.21 mmol) and stirred at room temperature for 2 h. The reaction mixture 
was diluted with EtOAc and washed with saturated Na2CO3 (2 x 20 mL) and brine (10 
mL), dried (MgSO4), filtered and concentrated under reduced pressure. Purification by 
column chromatography (100% EtOAc; then 0-5% MeOH in CH2Cl2) gave (R)-282 (415 
mg, 1.23 mmol, 58%) as a sticky white gum. Rf (10% MeOH in CH2Cl2) 0.44; [𝛂]𝐃𝟏𝟖 –
9.6 (c 0.45, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 7.77 (2H, d, J = 7.5 Hz, ArH), 7.59 
(2H, d, J = 7.4 Hz, ArH), 7.40 (2H, t, J = 7.4 Hz, ArH), 7.32 (2H, t, J = 7.4 Hz, ArH), 
5.13 (0.85H, d, J = 8.2 Hz, major rotamer NH-AOx), 5.04-4.85 (0.15H, m, minor rotamer 
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NH-AOx), 4.57 (1H, d, J = 6.6 Hz, OCHH-Ox), 4.54 (1H, d, J = 6.3 Hz, OCHH-Ox), 4.49-
4.37 (2H, m, CH2-Fmoc), 4.36-4.26 (2H, m, 2 x OCHH-Ox), 4.26-4.15 (1.85H, m, CH-
Fmoc, major rotamer CHα-AOx), 4.04-3.81 (0.15H, m, minor rotamer CHα-AOx), 1.57 
(2H, s, NH2-overlapping with H2O signal), 1.11 (2.55 H, d, J = 6.5 Hz, major rotamer 
CH3-AOx), 1.03-0.90 (0.45H, m, minor rotamer CH3-AOx); 13C-NMR (125 MHz, CDCl3) 
δ 156.3 (C=O), 144.1 (C, Ar), 144.0 (C, Ar), 141.5 (2 x C, Ar), 127.8 (2 x CH, Ar), 127.2 
(2 x CH, Ar), 125.2 (CH, Ar), 125.1 (CH, Ar), 120.14 (CH, Ar), 120.1 (CH, Ar), 83.0 
(OCH2, Ox), 82.4 (OCH2, Ox), 66.7 (CH2, Fmoc), 58.9 (C, Ox), 51.5 (CHα, AOx), 47.5 
(CH, Fmoc), 14.8 (CH3, AOx); IR (film) 3298 (NH), 2946, 2868, 1700 (C=O), 1529, 1448, 
1242, 1050, 970 cm−1; MS (ESI+) m/z 339 [M+H]+, 361 [M+Na]+; HRMS (ESI+) Calcd. 
for C18H20N5O2Na [M+Na]+: 361.1509, found 361.1511. 
 
Fmoc-L-AOx-NH2 (S)-282 
To (S,R)-277 (605 mg, 2.42 mmol) in MeOH (24 mL) was added 20% 
Pd(OH)2/C (242 mg). The reaction mixture was stirred under an 
atmosphere of H2 (balloon) at room temperature for 4 d. The reaction 
mixture was filtered through a plug of Celite® eluting with MeOH and the eluent 
concentrated under reduced pressure to give the crude diamine. To the crude diamine was 
added CH2Cl2 (10 mL), NaHCO3 (407 mg, 4.84 mmol) and Fmoc N-hydroxysuccinimide 
(816 mg, 2.42 mmol) and stirred at room temperature for 2 h. The reaction mixture was 
diluted with EtOAc and washed with saturated Na2CO3 (2 x 20 mL) and brine (10 mL), 
dried (MgSO4), filtered and concentrated under reduced pressure. Purification by column 
chromatography (100% EtOAc; then 0-5% MeOH in CH2Cl2) gave (S)-282 (407 mg, 1.20 
mmol, 50%) as a sticky white gum. [𝛂]𝐃𝟐𝟐 +7.1 (c 0.47, CHCl3); other data as described 
for (R)-282. 
 
(9H-Fluoren-9-yl)methyl (R)-(1-(3-(4-bromobenzamido)oxetan-3-
yl)ethyl)carbamate 304  
To (R)-282 (289 mg, 0.85 mmol) in CH2Cl2 (9.0 mL) was 
added DIPEA (297 µL, 1.71 mmol) and 4-bromobenzoyl 
chloride (375 mg, 1.71 mmol). The reaction mixture was 
stirred at room temperature for 16 h. The reaction mixture was diluted with CH2Cl2 (20 
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mL), washed with a saturated solution of NaHCO3 (20 mL) and brine (10 mL), dried 
(MgSO4), filtered and concentrated under reduced pressure. Purification by column 
chromatography (60% EtOAc in petroleum ether) gave 304 (384 mg, 0.74 mmol, 87%) 
as a white solid. A crystal suitable for X-ray analysis was grown from PhMe. Rf (60% 
EtOAc in petroleum ether) 0.43; mp 164-167 °C; [𝛂]𝐃𝟐𝟐 +23.5 (c 0.50, CHCl3); 1H-NMR 
(500 MHz, CDCl3) d 7.76 (2H, d, J = 7.6 Hz, ArH-Fmoc), 7.67 (2H, d, J = 8.0 Hz, ArH-
2), 7.61-7.53 (4H, m, ArH-Fmoc and ArH-3), 7.44-7.36 (2H, m, ArH-Fmoc), 7.33-7.25 
(2H, m, ArH-Fmoc), 6.91 (1H, s, NHCOAr), 5.93 (1H, d, J = 7.1 Hz, NH-AOx), 4.98 (1H, 
d, J = 6.6 Hz, OCHH-Ox), 4.92 (1H, d, J = 6.4 Hz, OCHH-Ox), 4.67 (1H, d, J = 6.7 Hz, 
OCHH-Ox), 4.57 (1H, d, J = 6.6 Hz, OCHH-Ox), 4.46-4.27 (3H, m, CH2-Fmoc and CH-
AOx), 4.23-4.16 (1H, m, CH-Fmoc), 1.36 (3H, d, J = 6.4 Hz, CH3-AOx); 13C-NMR (125 
MHz, CDCl3) d 167.1 (C=O, COAr), 157.0 (C=O, Fmoc), 143.94 (C, Ar-Fmoc), 143.89 
(C, Ar-Fmoc), 141.5 (C, Ar-Fmoc), 141.4 (C, Ar-Fmoc), 132.6 (C, Ar-1), 132.1 (2 x CH, 
Ar-3), 128.8 (2 x CH, Ar-2), 127.9 (2 x CH, Ar-Fmoc), 127.2 (2 x CH, Ar-Fmoc), 127.1 
(C, Ar-4), 125.2 (2 x CH, Ar-Fmoc), 120.1 (2x CH, Ar-Fmoc), 78.0 (OCH2, Ox), 77.5 
(OCH2, Ox), 67.1 (CH2, Fmoc), 60.7 (C, Ox), 52.6 (CH, AOx), 47.3 (CH, Fmoc), 15.5 
(CH3, AOx); IR (film) 3371 (NH), 3352 (NH), 2967, 2893, 1693 (C=O), 1643 (C=O), 
1516, 1248, 989 cm−1; MS (ESI+) m/z 543 [M(79Br)+Na]+, 545 [M(81Br)+Na]+; HRMS 
(ESI+) Calcd. for C27H25BrN2O4Na [M+Na]+: 543.0890 (79Br) and 545.0874 (81Br), found 
543.0890 (79Br) and 545.0873 (81Br). 
Crystal Data for C28.75H27BrN2O4 (M =544.43 g/mol): monoclinic, space group C2 (no. 
5), a = 25.7843(4) Å, b = 5.30700(10) Å, c = 18.5521(3) Å, β = 95.2280(10)°, V = 
2528.06(7) Å3, Z = 4, T = 100(2) K, µ(CuKα) = 2.526 mm-1, Dcalc = 1.430 g/cm3, 22540 
reflections measured (6.884° ≤ 2Θ ≤ 136.32°), 4460 unique (Rint = 0.0686, Rsigma = 
0.0454) which were used in all calculations. The final R1 was 0.0722 (I > 2σ(I)) and wR2 
was 0.2005 (all data). 
 
2-Phenylpropan-2-yl (S)-2-hydroxypropanoate (S)-307 
Following general procedure 7, L-lactic acid (1.05 g, 25.6 mmol) gave, 
after column chromatography (10-15% EtOAc in petroleum ether), (S)-
307 (1.47 g, 7.07 mmol, 61%) contaminated with traces of 2-phenyl-2-
propanol (~19:1 by 1H-NMR) as a colourless oil. Rf (15% EtOAc in petroleum ether) 
0.30; [𝛂]𝐃𝟐𝟐 −3.5 (c 0.50, CHCl3);  1H-NMR (500 MHz, CDCl3) d 7.39-7.32 (4H, m, ArH), 
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7.31-7.24 (1H, m, ArH), 4.24 (1H, q, J = 6.9 Hz, CH), 2.76 (1H, bs, OH), 1.82 (3H, s, 
CH3-cumyl), 1.80 (3H, s, CH3-cumyl), 1.45 (3H, d, J = 6.9 Hz, CHCH3); 13C-NMR (125 
MHz, CDCl3) d 174.6 (C=O), 145.1 (C, Ar), 128.5 (2 x CH, Ar), 127.5 (CH, Ar), 124.3 
(2 x CH, Ar), 83.5 (C, cumyl), 67.0 (CH), 28.8 (CH3, cumyl), 28.4 (CH3, cumyl), 20.6 
(CHCH3); IR (film) 3358 (OH), 3058, 2977, 2937, 1721 (C=O), 1446, 1368, 1219, 1123, 
1042 cm−1; MS (ESI+) m/z 231 [M+Na]+, 439 [2M+Na]+; HRMS (ESI+) Calcd. for 
C12H16O3Na [M+Na]+: 231.0992, found 231.0994. 
 
(R)-1-Oxo-1-[(2-phenylpropan-2-yl)oxy]propan-2-yl 4-nitrobenzoate 308 
To (S)-307 (1.27 g, 6.08 mmol) in CH2Cl2 (61 mL) was 
added triphenylphosphine (2.39 g, 9.12 mmol) and 4-
nitrobenzoic acid (1.52 g, 9.12 mmol) and the reaction 
mixture cooled to 0 °C. Diethyl azodicarboxylate (1.44 mL, 9.12 mmol) was added 
dropwise and the reaction mixture stirred at room temperature for 16 h. The reaction 
mixture was concentrated under reduced pressure and the crude mixture dissolved in 
EtOAc (150 mL). The organics were washed with a saturated solution of NaHCO3 (3 x 
50 mL) and brine (25 mL), dried (MgSO4), filtered and concentrated under reduced 
pressure. Purification by column chromatography (10% EtOAc in petroleum ether) gave 
308 (2.06 g, 5.77 mmol, 95%) as a yellow oil. Rf (10% EtOAc in petroleum ether) 0.30; [𝛂]𝐃𝟐𝟐 +6.9 (c 1.60, CHCl3); 1H-NMR (500 MHz, CDCl3) d 8.30-8.26 (2H, m, ArH-3), 
8.26-8.21 (2H, m, ArH-2), 7.39-7.29 (4H, m, ArH), 7.28-7.22 (1H, m, ArH), 5.35 (1H, q, 
J = 7.1 Hz, CH), 1.82 (3H, s, CH3-cumyl), 1.80 (3H, s, CH3-cumyl), 1.67 (3H, d, J = 7.1 
Hz, CHCH3); 13C-NMR (125 MHz, CDCl3) d 168.7 (C=O, cumyl), 164.2 (C=O, Bz), 
150.8 (C, Ar-1 or Ar-4), 145.0 (C, Ar-cumyl), 135.2 (C, Ar-1 or Ar-4), 131.1 (2 x CH, 
Ar-3), 128.5 (2 x CH, Ar), 127.5 (CH, Ar), 124.3 (2 x CH, Ar), 123.6 (2 x CH, Ar-2), 
83.7 (C, cumyl), 70.3 (CH), 28.8 (CH3, cumyl), 28.3 (CH3, cumyl), 17.0 (CH3, CHCH3); 
IR (film) 3112, 3058, 2985, 2940, 2877, 1753 (C=O), 1726 (C=O), 1525, 1346, 1268, 
1213, 1098 cm−1; MS (ESI+) m/z 380 [M+Na]+, 396 [M+K]+; HRMS (ESI+) Calcd. for 
C19H19NO6Na [M+Na]+: 380.1105, found 380.1110. 
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2-Phenylpropan-2-yl (R)-2-hydroxypropanoate (R)-307 
To 308 (3.12 g, 8.74 mmol) in MeOH (87 mL) was added K2CO3 (1.27 
g, 9.17 mmol) and the reaction mixture stirred at room temperature for 
5 min before it was quenched with a saturated solution of NH4Cl (150 
mL). The resulting mixture was extracted with EtOAc (3 x 150 mL) and the combined 
organics washed with brine (50 mL), dried (MgSO4), filtered and concentrated under 
reduced pressure. The crude product was purified by column chromatography (10-15% 
EtOAc in petroleum ether) to give (R)-307 (1.52 g, 7.32 mmol, 84%) as a colourless oil 
that became a white solid upon storage at −20 °C. mp 58-60 °C; [𝛂]𝐃𝟐𝟏 +1.0 (c 0.70, 
CHCl3); 1H-NMR (500 MHz, CDCl3) d 7.38-7.32 (4H, m, ArH), 7.31-7.24 (1H, m, ArH), 
4.23 (1H, qd, J = 6.8, 5.5 Hz, CH), 2.76 (1H, d, J = 5.2 Hz, OH), 1.82 (3H, s, CH3-cumyl), 
1.80 (3H, s, CH3-cumyl), 1.45 (3H, d, J = 6.9 Hz, CHCH3); other data as described for 
(S)-307. 
 
Fmoc-D-AOx-Ala-OCumyl (R,S)-255 
The synthesis of (R,S)-255 was adapted from a procedure 
originally published by Carreira and co-workers.47 
To (R)-307 (459 mg, 2.20 mmol) in CH2Cl2 (10 mL) at −20 °C was added DIPEA (825 
µL, 4.74 mmol) followed by the dropwise addition of a solution of triflic anhydride (408 
µL, 2.42 mmol) in CH2Cl2 (2.5 mL). The reaction mixture was allowed to reach room 
temperature and stirred for 1 h. Petroleum ether (12.5 mL) was added and the reaction 
mixture filtered through a plug of silica gel eluting with 50% CH2Cl2 in petroleum ether. 
The eluent was concentrated under reduced pressure to give triflate 283 (629 mg, 1.85 
mmol, 84%) which was used immediately without further purification. 
To triflate 283 in MeCN (4.0 mL) was added a solution of (R)-282 (377 mg, 1.12 mmol) 
and DIPEA (322 µL, 1.85 mmol) in MeCN (4.0 mL). The reaction mixture was stirred at 
30 °C for 20 h and then concentrated under reduced pressure. The crude material was 
purified by repeat column chromatography (30-40% EtOAc in petroleum ether; 10-20% 
EtOAc in CH2Cl2) to give (R,S)-255 (340 mg, 0.64 mmol, 57%, dr 98:2) as a white solid. 
Rf (30% EtOAc in petroleum ether) 0.21; mp 63-65 °C; [𝛂]𝐃𝟐𝟐 −18.4 (c 0.38, CHCl3); 1H-
NMR (500 MHz, CDCl3) d 7.76 (2H, d, J = 7.5 Hz, ArH-Fmoc), 7.58 (2H, d, J = 7.4 Hz, 
ArH-Fmoc), 7.43-7.23 (9H, m, ArH), 5.20 (0.85H, d, J = 8.3 Hz, major rotamer NH-AOx), 
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5.03 (0.15H, bs, minor rotamer NH-AOx), 4.61-4.40 (8H, m, CHCH2-Fmoc, CHa-AOx, 2 
x OCH2-Ox), 3.88-3.76 (1H, m, CHa-Ala), 2.07 (1H, bs, NH-Ala), 1.82 (3H, s, CH3-
cumyl), 1.79 (3H, s, CH3-cumyl), 1.38 (3H, d, J = 6.9 Hz, CH3-Ala), 1.12 (2.55H, d, J = 
6.4 Hz, major rotamer, CH3-AOx), 1.04-0.91 (0.45H, m, minor rotamer, CH3-AOx); 13C-
NMR (125 MHz, CDCl3) d 175.6 (C=O, Ala), 156.3 (C=O, Fmoc), 145.2 (C, Ar-cumyl), 
144.1 (2 x C, Ar-Fmoc), 141.5 (2 x C, Ar-Fmoc), 128.5 (2 x CH, Ar), 127.8 (2 x CH, Ar), 
127.5 (CH, Ar), 127.2 (2 x CH, Ar), 125.18 (CH, Ar), 125.2 (CH, Ar), 124.3 (2 x CH, 
Ar), 120.1 (2 x CH, Ar), 82.8 (C, Ox), 79.0 (OCH2, Ox), 77.9 (OCH2, Ox), 66.7 (CH2, 
Fmoc), 62.5 (C, Ox), 52.0 (CH, Fmoc or a-AOx), 51.2 (CH, a-Ala), 47.5 (CH, Fmoc or 
a-AOx), 28.8 (CH3, cumyl), 28.2 (CH3, cumyl), 21.7 (CH3, Ala), 14.6 (CH3, AOx); IR 
(film) 3332 (NH), 2977, 2942, 2875, 1719 (C=O), 1496, 1447, 1270, 1131 cm−1; MS 
(ESI+) m/z 529 [M+H]+, 551 [M+Na]+; HRMS (ESI+) Calcd. for C32H36N2O5Na 
[M+Na]+: 551.2516, found 551.2520; HPLC (Chiralcel OD-H (0.46 cm x 25 cm, 5 µm), 
20% isopropanol in hexane, 25 °C, 1.0 mL/min, 𝜆 = 254 nm) tR = 55 min (major), 97 
(minor).  
 
Fmoc-L-AOx-Ala-OCumyl (S,S)-255 
The synthesis of (S,S)-255 was adapted from a procedure 
originally published by Carreira and co-workers.47 
To (R)-307 (458 mg, 2.20 mmol) in CH2Cl2 (10 mL) at −20 °C was added DIPEA (824 
µL, 4.73 mmol) followed by the dropwise addition of a solution of triflic anhydride (407 
µL, 2.42 mmol) in CH2Cl2 (2.5 mL). The reaction mixture was allowed to reach room 
temperature and stirred for 1 h. Petroleum ether (12.5 mL) was added and the reaction 
mixture filtered through a plug of silica gel eluting with 50% CH2Cl2 in petroleum ether. 
The eluent was concentrated under reduced pressure to give triflate 283 (734 mg, 2.16 
mmol, 98%) which was used immediately without further purification. 
To triflate 283 in MeCN (4.0 mL) was added a solution of (S)-282 (338 mg, 1.00 mmol) 
and DIPEA (376 µL, 2.16 mmol) in MeCN (4.0 mL). The reaction mixture was stirred at 
30 °C for 20 h and then concentrated under reduced pressure. The crude material was 
purified by repeat column chromatography (30-40% EtOAc in petroleum ether; 10-20% 
EtOAc in CH2Cl2) to give (S,S)-255 (264 mg, 0.50 mmol, 50%, dr >98:2) as a white solid. 
Rf (30% EtOAc in petroleum ether) 0.21; mp 73-76 °C; [𝛂]𝐃𝟏𝟖 −13.4 (c 0.25, CHCl3); 1H-
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NMR (500 MHz, CDCl3) δ 7.76 (2H, d, J = 7.5 Hz, ArH-Fmoc), 7.59 (2H, d, J = 7.5 Hz, 
ArH-Fmoc), 7.44-7.21 (9H, m, ArH), 5.57 (0.9 H, d, J = 7.1 Hz, major rotamer NH-AOx), 
5.28-5.08 (0.1H, m, minor rotamer NH-AOx), 4.67-3.81 (8H, m, 2 x OCH2-Ox, CH2CH-
Fmoc, CHα-AOx), 3.79-3.64 (0.9H, m, major rotamer CHα-Ala), 3.63-3.51 (0.1H, m, 
minor rotamer CHα-Ala), 1.82 (3H, s, CH3-cumyl), 1.80-1.70 (4H, m, CH3-cumyl, NH-
Ala), 1.38 (3H, d, J = 6.8 Hz, CH3-Ala), 1.16 (2.7H, d, J = 5.9 Hz, major rotamer CH3-
AOx), 1.07-0.96 (0.3H, m, minor rotamer CH3-AOx); 13C-NMR (125 MHz, CDCl3) δ 
175.5 (C=O, Ala), 156.5 (C=O, Fmoc), 145.2 (C, Ar-cumyl), 144.12 (C, Ar-Fmoc), 
144.10 (C, Ar-Fmoc), 141.5 (2 x C, Ar-Fmoc), 128.5 (2 x CH, Ar), 127.8 (2 x CH, Ar), 
127.5 (CH, Ar), 127.2 (2 x CH, Ar), 125.4 (CH, Ar), 125.3 (CH, Ar), 124.4 (2 x CH, Ar), 
120.1 (2 x CH, Ar), 82.8 (C, cumyl), 79.1 (OCH2, Ox), 78.9 (OCH2, Ox), 66.8 (CH2, 
Fmoc), 62.4 (C, Ox), 52.1 (CH, α-Ala), 52.0 (CH, α-AOx), 47.4 (CH, Fmoc), 28.9 (CH3, 
cumyl), 28.1 (CH3, cumyl), 20.8 (CH3, Ala), 14.9 (CH3, AOx); IR (film) 3329 (NH), 2976, 
2937, 2876, 1718 (C=O), 1497, 1448, 1242, 1132, 1077 cm−1; MS (ESI+) m/z 529 
[M+H]+, 551 [M+Na]+, 567 [M+K]+; HRMS (ESI+) Calcd. for C32H36N2O5Na [M+Na]+: 
551.2516, found 551.2512; HPLC (Chiralcel OD-H (0.46 cm x 25 cm, 5 µm), 20% 
isopropanol in hexane, 25 °C, 1.0 mL/min, 𝜆 = 254 nm) tR = 56 min (minor), 87 min 
(major).  
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6.4 Chiral NMR Analysis of (S)-112 Using Pirkle’s Alcohol 
(S)-112 (6.7 mg, 0.036 mmol) and (S)-Pirkle’s alcohol (10.0 mg, 0.03 mmol) were added 
to CDCl3 (0.8 mL). 1H-NMR (700 MHz, CDCl3) analysis gave spectra A. Then (R)-112 
(2.2 mg, 0.012 mmol) and (S)-Pirkle’s alcohol (3.3 mg, 0.012 mmol) were added to the 
solution to give spectrum B. Integration of the signals at 0.89 (d, J = 6.8 Hz) and 0.88 (d, 
J = 6.8 Hz) ppm in spectra B relative to those in spectra A confirmed >95% ee (S)-112 
A. Expanded 1H-NMR (700 MHz, CDCl3) spectra of (S)-112 with (S)-Pirkle’s alcohol:  
 
B. Expanded 1H-NMR (700 MHz, CDCl3) spectra of (S)-112:(R)-112 (3:1) with (S)-
Pirkle’s alcohol: 
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A. 1H-NMR (700 MHz, CDCl3) spectra of (S)-112 with Pirkle’s alcohol: 
 
B. 1H-NMR (700 MHz, CDCl3) of (S)-112:(R)-112 (3:1) with Pirkle’s alcohol: 
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6.5 Configurational Integrity of (S,S)-219 and (S,R)-219 
The configurational integrity of the C-terminal amino acid residue during the synthesis 
and application of N-Fmoc-GOx-dipeptides was confirmed by the solution-phase synthesis 
of (S,S)-219 and (S,R)-219. Reaction of 210 with 2% TFA in CH2Cl2, followed by 
coupling with L- and D-phenylalanine tert-butyl ester with HCTU gave (S,S)-219 and 
(S,R)-219 respectively (Scheme 6.1). The diastereotopic purity of (S,S)-219 and (S,R)-
219 was determined by comparison of the CH3-Val region (0.96-0.66 ppm) in the crude 
1H-NMR (500 MHz, CDCl3) spectra. Integration of the signal at 0.77 (J = 6.8 Hz) ppm 
in spectrum A relative to that in spectrum B confirmed dr >95:5 indicating that no 
detectable epimerization arises during coupling. 
 
Scheme 6.1 C-Terminal couplings of oxetane containing dipeptides proceed with no detectable 
epimerisation. a Coupling conditions: H-Phe-OtBu･HCl (2.0 equiv), HCTU (1.0 equiv), DIPEA (4.0 equiv), 
CH2Cl2, rt. 
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A. Expanded 1H-NMR (500 MHz, CDCl3) of crude (S,S)-219 
 
B. Expanded 1H-NMR (500 MHz, CDCl3) of crude (S,R)-219 
 
 
 
 
  198 
A. 1H-NMR (500 MHz, CDCl3) of crude (S,S)-219 
 
B. 1H-NMR (500 MHz, CDCl3) of crude (S,R)-219 
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6.6 Microwave Assisted Solid-Phase Synthesis of Peptides  
Synthesis and Analysis of Ac-Ala-GOx-Phe-Ala-NH2 176 
176 was synthesised at the University of Leicester 
on a CEM Liberty1 automated microwave-assisted 
solid-phase peptide synthesiser (CEM Corporation) 
using an Fmoc/tBu protecting group strategy on a 0.1 mmol synthetic scale using Rink 
amide resin. 
Deprotection was carried out using 20% piperidine in DMF at 75 °C for 30 s and then 3 
min followed by washing. N-α-Fmoc protected amino acids (3 equiv) were coupled using 
HCTU (3 equiv) and DIPEA (6 equiv) at 75 °C for 5 min followed by washing.  
Oxetane containing dipeptide building block 175 (3 equiv) was dissolved in DMF (0.066 
M) followed by addition of HCTU (3 equiv) and DIPEA (6 equiv). The resulting solution 
was allowed to activate for 5 min before addition to the resin.  
N-terminal acetylation was carried out manually using Ac2O (3 equiv) and DIPEA (3 
equiv) in DMF at room temperature.  
The peptide was cleaved from the resin using a cleavage cocktail of 95% TFA, 2.5% H2O 
and 2.5% triisopropylsilane (TIS) for 1 h at room temperature before being drained and 
the cleavage cocktail blown off using a stream of nitrogen. The peptide was precipitated 
and washed three times in cold Et2O and spun down to a pellet before the Et2O was 
removed and the peptide dried under a steady stream of nitrogen.  
The crude peptide was purified by reverse-phase HPLC using a Dionex Ultimate 3000 
system with a Phenomenex Gemini-NX 5 µm C18 110 Å packed column with dimensions 
250 x 21.20 mm and collected fractions were lyophilized on a FreeZone Benchtop Freeze 
Dry System.  Purity was determined by analytical reverse-phase HPLC using a Dionex 
Ultimate 3000 system with a Phenomenex Gemini-NX 5 µm C18 110 Å packed column 
with dimensions 150 x 4.60 mm. Retention times (tR) are reported in minutes. 
Characterisation Data: HPLC Purity 98% (tR = 8.8 [5-100% MeCN+ 0.1% TFA in 
water + 0.1% TFA over 15 min], tR = 10.6 [5-50% MeCN+ 0.1% TFA in water + 0.1% 
TFA over 15 min]). HRMS (ESI+) Calcd. For C21H31N5O5Na [M+Na]+: 456.2217, found 
456.2219. 1H-NMR (400 MHz, CDCl3) δ 7.38-7.31 (1H, m, NH), 7.12-7.04 (6H, NH and 
ArH), 6.80-6.73 (1H, m, NH), 5.99 (1H, s, NH), 5.67 (1H, s, NH), 4.16 (1H, d, J = 6.4 
Hz, OCHH-Ox), 4.11-3.99 (5H, m, OCHH-Ox, OCH2-Ox, 2 x CHα-Ala), 3.67-3.54 (2H, 
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m, CHα-Phe and CHH-GOx), 3.28-3.20 (1H, m, CHH-GOx), 2.86 (1H, dd, J = 13.6, 6.5 
Hz, CHHβ-Phe), 2.76 (1H, dd, J = 13.4, 7.1 Hz, CHHβ-Phe), 1.72 (3H, s, Ac), 1.09-1.05 
(6H, m, 2 x CH3-Ala). 
 
Synthesis and Analysis of Peptides 225-233 
Synthesis and analysis of oxetane-modified peptides 225-233 was carried out by Dr 
Astrid Knuhtsen, Dr Alex Hoose and Dr Andrew Jamieson at the University of Glasgow. 
Experimental procedures and characterisation data is included in the supporting 
information of the Organic Letters publication and is available free of charge on the ACS 
Publications website.124 
https://pubs.acs.org/doi/suppl/10.1021/acs.orglett.7b01466 
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6.7 Determination of Diastereomeric Ratio  
The diastereomeric ratio of 257 was determined by integration 
of the CHα-Ala signals at 3.85-3.66 ppm (1H, m, 
diastereoisomer 1) and 3.66-3.47 ppm (1H, m, diastereoisomer 
2) in the crude 1H-NMR (300 MHz, CDCl3) spectrum.   
 
The diastereomeric ratio of 263 was determined by integration of 
the CH3-Ala signals at 1.68 ppm (3H, d, J = 6.8 Hz, diastereoisomer 
1) and 1.64 ppm (3H, d, J = 6.9 Hz, diastereoisomer 2) in the crude 
1H-NMR (400 MHz, CDCl3) spectrum.  
 
The diastereomeric ratio of 264 was determined by integration 
of the CHα-Val signals at 3.46 ppm (1H, dd, J = 10.3, 4.3 Hz, 
diastereoisomer 1) and 3.40 ppm (1H, dd, J = 10.3, 4.4 Hz, 
diastereoisomer 2) in the crude 1H-NMR (400 MHz, CDCl3) spectrum.  
 
The diastereomeric ratio of 132 was determined by integration of 
the NO2CH signals at 4.92 ppm (1H, q, J = 6.8 Hz, diastereoisomer 
1) and 4.87 ppm (1H, q, J = 6.9 Hz, diastereoisomer 2) in the crude 
1H-NMR (500 MHz, CDCl3) spectrum.  
 
The diastereomeric ratio of 265 was determined by integration of 
the OCHH-Ox signals at 4.45 ppm (1H, d, J = 7.7 Hz, 
diastereoisomer 1) and 4.39 ppm (1H, d, J = 7.8 Hz, 
diastereoisomer 2) in the crude 1H-NMR (400 MHz, CDCl3) spectrum.  
 
The diastereomeric ratio of 266 was determined by integration of 
the CHPh signals at 4.87 (1H, bs, diastereoisomer 1) and 4.82 ppm 
(1H, bs, diastereoisomer 2) in the crude 1H-NMR (400 MHz, 
CDCl3) spectrum.  
 
The diastereomeric ratio of 267 was determined by integration of the 
OCHH-Ox signals at 4.59 (1H, d, J = 7.8 Hz, diastereoisomer 1) and 
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4.48 ppm (1H, d, J = 7.4 Hz, diastereoisomer 2) in the crude 1H-NMR (300 MHz, CDCl3) 
spectrum.  
 
The diastereomeric ratio of 277 was determined by integration of the 
NO2CH signals at 5.05 ppm (1H, q, J = 6.9 Hz, diastereoisomer 1) and 
at 4.86 ppm (1H, q, J = 6.9 Hz, diastereoisomer 2) in the crude 1H-NMR 
(300 MHz, CDCl3) spectrum.  
 
The diastereomeric ratio of 278 was determined by integration of the 
OCHH-Ox signals at 4.59 ppm (1H, d, J = 7.1 Hz, diastereoisomer 1) 
and at 4.48 ppm (1H, d, J = 7.0 Hz, diastereoisomer 2) in the crude 1H-
NMR (400 MHz, CDCl3) spectrum.  
 
The diastereomeric ratio of 280 was determined by integration of the 
NO2CH signals at 5.54 ppm (1H, q, J = 7.1 Hz, diastereoisomer 1) and 
at 5.39 ppm (1H, q, J = 6.9 Hz, diastereoisomer 2) in the crude 1H-
NMR (300 MHz, CDCl3) spectrum.  
 
The diastereomeric ratio of 297 was determined by integration of the 
NO2CH signals at 4.80 ppm (1H, dd, J = 11.0, 3.1 Hz, diastereoisomer 
1) and at 4.71 ppm (1H, dd, J = 11.3, 2.9 Hz, diastereoisomer 2) in the 
crude 1H-NMR (400 MHz, CDCl3) spectrum.  
 
The diastereomeric ratio of 298 was determined by integration of the 
CHHPh signals at 3.30 ppm (1H, dd, J = 14.8, 4.1 Hz, diastereoisomer 
1) and at 3.20 ppm (1H, dd, J = 14.8, 3.4 Hz, diastereoisomer 2) in the 
crude 1H-NMR (400 MHz, CDCl3) spectrum.  
 
The diastereomeric ratio of 299 was determined by integration of the 
OCHH-Ox signals at 4.26 ppm (1H, d, J = 7.1 Hz, diastereoisomer 1) 
and at 4.19 ppm (1H, d, J = 7.6 Hz, diastereoisomer 2) in the crude 1H-
NMR (400 MHz, CDCl3) spectrum.  
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6.8 Diastereomeric Purity of (R,S)-277 and (S,R)-277  
Confirmation that (R,S)-277 was isolated as a single diastereoisomer (dr >95:5) was 
demonstrated by comparison of the NO2CH signals in the crude 1H-NMR (300 MHz, 
CDCl3) spectrum with the same region in the 1H-NMR (500 MHz, CDCl3) spectrum after 
column chromatography. Integration of the signals at 5.05 (q, J = 6.8 Hz) ppm and 4.86 
(q, J = 6.9 Hz) ppm in spectrum A relative to that in spectrum B confirmed dr >95:5. 1H-
NMR analysis of (S,R)-277 was identical and also confirmed dr >95:5. 
A. Expanded 1H-NMR (300 MHz, CDCl3) of crude (R,S)-277 
 
B. Expanded 1H-NMR (500 MHz, CDCl3) of (R,S)-277 after column chromatography  
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6.9 HPLC Analysis of (±,S)-255, (R,S)-255 and (S,S)-255 
HPLC analysis was conducted on an Agilent Technologies 1200 Series HPLC, using 
Chiralcel OD-H column (0.46 cm x 25 cm, 5 µm) at 25 °C, with detection by UV at 254 
nm. Samples were eluted at a flow rate of 1.0 mL/min with a mobile phase system 
composed of 20% isopropanol in hexane. Retention times (tR) are reported in minutes.  
(±,S)-255 
` 
 
 (R,S)-255
 
 (S,S)-255
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6.10 Solid-Phase Synthesis of KAAAA Peptides  
Synthesis of peptides 246, 248, 252 and 254 was carried out by Dr Ina Wilkening at the 
University of Warwick. 
Peptides were synthesised on a Prelude peptide synthesiser (ProteinTechnologies Inc.) 
using an Fmoc/tBu protecting group strategy on a 0.025 mmol synthetic scale using 
NovaSyn® TGR R resin (Novabiochem).  
The resin was manually loaded with Fmoc-Tyr(tBu)-OH as follows; resin (0.025 mmol), 
was pre-swollen in DMF for 1 h and washed with DMF. Fmoc-Tyr(tBu)-OH (115 mg, 
0.25 mmol), PyBOP (130 mg, 0.25 mmol) and DIPEA (87 µL, 0.50 mmol) in DMF (0.67 
M) were added to the resin and the mixture agitated at room temperature for 1 h. The 
solvent was removed and the resin washed several times with DMF. Loading was 
repeated in case of a positive TNBS-test. 
Deprotection was carried out in 20% piperidine in DMF at room temperature for 20 min 
followed by washing. N-α-Fmoc protected amino acids (10 equiv) were coupled using 
HATU activation with DIPEA or HCTU activation with NMM at room temperature for 
45 min followed by washing.  
Oxetane-containing dipeptide building blocks were first deprotected as follows; (S,S)-255 
or 215 (2.0 equivalents) in 2% TFA/CH2Cl2 (0.05 M) was stirred at room temperature 
until consumption of starting material. The reaction mixture was concentrated under 
reduced pressure and the resulting residue dissolved in CH2Cl2 and concentrated under 
reduced pressure (3x) to give the crude acid. The crude acid was manually double coupled 
using HATU (1.9 equiv) and DIPEA (6.0 equiv) at room temperature for 2-12 h until a 
negative TNBS test was observed.  
Peptide 248 was synthesised using HCTU activation with NMM. The first 12 amino acids 
were attached by double coupling at room temperature for 45 min whereas the last 5 
amino acids were attached by triple coupling at room temperature for 45 min. After each 
amino acid, the peptide was capped with Ac2O:NMM:DMF (5:5:90; v/v/v) at room 
temperature for 2 x 15 min. After the last amino acid, the Fmoc group was cleaved 
manually with 20% piperidine in DMF at room temperature for 20 min and the N-
terminus was capped with Ac2O:NMM:DMF (5:5:90; v/v/v) at room temperature for 2 x 
20 min.  
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Oxetane-modified peptides 246, 252 and 254 were synthesised using HATU activation 
with DIPEA. Amino acids were attached by triple couplings at room temperature for 45 
min. Incorporation of the deprotected oxetane-containing dipeptide building block was 
achieved as described above. In case of the N-terminal oxetane-modified peptides 252 
and 252 the last two coupling steps with alanine and lysine were also done manually 
under standard conditions.  
Peptide cleavage was performed using a cleavage cocktail of 95% TFA, 2.5% 
triisopropylsilane (TIS) and 2.5% water and the resin agitated at room temperature under 
nitrogen for 1 h. The cleavage cocktail was evaporated using a stream of nitrogen and the 
peptide was precipitated from solution with ice cold Et2O. Crude peptides were purified 
by preparative HPLC (Agilent Infinity 1260) using an Agilent PLRP-S column (100 Å, 8 
µm, 150 x 25 mm). Gradients were run using a solvent system consisting of A (H2O + 
0.1% TFA) and B (MeCN + 0.1% TFA), collected fractions were lyophilised on a 
ScanVac CoolSafe freeze dryer.  
Pure peptides were analysed on an Agilent Technologies 1200 Series RP-HPLC, using 
an Agilent Eclipse Plus C18 (5 µm, 4.6 x 150 mm) at 25 °C, with detection by UV at 214 
and 280 nm. Gradients were run using a solvent system consisting of solution A (5% 
MeCN in H2O + 0.1% TFA) and B (5% H2O in MeCN + 0.1% TFA). Two gradients were 
used to characterise each peptide; a gradient from 5-95% solution B over 20 min and a 
gradient from 5-50% solution B over 20 min. Analytical RP-HPLC data is recorded as 
column retention time (tR) in minutes (min). High-resolution mass spectra were recorded 
using a Bruker MaXis Impact.  
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Entry Peptide Sequence tR (min)a Purity (%)b,c 
1 
Ac-KAAAA-KAAAA-KAAAA-KGY-NH2, 248 
parent 
8.75 + 10.46 92 
2 
Ac-KAAAA-KAAOxAA-KAAAA-KGY-NH2, 246 
Central AOx 
7.83 + 8.61 90 
3 
Ac-KAAOxAA-KAAAA-KAAAA-KGY-NH2, 252 
N-Terminal AOx 
9.39 + 11.47 76 
4 
Ac-KAGOxAA-KAAAA-KAAAA-KGY-NH2, 254 
N-Terminal GOx 
9.35 + 11.38 90 
Peptide Characterisation Data – Table 1 a First tR is the gradient from 5-95% solution B over 20 min; 
second number is the gradient from 5-50% over 20 min. b At 214 nm. c Lowest purity of the two gradients 
run.  
 
Entry Peptide Sequence 
HRMS ΔMW 
(ppm) Calculated Observed 
1 
Ac-KAAAA-KAAAA-KAAAA-KGY-NH2, 248 
parent 
822.9808 
[M+2H]2+ 
822.9808 
[M+2H]2+ 
0.0 
2 
Ac-KAAAA-KAAOxAA-KAAAA-KGY-NH2, 246 
Central AOx 
858.9784 
[M+2Na]2+ 
858.9766 
[M+2Na]2+ 
2.1 
3 
Ac-KAAOxAA-KAAAA-KAAAA-KGY-NH2, 252 
N-Terminal AOx 
558.3334 
[M+3H]3+ 
558.3331 
[M+3H]+ 
-0.5 
4 
Ac-KAGOxAA-KAAAA-KAAAA-KGY-NH2, 254 
N-Terminal GOx 
851.9706 
[M+2Na]2+ 
851.9701 
[M+2Na]2+ 
-0.6 
Peptide Characterisation Data – Table 2 
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6.11 Circular Dichroism 
Concentration Determination 
Peptide samples were dissolved in 10 mM potassium phosphate buffer pH 7.0, 10 mM 
potassium phosphate buffer pH 7.0 + 1.0 NaCl, MeOH and 80% MeOH in water. 
Concentrations of peptides were determined spectroscopically using the extinction 
coefficient for tyrosine (ε275 = 1450 M−1 cm−1). Final concentrations ranged from 34 to 
100 µM in 10 mM potassium phosphate buffer pH 7.0, 43 to 165 µM in 10 mM potassium 
phosphate buffer pH 7.0 + 1.0 M NaCl, 153 to 192 µL in MeOH and 47 to 178 µM in 
80% MeOH in water. 
CD Measurements 
CD experiments were performed on a Jasco J-815 spectropolarimeter with temperature 
control which was routinely calibrated with (1S)-(+)-10-camphorsulfonic acid. Spectra 
were recorded in a 0.1 cm cuvette between 250 and 180 nm using a 1.0 nm pitch with a 
1.0 nm band width. Response time was set at 1 s with scanning speed at 100 nm/min and 
temperature of 0 or 5 °C. Each spectrum represents the average of 10 scans.  
CD Data Analysis 
The raw CD data was processed by subtraction of the solvent signal and converted to 
mean residue ellipticity θ XYZ using the equation: θ XYZ = θ/(10	x	𝐶	x	𝑁]	x	𝑙) (eq 4) 
where θ is the ellipticity in millidegrees, C, is the peptide molar concentration (M), l is 
the cell path length (cm), and Np is the number of peptide units (oxetane-modified 
peptides Np = 18; parent peptide 248 Np = 19).  
CD data was analysed for secondary structure using equations 1-3 (Method 1) described 
in Chapter 4 and DichroWeb (Selcon3, Ref. set 4, Method 2).142,143  
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